

# Increased Survival with Enzalutamide in Prostate Cancer

New England Journal of Medicine

367, 1187-1197

DOI: [10.1056/nejmoa1207506](https://doi.org/10.1056/nejmoa1207506)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Management of Castration-Resistant Prostate Cancer: A Global Approach. <i>Current Oncology</i> , 2012, 19, 32-36.	0.9	2
3	Activin A Stimulates AKR1C3 Expression and Growth in Human Prostate Cancer. <i>Endocrinology</i> , 2012, 153, 5726-5734.	1.4	37
4	Targeting the Androgen Receptor in the Management of Castration-Resistant Prostate Cancer: Rationale, Progress, and Future Directions. <i>Current Oncology</i> , 2012, 19, 22-31.	0.9	35
5	Management of Advanced Prostate Cancer in Senior Adults: The New Landscape. <i>Oncologist</i> , 2012, 17, 16-22.	1.9	19
6	Distinct Patterns of Dysregulated Expression of Enzymes Involved in Androgen Synthesis and Metabolism in Metastatic Prostate Cancer Tumors. <i>Cancer Research</i> , 2012, 72, 6142-6152.	0.4	175
7	Enzalutamide in Prostate Cancer after Chemotherapy. <i>New England Journal of Medicine</i> , 2012, 367, 2448-2449.	13.9	9
8	Pro-survival and anti-apoptotic properties of androgen receptor signaling by oxidative stress promote treatment resistance in prostate cancer. <i>Endocrine-Related Cancer</i> , 2012, 19, R243-R253.	1.6	60
9	Enzalutamide in metastatic CRPC—old dog, new tricks. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 613-614.	12.5	3
10	Aprepitant and control of emesis induced by 5-day chemotherapy. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 614-616.	12.5	0
11	New Agents in Metastatic Prostate Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 1403-1409.	2.3	13
13	New Perspectives in the Therapy of Castration Resistant Prostate Cancer. <i>Current Drug Targets</i> , 2012, 13, 1676-1686.	1.0	34
14	Enzalutamide (formerly MDV3100) as a new therapeutic option for men with metastatic castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2012, 14, 805-806.	0.8	5
15	Abiraterone acetate: a hat trick of clinical benefits. <i>Lancet Oncology</i> , The, 2012, 13, 1173-1174.	5.1	2
16	Re: Radical Prostatectomy Versus Observation for Localized Prostate Cancer. <i>European Urology</i> , 2012, 62, 1196.	0.9	3
17	Pelvic malignancies in older patients: New drugs in the elderly?. <i>Journal of Geriatric Oncology</i> , 2012, 3, S22-S23.	0.5	0
18	Management of advanced prostate cancer in senior adults: The new therapeutic landscape. <i>Journal of Geriatric Oncology</i> , 2012, 3, S11.	0.5	0
19	Enzalutamide — A Major Advance in the Treatment of Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2012, 367, 1256-1257.	13.9	20
20	Prostate cancer—from steroid transformations to clinical translation. <i>Nature Reviews Urology</i> , 2012, 9, 721-724.	1.9	17

#	ARTICLE	IF	CITATIONS
21	Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. <i>Trials</i> , 2012, 13, 168.	0.7	121
22	Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Oncology</i> , The, 2012, 13, 983-992.	5.1	1,182
23	Optimal Management of Recurrent Prostate Cancer in Older Patients. <i>Drugs and Aging</i> , 2012, 29, 871-883.	1.3	8
24	Brain metastases from prostate cancer: an emerging clinical problem with implications for the future therapeutic scenario. <i>Future Oncology</i> , 2012, 8, 1585-1595.	1.1	12
25	Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer. <i>Journal of Translational Medicine</i> , 2013, 11, 89.	1.8	84
26	Recent advances revolutionize treatment of metastatic prostate cancer. <i>Future Oncology</i> , 2013, 9, 1133-1144.	1.1	18
28	Prostate cancer therapy: going forwards by going backwards. <i>Lancet Oncology</i> , The, 2013, 14, 104-105.	5.1	43
29	Monitoring the Clinical Outcomes in Advanced Prostate Cancer: What Imaging Modalities and Other Markers Are Reliable?. <i>Seminars in Oncology</i> , 2013, 40, 375-392.	0.8	34
30	Androgen receptor modulators: a marriage of chemistry and biology. <i>Future Medicinal Chemistry</i> , 2013, 5, 1109-1120.	1.1	18
31	Radium-223 for the treatment of prostate cancer. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 379-387.	1.9	15
32	Cell mates: paracrine and stromal targets for prostate cancer therapy. <i>Nature Reviews Urology</i> , 2013, 10, 441-451.	1.9	32
33	Interplay Between Genomic Alterations and Androgen Receptor Signaling During Prostate Cancer Development and Progression. <i>Hormones and Cancer</i> , 2013, 4, 61-69.	4.9	42
34	Foolâ€™s gold, lost treasures, and the randomized clinical trial. <i>BMC Cancer</i> , 2013, 13, 193.	1.1	42
35	Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. <i>BMC Medicine</i> , 2013, 11, 108.	2.3	476
36	Optimal Therapy Sequencing in Metastatic Castration-Resistant Prostate Cancer. <i>Current Oncology Reports</i> , 2013, 15, 217-223.	1.8	1
37	New Agents in the Arsenal to Fight Castrate-Resistant Prostate Cancer. <i>Current Oncology Reports</i> , 2013, 15, 239-248.	1.8	10
38	Tasquinimod: A Novel Angiogenesis Inhibitorâ€™Development in Prostate Cancer. <i>Current Oncology Reports</i> , 2013, 15, 65-68.	1.8	6
39	Enzalutamide, a Second Generation Androgen Receptor Antagonist: Development and Clinical Applications in Prostate Cancer. <i>Current Oncology Reports</i> , 2013, 15, 69-75.	1.8	14

#	ARTICLE	IF	CITATIONS
40	Custirsen (OGX-011): Clusterin Inhibitor in Metastatic Prostate Cancer. <i>Current Oncology Reports</i> , 2013, 15, 113-118.	1.8	13
42	Abiraterone Acetate: Targeting Persistent Androgen Dependence in Castration-Resistant Prostate Cancer. <i>Advances in Therapy</i> , 2013, 30, 727-747.	1.3	14
43	Methylselenol prodrug enhances MDV3100 efficacy for treatment of castration-resistant prostate cancer. <i>International Journal of Cancer</i> , 2013, 133, 2225-2233.	2.3	21
44	The Future of Systemic Therapies for Localised Prostate Cancer. <i>Clinical Oncology</i> , 2013, 25, 506-513.	0.6	6
45	Androgen activity and markers of inflammation among men in NHANES III. <i>American Journal of Human Biology</i> , 2013, 25, 622-628.	0.8	17
46	New treatment developments applied to elderly patients with advanced prostate cancer. <i>Cancer Treatment Reviews</i> , 2013, 39, 578-583.	3.4	21
47	Current, new and novel therapy for castration-resistant prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 819-827.	1.1	9
48	A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 537-544.	1.1	75
49	Translational Molecular Imaging of Prostate Cancer. <i>Current Radiology Reports</i> , 2013, 1, 216-226.	0.4	14
50	Picking the Optimal Duration of Hormonal Therapy in Men With High-Risk and Locally Advanced Prostate Cancer Treated With Radiotherapy. <i>Seminars in Radiation Oncology</i> , 2013, 23, 206-214.	1.0	7
53	A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer. <i>Cell</i> , 2013, 154, 1074-1084.	13.5	257
54	Metastatic castrate-resistant prostate cancer, dawn of a new age of management. <i>BJU International</i> , 2013, 111, E9-E10.	1.3	8
57	Metabolic and Prostate-Specific Antigen Response After Abiraterone Acetate Withdrawal: A New Clinical Scenario for Castration-Resistant Prostate Cancer?. <i>Clinical Genitourinary Cancer</i> , 2013, 11, e10-e14.	0.9	5
58	Development, validation and application of a stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of keto-androgens in human serum. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2013, 138, 281-289.	1.2	45
59	Lower Baseline Prostate-specific Antigen Is Associated With a Greater Overall Survival Benefit From Sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) Trial. <i>Urology</i> , 2013, 81, 1297-1302.	0.5	211
60	Overview of the latest treatments for castration-resistant prostate cancer. <i>Nature Reviews Urology</i> , 2013, 10, 522-528.	1.9	51
61	A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer. <i>British Journal of Cancer</i> , 2013, 109, 1711-1716.	2.9	49
62	Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade. <i>Cell</i> , 2013, 155, 1309-1322.	13.5	801

#	ARTICLE	IF	CITATIONS
63	A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509. <i>Cancer Discovery</i> , 2013, 3, 1020-1029.	7.7	497
64	Molecular Pathways: Blockade of the PRLR Signaling Pathway as a Novel Antihormonal Approach for the Treatment of Breast and Prostate Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 1644-1650.	3.2	46
65	Abiraterone Acetate: A Review of Its Use in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Drugs</i> , 2013, 73, 2077-2091.	4.9	47
66	Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2013, 369, 213-223.	13.9	2,723
67	Development of Therapeutic Combinations Targeting Major Cancer Signaling Pathways. <i>Journal of Clinical Oncology</i> , 2013, 31, 1592-1605.	0.8	249
68	Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. <i>Annals of Oncology</i> , 2013, 24, 1802-1807.	0.6	288
69	Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). <i>Annals of Oncology</i> , 2013, 24, 1807-1812.	0.6	310
70	A Road Map to Comprehensive Androgen Receptor Axis Targeting for Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2013, 73, 4599-4605.	0.4	82
71	Enzalutamide: A Review of Its Use in Metastatic, Castration-Resistant Prostate Cancer. <i>Drugs</i> , 2013, 73, 1723-1732.	4.9	32
72	Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2013, 49, 3821-3830.	1.3	183
73	Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. <i>Oncogene</i> , 2013, 32, 5501-5511.	2.6	646
74	TAK-441, a novel investigational smoothed antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling. <i>International Journal of Cancer</i> , 2013, 133, 1955-1966.	2.3	43
75	Management of Patients with Castration-Resistant Disease. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 1243-1260.	0.9	2
76	Management of Hormone-Sensitive Metastatic Prostate Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 1221-1241.	0.9	4
77	A 45-Year-Old With Neuroendocrine Carcinoma of the Prostate. <i>Urology</i> , 2013, 81, 714-716.	0.5	2
78	Molecular Classification of Prostate Cancer Progression: Foundation for Marker-Driven Treatment of Prostate Cancer. <i>Cancer Discovery</i> , 2013, 3, 849-861.	7.7	120
80	Evolution of the Treatment Paradigm for Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Advances in Therapy</i> , 2013, 30, 1041-1066.	1.3	7
81	Time to prostate specific antigen (PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel chemotherapy. <i>Medical Oncology</i> , 2013, 30, 719.	1.2	14

#	ARTICLE	IF	CITATIONS
84	Abiraterone and its place in the treatment of metastatic CRPC. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 6-8.	12.5	14
85	Are urologists ready to manage castration-resistant disease?. <i>Nature Reviews Urology</i> , 2013, 10, 133-134.	1.9	3
86	Phase II Trial Assessing Granulocyte-macrophageâ€”Colony Stimulating Factor, Ketoconazole Plus Mitoxantrone in Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel Treatments. <i>Cancer Investigation</i> , 2013, 31, 177-182.	0.6	6
87	To Market, To Marketâ€”2012. <i>Annual Reports in Medicinal Chemistry</i> , 2013, 48, 471-546.	0.5	14
88	Selectively Targeting Prostate Cancer with Antiandrogen Equipped Histone Deacetylase Inhibitors. <i>ACS Chemical Biology</i> , 2013, 8, 2550-2560.	1.6	58
89	The hurdle of antiandrogen drug resistance: drug design strategies. <i>Expert Opinion on Drug Discovery</i> , 2013, 8, 1491-1501.	2.5	6
90	Defining the optimal approach to the patient with postradiation prostateâ€”specific antigen recurrence using outcome data from a prospective randomized trial. <i>Cancer</i> , 2013, 119, 3280-3286.	2.0	5
91	Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3525-3530.	0.8	223
92	Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2? A meta-analysis of published trials. <i>Prostate Cancer and Prostatic Diseases</i> , 2013, 16, 323-327.	2.0	10
93	New and Emerging Therapies for Bone Metastases in Genitourinary Cancers. <i>European Urology</i> , 2013, 63, 309-320.	0.9	42
94	Hits identified in library screening demonstrate selective CYP17A1 lyase inhibition. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2013, 134, 75-79.	1.2	15
95	Prostate cancer: ESMO Consensus Conference Guidelines 2012. <i>Annals of Oncology</i> , 2013, 24, 1141-1162.	0.6	137
96	Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cell Lines. <i>Cancer Research</i> , 2013, 73, 483-489.	0.4	570
97	Frequency of brain metastases from prostate cancer: an 18-year single-institution experience. <i>Journal of Neuro-Oncology</i> , 2013, 111, 163-167.	1.4	25
98	New prostate cancer drugs hold promise. <i>Cancer</i> , 2013, 119, 247-248.	2.0	1
99	Improving outcomes in high-risk prostate cancer with radiotherapy. <i>Reports of Practical Oncology and Radiotherapy</i> , 2013, 18, 333-337.	0.3	15
100	Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 1307-1316.	5.1	205
101	Management of prostate cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013. <i>Lancet Oncology</i> , The, 2013, 14, e524-e534.	5.1	42

#	ARTICLE	IF	CITATIONS
102	Neoadjuvant and Adjuvant Hormonal and Chemotherapy for Prostate Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 1189-1204.	0.9	5
103	Metastatic castration-resistant prostate cancer. Part 1: the challenges of the disease and its treatment. <i>European Journal of Oncology Nursing</i> , 2013, 17, S1-S6.	0.9	8
104	Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. <i>Lancet Oncology, The</i> , 2013, 14, 760-768.	5.1	256
105	Re: Axel Heidenreich, David Pfister. Treatment Decisions for Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel Chemotherapy: The Role of Cabazitaxel in the Continuum of Care. <i>Eur Urol</i> 2012;62:1201-4. <i>European Urology</i> , 2013, 64, e62-e64.	0.9	0
106	Renal-cell carcinoma: a step closer to a new classification. <i>Lancet Oncology, The</i> , 2013, 14, 105-107.	5.1	7
107	Castration-resistant Prostate Cancer: Where We Stand in 2013 and What Urologists Should Know. <i>European Urology</i> , 2013, 64, 260-265.	0.9	35
108	Improved Survival in a Cohort of Trial Participants with Metastatic Castration-resistant Prostate Cancer Demonstrates the Need for Updated Prognostic Nomograms. <i>European Urology</i> , 2013, 64, 300-306.	0.9	85
109	Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer: Results of a Compassionate Use Program in The Netherlands. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 238-250.e1.	0.9	26
110	Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer. <i>Prostate</i> , 2013, 73, 1291-1305.	1.2	89
111	Contemporary Issues in Radiotherapy for Clinically Localized Prostate Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 1137-1162.	0.9	4
113	Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2013, 14, 893-900.	5.1	139
114	Biochemical and Objective Response to Abiraterone Acetate Withdrawal: Incidence and Clinical Relevance of a New Scenario for Castration-resistant Prostate Cancer. <i>Urology</i> , 2013, 82, 1090-1093.	0.5	22
116	Luteinizing Hormone-Releasing Hormone Agonists: A Quick Reference for Prevalence Rates of Potential Adverse Effects. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 375-384.	0.9	65
118	Angiogenesis and anti-angiogenic therapy in prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 87, 122-131.	2.0	34
119	Prostate cancer vaccines. <i>Expert Review of Vaccines</i> , 2013, 12, 253-262.	2.0	12
120	Hsp90: Still a viable target in prostate cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2013, 1835, 211-218.	3.3	32
121	Validation and clinical utility of prostate cancer biomarkers. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 225-234.	12.5	83
122	The Discovery of Novel Human Androgen Receptor Antagonist Chemotypes Using a Combined Pharmacophore Screening Procedure. <i>ChemMedChem</i> , 2013, 8, 644-651.	1.6	27

#	ARTICLE	IF	CITATIONS
123	Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 1945-1948.	1.0	46
124	Novel Therapies for the Treatment of Advanced Prostate Cancer. <i>Current Treatment Options in Oncology</i> , 2013, 14, 109-126.	1.3	18
125	Management of cancer treatment-induced bone loss. <i>Nature Reviews Rheumatology</i> , 2013, 9, 365-374.	3.5	77
126	Novel Strategies to Test Biological Hypotheses in Early Drug Development for Advanced Prostate Cancer. <i>Clinical Chemistry</i> , 2013, 59, 75-84.	1.5	11
127	Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2013, 15, 342-349.	0.8	27
128	AKR1C3 as a target in castrate resistant prostate cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2013, 137, 136-149.	1.2	117
129	Locally Advanced Prostate Cancer: Current Controversies and Optimisation Opportunities. <i>Clinical Oncology</i> , 2013, 25, 499-505.	0.6	10
130	Ex vivo culture of human prostate tissue and drug development. <i>Nature Reviews Urology</i> , 2013, 10, 483-487.	1.9	111
131	Metabolic and toxicological considerations of newly approved prostate cancer drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 835-846.	1.5	4
132	Management of Castrate Resistant Prostate Cancer—Recent Advances and Optimal Sequence of Treatments. <i>Current Urology Reports</i> , 2013, 14, 174-183.	1.0	16
133	Autophagy and Prostate Cancer Therapeutics. , 2013, , 497-518.		4
134	Commentary on: Abiraterone in Metastatic Prostate Cancer Without Previous Chemotherapy. <i>Urology</i> , 2013, 81, 1121-1122.	0.5	0
135	Minireview: Androgen Metabolism in Castration-Resistant Prostate Cancer. <i>Molecular Endocrinology</i> , 2013, 27, 708-714.	3.7	64
136	Steroidal 5 $\alpha$ -reductase and 17 $\beta$ -hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2013, 137, 199-222.	1.2	50
137	Castration-Resistant Prostate Cancer: AUA Guideline. <i>Journal of Urology</i> , 2013, 190, 429-438.	0.2	206
138	A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer. <i>Investigational New Drugs</i> , 2013, 31, 1044-1050.	1.2	14
139	Novel therapeutic approaches for the treatment of castration-resistant prostate cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2013, 138, 248-256.	1.2	36
140	Androgens and prostate cancer; pathogenesis and deprivation therapy. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2013, 27, 603-616.	2.2	71



#	ARTICLE	IF	CITATIONS
141	Abiraterone and Novel Antiandrogens: Overcoming Castration Resistance in Prostate Cancer. Annual Review of Medicine, 2013, 64, 1-13.	5.0	42
142	Trial watch. Oncolmmunology, 2013, 2, e23803.	2.1	92
143	Preoperative therapy for localized prostate cancer: A comprehensive overview. Maturitas, 2013, 74, 3-9.	1.0	5
144	Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocrine-Related Cancer, 2013, 20, R83-R99.	1.6	272
145	Radium-223 Chloride: Extending Life in Prostate Cancer Patients by Treating Bone Metastases. Clinical Cancer Research, 2013, 19, 5822-5827.	3.2	37
146	±-Emitting radium-223 additional choices, more unknowns. Nature Reviews Clinical Oncology, 2013, 10, 612-613.	12.5	1
147	Downregulation of Androgen Receptor Transcription by Promoter G-Quadruplex Stabilization as a Potential Alternative Treatment for Castrate-Resistant Prostate Cancer. Biochemistry, 2013, 52, 1429-1436.	1.2	23
148	Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. European Journal of Cancer, 2013, 49, 3648-3657.	1.3	77
149	Mechanisms of Androgen Receptor Activation in Castration-Resistant Prostate Cancer. Endocrinology, 2013, 154, 4010-4017.	1.4	68
151	AERIO News in brief. Oncologie, 2013, 15, 543-547.	0.2	2
152	The prognostic significance of loss of the androgen receptor and neuroendocrine differentiation in prostate biopsy specimens among castration-resistant prostate cancer patients. Molecular and Clinical Oncology, 2013, 1, 257-262.	0.4	39
153	Pharmacogenetics- and pharmacogenomics-based rational clinical trial designs in oncology. Personalized Medicine, 2013, 10, 859-869.	0.8	2
154	Prostate cancer vaccines: an old yet novel target, the androgen receptor. Expert Review of Vaccines, 2013, 12, 249-251.	2.0	1
155	Functional and pharmacodynamic evaluation of metronomic cyclophosphamide and docetaxel regimen in castration-resistant prostate cancer. Future Oncology, 2013, 9, 1375-1388.	1.1	15
157	Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?. British Journal of Cancer, 2013, 108, 9-13.	2.9	52
158	A Convenient Synthesis of 4-amino-2-fluoro-N-methyl-benzamide. Journal of Chemical Research, 2013, 37, 615-616.	0.6	1
159	Androgen deprivation treatment in prostate cancer. BMJ, The, 2013, 346, e8555-e8555.	3.0	13
160	Tasquinimod: a novel drug in advanced prostate cancer. Future Oncology, 2013, 9, 1271-1281.	1.1	10

#	ARTICLE	IF	CITATIONS
161	Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 1740-1747.	0.8	184
162	Clinical appraisal of abiraterone in the treatment of metastatic prostatic cancer: patient considerations, novel opportunities, and future directions. <i>OncoTargets and Therapy</i> , 2013, 6, 9.	1.0	9
163	Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, 357-367.	2.0	4
164	Biosemitic Entropy of the Genome: Mutations and Epigenetic Imbalances Resulting in Cancer. <i>Entropy</i> , 2013, 15, 234-261.	1.1	18
165	New Players for Advanced Prostate Cancer and the Rationalisation of Insulin-Sensitising Medication. <i>International Journal of Cell Biology</i> , 2013, 2013, 1-13.	1.0	30
166	Emerging Molecularly Targeted Therapies in Castration Refractory Prostate Cancer. <i>Prostate Cancer</i> , 2013, 2013, 1-12.	0.4	18
167	Experimental Evidence of Persistent Androgen-Receptor-Dependency in Castration-Resistant Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2013, 14, 15615-15635.	1.8	37
168	A Urologic Oncology Roundtable Discussion: How to Choose Among the Available Therapies for the Treatment of Castration-Resistant Prostate Cancer. <i>Postgraduate Medicine</i> , 2013, 125, 114-116.	0.9	1
169	Aberrant BAF57 Signaling Facilitates Prometastatic Phenotypes. <i>Clinical Cancer Research</i> , 2013, 19, 2657-2667.	3.2	32
171	The Androgen Receptor, Androgen Synthesis, and New Designer Antiandrogens for Metastatic Castration-Resistant Prostate Cancer. <i>American Journal of Therapeutics</i> , 2013, 20, 128-131.	0.5	1
172	The changing landscape in metastatic castration-resistant prostate cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2013, 7, 243-248.	0.5	4
173	The Changing Natural History of Metastatic Prostate Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2013, 19, 19-24.	1.0	37
174	Castrate-resistant prostate cancer. <i>Current Opinion in Urology</i> , 2013, 23, 201-207.	0.9	6
176	Potential Predictive Biomarkers for Individualizing Treatment for Men With Castration-Resistant Prostate Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2013, 19, 25-33.	1.0	13
177	Demystifying Immunotherapy in Prostate Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2013, 19, 50-58.	1.0	20
178	Androgen Receptor Antagonists in Castration-Resistant Prostate Cancer. <i>Cancer Journal (Sudbury,)</i> Tj ETQq1 1 0.784314 rgBTJ/Overlock	1.0	106
179	Lessons from in-vivo models of castration-resistant prostate cancer. <i>Current Opinion in Urology</i> , 2013, 23, 214-219.	0.9	8
180	Novel imaging techniques reshape the landscape in high-risk prostate cancers. <i>Current Opinion in Urology</i> , 2013, 23, 323-330.	0.9	19

#	ARTICLE	IF	CITATIONS
181	Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer. <i>Current Opinion in Oncology</i> , 2013, 25, 252-260.	1.1	35
182	Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. <i>Annals of Oncology</i> , 2013, 24, 2402-2408.	0.6	126
183	Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration-Resistant Prostate Cancer. <i>Oncologist</i> , 2013, 18, 163-173.	1.9	145
184	Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Men Treated With Second-Line Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1729-1737.	3.0	150
185	Long-term Survival and Biomarker Correlates of Tasquinimod Efficacy in a Multicenter Randomized Study of Men with Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 6891-6901.	3.2	49
186	Targeting inflammatory cytokines-androgen receptor (AR) signaling with ASC-J9 <sup>®</sup> to better battle prostate cancer progression. <i>Oncolmmunology</i> , 2013, 2, e26853.	2.1	19
187	Castration Therapy Results in Decreased Ku70 Levels in Prostate Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 1547-1556.	3.2	62
188	Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Previously Received Docetaxel: U.S. Food and Drug Administration Drug Approval Summary. <i>Clinical Cancer Research</i> , 2013, 19, 6067-6073.	3.2	40
189	Prevalence of Pain and Analgesic Use in Men With Metastatic Prostate Cancer Using a Patient-Reported Outcome Measure. <i>Journal of Oncology Practice</i> , 2013, 9, 223-229.	2.5	29
190	Phase II Study of Lutetium-177 <sup>®</sup> -Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 5182-5191.	3.2	370
191	Perspectives on Treatment of Metastatic Castration-Resistant Prostate Cancer. <i>Oncologist</i> , 2013, 18, 558-567.	1.9	26
192	Bazedoxifene Exhibits Antiestrogenic Activity in Animal Models of Tamoxifen-Resistant Breast Cancer: Implications for Treatment of Advanced Disease. <i>Clinical Cancer Research</i> , 2013, 19, 2420-2431.	3.2	127
193	Prostate-Specific Antigen Changes As Surrogate for Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Second-Line Chemotherapy. <i>Journal of Clinical Oncology</i> , 2013, 31, 3944-3950.	0.8	83
194	Androgen Receptor Signaling Regulates DNA Repair in Prostate Cancers. <i>Cancer Discovery</i> , 2013, 3, 1245-1253.	7.7	421
195	Heightened Optimism in the Treatment of Advanced Prostate Cancer. <i>Home Health Care Management and Practice</i> , 2013, 25, 3-5.	0.4	0
196	The diverse heterogeneity of molecular alterations in prostate cancer identified through next-generation sequencing. <i>Asian Journal of Andrology</i> , 2013, 15, 301-308.	0.8	39
197	Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2013, 24, vi106-vi114.	0.6	91
198	Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation. <i>PLoS ONE</i> , 2013, 8, e63563.	1.1	104

#	ARTICLE	IF	CITATIONS
199	Enzalutamide for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 679-685.	0.9	18
200	Next-generation therapy for residual prostate cancer. <i>Immunotherapy</i> , 2013, 5, 1235-1241.	1.0	1
201	Spongian Diterpenoids Inhibit Androgen Receptor Activity. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 621-631.	1.9	12
202	Novel chemotherapies in development for management of castration-resistant prostate cancer. <i>Current Opinion in Urology</i> , 2013, 23, 220-229.	0.9	6
203	Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer. <i>Current Opinion in Urology</i> , 2013, 23, 208-213.	0.9	8
204	Bone Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer. <i>Cancer Journal (Sudbury, MA)</i> 19:1078-1087 (2013)	1.0	27
205	Targeted $\alpha$ -Particle Therapy of Bone Metastases in Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2013, 38, 966-971.	0.7	46
206	Androgen-responsive Serum Response Factor target genes regulate prostate cancer cell migration. <i>Carcinogenesis</i> , 2013, 34, 1737-1746.	1.3	37
207	TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 17492-17497.	3.3	147
208	Rationale for Stereotactic Body Radiation Therapy in Treating Patients with Oligometastatic Hormone-Negative Prostate Cancer. <i>Frontiers in Oncology</i> , 2013, 3, 293.	1.3	20
209	CUA-CUOG Guidelines for the Management of Castration Resistant Prostate Cancer (CRPC): 2013 Update. <i>Canadian Urological Association Journal</i> , 2013, 7, 231.	0.3	15
210	Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide. <i>Clinical Medicine Insights: Oncology</i> , 2013, 7, CMO.S11670.	0.6	22
211	Emerging treatments in management of prostate cancer: biomarker validation and endpoints for immunotherapy clinical trial design. <i>ImmunoTargets and Therapy</i> , 2013, 3, 1.	2.7	4
212	Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms. <i>Prostate Cancer</i> , 2013, 2013, 1-10.	0.4	33
213	A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth <i>In Vitro</i> and <i>In Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2013, 12, 567-576.	1.9	94
214	New horizons for prostate cancer: part 2. <i>Trends in Urology &amp; Men's Health</i> , 2013, 4, 13-16.	0.2	0
215	Beyond the Ligand-Binding Pocket: Targeting Alternate Sites in Nuclear Receptors. <i>Medicinal Research Reviews</i> , 2013, 33, 1081-1118.	5.0	59
216	Fighting Prostate Cancer with Radium-223 – Not Your Madame's Isotope. <i>New England Journal of Medicine</i> , 2013, 369, 276-278.	13.9	18

#	ARTICLE	IF	CITATIONS
217	The current and future role of sequence-based analysis in prostate cancer treatment. <i>Personalized Medicine</i> , 2013, 10, 257-273.	0.8	0
218	Metastatic castrate-resistant prostate cancer: a discussion of the physical and psychosocial effects. <i>International Journal of Urological Nursing</i> , 2013, 7, 98-105.	0.1	2
219	â€œSurvivorshipâ€™™ in prostate cancer II: the need for ongoing patient support. <i>Trends in Urology &amp; Men's Health</i> , 2013, 4, 29-31.	0.2	0
220	Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. <i>Annals of Oncology</i> , 2013, 24, 1813-1821.	0.6	481
222	The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer. <i>Cancer</i> , 2013, 119, 3636-3643.	2.0	17
223	Androgen activity, ischaemic heart disease and risk factors among men in <scp>NHANES III</scp>. <i>European Journal of Clinical Investigation</i> , 2013, 43, 1273-1281.	1.7	16
224	Role of the androgen receptor in prostate cancer. <i>Trends in Urology &amp; Men's Health</i> , 2013, 4, 26-30.	0.2	0
225	Emerging drugs for prostate cancer. <i>Expert Opinion on Emerging Drugs</i> , 2013, 18, 533-550.	1.0	10
226	Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 6997-7002.	3.3	210
227	Clinical Cancer Advances 2012: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2013, 31, 131-161.	0.8	40
228	New Paradigms in Microtubule-Mediated Endocrine Signaling in Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 555-566.	1.9	20
229	Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2013, 9, 889-897.	1.1	38
230	Is there an optimal treatment sequencing strategy for metastatic castration-resistant prostate cancer?. <i>Future Oncology</i> , 2013, 9, 619-622.	1.1	2
231	First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. <i>British Journal of Cancer</i> , 2013, 109, 2579-2586.	2.9	78
232	Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer. <i>British Journal of Cancer</i> , 2013, 109, 1079-1084.	2.9	18
233	Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer. <i>British Journal of Cancer</i> , 2013, 109, 325-331.	2.9	34
234	Evidence for the efficacy of enzalutamide in postchemotherapy metastatic castrate-resistant prostate cancer. <i>Therapeutic Advances in Urology</i> , 2013, 5, 201-210.	0.9	38
235	AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function <i>In Vitro</i> and <i>In Vivo</i>. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1715-1727.	1.9	73

#	ARTICLE	IF	CITATIONS
236	Enzalutamide: A Novel Antiandrogen for Patients with Castrate-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 1335-1339.	3.2	70
237	Plasma Levels of Nitrate and Risk of Prostate Cancer: A Prospective Study Letter. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1637-1637.	1.1	0
238	Therapeutic windows and opportunity cost cast upon prostate cancer's fatal shore. <i>Annals of Oncology</i> , 2013, 24, 1717-1720.	0.6	1
239	Abiraterone acetate for the treatment of castrate-refractory prostate cancer. <i>Aging Health</i> , 2013, 9, 9-23.	0.3	0
240	Sequencing Systemic Therapies in Metastatic Castration-Resistant Prostate Cancer. <i>Cancer Control</i> , 2013, 20, 181-187.	0.7	10
241	Building on Sipuleucel-T for Immunologic Treatment of Castration-Resistant Prostate Cancer. <i>Cancer Control</i> , 2013, 20, 7-16.	0.7	18
242	Prostate-specific antigen response rate of sequential chemotherapy in castration-resistant prostate cancer: the results of real life practice. <i>Prostate International</i> , 2013, 1, 125-132.	1.2	7
243	NCCN Task Force Report: Bone Health in Cancer Care. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, S-1-S-50.	2.3	245
244	Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer. <i>Clinical Medicine Insights Urology</i> , 2013, 7, CMU.S8337.	0.4	4
245	Recent Progress in Pharmaceutical Therapies for Castration-Resistant Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2013, 14, 13958-13978.	1.8	45
246	New Developments in the Management of Prostate Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 653-657.	2.3	16
248	Potential use of custirsen to treat prostate cancer. <i>OncoTargets and Therapy</i> , 2013, 6, 785.	1.0	22
249	Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer. <i>Core Evidence</i> , 2013, 8, 27.	4.7	22
250	Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer. <i>Drug Design, Development and Therapy</i> , 2013, 7, 875.	2.0	33
251	Hormonal therapy in metastatic prostate cancer: current perspectives and controversies. <i>Oncology Reviews</i> , 2013, 7, 6.	0.8	2
252	Evaluación positiva de medicamentos: 2º Trimestre 2013. <i>Sanidad Militar</i> , 2013, 69, 206-209.	0.0	0
253	Hedgehog Signaling in Prostate Cancer and Its Therapeutic Implication. <i>International Journal of Molecular Sciences</i> , 2013, 14, 13979-14007.	1.8	95
254	New Therapeutics to Treat Castrate-Resistant Prostate Cancer. <i>Scientific World Journal</i> , The, 2013, 2013, 1-8.	0.8	22

#	ARTICLE	IF	CITATIONS
255	Overcoming mutation-based resistance to antiandrogens with rational drug design. <i>ELife</i> , 2013, 2, e00499.	2.8	334
256	Neuroendocrine Prostate Cancer. , 2014, , 2456-2463.		0
257	Glucocorticoids and prostate cancer treatment: friend or foe?. <i>Asian Journal of Andrology</i> , 2014, 16, 354.	0.8	37
258	Androgen Receptor Antagonists in the Treatment of Prostate Cancer. <i>Clinical Immunology, Endocrine and Metabolic Drugs</i> , 2014, 1, 11-19.	0.3	7
260	Inhibition of Hsp90 Augments Docetaxel Therapy in Castrate Resistant Prostate Cancer. <i>PLoS ONE</i> , 2014, 9, e103680.	1.1	11
261	Looking beyond Androgen Receptor Signaling in the Treatment of Advanced Prostate Cancer. <i>Advances in Andrology</i> , 2014, 2014, 1-9.	0.4	1
262	Prostate Cancer and Bone: The Elective Affinities. <i>BioMed Research International</i> , 2014, 2014, 1-14.	0.9	32
263	Development of cabozantinib for the treatment of prostate cancer. <i>Core Evidence</i> , 2014, 9, 61.	4.7	4
264	Antibody-drug conjugates targeting prostate-specific membrane antigen. <i>Frontiers in Bioscience - Landmark</i> , 2014, 19, 12.	3.0	18
265	Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer &ndash; role of radium-223. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 373.	0.9	8
266	Advanced prostate cancer &ndash; patient survival and potential impact of enzalutamide and other emerging therapies. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 651.	0.9	6
267	Androgen Receptor Activation in Castration-Recurrent Prostate Cancer: The Role of Src-Family and Ack1 Tyrosine Kinases. <i>International Journal of Biological Sciences</i> , 2014, 10, 620-626.	2.6	28
268	Beyond T and DHT - Novel Steroid Derivatives Capable of Wild Type Androgen Receptor Activation. <i>International Journal of Biological Sciences</i> , 2014, 10, 602-613.	2.6	33
269	Radium-223 in metastatic castration resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2014, 16, 348.	0.8	12
270	Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer. <i>Research and Reports in Urology</i> , 2014, 6, 97.	0.6	19
271	Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer. <i>OncoTargets and Therapy</i> , 2014, 7, 223.	1.0	16
272	Population-based impact on overall survival after the introduction of docetaxel as standard therapy for metastatic castration resistant prostate cancer. <i>Canadian Urological Association Journal</i> , 2014, 8, 520.	0.3	4
273	Targeting Androgen Receptor Action for Prostate Cancer Treatment: Does the Post-Receptor Level Provide Novel Opportunities?. <i>International Journal of Biological Sciences</i> , 2014, 10, 576-587.	2.6	16



#	ARTICLE	IF	CITATIONS
274	Short-term enzalutamide treatment for the potential remission of active surveillance or intermediate-risk prostate cancer: a case study, review, and the need for a clinical trial. <i>Research and Reports in Urology</i> , 2014, 6, 71.	0.6	1
275	Further analysis of PREVAIL: Enzalutamide use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2014, 16, 803.	0.8	2
276	Androgen Signaling Pathway and the Development of Novel Drugs for the Management of Castration-Resistant Prostate Cancer. <i>Journal of the Nihon University Medical Association</i> , 2014, 73, 134-139.	0.0	0
277	Building on Prostate Cancer Working Group 2 to Change the Paradigm from Palliation to Cure. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e204-e212.	1.8	2
278	PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. <i>Asian Journal of Andrology</i> , 2014, 16, 378.	0.8	217
281	High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development. <i>Cancer Research</i> , 2014, 74, 1272-1283.	0.4	304
282	BET bromodomain inhibitorsâ€”A novel epigenetic approach in castration-resistant prostate cancer. <i>Cancer Biology and Therapy</i> , 2014, 15, 1583-1585.	1.5	26
283	Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 3436-3448.	0.8	201
284	The Renaissance of CYP17 Inhibitors for the Treatment of Prostate Cancer. , 2014, , 319-356.		3
285	Pharmacotherapeutic Management of Metastatic, Castration-Resistant Prostate Cancer in the Elderly: Focus on Non-Chemotherapy Agents. <i>Drugs and Aging</i> , 2014, 31, 873-882.	1.3	13
286	Quantification of skeletal metastases in castrateâ€”resistant prostate cancer predicts progressionâ€”free and overall survival. <i>BJU International</i> , 2014, 114, E70-E73.	1.3	30
288	Trial Watch. <i>Oncolmmunology</i> , 2014, 3, e28185.	2.1	36
289	Terrestrosin D, a Steroidal Saponin from <i>Tribulus terrestris</i> L., Inhibits Growth and Angiogenesis of Human Prostate Cancer in vitro and in vivo. <i>Pathobiology</i> , 2014, 81, 123-132.	1.9	34
290	Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy. <i>Prostate Cancer and Prostatic Diseases</i> , 2014, 17, 23-27.	2.0	30
291	Phase I/II Trial of Orteronel (TAK-700)â€”an Investigational 17,20-Lyase Inhibitorâ€”in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1335-1344.	3.2	34
292	Sex Hormones and Related Compounds, Including Hormonal Contraceptives. <i>Side Effects of Drugs Annual</i> , 2014, 36, 615-634.	0.6	1
293	Steroidogenic Germline Polymorphism Predictors of Prostate Cancer Progression in the Estradiol Pathway. <i>Clinical Cancer Research</i> , 2014, 20, 2971-2983.	3.2	27
294	Contemporary pharmacotherapy for the prevention of skeletal complications in patients with prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2513-2524.	0.9	1



#	ARTICLE	IF	CITATIONS
295	Can Targeting the Androgen Receptor in Localized Prostate Cancer Provide Insights Into Why Men With Metastatic Castration-Resistant Prostate Cancer Die?. <i>Journal of Clinical Oncology</i> , 2014, 32, 3689-3691.	0.8	2
296	PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials. <i>Tumor Biology</i> , 2014, 35, 10601-10607.	0.8	23
297	No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1135-1140.	1.1	26
298	Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy. <i>Therapeutic Advances in Urology</i> , 2014, 6, 3-14.	0.9	50
299	A Phase 2 Study of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer Who Had Received Docetaxel-based Chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 1206-1215.	0.6	29
301	Progress and controversies: Radiation therapy for prostate cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2014, 64, 389-407.	157.7	44
302	Sustained Exposure to the Investigational Kisspeptin Analog, TAK-448, Down-Regulates Testosterone into the Castration Range in Healthy Males and in Patients With Prostate Cancer: Results From Two Phase 1 Studies. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E1445-E1453.	1.8	49
303	Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model. <i>Oncogene</i> , 2014, 33, 4521-4530.	2.6	168
304	Gemcitabine+oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed. <i>British Journal of Cancer</i> , 2014, 110, 2472-2478.	2.9	18
305	Androgen metabolism in prostate cancer: from molecular mechanisms to clinical consequences. <i>British Journal of Cancer</i> , 2014, 111, 1249-1254.	2.9	66
306	Inhibition of the androgen receptor by mineralocorticoids at levels physiologically achieved in serum in patients treated with abiraterone acetate. <i>Prostate Cancer and Prostatic Diseases</i> , 2014, 17, 292-299.	2.0	10
307	Novel bone-targeting agents in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2014, 17, 112-118.	2.0	3
308	Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1283-1294.	1.1	11
309	Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. <i>Cancer</i> , 2014, 120, 3346-3352.	2.0	128
310	Reply: Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer. <i>British Journal of Cancer</i> , 2014, 110, 267-268.	2.9	1
311	Advances in systemic therapies for metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2014, 10, 2213-2226.	1.1	4
312	Potential value of rapid prostate-specific antigen decline in identifying primary resistance to abiraterone acetate and enzalutamide. <i>Future Oncology</i> , 2014, 10, 985-993.	1.1	23
313	Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer. <i>Urology Annals</i> , 2014, 6, 278.	0.3	3

#	ARTICLE	IF	CITATIONS
314	Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. <i>Annals of Oncology</i> , 2014, 25, 657-662.	0.6	94
315	ECF chemotherapy for liver metastases due to castration-resistant prostate cancer. <i>Canadian Urological Association Journal</i> , 2014, 8, 353.	0.3	2
316	Bioclinical Parameters Driving Decision-Making of Subsequent Lines of Treatment in Metastatic Castration-Resistant Prostate Cancer. <i>BioMed Research International</i> , 2014, 2014, 1-7.	0.9	8
317	Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy. <i>Core Evidence</i> , 2015, 10, 1.	4.7	48
318	Exploiting Synergy: Immune-Based Combinations in the Treatment of Prostate Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 351.	1.3	15
319	Next-generation steroidogenesis inhibitors, dutasteride and abiraterone, attenuate but still do not eliminate androgen biosynthesis in 22RV1 cells in vitro. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2014, 144, 436-444.	1.2	14
320	From Bench to Bedside: Immunotherapy for Prostate Cancer. <i>BioMed Research International</i> , 2014, 2014, 1-11.	0.9	18
321	A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration resistant prostate cancer. <i>Canadian Urological Association Journal</i> , 2014, 8, 583.	0.3	7
322	PMA induces androgen receptor downregulation and cellular apoptosis in prostate cancer cells. <i>Journal of Molecular Endocrinology</i> , 2014, 53, 31-41.	1.1	12
323	Lysine-Specific Demethylase 1 Has Dual Functions as a Major Regulator of Androgen Receptor Transcriptional Activity. <i>Cell Reports</i> , 2014, 9, 1618-1627.	2.9	115
324	Predicting response to androgen receptor signalling inhibition. <i>Nature Reviews Urology</i> , 2014, 11, 433-435.	1.9	3
326	Sipuleucel-T and immunotherapy in the treatment of prostate cancer. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 709-719.	1.4	8
327	Treatment sequencing for CRPC—what do we know?. <i>Nature Reviews Urology</i> , 2014, 11, 189-190.	1.9	9
328	The potential detrimental effect of corticosteroids in prostate cancer. <i>Future Oncology</i> , 2014, 10, 325-327.	1.1	2
329	Chemotherapeutic inhibitors in the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 11-22.	0.9	4
330	Targeting the androgen receptor in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2014, 10, 329-332.	1.1	1
331	PROSTVAC <sup>®</sup> targeted immunotherapy candidate for prostate cancer. <i>Immunotherapy</i> , 2014, 6, 235-247.	1.0	7
332	Beyond abiraterone. <i>Cancer Biology and Therapy</i> , 2014, 15, 149-155.	1.5	8

#	ARTICLE	IF	CITATIONS
333	Phase I, Dose-Escalation Study of the Targeted Cytotoxic LHRH Analog AEZS-108 in Patients with Castration- and Taxane-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 6277-6283.	3.2	39
334	Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone. <i>Prostate</i> , 2014, 74, 1278-1285.	1.2	84
335	Bone Metastases in Castration-Resistant Prostate Cancer: Associations between Morphologic CT Patterns, Glycolytic Activity, and Androgen Receptor Expression on PET and Overall Survival. <i>Radiology</i> , 2014, 271, 220-229.	3.6	88
336	GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 18261-18266.	3.3	114
337	Utility of FDG-PET in clinical neuroendocrine prostate cancer. <i>Prostate</i> , 2014, 74, 1153-1159.	1.2	55
339	"Charting a new course for prostate cancer" - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1253-1256.	1.1	7
340	Castrate-resistant prostate cancer: the future of antiandrogens. <i>Trends in Urology &amp; Men's Health</i> , 2014, 5, 7-10.	0.2	0
341	Steroid Receptors Aplenty in Prostate Cancer. <i>New England Journal of Medicine</i> , 2014, 370, 970-971.	13.9	32
342	Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. <i>Cancer</i> , 2014, 120, 968-975.	2.0	121
343	Molecular pathology and prostate cancer therapeutics: from biology to bedside. <i>Journal of Pathology</i> , 2014, 232, 178-184.	2.1	34
344	No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. <i>Cancer</i> , 2014, 120, 818-823.	2.0	112
345	AERIO news in brief. <i>Oncologie</i> , 2014, 16, 458-461.	0.2	0
346	Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide. <i>Prostate</i> , 2014, 74, 1691-1696.	1.2	52
347	TGF- $\beta^2$ cascade regulation by PPP1 and its interactors - impact on prostate cancer development and therapy. <i>Journal of Cellular and Molecular Medicine</i> , 2014, 18, 555-567.	1.6	17
348	SEOM Clinical guidelines for the treatment of metastatic prostate cancer. <i>Clinical and Translational Oncology</i> , 2014, 16, 1060-1066.	1.2	11
349	Bone health in patients with prostate cancer. <i>Actas Urológicas Españolas (English Edition)</i> , 2014, 38, 685-693.	0.2	1
350	Identification of a Potent Antiandrogen that Targets the BF3 Site of the Androgen Receptor and Inhibits Enzalutamide-Resistant Prostate Cancer. <i>Chemistry and Biology</i> , 2014, 21, 1476-1485.	6.2	59
351	Looking forward, looking back - 10 years in urology. <i>Nature Reviews Urology</i> , 2014, 11, 649-655.	1.9	4

#	ARTICLE	IF	CITATIONS
352	Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, 205-215.	0.7	6
353	HES6 drives a critical $\text{AR}$ transcriptional programme to induce castration-resistant prostate cancer through activation of an $\text{E}2\text{F}$ -mediated cell cycle network. <i>EMBO Molecular Medicine</i> , 2014, 6, 651-661.	3.3	74
354	Beyond the androgen receptor: New approaches to treating metastatic prostate cancer. Report of the 2013 Prostate Cancer Meeting. <i>Prostate</i> , 2014, 74, 314-320.	1.2	14
355	The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. <i>Nature Communications</i> , 2014, 5, 5383.	5.8	522
356	Inhibition of Protein Kinase C/Twist1 Signaling Augments Anticancer Effects of Androgen Deprivation and Enzalutamide in Prostate Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 951-961.	3.2	42
357	The androgen receptor and clinical challenges. <i>Trends in Urology &amp; Men's Health</i> , 2014, 5, 39-42.	0.2	0
358	Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells. <i>Prostate</i> , 2014, 74, 201-209.	1.2	83
359	Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate. <i>Scandinavian Journal of Urology</i> , 2014, 48, 268-275.	0.6	59
360	Hyperpolarized $^{13}\text{C}$ MR for Molecular Imaging of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1567-1572.	2.8	58
361	Androgen receptor antagonists for prostate cancer therapy. <i>Endocrine-Related Cancer</i> , 2014, 21, T105-T118.	1.6	116
362	Effectiveness and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma: data on Korean patients obtained by the cabazitaxel compassionate-use program. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 1005-1013.	1.1	14
363	Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer. <i>Supportive Care in Cancer</i> , 2014, 22, 3219-3226.	1.0	12
364	Comparing Hospital-Based Resource Utilization and Costs for Prostate Cancer Patients With and Without Bone Metastases. <i>Applied Health Economics and Health Policy</i> , 2014, 12, 547-557.	1.0	15
365	Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 51-61.	1.1	1
366	Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC). <i>BMC Urology</i> , 2014, 14, 55.	0.6	27
367	PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche. <i>Journal of Translational Medicine</i> , 2014, 12, 275.	1.8	25
368	Trial watch: Dendritic cell-based anticancer therapy. <i>Oncotarget</i> , 2014, 3, e963424.	2.1	62
369	Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer. <i>Future Oncology</i> , 2014, 10, 219-231.	1.1	30

#	ARTICLE	IF	CITATIONS
370	Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel. <i>Anti-Cancer Drugs</i> , 2014, 25, 1081-1088.	0.7	12
371	Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation. <i>American Journal of Surgical Pathology</i> , 2014, 38, 756-767.	2.1	439
372	Therapeutic options and multifaceted treatment paradigms in metastatic castrate-resistant prostate cancer. <i>Current Opinion in Oncology</i> , 2014, 26, 265-273.	1.1	6
373	Testosterone and cardiovascular disease. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2014, 21, 202-208.	1.2	11
374	Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. <i>Annals of Oncology</i> , 2014, 25, 429-434.	0.6	103
375	Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1925-1934.	3.2	36
377	Mechanisms of Resistance to Intermittent Androgen Deprivation in Patients with Prostate Cancer Identified by a Novel Computational Method. <i>Cancer Research</i> , 2014, 74, 3673-3683.	0.4	46
378	Update in Systemic Therapy of Urologic Malignancies. <i>Postgraduate Medicine</i> , 2014, 126, 44-54.	0.9	6
379	Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial. <i>European Urology</i> , 2014, 66, 799-802.	0.9	56
380	Applications of ImmunoPET: Using 124I-Anti-PSCA A11 Minibody for Imaging Disease Progression and Response to Therapy in Mouse Xenograft Models of Prostate Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 6367-6378.	3.2	29
381	Molecular Mechanisms of Prostate Cancer Progression After Castration. <i>Current Clinical Urology</i> , 2014, , 31-41.	0.0	0
382	Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxelâ€”an Indirect Comparison. <i>Clinical Medicine Insights: Oncology</i> , 2014, 8, CMO.S13671.	0.6	16
383	The Evolution of Prostate Cancer Therapy: Targeting the Androgen Receptor. <i>Frontiers in Oncology</i> , 2014, 4, 295.	1.3	28
384	Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer. <i>Endocrine-Related Cancer</i> , 2014, 21, T87-T103.	1.6	127
385	Unintended Consequences of Expensive Cancer Therapeuticsâ€”The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2014, 140, 1225.	1.2	263
386	GnRH agonists and the rapidly increasing use of combined androgen blockade in prostate cancer. <i>Endocrine-Related Cancer</i> , 2014, 21, R301-R317.	1.6	36
387	The metastatic castration-resistant prostate cancer treatment paradigm: more choices, more questions. <i>Asian Journal of Andrology</i> , 2014, 16, 331.	0.8	0
388	Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer. <i>Asian Journal of Andrology</i> , 2014, 16, 401.	0.8	14

#	ARTICLE	IF	CITATIONS
389	Novel agents in the management of castration resistant prostate cancer. <i>Journal of Carcinogenesis</i> , 2014, 13, 5.	2.5	20
390	The Oncological Outcomes and Risk Stratification in Docetaxel Chemotherapy for Castration-resistant Prostate Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 860-867.	0.6	15
391	Castrate-Resistant Prostate Cancer with Peritoneal Metastases Treated with Docetaxel-Based Chemotherapy. <i>Urologia Internationalis</i> , 2014, 93, 49-54.	0.6	6
392	Enzalutamide for the treatment of prostate cancer: results and implications of the AFFIRM trial. <i>Future Oncology</i> , 2014, 10, 351-362.	1.1	7
393	Pathologic fracture in patients with metastatic prostate cancer. <i>Current Opinion in Urology</i> , 2014, 24, 595-600.	0.9	8
394	The transcriptional programme of the androgen receptor (<sc>AR</sc>) in prostate cancer. <i>BJU International</i> , 2014, 113, 358-366.	1.3	38
395	Dual PI3K/mTOR Inhibitor NVP-BEZ235 Sensitizes Docetaxel in Castration Resistant Prostate Cancer. <i>Journal of Urology</i> , 2014, 191, 227-234.	0.2	60
396	Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer. <i>European Journal of Cancer</i> , 2014, 50, 1042-1043.	1.3	0
397	The current role and limitations of surrogate endpoints in advanced prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 28.e1-28.e9.	0.8	14
398	The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2014, 66, 646-652.	0.9	126
399	Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Prostate Cancer Clinical Trials: Potential Roles and Possible Pitfalls. <i>Translational Oncology</i> , 2014, 7, 120-129.	1.7	20
400	External Validation of a Prognostic Model Predicting Overall Survival in Metastatic Castrate-resistant Prostate Cancer Patients Treated with Abiraterone. <i>European Urology</i> , 2014, 66, 8-11.	0.9	21
401	Lenalidomide Monotherapy in Chemotherapy-Naive, Castration-Resistant Prostate Cancer Patients: Final Results of a Phase II Study. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 27-32.	0.9	19
402	Visceral Disease in Castration-resistant Prostate Cancer. <i>European Urology</i> , 2014, 65, 270-273.	0.9	172
403	Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. <i>Lancet Oncology</i> , The, 2014, 15, 738-746.	5.1	433
404	Serum testosterone levels after medical or surgical androgen deprivation: A comprehensive review of the literature. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 38.e17-38.e28.	0.8	40
405	Exercise as Treatment for Androgen Deprivation Therapyâ€™Associated Physical Dysfunction: Ready for Prime Time?. <i>European Urology</i> , 2014, 65, 873-874.	0.9	4
406	Impact of Enzalutamide Administration on Primary Prostate Cancer Volume: A Metabolic Evaluation by Choline Positron Emission Tomography in Castration-Resistant Prostate Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 312-316.	0.9	21

#	ARTICLE	IF	CITATIONS
407	Toward a common therapeutic framework in castration-resistant prostate cancer: A model for urologic oncology and medical oncology interaction. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 380-382.	0.8	3
408	Health resource utilization associated with skeletal-related events in patients with bone metastases: Results from a multinational retrospective " prospective observational study " a cohort from 4 European countries. <i>Journal of Bone Oncology</i> , 2014, 3, 40-48.	1.0	40
409	Sequencing Systemic Therapies in Advanced Prostate Cancer: Spoiled for Choice But Not for Evidence. <i>European Urology</i> , 2014, 66, 466-467.	0.9	5
410	Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. <i>Oncogene</i> , 2014, 33, 2815-2825.	2.6	289
411	Castration-Resistant Prostate Cancer: From New Pathophysiology to New Treatment. <i>European Urology</i> , 2014, 65, 289-299.	0.9	113
412	Strontium-89 for prostate cancer with bone metastases: the potential of cancer control and improvement of overall survival. <i>Annals of Nuclear Medicine</i> , 2014, 28, 11-16.	1.2	23
413	AR function in promoting metastatic prostate cancer. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 399-411.	2.7	73
414	The role of epithelial plasticity in prostate cancer dissemination and treatment resistance. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 441-468.	2.7	59
415	Evidence for compliance with long-term medication: a systematic review of randomised controlled trials. <i>International Journal of Clinical Pharmacy</i> , 2014, 36, 128-135.	1.0	4
416	Bone-targeting agents in prostate cancer. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 619-628.	2.7	26
417	Novel drugs targeting the androgen receptor pathway in prostate cancer. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 567-579.	2.7	29
418	Systemic Therapy of Bone Metastases. <i>Cancer Metastasis - Biology and Treatment</i> , 2014, , 247-273.	0.1	0
419	Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. <i>European Journal of Cancer</i> , 2014, 50, 78-84.	1.3	178
420	Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and Abiraterone. <i>European Urology</i> , 2014, 65, 30-36.	0.9	248
421	Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: Results of the European compassionate-use programme. <i>European Journal of Cancer</i> , 2014, 50, 1090-1099.	1.3	88
422	Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 91, 197-209.	2.0	15
423	Enzalutamide After Docetaxel and Abiraterone Therapy in Metastatic Castration-Resistant Prostate Cancer. <i>Advances in Therapy</i> , 2014, 31, 234-241.	1.3	56
424	Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. <i>Breast Cancer Research</i> , 2014, 16, R7.	2.2	315



#	ARTICLE	IF	CITATIONS
425	Importance of Breast Cancer Subtype in the Development of Androgen-Receptor-Directed Therapy. Current Breast Cancer Reports, 2014, 6, 71-78.	0.5	13
426	Cabozantinib: a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma. Cancer Chemotherapy and Pharmacology, 2014, 73, 219-222.	1.1	10
427	AERIO News in Brief. Oncologie, 2014, 16, 69-72.	0.2	0
428	Mapping the FACT-P to the Preference-Based EQ-5D Questionnaire in Metastatic Castration-Resistant Prostate Cancer. Value in Health, 2014, 17, 238-244.	0.1	21
429	Targeting kallikrein-related peptidases in prostate cancer. Expert Opinion on Therapeutic Targets, 2014, 18, 365-383.	1.5	25
430	Broad-Spectrum Therapeutic Suppression of Metastatic Melanoma through Nuclear Hormone Receptor Activation. Cell, 2014, 156, 986-1001.	13.5	149
431	Inhibition of RSK/YB-1 signaling enhances the anti-cancer effect of enzalutamide in prostate cancer. Prostate, 2014, 74, 959-969.	1.2	19
432	Humoral response to a viral glycan correlates with survival on PROSTVAC-VF. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E1749-58.	3.3	41
433	New agents for prostate cancer. Annals of Oncology, 2014, 25, 1700-1709.	0.6	51
434	Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer. Molecular Cancer Therapeutics, 2014, 13, 1270-1284.	1.9	131
435	Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study. European Urology, 2014, 65, 1058-1066.	0.9	372
437	One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): Toward an upfront simplified all-in-one imaging approach?. Prostate, 2014, 74, 469-477.	1.2	79
438	Sex hormones and related compounds, including hormonal contraceptives. Side Effects of Drugs Annual, 2014, , 731-745.	0.6	0
439	NFI Transcription Factors Interact with FOXA1 to Regulate Prostate-Specific Gene Expression. Molecular Endocrinology, 2014, 28, 949-964.	3.7	70
440	Circulating tumour cells—monitoring treatment response in prostate cancer. Nature Reviews Clinical Oncology, 2014, 11, 401-412.	12.5	110
441	Circulating Tumor Cells in Prostate Cancer Diagnosis and Monitoring: An Appraisal of Clinical Potential. Molecular Diagnosis and Therapy, 2014, 18, 389-402.	1.6	51
442	High-risk prostate cancer—classification and therapy. Nature Reviews Clinical Oncology, 2014, 11, 308-323.	12.5	340
443	Managing bone metastases and reducing skeletal related events in prostate cancer. Nature Reviews Clinical Oncology, 2014, 11, 335-345.	12.5	110



#	ARTICLE	IF	CITATIONS
444	Response to Subsequent Docetaxel in a Patient Cohort With Metastatic Castration-Resistant Prostate Cancer After Abiraterone Acetate Treatment. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e167-e172.	0.9	32
445	Evolution of androgen receptor targeted therapy for advanced prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 365-376.	12.5	172
446	Taxane Mechanisms of Action: Potential Implications for Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2014, 65, 1198-1204.	0.9	107
447	Second-line treatment options in metastatic castration-resistant prostate cancer: A comparison of key trials with recently approved agents. <i>Cancer Treatment Reviews</i> , 2014, 40, 170-177.	3.4	39
448	Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 76-82.	0.8	148
449	Molecular alterations and emerging targets in castration resistant prostate cancer. <i>European Journal of Cancer</i> , 2014, 50, 753-764.	1.3	44
450	Beyond Sipuleucel-T: Immune Approaches to Treating Prostate Cancer. <i>Current Treatment Options in Oncology</i> , 2014, 15, 115-126.	1.3	13
451	p300 Acetyltransferase Regulates Androgen Receptor Degradation and PTEN-Deficient Prostate Tumorigenesis. <i>Cancer Research</i> , 2014, 74, 1870-1880.	0.4	80
452	Immunotherapy for prostate cancer: recent developments and future challenges. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 641-655.	2.7	53
453	Androgen receptor signaling in prostate cancer. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 413-427.	2.7	204
454	Thérapies ciblées et biomarqueurs compagnons dans les cancers de la prostate métastatiques. <i>Medicine Nucleaire</i> , 2014, 38, 31-37.	0.2	0
455	EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2014, 65, 467-479.	0.9	1,304
456	New therapeutic options in metastatic castration-resistant prostate cancer: Can cost-effectiveness analysis help in treatment decisions?. <i>Journal of Oncology Pharmacy Practice</i> , 2014, 20, 417-425.	0.5	22
457	Bone Metastases. <i>Cancer Metastasis - Biology and Treatment</i> , 2014, , .	0.1	5
458	Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 469-487.	1.9	19
459	Concept and viability of androgen annihilation for advanced prostate cancer. <i>Cancer</i> , 2014, 120, 2628-2637.	2.0	16
460	P059 Efficacy and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma: Data on Korean patients obtained by the cabazitaxel compassionate use program. <i>European Urology Supplements</i> , 2014, 13, 131.	0.1	0
461	Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 73-80.	1.1	24

#	ARTICLE	IF	CITATIONS
462	Precision medicine for prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1305-1315.	1.1	11
463	Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development. <i>Expert Opinion on Emerging Drugs</i> , 2014, 19, 459-470.	1.0	24
464	Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. <i>Lancet Oncology</i> , The, 2014, 15, 1397-1406.	5.1	351
465	Effect of docetaxel on safety and efficacy of radium-223. <i>Lancet Oncology</i> , The, 2014, 15, 1292-1293.	5.1	2
466	Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1369-1378.	1.1	30
467	Androgen biosynthesis in castration-resistant prostate cancer. <i>Endocrine-Related Cancer</i> , 2014, 21, T67-T78.	1.6	35
468	Bone-Targeting Radiopharmaceuticals for the Treatment of Bone-Metastatic Castration-Resistant Prostate Cancer: Exploring the Implications of New Data. <i>Oncologist</i> , 2014, 19, 1012-1018.	1.9	14
469	FGF23: Mediator of poor prognosis in a sizeable subgroup of patients with castration-resistant prostate cancer presenting with severe hypophosphatemia?. <i>Medical Hypotheses</i> , 2014, 83, 482-487.	0.8	19
470	KLK3, PCA3, and TMPRSS2-ERG expression in the peripheral blood mononuclear cell fraction from castration-resistant prostate cancer patients and response to docetaxel treatment. <i>Prostate</i> , 2014, 74, 1222-1230.	1.2	28
471	Personalizing prostate cancer therapy: the way forward. <i>Drug Discovery Today</i> , 2014, 19, 1483-1487.	3.2	7
472	Enzalutamide (Xtandi) for Patients With Metastatic, Resistant Prostate Cancer. <i>Annals of Pharmacotherapy</i> , 2014, 48, 530-537.	0.9	11
473	Muscle and bone effects of androgen deprivation therapy: current and emerging therapies. <i>Endocrine-Related Cancer</i> , 2014, 21, R371-R394.	1.6	50
475	Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy. <i>Oncogene</i> , 2014, 33, 5053-5064.	2.6	41
476	Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1769-1781.	1.4	4
477	Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. <i>British Journal of Cancer</i> , 2014, 111, 2248-2253.	2.9	52
478	Canonical Androstenedione Reduction Is the Predominant Source of Signaling Androgens in Hormone-Refractory Prostate Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5547-5557.	3.2	43
479	Androgen Receptor Splice Variants in the Era of Enzalutamide and Abiraterone. <i>Hormones and Cancer</i> , 2014, 5, 265-273.	4.9	102
480	Advances in Androgen Receptor Targeted Therapy for Prostate Cancer. <i>Journal of Cellular Physiology</i> , 2014, 229, 271-276.	2.0	58

#	ARTICLE	IF	CITATIONS
482	NICE guidance on enzalutamide for metastatic hormone-relapsed prostate cancer. <i>Lancet Oncology, The</i> , 2014, 15, 1058-1059.	5.1	2
483	Quantitative determination of enzalutamide, an anti-prostate cancer drug, in rat plasma using liquid chromatography-tandem mass spectrometry, and its application to a pharmacokinetic study. <i>Biomedical Chromatography</i> , 2014, 28, 1112-1117.	0.8	25
484	Emerging mechanisms of enzalutamide resistance in prostate cancer. <i>Nature Reviews Urology</i> , 2014, 11, 712-716.	1.9	107
486	The best fit for enzalutamide in metastatic prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 504-506.	12.5	3
487	Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1136-1142.	0.8	268
488	Critical Evaluation of Disease Stabilization As a Measure of Activity of Systemic Therapy: Lessons From Trials With Arms in Which Patients Do Not Receive Active Treatment. <i>Journal of Clinical Oncology</i> , 2014, 32, 260-263.	0.8	19
489	Salud 3sea en pacientes con c3ncer de pr3stata. <i>Actas Urol3gicas Espa3olas</i> , 2014, 38, 685-693.	0.3	1
490	Safety of antiandrogen therapy for treating prostate cancer. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 1483-1499.	1.0	24
491	Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval Summary. <i>Clinical Cancer Research</i> , 2014, 20, 9-14.	3.2	128
492	Enzalutamide: looking back at its preclinical discovery. <i>Expert Opinion on Drug Discovery</i> , 2014, 9, 837-845.	2.5	10
493	Real-world experience with abiraterone. <i>Lancet Oncology, The</i> , 2014, 15, 1188-1190.	5.1	0
494	New prostate cancer drugs: extending and improving life. <i>Lancet Oncology, The</i> , 2014, 15, 1052-1054.	5.1	0
495	Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance). <i>Journal of Clinical Oncology</i> , 2014, 32, 1143-1150.	0.8	217
496	Discovery of Small-Molecule Inhibitors Selectively Targeting the DNA-Binding Domain of the Human Androgen Receptor. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 6458-6467.	2.9	102
497	PIP5K11 inhibition as a therapeutic strategy for prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 12578-12579.	3.3	11
498	Management of Castration Resistant Prostate Cancer. <i>Current Clinical Urology</i> , 2014, , .	0.0	2
499	Genomic Prostate Cancer Classifier Predicts Biochemical Failure and Metastases in Patients After Postoperative Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 1038-1046.	0.4	149
500	Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. <i>Lancet Oncology, The</i> , 2014, 15, e404-e414.	5.1	196

#	ARTICLE	IF	CITATIONS
501	Androgen Receptor Expression and Outcomes in Early Breast Cancer: A Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt319-djt319.	3.0	279
502	Prostate cancer: Review in 2014. <i>Diagnostic and Interventional Imaging</i> , 2014, 95, 739-742.	1.8	8
503	Cancer de la prostate: mise au point 2014. <i>Diagnostic and Interventional Imaging</i> , 2014, 95, 725-728.	0.0	0
504	Progression-free survival as an end-point in solid tumours – Perspectives from clinical trials and clinical practice. <i>European Journal of Cancer</i> , 2014, 50, 2303-2308.	1.3	32
505	Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. <i>Lancet Oncology</i> , The, 2014, 15, 975-985.	5.1	172
506	Will new AR inhibitors reshape the prostate cancer landscape?. <i>Lancet Oncology</i> , The, 2014, 15, 912-913.	5.1	0
507	Strategies for targeting the androgen receptor axis in prostate cancer. <i>Drug Discovery Today</i> , 2014, 19, 1493-1497.	3.2	18
508	Targeting the Androgen Receptor with Steroid Conjugates. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 8224-8237.	2.9	34
509	A new dawn for gemtuzumab ozogamicin?. <i>Lancet Oncology</i> , The, 2014, 15, 913-914.	5.1	11
510	The role of transcription factors in prostate cancer and potential for future RNA interference therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 633-649.	1.5	44
511	Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. <i>Nature</i> , 2014, 510, 278-282.	13.7	811
512	Organoid Cultures Derived from Patients with Advanced Prostate Cancer. <i>Cell</i> , 2014, 159, 176-187.	13.5	1,184
513	Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. <i>Lancet Oncology</i> , The, 2014, 15, 1147-1156.	5.1	181
514	Molecular insights into the development of T cell-based immunotherapy for prostate cancer. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 1547-1557.	1.3	7
516	Drug costs in the management of metastatic castration-resistant prostate cancer in Canada. <i>BMC Health Services Research</i> , 2014, 14, 252.	0.9	31
517	Patient-reported outcome labeling claims and measurement approach for metastatic castration-resistant prostate cancer treatments in the United States and European Union. <i>Health and Quality of Life Outcomes</i> , 2014, 12, 104.	1.0	26
518	Molecular Pathways: Targeting Resistance in the Androgen Receptor for Therapeutic Benefit. <i>Clinical Cancer Research</i> , 2014, 20, 791-798.	3.2	63
519	AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 1028-1038.	13.9	2,233

#	ARTICLE	IF	CITATIONS
520	Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 671-677.	0.8	410
521	Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2014, 74, 1560-1568.	1.2	36
522	Ligand-Independent and Tissue-Selective Androgen Receptor Inhibition by Pyrvinium. <i>ACS Chemical Biology</i> , 2014, 9, 692-702.	1.6	46
523	Targeting the Androgen Receptor in Prostate Cancer – A Resilient Foe. <i>New England Journal of Medicine</i> , 2014, 371, 1067-1069.	13.9	38
524	Radium-223 dichloride for the treatment of metastatic prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2105-2111.	0.9	4
525	Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 227-235.	1.1	19
526	Trilateral retinoblastoma: a systematic review and meta-analysis. <i>Lancet Oncology</i> , The, 2014, 15, 1157-1167.	5.1	126
527	Docetaxel in Castration-Resistant Prostate Cancer: A Single-Centre Experience. <i>Cancer Investigation</i> , 2014, 32, 445-450.	0.6	0
530	The use of the EVITA algorithm for clinical assessment of novel agents used in prostate cancer, metastatic melanoma, and systemic lupus erythematosus. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 983-990.	0.8	0
531	The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy. <i>World Journal of Urology</i> , 2014, 32, 669-676.	1.2	36
532	Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 555-566.	2.7	45
533	Mouse models of prostate cancer: picking the best model for the question. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 377-397.	2.7	100
534	Emerging strategies to overcome resistance to endocrine therapy for breast cancer. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 791-807.	2.7	23
535	A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients. <i>Investigational New Drugs</i> , 2014, 32, 1005-1016.	1.2	29
536	Targeting the androgen receptor in prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1427-1437.	0.9	38
537	Metastatic castration resistant prostate cancer: Current strategies of management in the Middle East. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 90, 36-48.	2.0	3
539	Glucocorticoid Receptor Activity Contributes to Resistance to Androgen-Targeted Therapy in Prostate Cancer. <i>Hormones and Cancer</i> , 2014, 5, 72-89.	4.9	223
540	The Link Between Androgen Receptor Splice Variants and Castration-Resistant Prostate Cancer. <i>Hormones and Cancer</i> , 2014, 5, 207-217.	4.9	64

#	ARTICLE	IF	CITATIONS
541	External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer. <i>BMC Urology</i> , 2014, 14, 31.	0.6	13
542	Metastatic castrate-resistant prostate cancer with a late, complete and durable response to docetaxel chemotherapy: a case report. <i>Journal of Medical Case Reports</i> , 2014, 8, 122.	0.4	3
543	Maintaining and reprogramming genomic androgen receptor activity in prostate cancer. <i>Nature Reviews Cancer</i> , 2014, 14, 187-198.	12.8	152
544	Galeterone Prevents Androgen Receptor Binding to Chromatin and Enhances Degradation of Mutant Androgen Receptor. <i>Clinical Cancer Research</i> , 2014, 20, 4075-4085.	3.2	81
545	Prognostic and predictive value of plasma testosterone levels in patients receiving first-line chemotherapy for metastatic castrate-resistant prostate cancer. <i>British Journal of Cancer</i> , 2014, 110, 2201-2208.	2.9	19
546	Prostate Cancer in the Elderly Patient. <i>Journal of Clinical Oncology</i> , 2014, 32, 2523-2530.	0.8	40
547	Time to evolve trial design after everolimus failure. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 506-507.	12.5	53
548	Lyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancer. <i>Oncogenesis</i> , 2014, 3, e115-e115.	2.1	27
549	Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. <i>Lancet Oncology</i> , The, 2014, 15, 1263-1268.	5.1	46
550	Constitutive Activity of the Androgen Receptor. <i>Advances in Pharmacology</i> , 2014, 70, 327-366.	1.2	47
551	Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype. <i>Oncogene</i> , 2014, 33, 5666-5674.	2.6	74
552	Castration-resistant prostate cancer: latest evidence and therapeutic implications. <i>Therapeutic Advances in Medical Oncology</i> , 2014, 6, 167-179.	1.4	67
553	Efficacy and Safety of Abiraterone Acetate in an Elderly Patient Subgroup (Aged 75 and Older) with Metastatic Castration-resistant Prostate Cancer After Docetaxel-based Chemotherapy. <i>European Urology</i> , 2014, 65, 875-883.	0.9	74
554	Validation of a method for quantifying enzalutamide and its major metabolites in human plasma by LC-MS/MS. <i>Bioanalysis</i> , 2014, 6, 737-744.	0.6	30
555	Enzalutamide in Metastatic Prostate Cancer before Chemotherapy. <i>New England Journal of Medicine</i> , 2014, 371, 424-433.	13.9	2,456
556	Towards Random Sequencing or Precision Medicine in Castration-resistant Prostate Cancer?. <i>European Urology</i> , 2014, 65, 37-38.	0.9	4
557	Maximal Testosterone Suppression in Prostate Cancer—Free vs Total Testosterone. <i>Urology</i> , 2014, 83, 1217-1222.	0.5	16
558	Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy. <i>European Urology</i> , 2014, 66, 32-39.	0.9	139

#	ARTICLE	IF	CITATIONS
559	Estimating scenarios for survival time in men starting systemic therapies for castration-resistant prostate cancer: A systematic review of randomised trials. <i>European Journal of Cancer</i> , 2014, 50, 1916-1924.	1.3	32
560	Enzalutamide monotherapy in hormone-naïve prostate cancer: primary analysis of an open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2014, 15, 592-600.	5.1	73
561	Anti-androgen monotherapy for metastatic prostate cancer. <i>Lancet Oncology</i> , The, 2014, 15, 543-544.	5.1	20
562	Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents. <i>European Urology</i> , 2014, 66, 459-465.	0.9	128
563	Proper Sequencing of Treatment for Castrate Resistant Prostate Cancer. <i>Urology Practice</i> , 2014, 1, 2-6.	0.2	2
564	Determining the Optimal Treatment for Metastatic Castration-resistant Prostate Cancer: Age Should Not Be a Factor. <i>European Urology</i> , 2014, 65, 884-886.	0.9	3
565	Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302). <i>European Urology</i> , 2014, 66, 815-825.	0.9	221
566	Initial Results of a Prospective Clinical Trial Examining a Novel Rectal Obturator to Localise the Prostate and Spare the Rectum during Radical Prostate Radiotherapy. <i>Clinical Oncology</i> , 2014, 26, e3.	0.6	1
567	MP24-08 INHIBITION OF CONSTITUTIVELY ACTIVE STAT3 REVERSES ENZALUTAMIDE RESISTANCE IN LNCAP DERIVATIVE PROSTATE CANCER CELLS. <i>Journal of Urology</i> , 2014, 191, .	0.2	0
568	A C-14 labeled Pyridine polyamide localizes to a subcutaneous prostate cancer tumor. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 4371-4375.	1.4	14
569	Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 700-712.	5.1	1,280
570	Endocrine aspects of bone metastases. <i>Lancet Diabetes and Endocrinology</i> , the, 2014, 2, 500-512.	5.5	95
571	Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 31.e25-31.e33.	0.8	16
572	Prostate-specific antigen growth rate constant after first-line cytotoxic chemotherapy in metastatic castration-resistant prostate cancer: A monoinstitutional experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 42.e1-42.e5.	0.8	1
573	Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate-resistant prostate cancer. <i>European Journal of Cancer</i> , 2014, 50, 1040-1041.	1.3	22
574	miR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells. <i>Biochemical Pharmacology</i> , 2014, 87, 579-597.	2.0	83
575	Taxanes in the management of metastatic castration-resistant prostate cancer: Efficacy and management of toxicity. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 91, 248-256.	2.0	28
576	Ca <sup>v</sup> 1.3 channel L-type protein is overexpressed and modulates androgen receptor transactivation in prostate cancers <sup>11</sup> This work was partially supported by grants from DoD PCRP program (W81XWH-09-1-0455) and KUMC Valk Foundation to Dr Benyi Li, and grants from China Natural Science Foundation to Dr Benyi Li (NSFC #81172427) and Dr Jun Yang (NSFC #81101927). This project was also supported by the "Chutian Scholar" program funded by Hubei Province of China dedicated to China Three Gorges University.. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 524-536.	0.8	61



#	ARTICLE	IF	CITATIONS
577	Destruction of Full-Length Androgen Receptor by Wild-Type SPOP, but Not Prostate-Cancer-Associated Mutants. <i>Cell Reports</i> , 2014, 6, 657-669.	2.9	217
578	Role of Sorafenib in Overcoming Resistance of Chemotherapy-Failure Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 100-105.	0.9	13
579	Metronomic Oral Cyclophosphamide Chemotherapy Possibly Contributes to Stabilization of Disease in Patients With Metastatic Castration-Resistant Prostate Cancer: A Prospective Analysis of Consecutive Cases. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e197-e203.	0.9	12
580	Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel. <i>European Journal of Cancer</i> , 2014, 50, 1617-1627.	1.3	133
581	Emergence of <scp>FGFR</scp> family gene fusions as therapeutic targets in a wide spectrum of solid tumours. <i>Journal of Pathology</i> , 2014, 232, 4-15.	2.1	100
582	Prostate cancer vaccines in combination with additional treatment modalities. <i>Immunologic Research</i> , 2014, 59, 236-242.	1.3	15
583	Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 3198-3210.	3.2	294
584	Challenges of managing elderly men with prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 354-364.	12.5	20
585	Activity of Cabazitaxel After Docetaxel and Abiraterone Acetate Therapy in Patients With Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 428-432.	0.9	33
586	Mitochondrial protein cyclophilin-D-mediated programmed necrosis attributes to berberine-induced cytotoxicity in cultured prostate cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2014, 450, 697-703.	1.0	48
587	Metabolism of Human Diseases. , 2014, , .		4
588	Docetaxelâ€™carboxymethylcellulose nanoparticles display enhanced anti-tumor activity in murine models of castration-resistant prostate cancer. <i>International Journal of Pharmaceutics</i> , 2014, 471, 224-233.	2.6	35
589	Role of Immunotherapy in Castrationâ€™Resistant Prostate Cancer (<scp>CRPC</scp>). <i>BJU International</i> , 2014, 113, 367-375.	1.3	7
590	Treatment options in castration-resistant prostate cancer: Current therapies and emerging docetaxel-based regimens. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 70-79.	0.8	30
592	Prostate cancer: considering the treatment options. <i>Nursing and Residential Care</i> , 2014, 16, 548-550.	0.1	0
593	Challenges in overcoming hormonal resistance in prostate cancer. <i>Clinical Investigation</i> , 2014, 4, 153-162.	0.0	0
594	Targeting the PI3K/Akt pathway in prostate cancer: Challenges and opportunities (Review). <i>International Journal of Oncology</i> , 2014, 45, 1793-1801.	1.4	142
595	Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (Review). <i>International Journal of Oncology</i> , 2014, 45, 1337-1344.	1.4	14



#	ARTICLE	IF	CITATIONS
597	Sequential Treatment with Taxanes and Novel Anti-Androgenic Compounds in Castration-Resistant Prostate Cancer. <i>Oncology Research and Treatment</i> , 2014, 37, 492-498.	0.8	9
598	Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer. <i>Clinical Investigation</i> , 2014, 4, 935-950.	0.0	25
599	Orteronel for the treatment of prostate cancer. <i>Future Oncology</i> , 2014, 10, 803-811.	1.1	16
601	Novel anti-androgen receptor signaling agents: Understanding the mechanisms of resistance. <i>Asian Journal of Urology</i> , 2014, 1, 30-39.	0.5	1
602	New Therapeutic Options for Castration-resistant Prostate Cancer. <i>The Journal of Oncopathology</i> , 2014, 1, 23-32.	0.1	0
603	How I Treat Metastatic Prostate Cancer. <i>The Journal of Oncopathology</i> , 2014, 2, 13-26.	0.1	1
604	Unusual small bowel metastatic localization in a castration-resistant prostate cancer patient. <i>Clinical Practice (London, England)</i> , 2014, 11, 559-562.	0.1	1
605	Effects of Abiraterone Acetate on Chronic Kidney Disease in 2 Patients With Metastatic Castration-resistant Prostate Cancer. <i>Medicine (United States)</i> , 2014, 93, e163.	0.4	4
606	Weekly low-dose docetaxel is an effective treatment with fewer adverse events for metastatic castration-resistant prostate cancer in Taiwanese patients. <i>Urological Science</i> , 2015, 26, 267-270.	0.2	2
607	Tectonic-1 contributes to the growth and migration of prostate cancer cells in vitro. <i>International Journal of Molecular Medicine</i> , 2015, 36, 931-938.	1.8	11
609	Prostate cancer multidisciplinary care: improving patient outcomes. <i>Trends in Urology &amp; Men's Health</i> , 2015, 6, 18-20.	0.2	1
610	Targeting the interleukin-11 receptor $\hat{\pm}$ in metastatic prostate cancer: A first-in-man study. <i>Cancer</i> , 2015, 121, 2411-2421.	2.0	44
611	Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2015, 115, 744-752.	1.3	47
612	Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme. <i>BJU International</i> , 2015, 115, 764-771.	1.3	17
613	Renin-angiotensin system blockade: Its contribution and controversy. <i>International Journal of Urology</i> , 2015, 22, 721-730.	0.5	19
615	Exercise interventions for men with prostate cancer. <i>The Cochrane Library</i> , 0, , .	1.5	2
616	Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. <i>Scientific Reports</i> , 2015, 5, 12007.	1.6	282
617	Nelfinavir and Nelfinavir Analogs Block Site-2 Protease Cleavage to Inhibit Castration-Resistant Prostate Cancer. <i>Scientific Reports</i> , 2015, 5, 9698.	1.6	45

#	ARTICLE	IF	CITATIONS
618	Present, Emerging and Possible Future Biomarkers in Castration Resistant Prostate Cancer (CRPC). Current Cancer Drug Targets, 2015, 15, 243-255.	0.8	15
619	Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy. Experimental Hematology and Oncology, 2015, 5, 15.	2.0	10
620	Carboplatin-etoposide combination chemotherapy in metastatic castration-resistant prostate cancer: A retrospective study. Molecular and Clinical Oncology, 2015, 3, 1208-1212.	0.4	12
621	Navigating Treatment of Metastatic Castration-Resistant Prostate Cancer: Nursing Perspectives. Clinical Journal of Oncology Nursing, 2015, 19, 723-732.	0.3	6
622	Current and Emerging Therapies for Bone Metastatic Castration-Resistant Prostate Cancer. Cancer Control, 2015, 22, 109-120.	0.7	41
623	Prognostic Significance and Functional Role of CEP57 in Prostate Cancer. Translational Oncology, 2015, 8, 487-496.	1.7	9
630	Targeting molecular resistance in castration-resistant prostate cancer. BMC Medicine, 2015, 13, 206.	2.3	52
631	Persistent androgen receptor addiction in castration-resistant prostate cancer. Journal of Hematology and Oncology, 2015, 8, 128.	6.9	59
632	Ad-REIC Gene Therapy: Promising Results in a Patient with Metastatic CRPC following Chemotherapy. Clinical Medicine Insights: Oncology, 2015, 9, CMO.S23252.	0.6	27
633	Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 479-482.	0.6	26
634	Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition. Prostate, 2015, 75, 1341-1353.	1.2	87
635	Oncology service initiatives and research in regional Australia. Australian Journal of Rural Health, 2015, 23, 40-48.	0.7	17
636	High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy. International Journal of Urology, 2015, 22, 827-833.	0.5	23
637	Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate. Anti-Cancer Drugs, 2015, 26, 884-887.	0.7	4
638	Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance. Clinical Pharmacology and Therapeutics, 2015, 98, 582-589.	2.3	57
639	Targeting the relaxin hormonal pathway in prostate cancer. International Journal of Cancer, 2015, 137, 2287-2295.	2.3	18
640	Development of enzalutamide for metastatic castration-resistant prostate cancer. Annals of the New York Academy of Sciences, 2015, 1358, 13-27.	1.8	9
641	Sequences and combinations of multifaceted therapy in advanced prostate cancer. Current Opinion in Oncology, 2015, 27, 201-208.	1.1	7

#	ARTICLE	IF	CITATIONS
642	Clinical Research in Metastatic Prostate Cancer: A Focus on Impact and Value. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 17-21.	1.8	4
643	Hormones in cancer. , 0, , 24-41.		0
644	Why Chemotherapy Should be Given Early for Men with Metastatic Prostate Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e263-e269.	1.8	1
645	Radium-223 dichloride: illustrating the benefits of a multidisciplinary approach for patients with metastatic castration-resistant prostate cancer. Journal of Multidisciplinary Healthcare, 2015, 8, 279.	1.1	15
646	MicroRNAs in Prostate Cancer: Small RNAs with Big Roles. Journal of Clinical & Cellular Immunology, 2015, 06, .	1.5	0
648	Determination of the Androgen Receptor Inhibitor Enzalutamide and its Metabolites in Animal Plasma and Brain Homogenates Using LC-MS/MS and its Application to Pharmacokinetic Studies. Chromatography, 2015, 36, 115-122.	0.8	8
649	Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis. Archivio Italiano Di Urologia Andrologia, 2015, 87, 121.	0.4	8
650	Biomarkers for determination prostate cancer: implication for diagnosis and prognosis. Neoplasma, 2015, 62, 683-691.	0.7	18
651	QSAR Analysis of 3- and 4-substituted 7-hydroxycoumarins as Novel 17 $\beta$ -HSD3 Inhibitors. Chemotherapy, 2015, 04, .	0.0	0
653	Evaluation of Alpha-Therapy with Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer – the Role of Gamma Scintigraphy in Dosimetry and Pharmacokinetics. Diagnostics, 2015, 5, 358-368.	1.3	13
654	Immunotherapeutic Approaches in Prostate Cancer: Combinations and Clinical Integration. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e275-e283.	1.8	2
655	Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer – Preliminary Results of the Response Evaluation Using F-18-Fluoride PET/CT. Diagnostics, 2015, 5, 413-427.	1.3	41
656	Immune Infiltration and Prostate Cancer. Frontiers in Oncology, 2015, 5, 128.	1.3	161
657	Enzalutamide for the treatment of metastatic castration-resistant prostate cancer. Drug Design, Development and Therapy, 2015, 9, 3325.	2.0	44
658	Enzalutamide for patients with metastatic castration-resistant prostate cancer. OncoTargets and Therapy, 2015, 8, 871.	1.0	18
659	Poly (A) Binding Protein Cytoplasmic 1 Is a Novel Co-Regulator of the Androgen Receptor. PLoS ONE, 2015, 10, e0128495.	1.1	17
660	Novel Imidazopyridine Derivatives Possess Anti-Tumor Effect on Human Castration-Resistant Prostate Cancer Cells. PLoS ONE, 2015, 10, e0131811.	1.1	23
661	A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer. Cancer Management and Research, 2015, 7, 153.	0.9	7

#	ARTICLE	IF	CITATIONS
662	Maintenance Therapy Containing Metformin and/or Zylflamend for Advanced Prostate Cancer: A Case Series. <i>Case Reports in Oncological Medicine</i> , 2015, 2015, 1-5.	0.2	10
663	EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer. <i>Oncotarget</i> , 2015, 6, 3811-3824.	0.8	63
664	<i>Cancer Therapeutics.</i> , 2015, , 635-650.e1.		0
665	Continuous use of enzalutamide in a patient who developed enzalutamide-induced thrombocytopenia. <i>BMJ Case Reports</i> , 2015, 2015, bcr2015212567.	0.2	3
666	Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. <i>Nature</i> , 2015, 523, 347-351.	13.7	221
667	Integrative Clinical Genomics of Advanced Prostate Cancer. <i>Cell</i> , 2015, 161, 1215-1228.	13.5	2,660
668	A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 774-779.	0.6	8
669	Imaging of Ra-223 with a small-pixel CdTe detector. <i>Journal of Instrumentation</i> , 2015, 10, C01029-C01029.	0.5	7
670	Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2015, 1, 582.	3.4	552
671	Targeted Therapies for Prostate Cancer. <i>Cancer Investigation</i> , 2015, 33, 276-285.	0.6	7
672	Shifting paradigms in the estimation of survival for castration-resistant prostate cancer: A tertiary academic center experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 338.e1-338.e7.	0.8	32
673	Targeting the androgen receptor in prostate and breast cancer: several new agents in development. <i>Endocrine-Related Cancer</i> , 2015, 22, R87-R106.	1.6	76
674	Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Expanded access in North America. <i>Prostate</i> , 2015, 75, 836-844.	1.2	17
676	AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer – results of two parallel first-in-human phase I studies. <i>Investigational New Drugs</i> , 2015, 33, 679-690.	1.2	43
677	Pharmacokinetic Drug Interaction Studies with Enzalutamide. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1057-1069.	1.6	117
678	Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer. <i>Advances in Cancer Research</i> , 2015, 127, 123-158.	1.9	34
679	Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC). <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2015, 153, 105-113.	1.2	41
681	Hormonal Therapy in Oncology: A Primer for the Radiologist. <i>American Journal of Roentgenology</i> , 2015, 204, W620-W630.	1.0	20

#	ARTICLE	IF	CITATIONS
682	The development of abiraterone acetate for castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 289-294.	0.8	14
683	Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 4133-4142.	3.2	57
684	Sequencing of agents in castration-resistant prostate cancer. <i>Lancet Oncology</i> , The, 2015, 16, e279-e292.	5.1	141
685	Targeting bone metastases in prostate cancer: improving clinical outcome. <i>Nature Reviews Urology</i> , 2015, 12, 340-356.	1.9	87
686	Restless Legs Syndrome—An Emerging Potential Side Effect of Enzalutamide: Report of 2 Cases. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e385-e386.	0.9	5
687	Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 649-666.	1.1	6
688	Present and future of personalized medicine in adult genitourinary tumors. <i>Future Oncology</i> , 2015, 11, 1381-1388.	1.1	10
689	Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015, 4, 386-395.	1.3	14
690	Treatment of metastatic prostate cancer. <i>Trends in Urology &amp; Men's Health</i> , 2015, 6, 7-12.	0.2	5
691	Bias in progression-free survival analysis due to intermittent assessment of progression. <i>Statistics in Medicine</i> , 2015, 34, 3181-3193.	0.8	21
692	Clinical perspectives: Practical insights from clinical experience with cabazitaxel in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2015, 11, 199-207.	0.7	5
693	Disparities in Castration-Resistant Prostate Cancer Trials. <i>Journal of Clinical Oncology</i> , 2015, 33, 1101-1103.	0.8	43
694	The Negative Is Not So Negative: What Do We Learn From Trials With Orteronel?. <i>Journal of Clinical Oncology</i> , 2015, 33, 3221-3221.	0.8	3
695	Reply to K. Lu. <i>Journal of Clinical Oncology</i> , 2015, 33, 3222-3222.	0.8	0
696	Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer. <i>Journal of Translational Medicine</i> , 2015, 13, 150.	1.8	12
697	Systemic Medical Treatment in Men with Metastatic Castration-Resistant Prostate Cancer: Recommendations for Daily Routine. <i>Oncology Research and Treatment</i> , 2015, 38, 654-668.	0.8	4
698	Advances in the Treatment of Metastatic Prostate Cancer. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1719-1733.	1.4	21
699	Efficacy of degarelix in prostate cancer patients following failure on luteinizing hormone-releasing hormone agonist treatment: results from an open-label, multicentre, uncontrolled, phase II trial (CS27). <i>Therapeutic Advances in Urology</i> , 2015, 7, 105-115.	0.9	10

#	ARTICLE	IF	CITATIONS
700	Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study. <i>Urology</i> , 2015, 86, 1206-1211.	0.5	34
701	Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 701-711.	12.8	1,044
702	Contemporary Systemic Therapy for Urologic Malignancies in Geriatric Patients. <i>Clinics in Geriatric Medicine</i> , 2015, 31, 645-665.	1.0	1
703	Docetaxel in very elderly men with metastatic castration-resistant prostate cancer. <i>Prostate International</i> , 2015, 3, 42-46.	1.2	18
704	Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1971-1975.	3.3	17
705	Role of STAT3 pathway in genitourinary tumors. <i>Future Science OA</i> , 2015, 1, FSO15.	0.9	58
706	The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). <i>Journal of the National Cancer Institute</i> , 2015, 107, djv261.	3.0	53
707	Phase I/II Study of Azacitidine, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 22-31.	0.9	63
708	Clinical Decision Making in Castration-resistant Prostate Cancer According to Baseline Prostate-specific Antigen: Are We Measuring Disease Burden or Disease Biology?. <i>European Urology</i> , 2015, 67, 231-232.	0.9	3
709	Switching and withdrawing hormonal agents for castration-resistant prostate cancer. <i>Nature Reviews Urology</i> , 2015, 12, 37-47.	1.9	60
710	Selective Estrogen Receptor Alpha Agonist GTX-758 Decreases Testosterone with Reduced Side Effects of Androgen Deprivation Therapy in Men with Advanced Prostate Cancer. <i>European Urology</i> , 2015, 67, 334-341.	0.9	15
711	Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 473-485.	0.9	24
712	Re: AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer. <i>European Urology</i> , 2015, 67, 349-350.	0.9	2
713	Radium-223 dichloride: a new paradigm in the treatment of prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 339-348.	1.1	8
714	Update on systemic therapy for advance prostate cancer. <i>Current Problems in Cancer</i> , 2015, 39, 52-62.	1.0	1
715	Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. <i>European Urology</i> , 2015, 68, 147-153.	0.9	73
716	Raising the Bar for Antineoplastic Agents: How to Choose Threshold Values for Superiority Trials in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 1036-1043.	3.2	31
717	The year chemotherapy finally gets some respect!. <i>Nature Reviews Urology</i> , 2015, 12, 71-72.	1.9	4

#	ARTICLE	IF	CITATIONS
718	A Targetable GATA2-IGF2 Axis Confers Aggressiveness in Lethal Prostate Cancer. <i>Cancer Cell</i> , 2015, 27, 223-239.	7.7	128
719	Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 1571-1576.	3.3	148
720	Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study. <i>BJU International</i> , 2015, 115, 65-73.	1.3	9
721	Enzalutamide in European and North American men participating in the AFFIRM trial. <i>BJU International</i> , 2015, 115, 41-49.	1.3	13
722	Burden of Hospital Admissions and Utilization of Hospice Care in Metastatic Prostate Cancer Patients. <i>Urology</i> , 2015, 85, 343-350.	0.5	21
723	Re: 5-Year Longitudinal Follow-up after Retropubic and Transobturator Midurethral Slings. <i>European Urology</i> , 2015, 67, 348.	0.9	1
724	Implementing newer agents for the management of castrate-resistant prostate cancer: what is known and what is needed?. <i>BJU International</i> , 2015, 115, 364-372.	1.3	8
725	Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. <i>EMBO Reports</i> , 2015, 16, 280-296.	2.0	200
726	Re: Activity and Safety of ODM-201 in Patients with Progressive Metastatic Castration-resistant Prostate Cancer (ARADES): An Open-label Phase 1 Dose-escalation and Randomised Phase 2 Dose Expansion Trial. <i>European Urology</i> , 2015, 67, 348-349.	0.9	1
727	Metastatic castration-resistant prostate cancer: time for innovation. <i>Future Oncology</i> , 2015, 11, 91-106.	1.1	32
728	Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. <i>Prostate Cancer and Prostatic Diseases</i> , 2015, 18, 122-127.	2.0	78
729	Enzalutamide: A new prostate cancer targeted therapy against the androgen receptor. <i>Cancer Treatment Reviews</i> , 2015, 41, 247-253.	3.4	4
730	An update on enzalutamide in the treatment of prostate cancer. <i>Therapeutic Advances in Urology</i> , 2015, 7, 9-21.	0.9	41
731	Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5. <i>Journal of Clinical Oncology</i> , 2015, 33, 723-731.	0.8	127
732	Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 392-399.	0.9	36
733	Î³-oryzanol reduces caveolin-1 and PCGEM1 expression, markers of aggressiveness in prostate cancer cell lines. <i>Prostate</i> , 2015, 75, 783-797.	1.2	22
734	Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Oncology</i> , The, 2015, 16, 152-160.	5.1	1,100
735	New Treatment Options for Patients With Metastatic Prostate Cancer: What Is The Optimal Sequence?. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 271-279.	0.9	34



#	ARTICLE	IF	CITATIONS
736	Enzalutamide for treatment of CRPC: Rationale for sequencing and potential clinical biomarker for resistance. <i>Cancer Biology and Therapy</i> , 2015, 16, 201-203.	1.5	0
737	Predicting treatment response in castration-resistant prostate cancer: could androgen receptor variant-7 hold the key?. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 143-145.	1.1	22
738	Is there an antiandrogen withdrawal syndrome with enzalutamide?. <i>BJU International</i> , 2015, 115, 373-380.	1.3	34
739	Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents. <i>British Journal of Cancer</i> , 2015, 112, 1166-1174.	2.9	59
740	Failure of ELM-PC 5: An Ineffective Drug or an Unfit End Point?. <i>Journal of Clinical Oncology</i> , 2015, 33, 679-681.	0.8	6
741	Role of polymer-drug conjugates in organ-specific delivery systems. <i>Journal of Drug Targeting</i> , 2015, 23, 387-416.	2.1	19
742	Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223. <i>Scandinavian Journal of Urology</i> , 2015, 49, 211-217.	0.6	37
743	Sequencing of Cabazitaxel and Abiraterone Acetate After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Treatment Patterns and Clinical Outcomes in Multicenter Community-Based US Oncology Practices. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 309-318.	0.9	43
744	Long-term Safety and Antitumor Activity in the Phase 1&2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2015, 68, 795-801.	0.9	39
745	Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 749-754.	0.9	11
746	Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth. <i>Clinical Cancer Research</i> , 2015, 21, 1675-1687.	3.2	108
747	Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results. <i>Journal of Clinical Oncology</i> , 2015, 33, 1356-1363.	0.8	120
748	Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy. <i>European Urology</i> , 2015, 67, 1160-1167.	0.9	192
749	[18F]Fluoromethylcholine as a Chemotherapy Response Read-Out in Prostate Cancer Cells. <i>Molecular Imaging and Biology</i> , 2015, 17, 319-327.	1.3	10
750	Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel&prednisone in metastatic castration-resistant prostate cancer. <i>Investigational New Drugs</i> , 2015, 33, 397-408.	1.2	15
751	Systemic Therapy for the Treatment of Hormone-Sensitive Metastatic Prostate Cancer: from Intermittent Androgen Deprivation Therapy to Chemotherapy. <i>Current Urology Reports</i> , 2015, 16, 13.	1.0	4
752	Battling resistance mechanisms in antihormonal prostate cancer treatment: Novel agents and combinations. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 310-321.	0.8	27
753	Transcription factors and chromatin proteins as therapeutic targets in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1855, 183-192.	3.3	24



#	ARTICLE	IF	CITATIONS
754	Corticosteroids in the Management of Prostate Cancer: A Critical Review. <i>Current Treatment Options in Oncology</i> , 2015, 16, 6.	1.3	27
755	The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors. <i>International Journal of Cancer</i> , 2015, 136, E27-38.	2.3	87
756	Transcription of <i>Nrdp1</i> by the androgen receptor is regulated by nuclear filamin A in prostate cancer. <i>Endocrine-Related Cancer</i> , 2015, 22, 369-386.	1.6	16
757	Sequencing current therapies in the treatment of metastatic prostate cancer. <i>Cancer Treatment Reviews</i> , 2015, 41, 332-340.	3.4	38
758	Prolactin-Induced Prostate Tumorigenesis. <i>Advances in Experimental Medicine and Biology</i> , 2015, 846, 221-242.	0.8	29
759	Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. <i>Annals of Oncology</i> , 2015, 26, 1589-1604.	0.6	279
760	The 2014 CUA-CUOG Guidelines for the Management of Castration Resistant Prostate Cancer (CRPC). <i>Canadian Urological Association Journal</i> , 2015, 9, 90.	0.3	82
761	Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes. <i>Cancer Research</i> , 2015, 75, 3663-3671.	0.4	158
762	Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Pharmacokinetics</i> , 2015, 54, 989-991.	1.6	1
763	Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 439-445.	1.1	6
764	Optimal sequence of bone target drugs in metastatic prostatic cancer. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 923-929.	1.1	1
765	American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. <i>Journal of Clinical Oncology</i> , 2015, 33, 2563-2577.	0.8	783
766	Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies. <i>Journal of Urology</i> , 2015, 194, 1537-1547.	0.2	179
767	Pharmacokinetics of enzalutamide, an anti-prostate cancer drug, in rats. <i>Archives of Pharmacal Research</i> , 2015, 38, 2076-2082.	2.7	21
768	Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer. <i>European Journal of Cancer</i> , 2015, 51, 1946-1952.	1.3	63
769	Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 737-746.	13.9	2,112
770	Fully-automated synthesis of $^{16}\text{O}$ - $^{18}\text{F}$ -fluoro- $5\alpha$ -dihydrotestosterone (FDHT) on the ELIXYS radiosynthesizer. <i>Applied Radiation and Isotopes</i> , 2015, 103, 9-14.	0.7	10
771	Should docetaxel be administered earlier in prostate cancer therapy?. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 977-979.	1.1	3

#	ARTICLE	IF	CITATIONS
772	Prognostic Factors in Patients Treated with <sup>223</sup> Ra: The Role of Skeletal Tumor Burden on Baseline <sup>18</sup> F-Fluoride PET/CT in Predicting Overall Survival. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1177-1184.	2.8	111
773	Re: Enzalutamide in Metastatic Prostate Cancer Before Chemotherapy. <i>European Urology</i> , 2015, 67, 174.	0.9	2
774	Importance of cycles of chemotherapy and postdocetaxel novel therapies in metastatic castration-resistant prostate cancer. <i>Prostate International</i> , 2015, 3, 51-55.	1.2	23
775	Molecular landscape of prostate cancer: Implications for current clinical trials. <i>Cancer Treatment Reviews</i> , 2015, 41, 761-766.	3.4	53
776	Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2015, 26, v69-v77.	0.6	346
777	New advances in genitourinary cancer: evidence gathered in 2014. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 443-464.	2.7	4
778	Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease. <i>Hormones and Cancer</i> , 2015, 6, 206-213.	4.9	88
779	The use of collagen-based scaffolds to simulate prostate cancer bone metastases with potential for evaluating delivery of nanoparticulate gene therapeutics. <i>Biomaterials</i> , 2015, 66, 53-66.	5.7	90
780	Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells. <i>European Urology</i> , 2015, 68, 939-945.	0.9	223
781	Androgen deprivation of prostate cancer: Leading to a therapeutic dead end. <i>Cancer Letters</i> , 2015, 367, 12-17.	3.2	109
782	Prostate-specific antigen kinetic profiles during androgen deprivation therapy as prognostic factors in castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 203.e1-203.e9.	0.8	11
783	Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 265.e15-265.e21.	0.8	6
785	"Natural course" of disease in patients with metastatic castrate-resistant prostate cancer: Survival and prognostic factors without life-prolonging treatment. <i>Scandinavian Journal of Urology</i> , 2015, 49, 440-445.	0.6	6
786	Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer. <i>Journal of Urology</i> , 2015, 194, 1277-1284.	0.2	65
787	Treatment of mCRPC in the AR-axis-targeted therapy-resistant state. <i>Annals of Oncology</i> , 2015, 26, 2044-2056.	0.6	89
788	The third line of treatment for metastatic prostate cancer patients: Option or strategy?. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 265-271.	2.0	15
789	Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 655-663.	2.0	21
790	Androgen pathway resistance in prostate cancer and therapeutic implications. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1521-1537.	0.9	50

#	ARTICLE	IF	CITATIONS
791	Using circulating tumor cells to inform on prostate cancer biology and clinical utility. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2015, 52, 191-210.	2.7	20
793	Long-term Efficacy and Safety Results: Can Enzalutamide Challenge the Dogma of Androgen Deprivation Therapy in Hormone-naïve Prostate Cancer?. <i>European Urology</i> , 2015, 68, 802-804.	0.9	0
794	Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). <i>European Urology</i> , 2015, 67, 1028-1038.	0.9	340
795	Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1037-1048.	1.1	5
796	Early side effects and first results of radioligand therapy with <sup>177</sup> Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. <i>EJNMMI Research</i> , 2015, 5, 114.	1.1	250
797	The incidence and relative risk of cardiovascular toxicity in patients treated with new hormonal agents for castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2015, 51, 1970-1977.	1.3	31
798	Clinical Pharmacokinetic Studies of Enzalutamide. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1043-1055.	1.6	112
799	The androgen receptor for the radiation oncologist. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2015, 19, 220-227.	0.6	4
800	Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance. <i>Reports of Practical Oncology and Radiotherapy</i> , 2015, 20, 259-272.	0.3	16
801	Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 308-318.	2.0	17
803	Emerging drugs for the treatment of bone metastasis. <i>Expert Opinion on Emerging Drugs</i> , 2015, 20, 637-651.	1.0	5
804	A novel prostate cancer therapeutic strategy using icaritin-activated arylhydrocarbon-receptor to co-target androgen receptor and its splice variants. <i>Carcinogenesis</i> , 2015, 36, 757-768.	1.3	47
805	Objective Palliative Prognostic Score Among Patients With Advanced Cancer. <i>Journal of Pain and Symptom Management</i> , 2015, 49, 690-696.	0.6	29
806	Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results. <i>European Urology</i> , 2015, 68, 787-794.	0.9	37
807	A Perivesical Mass in a 79-Year-old With a Treated Adenocarcinoma of the Prostate. <i>Urology</i> , 2015, 85, 713-716.	0.5	0
808	Current role of cabozantinib in metastatic castration-resistant prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 151-156.	1.1	11
809	Enzalutamide: Development from bench to bedside. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 280-288.	0.8	36
810	The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer. <i>Chemico-Biological Interactions</i> , 2015, 234, 332-338.	1.7	57

#	ARTICLE	IF	CITATIONS
811	Integrating Bone Targeting Radiopharmaceuticals Into the Management of Patients With Castrate-Resistant Prostate Cancer With Symptomatic Bone Metastases. <i>Current Treatment Options in Oncology</i> , 2015, 16, 325.	1.3	8
812	Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 509-521.	5.1	174
813	<sup>18</sup> F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1276-1283.	3.3	83
814	Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents. <i>Supportive Care in Cancer</i> , 2015, 23, 1157-1168.	1.0	31
815	Posterior reversible encephalopathy syndrome induced by enzalutamide in a patient with castration-resistant prostate cancer. <i>Investigational New Drugs</i> , 2015, 33, 751-754.	1.2	18
816	Treatment of skeletal metastases with <sup>223</sup> Ra-chloride. <i>Clinical and Translational Imaging</i> , 2015, 3, 159-165.	1.1	1
817	Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France. <i>BMC Cancer</i> , 2015, 15, 222.	1.1	20
818	Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate-Treated Castration-Resistant Prostate Cancer Patients. <i>Clinical Cancer Research</i> , 2015, 21, 3170-3177.	3.2	57
819	Targeting the adaptive molecular landscape of castration-resistant prostate cancer. <i>EMBO Molecular Medicine</i> , 2015, 7, 878-894.	3.3	110
820	Efficacy and safety of docetaxel and prednisolone for castration-resistant prostate cancer: a multi-institutional retrospective study in Japan. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 682-687.	0.6	4
821	Systemic treatment of bone metastases in castration-resistant prostate cancer (CRPC): pre-clinical to clinical point of view. , 2015, , 637-646.		1
822	Beyond the Vascular Endothelial Growth Factor Axis: Update on Role of Imaging in Nonantiangiogenic Molecular Targeted Therapies in Oncology. <i>American Journal of Roentgenology</i> , 2015, 204, 919-932.	1.0	10
823	Current and Emerging Immunotherapies for Castration-resistant Prostate Cancer. <i>Urology</i> , 2015, 85, 976-986.	0.5	13
824	Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2315-2324.	3.2	407
825	Enzalutamide: A Review of Its Use in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. <i>Drugs and Aging</i> , 2015, 32, 243-249.	1.3	5
827	Orteronel plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. <i>Lancet Oncology</i> , The, 2015, 16, 338-348.	5.1	106
828	Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1348-1355.	0.8	343
829	Multiple Molecular Subtypes of Triple-Negative Breast Cancer Critically Rely on Androgen Receptor and Respond to Enzalutamide <i>In Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2015, 14, 769-778.	1.9	184

#	ARTICLE	IF	CITATIONS
830	Enzalutamide After Docetaxel and Abiraterone Acetate Treatment in Prostate Cancer: A Pooled Analysis of 10 Case Series. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 193-198.	0.9	22
831	Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (<sc>mCRPC</sc>). <i>BJU International</i> , 2015, 116, 17-29.	1.3	19
832	Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 809-824.	1.9	43
833	Radiotherapy for high-risk prostate cancer. <i>Nature Reviews Urology</i> , 2015, 12, 145-154.	1.9	25
834	Regulation of vascular endothelial growth factor in prostate cancer. <i>Endocrine-Related Cancer</i> , 2015, 22, R107-R123.	1.6	47
835	Targeting extra-gonadal androgens in castration-resistant prostate cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2015, 145, 157-163.	1.2	13
836	Prospective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate cancer patients. <i>Prostate Cancer and Prostatic Diseases</i> , 2015, 18, 144-148.	2.0	11
837	Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer. <i>Cancer Research</i> , 2015, 75, 1413-1422.	0.4	207
838	Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial. <i>Annals of Oncology</i> , 2015, 26, 179-185.	0.6	66
839	Novel Actions of Next-Generation Taxanes Benefit Advanced Stages of Prostate Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 795-807.	3.2	89
840	Parotid gland metastasis from prostate cancer. <i>Anti-Cancer Drugs</i> , 2015, 26, 367-370.	0.7	2
841	Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study. <i>Science Translational Medicine</i> , 2015, 7, 269ra2.	5.8	205
842	Targeting the MLL complex in castration-resistant prostate cancer. <i>Nature Medicine</i> , 2015, 21, 344-352.	15.2	165
843	<sup>223</sup> Ra and other bone-targeting radiopharmaceuticals—the translation of radiation biology into clinical practice. <i>British Journal of Radiology</i> , 2015, 88, 20140752.	1.0	17
844	Biomarker development in the context of urologic cancers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 295-301.	0.8	20
845	Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer. <i>European Urology</i> , 2015, 68, 42-50.	0.9	115
847	The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2015, 51, 2562-2569.	1.3	59
848	GLIPR1- <sup>1</sup> synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells. <i>Molecular Cancer</i> , 2015, 14, 122.	7.9	24

#	ARTICLE	IF	CITATIONS
849	Castration radiosensitizes prostate cancer tissue by impairing DNA double-strand break repair. <i>Science Translational Medicine</i> , 2015, 7, 312re11.	5.8	73
850	Plasma <i>AR</i> and abiraterone-resistant prostate cancer. <i>Science Translational Medicine</i> , 2015, 7, 312re10.	5.8	366
851	Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ER $\pm$ -positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 225-237.	1.1	45
852	Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809). <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 2469-2474.	1.4	26
853	Health-related quality of life in men with metastatic castration-resistant prostate cancer. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 941-949.	0.7	3
854	Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions. <i>Expert Review of Vaccines</i> , 2015, 14, 1529-1541.	2.0	33
855	Using routinely collected data to stratify prostate cancer patients into phases of care in the United Kingdom: implications for resource allocation and the cancer survivorship programme. <i>British Journal of Cancer</i> , 2015, 112, 1594-1602.	2.9	16
856	Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy. <i>Therapeutic Advances in Urology</i> , 2015, 7, 194-202.	0.9	29
857	U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. <i>Oncologist</i> , 2015, 20, 960-966.	1.9	32
858	Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients. <i>Future Oncology</i> , 2015, 11, 2881-2891.	1.1	12
859	Re: Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) plus Prednisone with Placebo plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer that has Progressed during or after Docetaxel-Based Therapy: ELM-PC 5. <i>Journal of Urology</i> , 2015, 194, 990-990.	0.2	2
860	Low-Dose Estramustine Phosphate and Concomitant Low-Dose Acetylsalicylic Acid in Heavily Pretreated Patients With Advanced Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 441-446.	0.9	7
861	2-weekly docetaxel: issues for clinical practice. <i>Cancer Biology and Therapy</i> , 2015, 16, 17-18.	1.5	0
862	A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). <i>Annals of Oncology</i> , 2015, 26, 1547-1573.	0.6	635
863	Assessment of anticancer-treatment outcome in patients with metastatic castration-resistant prostate cancer "going beyond PSA and imaging, a systematic literature review. <i>Annals of Oncology</i> , 2015, 26, 2221-2247.	0.6	10
864	siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 4845-4855.	3.2	60
865	High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting. <i>European Journal of Cancer</i> , 2015, 51, 2570-2577.	1.3	91
866	Therapy escape mechanisms in the malignant prostate. <i>Seminars in Cancer Biology</i> , 2015, 35, 133-144.	4.3	59



#	ARTICLE	IF	CITATIONS
867	Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer. <i>Urology</i> , 2015, 86, 852-861.	0.5	42
868	Treatment With Galeterone in an Elderly Man With Castration-Resistant Prostate Cancer: A Case Report. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e325-e328.	0.9	6
869	The role of clusterin in prostate cancer: treatment resistance and potential as a therapeutic target. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1049-1061.	1.1	21
870	ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1007-1017.	1.1	63
871	Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 498-506.	2.0	54
872	The insulin-like growth factor (IGF) axis as an anticancer target in prostate cancer. <i>Cancer Letters</i> , 2015, 367, 113-121.	3.2	46
874	Integrating Immunotherapies in Prostate Cancer. <i>Current Oncology Reports</i> , 2015, 17, 45.	1.8	3
875	Drug therapies for metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2015, 11, 2395-2403.	1.1	1
876	Dual targeting of mTORC1 and mTORC2 by INK-128 potently inhibits human prostate cancer cell growth in vitro and in vivo. <i>Tumor Biology</i> , 2015, 36, 8177-8184.	0.8	23
877	What is the Need for Prostatic Biomarkers in Prostate Cancer Management?. <i>Current Urology Reports</i> , 2015, 16, 70.	1.0	11
878	Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. <i>Cancer Treatment Reviews</i> , 2015, 41, 884-892.	3.4	141
879	YAP1 and AR interactions contribute to the switch from androgen-dependent to castration-resistant growth in prostate cancer. <i>Nature Communications</i> , 2015, 6, 8126.	5.8	90
880	Emerging agents for the therapy of advanced prostate cancer. <i>Future Oncology</i> , 2015, 11, 2775-2787.	1.1	10
881	RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. <i>Science</i> , 2015, 349, 1351-1356.	6.0	614
882	Pri sORF peptides induce selective proteasome-mediated protein processing. <i>Science</i> , 2015, 349, 1356-1358.	6.0	90
883	Gastrointestinal metastases from prostate cancer: a review of the literature. <i>Future Oncology</i> , 2015, 11, 691-702.	1.1	2
885	Complete Biochemical Response (Prostate Specific Antigen) to Sipuleucel-T in Metastatic Castrate-Resistant Prostate Cancer: A Case Report With Docetaxel Chemotherapy Administered Just Before Sipuleucel-T. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e361-e364.	0.9	1
886	Re: A Randomized Trial of Robot-assisted Laparoscopic Radical Cystectomy. <i>European Urology</i> , 2015, 67, 173-174.	0.9	1



#	ARTICLE	IF	CITATIONS
887	Palliative pelvic radiotherapy for symptomatic incurable prostate cancer – A prospective multicenter study. <i>Radiotherapy and Oncology</i> , 2015, 115, 314-320.	0.3	25
888	miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src. <i>Cancer Research</i> , 2015, 75, 5309-5317.	0.4	63
889	The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. <i>Cell Reports</i> , 2015, 12, 922-936.	2.9	216
890	Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer. <i>Current Treatment Options in Oncology</i> , 2015, 16, 57.	1.3	30
891	Predictors of castration-resistant prostate cancer after dose-escalated external beam radiotherapy. <i>Prostate</i> , 2015, 75, 175-182.	1.2	11
892	Efficacy of Enzalutamide Following Abiraterone Acetate in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Patients. <i>European Urology</i> , 2015, 67, 23-29.	0.9	142
893	Bicalutamide dose increase in castration-resistant disease. <i>Nature Reviews Urology</i> , 2015, 12, 132-133.	1.9	3
894	Targeted radionuclides for prostate cancer bone metastases. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 2-6.	0.8	0
895	The burden of skeletal-related events in patients with prostate cancer and bone metastasis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 17.e9-17.e18.	0.8	24
896	Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. <i>Medical Oncology</i> , 2015, 32, 443.	1.2	16
897	Health Technology Assessment of Cancer Drugs in Canada, the United Kingdom and Australia: Should the United States Take Notice?. <i>Applied Health Economics and Health Policy</i> , 2015, 13, 291-302.	1.0	13
898	Immunotherapy in prostate cancer: review of the current evidence. <i>Clinical and Translational Oncology</i> , 2015, 17, 339-357.	1.2	25
899	Radionuclide Therapy for Osseous Metastases in Prostate Cancer. <i>Seminars in Nuclear Medicine</i> , 2015, 45, 66-80.	2.5	21
900	Treatment of castration-resistant prostate cancer and bone metastases with radium-223 dichloride. <i>International Journal of Urological Nursing</i> , 2015, 9, 3-13.	0.1	17
902	The “Artificial” Docetaxel Space: The Evolving Treatment Paradigm of Metastatic Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2015, 67, 30-32.	0.9	3
903	Effects of luteinizing hormone receptor signaling in prostate cancer cells. <i>Prostate</i> , 2015, 75, 141-150.	1.2	14
904	Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort. <i>European Urology</i> , 2015, 67, 310-318.	0.9	35
905	Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. <i>Oncogene</i> , 2015, 34, 1745-1757.	2.6	147

#	ARTICLE	IF	CITATIONS
906	Outcomes with Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Who Have Poor Performance Status. <i>European Urology</i> , 2015, 67, 441-447.	0.9	40
907	Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies. <i>European Urology</i> , 2015, 68, 228-235.	0.9	144
908	Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2015, 67, 53-60.	0.9	205
909	A Phase II Study of GW786034 (Pazopanib) With or Without Bicalutamide in Patients With Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 124-129.	0.9	14
910	Combined blockade of testicular and locally made androgens in prostate cancer: A highly significant medical progress based upon intracrinology. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2015, 145, 144-156.	1.2	18
911	Metastatic Castration-resistant Prostate Cancer: Piling Up the Benefits of Chemotherapy. <i>European Urology</i> , 2015, 68, 236-237.	0.9	2
912	Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer. <i>Oncogene</i> , 2015, 34, 4311-4319.	2.6	122
913	Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 59-69.	1.9	85
914	Understanding the Mechanisms of Androgen Deprivation Resistance in Prostate Cancer at the Molecular Level. <i>European Urology</i> , 2015, 67, 470-479.	0.9	225
915	Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models. <i>European Urology</i> , 2015, 67, 986-990.	0.9	91
916	Simultaneous Targeting of the Akt and Androgen Receptor Pathways. <i>European Urology</i> , 2015, 67, 991-992.	0.9	0
917	Castration-Resistant Prostate Cancer: AUA Guideline Amendment. <i>Journal of Urology</i> , 2015, 193, 491-499.	0.2	134
918	Quo vadis: Advanced prostate cancer—clinical care and clinical research in the era of multiple androgen receptor-directed therapies. <i>Cancer</i> , 2015, 121, 361-371.	2.0	9
919	DNA damage response and prostate cancer: defects, regulation and therapeutic implications. <i>Oncogene</i> , 2015, 34, 2815-2822.	2.6	81
920	Androgen receptor: structure, role in prostate cancer and drug discovery. <i>Acta Pharmacologica Sinica</i> , 2015, 36, 3-23.	2.8	602
921	Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis. <i>European Urology</i> , 2015, 68, 317-324.	0.9	96
922	Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort. <i>World Journal of Urology</i> , 2015, 33, 833-839.	1.2	5
923	Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?. <i>World Journal of Urology</i> , 2015, 33, 1079-1085.	1.2	34

#	ARTICLE	IF	CITATIONS
924	Efficacy Outcomes by Baseline Prostate-specific Antigen Quartile in the AFFIRM Trial. <i>European Urology</i> , 2015, 67, 223-230.	0.9	31
925	Bone metastases in prostate cancer: pathophysiology, clinical complications, actual treatment, and future directions. , 2015, , 657-663.		1
926	Splice variants of androgen receptor and prostate cancer. <i>Oncology Reviews</i> , 2016, 10, 297.	0.8	6
927	Contemporary Management of Prostate Cancer. <i>F1000Research</i> , 2016, 5, 179.	0.8	9
928	Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions. <i>Clinical Interventions in Aging</i> , 2017, Volume 12, 19-28.	1.3	8
929	Immune checkpoint inhibitors and prostate cancer: a new frontier?. <i>Oncology Reviews</i> , 2016, 10, 293.	0.8	47
931	Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer. <i>International Journal of Biological Sciences</i> , 2016, 12, 409-426.	2.6	32
932	Reconsideration of Hormonal Therapy in the Era of Next-Generation Hormonal Therapy. , 0, , .		0
933	Dilated Cardiomyopathy after Sequential Therapy with Abiraterone and Enzalutamide. <i>Oncology &amp; Cancer Case Reports</i> , 2016, 02, .	0.1	0
934	Castration-resistant prostate cancer: current status of therapy with Radium-223 associated with anti-androgens (enzalutamide and abiraterone) - a systematic literature review. , 2016, 95, 82.	0.0	0
935	Targeted Therapy for Metastatic Prostate Cancer with Radionuclides. , 2016, , .		5
936	Radium-223 and concomitant therapies: prospects and prudence. <i>Translational Andrology and Urology</i> , 2016, 5, 968-970.	0.6	2
937	Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer. <i>Yonsei Medical Journal</i> , 2016, 57, 1070.	0.9	9
938	Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis. <i>Journal of Immunology Research</i> , 2016, 2016, 1-10.	0.9	4
939	Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2016, 10s1, CMO.Ss34534.	0.6	14
940	Galeterone for the treatment of advanced prostate cancer: the evidence to date. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 2289-2297.	2.0	43
941	Therapeutic response and side effects of repeated radioligand therapy with <sup>177</sup> Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. <i>Oncotarget</i> , 2016, 7, 12477-12488.	0.8	226
942	Next generation biomarkers in prostate cancer. <i>Frontiers in Bioscience - Landmark</i> , 2016, 21, 328-342.	3.0	14

#	ARTICLE	IF	CITATIONS
943	Contemporary agents in the management of metastatic castration-resistant prostate cancer. Canadian Urological Association Journal, 2016, 10, 414.	0.3	24
944	Androgen deprivation therapy as backbone therapy in the management of prostate cancer. OncoTargets and Therapy, 2016, Volume 9, 7263-7274.	1.0	41
945	Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 163-170.	0.5	17
946	Impact of enzalutamide on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives. Research and Reports in Urology, 2016, Volume 8, 217-224.	0.6	4
947	Effect of <math>N</math>-methyl deuteration on metabolism and pharmacokinetics of enzalutamide. Drug Design, Development and Therapy, 2016, Volume 10, 2181-2191.	2.0	27
948	Targeting the Bone Microenvironment in Metastatic Castration-Resistant Prostate Cancer. Current Drug Targets, 2016, 17, 276-289.	1.0	6
949	Cancer-Associated Fibroblasts Modify the Response of Prostate Cancer Cells to Androgen and Anti-Androgens in Three-Dimensional Spheroid Culture. International Journal of Molecular Sciences, 2016, 17, 1458.	1.8	53
950	The PREVAIL trial of enzalutamide in men with chemotherapy-naïve, metastatic castration-resistant prostate cancer: <i>Post hoc</i> analysis of Korean patients. Investigative and Clinical Urology, 2016, 57, 174.	1.0	15
951	Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer. Frontiers in Oncology, 2016, 6, 24.	1.3	20
952	A Perspective of Immunotherapy for Prostate Cancer. Cancers, 2016, 8, 64.	1.7	28
953	Advantages and Disadvantages of Bone Protective Agents in Metastatic Prostate Cancer: Lessons Learned. Dentistry Journal, 2016, 4, 28.	0.9	3
954	Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer. International Journal of Molecular Sciences, 2016, 17, 1097.	1.8	22
955	Role of the Androgen-Androgen Receptor Axis in the Treatment Resistance of Advanced Prostate Cancer: From Androgen-Dependent to Castration Resistant and Further. Journal of UOEH, 2016, 38, 129-138.	0.3	17
956	Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer. PLoS ONE, 2016, 11, e0152861.	1.1	30
957	Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer. PLoS ONE, 2016, 11, e0158952.	1.1	45
958	11-Ketotestosterone and 11-Ketodihydrotestosterone in Castration Resistant Prostate Cancer: Potent Androgens Which Can No Longer Be Ignored. PLoS ONE, 2016, 11, e0159867.	1.1	113
959	Antiandrogen Monotherapy in the Treatment of Prostate Cancer. , 2016, , 515-521.		1
960	Sipuleucel-T “ A Model for Immunotherapy Trial Development. , 2016, , 523-531.		0

#	ARTICLE	IF	CITATIONS
961	Second-Line Hormonal for Castrate-Resistant Prostate Cancer. , 2016, , 533-540.		1
962	Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival. <i>Frontiers in Pharmacology</i> , 2016, 7, 123.	1.6	35
963	Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone. <i>Frontiers in Pharmacology</i> , 2016, 7, 376.	1.6	127
964	A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer. <i>International Journal of Nanomedicine</i> , 2016, 11, 179.	3.3	10
965	Linee guida Carcinoma della Prostata - AIRO, 2016. <i>Tumori</i> , 2016, 102, S1-S79.	0.6	4
966	Detection of AR-V7 mRNA in whole blood may not predict the effectiveness of novel endocrine drugs for castration-resistant prostate cancer. <i>Research and Reports in Urology</i> , 2016, 8, 21.	0.6	33
967	Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer. <i>Oncotarget</i> , 2016, 7, 32210-32220.	0.8	87
968	Current advances in intratumoral androgen metabolism in castration-resistant prostate cancer. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2016, 23, 264-270.	1.2	1
969	Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2016, 23, 279-290.	1.2	16
970	Media Reporting of Practiceâ€Changing Clinical Trials in Oncology: A North American Perspective. <i>Oncologist</i> , 2016, 21, 269-278.	1.9	5
971	Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer. <i>Prostate</i> , 2016, 76, 325-334.	1.2	25
972	Patient-Derived Prostate Cancer: from Basic Science to the Clinic. <i>Hormones and Cancer</i> , 2016, 7, 236-240.	4.9	8
973	Use of androgen receptor signaling-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer: a call for patient-centered studies. <i>Journal of Comparative Effectiveness Research</i> , 2016, 5, 5-7.	0.6	2
974	Abiraterone acetate for metastatic castrationâ€resistant prostate cancer after docetaxel failure: A randomized, doubleâ€blind, placeboâ€controlled phase 3 bridging study. <i>International Journal of Urology</i> , 2016, 23, 404-411.	0.5	26
975	Androgen ablation elicits PP1-dependence for AR stabilization and transactivation in prostate cancer. <i>Prostate</i> , 2016, 76, 649-661.	1.2	8
976	Is computed tomography a necessary part of a metastatic evaluation for castrationâ€resistant prostate cancer? Results from <scp>the Shared Equal Access Regional Cancer Hospital Database</scp>. <i>Cancer</i> , 2016, 122, 222-229.	2.0	6
977	Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptorâ€variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer. <i>International Journal of Cancer</i> , 2016, 139, 1632-1647.	2.3	9
978	Cabazitaxel as second-line or third-line therapy in patients with metastatic castration-resistant prostate cancer. <i>Anti-Cancer Drugs</i> , 2016, 27, 695-701.	0.7	3

#	ARTICLE	IF	CITATIONS
979	Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study. <i>Prostate</i> , 2016, 76, 286-293.	1.2	30
980	Patient-reported outcomes in metastatic castration-resistant prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 643-650.	12.5	27
981	Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes. <i>BMC Cancer</i> , 2016, 16, 377.	1.1	28
982	Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells. <i>Molecular Pharmacology</i> , 2016, 90, 225-237.	1.0	18
983	Phase I Trial of Anti-PSMA Designer CAR T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2 Cell Pharmacodynamics as a Determinant of Clinical Response. <i>Prostate</i> , 2016, 76, 1257-1270.	1.2	208
984	Precision medicine for advanced prostate cancer. <i>Current Opinion in Urology</i> , 2016, 26, 231-239.	0.9	23
985	The evolving role of immunotherapy in prostate cancer. <i>Current Opinion in Oncology</i> , 2016, 28, 232-240.	1.1	10
986	Immunotherapy for genitourinary cancer. <i>Anti-Cancer Drugs</i> , 2016, 27, 585-599.	0.7	4
987	Development and Implementation of a High-Throughput High-Content Screening Assay to Identify Inhibitors of Androgen Receptor Nuclear Localization in Castration-Resistant Prostate Cancer Cells. <i>Assay and Drug Development Technologies</i> , 2016, 14, 226-239.	0.6	26
988	Neurological sequelae of cancer immunotherapies and targeted therapies. <i>Lancet Oncology</i> , The, 2016, 17, e529-e541.	5.1	71
989	The Natural History and Outcome Predictors of Metastatic Castration-resistant Prostate Cancer. <i>European Urology Focus</i> , 2016, 2, 480-487.	1.6	15
990	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. , 2016, 4, 92.		31
991	Acute Aortic Dissection Following Treatment for Castration-Resistant Prostate Cancer. <i>Oncology Nursing Forum</i> , 2016, 43, 413-416.	0.5	3
992	Estrogen receptors $\beta$ 1 and $\beta$ 2 and aromatase as independent predictors for prostate cancer outcome. <i>Scientific Reports</i> , 2016, 6, 33114.	1.6	30
993	Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer. <i>Nature Communications</i> , 2016, 7, 13122.	5.8	76
994	The Role of Testosterone in the Treatment of Castration-Resistant Prostate Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2016, 22, 330-333.	1.0	8
995	Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer. <i>Medicine (United States)</i> , 2016, 95, e4636.	0.4	6
996	Androgen Receptor and Beyond, Targeting Androgen Signaling in Castration-Resistant Prostate Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2016, 22, 326-329.	1.0	11

#	ARTICLE	IF	CITATIONS
997	Immune Therapy for Prostate Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2016, 22, 334-341.	1.0	16
998	Optimal Treatment Sequence for Metastatic Castration-resistant Prostate Cancer. <i>European Urology Focus</i> , 2016, 2, 488-498.	1.6	38
999	The Molecular Evolution of Castration-resistant Prostate Cancer. <i>European Urology Focus</i> , 2016, 2, 506-513.	1.6	41
1000	Understanding Mechanisms of Resistance in Metastatic Castration-resistant Prostate Cancer: The Role of the Androgen Receptor. <i>European Urology Focus</i> , 2016, 2, 499-505.	1.6	55
1002	Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis. <i>BMC Research Notes</i> , 2016, 9, 471.	0.6	16
1003	Mind the gap: An analysis of foregone health gains from unfunded cancer medicines in New Zealand. <i>Seminars in Oncology</i> , 2016, 43, 625-637.	0.8	13
1004	Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer. <i>Journal of Medical Economics</i> , 2016, 19, 777-784.	1.0	25
1005	Striving Toward a Cure for Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2075-2078.	0.8	6
1006	Trial Level Analysis of Prostate-Specific Antigen-Related Versus Unrelated Endpoints in Phase III Trials of First-Line and Second-Line Medical Treatments of Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 389-397.	0.9	5
1007	Targeting persistent androgen receptor signaling in castration-resistant prostate cancer. <i>Medical Oncology</i> , 2016, 33, 44.	1.2	40
1008	Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm. <i>Oncolmmunology</i> , 2016, 5, e1107698.	2.1	28
1009	Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer. <i>Radiology</i> , 2016, 280, 151-160.	3.6	51
1010	Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. <i>European Urology</i> , 2016, 70, 963-970.	0.9	104
1011	Cabazitaxel for metastatic hormone-relapsed prostate cancer treated with docetaxel. <i>Lancet Oncology, The</i> , 2016, 17, 872-873.	5.1	2
1012	Design and synthesis of peptide conjugates of phosphoramidate mustard as prodrugs activated by prostate-specific antigen. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 2697-2706.	1.4	11
1013	Diagnostic Gleason score and castration-resistant prostate cancer. <i>Annals of Oncology</i> , 2016, 27, 962-964.	0.6	4
1014	Histone Deacetylase Inhibition in Prostate Cancer Triggers miR-320a-Mediated Suppression of the Androgen Receptor. <i>Cancer Research</i> , 2016, 76, 4192-4204.	0.4	41
1015	A prospective study examining elder-relevant outcomes in older adults with prostate cancer undergoing treatment with chemotherapy or abiraterone. <i>Journal of Geriatric Oncology</i> , 2016, 7, 81-89.	0.5	24



#	ARTICLE	IF	CITATIONS
1017	Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting. <i>Prostate Cancer and Prostatic Diseases</i> , 2016, 19, 231-241.	2.0	142
1018	What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidence. <i>Therapeutic Advances in Urology</i> , 2016, 8, 272-278.	0.9	14
1019	Structures of androgen receptor bound with ligands: advancing understanding of biological functions and drug discovery. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 1267-1282.	1.5	26
1020	The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 681-696.	1.1	7
1021	Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells. <i>Cancer Research</i> , 2016, 76, 2731-2742.	0.4	79
1022	In touch with your feminine side: how oestrogen metabolism impacts prostate cancer. <i>Endocrine-Related Cancer</i> , 2016, 23, R249-R266.	1.6	16
1023	Specialty pharmacy services for patients receiving oral medications for solid tumors. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 775-796.	0.5	14
1024	Charting Recent Progress and Challenges in Metastatic Castration-resistant Prostate Cancer: Is There an Optimal Treatment Sequence?. <i>European Urology Focus</i> , 2016, 2, 426-440.	1.6	3
1025	Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate Cancer. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 255-263.	1.6	10
1026	Systematic review: does endocrine therapy prolong survival in patients with prostate cancer?. <i>Scandinavian Journal of Urology</i> , 2016, 50, 135-143.	0.6	15
1027	Anti-tumour activity of platinum compounds in advanced prostate cancer—a systematic literature review. <i>Annals of Oncology</i> , 2016, 27, 975-984.	0.6	76
1028	African American Participation in Oncology Clinical Trials—Focus on Prostate Cancer: Implications, Barriers, and Potential Solutions. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 105-116.	0.9	32
1029	Is Gleason Grade 5 Prostate Cancer Resistant to Conventional Androgen Deprivation Therapy?. <i>European Urology</i> , 2016, 69, 761-763.	0.9	7
1030	Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy. <i>BMC Urology</i> , 2016, 16, 13.	0.6	13
1031	The role of epigenetics and long noncoding RNA MIAT in neuroendocrine prostate cancer. <i>Epigenomics</i> , 2016, 8, 721-731.	1.0	94
1032	Defining and Targeting the Oncogenic Drivers of Neuroendocrine Prostate Cancer. <i>Cancer Cell</i> , 2016, 29, 431-432.	7.7	14
1033	Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors. <i>European Journal of Cancer</i> , 2016, 61, 44-51.	1.3	40
1034	Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1369-1380.	1.6	74

#	ARTICLE	IF	CITATIONS
1035	Novel Therapies in Castration-Resistant Prostate Cancer. , 2016, , 259-269.		0
1036	Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2016, 70, 599-608.	0.9	111
1037	PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges. <i>Prostate Cancer and Prostatic Diseases</i> , 2016, 19, 223-230.	2.0	121
1038	Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2016, 2, 1598.	3.4	290
1039	The Effect of Time to Castration Resistance on Outcomes With Abiraterone and Enzalutamide in Metastatic Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 381-388.	0.9	12
1040	Predictors of Chemotherapy-Induced Toxicity and Treatment Outcomes in Elderly Versus Younger Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e559-e568.	0.9	14
1041	Value of treatment in clinical trials versus the real world: the case of abiraterone acetate (Zytiga) for postchemotherapy metastatic castration-resistant prostate cancer patients in Sweden. <i>Scandinavian Journal of Urology</i> , 2016, 50, 286-291.	0.6	13
1043	Radium-223 outcomes after multiple lines of metastatic castration-resistant prostate cancer therapy in clinical practice: implication of pre-treatment spinal epidural disease. <i>Prostate Cancer and Prostatic Diseases</i> , 2016, 19, 271-276.	2.0	3
1044	Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials. <i>European Journal of Cancer</i> , 2016, 61, 111-121.	1.3	51
1045	AICAR induces AMPK-independent programmed necrosis in prostate cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2016, 474, 277-283.	1.0	29
1046	Treatment of Metastatic Prostate Cancer in Older Adults. <i>Current Oncology Reports</i> , 2016, 18, 63.	1.8	6
1047	Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2016, 19, 398-405.	2.0	12
1048	Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer. <i>Asian Journal of Urology</i> , 2016, 3, 185-194.	0.5	20
1049	Immune phenotypes of prostate cancer cells: Evidence of epithelial immune cell-like transition?. <i>Asian Journal of Urology</i> , 2016, 3, 195-202.	0.5	12
1050	Non-invasive actionable biomarkers for metastatic prostate cancer. <i>Asian Journal of Urology</i> , 2016, 3, 170-176.	0.5	8
1051	Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer. <i>Oncology</i> , 2016, 91, 267-273.	0.9	10
1052	Therapeutic management of bone metastasis in prostate cancer: an update. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 1199-1211.	1.1	9
1053	Prostate cancer perspectives after chaarted: Optimizing treatment sequence. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 107, 119-127.	2.0	6

#	ARTICLE	IF	CITATIONS
1054	PARP inhibitors and stratified treatment of prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 1213-1215.	1.1	6
1055	PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013. <i>Journal of Nuclear Medicine</i> , 2016, 57, 975-1045.	2.8	158
1056	Achieving resistance specificity in prostate cancer. <i>Chemico-Biological Interactions</i> , 2016, 260, 243-247.	1.7	4
1057	Feasibility of classical secondary hormonal therapies prior to docetaxel therapy in Japanese patients with castration-resistant prostate cancer: Multicenter retrospective study. <i>Prostate International</i> , 2016, 4, 140-144.	1.2	0
1058	Impact of intense systemic therapy and improved survival on the use of palliative radiotherapy in patients with bone metastases from prostate cancer. <i>Oncology Letters</i> , 2016, 12, 2930-2935.	0.8	10
1059	Understanding the role of new systemic agents in the treatment of prostate cancer. <i>BJU International</i> , 2016, 118, 8-13.	1.3	15
1060	UGT2B17 Expedites Progression of Castration-Resistant Prostate Cancers by Promoting Ligand-Independent AR Signaling. <i>Cancer Research</i> , 2016, 76, 6701-6711.	0.4	37
1061	Factors predicting efficacy and adverse effects of enzalutamide in Japanese patients with castration-resistant prostate cancer: results of retrospective multi-institutional study. <i>International Journal of Clinical Oncology</i> , 2016, 21, 1155-1161.	1.0	21
1062	Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer. <i>Cell</i> , 2016, 166, 1041-1054.	13.5	206
1063	Multivalent Peptoid Conjugates Which Overcome Enzalutamide Resistance in Prostate Cancer Cells. <i>Cancer Research</i> , 2016, 76, 5124-5132.	0.4	19
1064	Enzalutamide Reduces the Bone Mass in the Axial But Not the Appendicular Skeleton in Male Mice. <i>Endocrinology</i> , 2016, 157, 969-977.	1.4	20
1065	Cancer treatment and survivorship statistics, 2016. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 271-289.	157.7	4,123
1066	Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic. <i>International Journal of Urology</i> , 2016, 23, 654-665.	0.5	65
1067	Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. <i>Lancet Oncology</i> , The, 2016, 17, 1306-1316.	5.1	259
1068	Utility of novel androgen receptor therapies in the real world: A nuanced approach. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 340-347.	0.8	2
1069	Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11). <i>Prostate</i> , 2016, 76, 1519-1527.	1.2	16
1070	Systems Pharmacology Modeling of Prostate-Specific Antigen in Patients With Prostate Cancer Treated With an Androgen Receptor Antagonist and Down-Regulator. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2016, 5, 258-263.	1.3	3
1071	Patient-reported outcome measures in metastatic prostate cancer. <i>Trends in Urology &amp; Men's Health</i> , 2016, 7, 28-32.	0.2	9

#	ARTICLE	IF	CITATIONS
1072	Enzalutamide in Japanese patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer: A post-hoc analysis of the placebo-controlled PREVAIL trial. <i>International Journal of Urology</i> , 2016, 23, 395-403.	0.5	23
1073	Smart Materials for Controlled Drug Release. , 2016, , 98-135.		0
1074	Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation. <i>Prostate</i> , 2016, 76, 32-40.	1.2	13
1075	Chemotherapy following radium-223 dichloride treatment in ALSYMPCA. <i>Prostate</i> , 2016, 76, 905-916.	1.2	58
1076	Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2016, 117, 215-225.	1.3	94
1077	Novel agents for castration-resistant prostate cancer: Early experience and beyond. <i>International Journal of Urology</i> , 2016, 23, 114-121.	0.5	31
1078	Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer. <i>International Journal of Urology</i> , 2016, 23, 360-369.	0.5	62
1079	Uncontrolled diabetes predicts poor response to novel antiandrogens. <i>Endocrine-Related Cancer</i> , 2016, 23, 691-698.	1.6	14
1080	HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. <i>Lancet Oncology</i> , The, 2016, 17, 1435-1444.	5.1	107
1081	Sintokamide A Is a Novel Antagonist of Androgen Receptor That Uniquely Binds Activation Function-1 in Its Amino-terminal Domain. <i>Journal of Biological Chemistry</i> , 2016, 291, 22231-22243.	1.6	47
1082	Prescribing Patterns of Oral Antineoplastic Therapies Observed in the Treatment of Patients With Advanced Prostate Cancer Between 2012 and 2014: Results of an Oncology EMR Analysis. <i>Clinical Therapeutics</i> , 2016, 38, 1817-1824.	1.1	14
1083	Highlights in Genitourinary (Prostate) Cancer. <i>JAMA Oncology</i> , 2016, 2, 1257.	3.4	0
1084	The safety and efficacy of radium-223 dichloride for the treatment of advanced prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 911-918.	1.1	16
1085	Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients. <i>Investigational New Drugs</i> , 2016, 34, 760-770.	1.2	29
1086	Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 106, 14-24.	2.0	10
1087	Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. <i>Endocrine-Related Cancer</i> , 2016, 23, T179-T197.	1.6	132
1088	Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer. <i>Oncologist</i> , 2016, 21, 1427-1435.	1.9	60
1089	Presurgical window of opportunity trial design as a platform for testing anticancer drugs: Pros, cons and a focus on breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 106, 132-142.	2.0	9

#	ARTICLE	IF	CITATIONS
1090	Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 617-623.	0.4	12
1091	Personalized treatment of prostate cancer: better knowledge of the patient, the disease and the medicine. <i>Future Oncology</i> , 2016, 12, 2359-2361.	1.1	4
1092	Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer. <i>Targeted Oncology</i> , 2016, 11, 569-577.	1.7	15
1093	Drug discovery in advanced prostate cancer: translating biology into therapy. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 699-718.	21.5	111
1094	MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2155-2165.	1.9	58
1095	Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. <i>Journal of Clinical Oncology</i> , 2016, 34, 3005-3013.	0.8	202
1096	Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide. <i>Prostate</i> , 2016, 76, 1484-1490.	1.2	29
1097	Emerging data on androgen receptor splice variants in prostate cancer. <i>Endocrine-Related Cancer</i> , 2016, 23, T199-T210.	1.6	47
1098	The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. <i>ESMO Open</i> , 2016, 1, e000066.	2.0	17
1099	Sequencing Treatment for Castration-Resistant Prostate Cancer. <i>Current Treatment Options in Oncology</i> , 2016, 17, 64.	1.3	29
1100	Cancer Drug Discovery. , 2016, , .		6
1101	Dysregulation of miRNAs-COUP-TFII-FOXM1-CENPF axis contributes to the metastasis of prostate cancer. <i>Nature Communications</i> , 2016, 7, 11418.	5.8	83
1102	Therapy Update for Metastatic Castration-Resistant Prostate Cancer. <i>The Consultant Pharmacist</i> , 2016, 31, 581-592.	0.4	0
1103	Androgen Receptor Tumor Suppressor Function Is Mediated by Recruitment of Retinoblastoma Protein. <i>Cell Reports</i> , 2016, 17, 966-976.	2.9	66
1104	Antiproliferative Effect of Androgen Receptor Inhibition in Mesenchymal Stem-Like Triple-Negative Breast Cancer. <i>Cellular Physiology and Biochemistry</i> , 2016, 38, 1003-1014.	1.1	54
1105	Cheminformatics Modeling of Adverse Drug Responses by Clinically Relevant Mutants of Human Androgen Receptor. <i>Journal of Chemical Information and Modeling</i> , 2016, 56, 2507-2516.	2.5	16
1106	Advances in the management of castration resistant prostate cancer. <i>BMJ, The</i> , 2016, 355, i4405.	3.0	71
1107	New Drugs in the Treatment of Elderly Patients with Metastatic Castration-Resistance Prostate Cancer. <i>Tumori</i> , 2016, 102, 361-366.	0.6	1

#	ARTICLE	IF	CITATIONS
1108	Management of Patients with Castration-Resistant Prostate Cancer (CRPC): Results of an Italian Survey Using the Delphi Method. <i>Tumori</i> , 2016, 102, 514-520.	0.6	2
1109	Nurse-led clinic for men receiving targeted therapies for metastatic hormone-relapsed prostate cancer. <i>Cancer Nursing Practice</i> , 2016, 15, 32-36.	0.2	0
1110	Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2016, 10s1, CMO.S34535.	0.6	34
1111	Gleason score and the risk of cause-specific and all-cause mortality following radiation with or without 6 months of androgen deprivation therapy for men with unfavorable-risk prostate cancer. <i>Journal of Radiation Oncology</i> , 2016, 5, 301-308.	0.7	0
1112	Successful Treatment of Hepatic Metastases of Hormone Refractory Prostate Cancer Using Radioligand Therapy With <sup>177</sup> Lu-PSMA-617. <i>Clinical Nuclear Medicine</i> , 2016, 41, 894-895.	0.7	5
1113	The evolving role of chemotherapy in prostate cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2016, 10, 262-265.	0.5	1
1114	Radioligand Therapy With <sup>177</sup> Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2016, 41, 522-528.	0.7	153
1115	Nanotherapy silencing the interleukin-8 gene produces regression of prostate cancer by inhibition of angiogenesis. <i>Immunology</i> , 2016, 148, 387-406.	2.0	24
1116	An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer. <i>Advances in Therapy</i> , 2016, 33, 1072-1093.	1.3	40
1117	Carnosic acid promotes degradation of the androgen receptor and is regulated by the unfolded protein response pathway <i>in vitro</i> and <i>in vivo</i> . <i>Carcinogenesis</i> , 2016, 37, 827-838.	1.3	13
1119	Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: "Game Over"? <i>Targeted Oncology</i> , 2016, 11, 431-446.	1.7	7
1120	Targeting Oct1 genomic function inhibits androgen receptor signaling and castration-resistant prostate cancer growth. <i>Oncogene</i> , 2016, 35, 6350-6358.	2.6	41
1121	Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. <i>Journal of Clinical Oncology</i> , 2016, 34, 2925-2934.	0.8	538
1122	PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 7124-7129.	3.3	627
1123	Hyperthermic Oncology from Bench to Bedside. , 2016, , .		5
1124	Is there room for chemotherapy in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) in the era of targeted hormone therapy?. <i>Memo - Magazine of European Medical Oncology</i> , 2016, 9, 93-95.	0.3	0
1125	Metabolic syndrome in prostate cancer: impact on risk and outcomes. <i>Future Oncology</i> , 2016, 12, 1947-1955.	1.1	6
1126	A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer. <i>Cancer Treatment Reviews</i> , 2016, 48, 25-33.	3.4	22



#	ARTICLE	IF	CITATIONS
1127	Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study. <i>European Urology</i> , 2016, 69, 834-840.	0.9	49
1128	Translational and clinical implications of the genetic landscape of prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 597-610.	12.5	63
1129	Co-targeting hexokinase 2-mediated Warburg effect and ULK1-dependent autophagy suppresses tumor growth of PTEN- and TP53- deficiency-driven castration-resistant prostate cancer. <i>EBioMedicine</i> , 2016, 7, 50-61.	2.7	56
1130	Activation of P-TEFb by Androgen Receptor-Regulated Enhancer RNAs in Castration-Resistant Prostate Cancer. <i>Cell Reports</i> , 2016, 15, 599-610.	2.9	101
1131	RECIST 1.1 – Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. <i>European Journal of Cancer</i> , 2016, 62, 138-145.	1.3	211
1132	The Effects of Enzalutamide Monotherapy on Multiparametric 3T MR Imaging in Prostate Cancer. <i>Urology Case Reports</i> , 2016, 7, 67-69.	0.1	2
1133	Implementation of the AUA Castration Resistant Prostate Cancer Guidelines into Practice: Establishing a Multidisciplinary Clinic. <i>Urology Practice</i> , 2016, 3, 203-209.	0.2	4
1134	Targeting intratumoral androgens: statins and beyond. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 388-395.	1.4	7
1135	Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer. <i>BMC Cancer</i> , 2016, 16, 214.	1.1	35
1136	Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics. <i>BMC Medicine</i> , 2016, 14, 67.	2.3	53
1137	Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide. <i>EJNMMI Research</i> , 2016, 6, 23.	1.1	37
1138	Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2636-2643.	0.8	77
1139	Low-dose docetaxel, estramustine and prednisolone combination chemotherapy for castration-resistant prostate cancer. <i>Molecular and Clinical Oncology</i> , 2016, 4, 942-946.	0.4	10
1140	Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer. <i>European Urology</i> , 2016, 70, 985-992.	0.9	119
1141	The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1702-1712.	1.9	73
1142	Targeting fatty acid synthase with ASC-J9 suppresses proliferation and invasion of prostate cancer cells. <i>Molecular Carcinogenesis</i> , 2016, 55, 2278-2290.	1.3	39
1143	The STEAP1<sub>262</sub> peptide encapsulated into PLGA microspheres elicits strong cytotoxic T cell immunity in HLA-A*0201 transgenic mice – A new approach to immunotherapy against prostate carcinoma. <i>Prostate</i> , 2016, 76, 456-468.	1.2	15
1144	Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies. <i>Prostate</i> , 2016, 76, 512-520.	1.2	19



#	ARTICLE	IF	CITATIONS
1145	“First, do no harm”™: managing the metabolic impacts of androgen deprivation in men with advanced prostate cancer. <i>Internal Medicine Journal</i> , 2016, 46, 141-148.	0.5	10
1146	Androgen-induced Long Noncoding RNA (lncRNA) SOCS2-AS1 Promotes Cell Growth and Inhibits Apoptosis in Prostate Cancer Cells. <i>Journal of Biological Chemistry</i> , 2016, 291, 17861-17880.	1.6	122
1147	Cholesterol Sulfonation Enzyme, SULT2B1b, Modulates AR and Cell Growth Properties in Prostate Cancer. <i>Molecular Cancer Research</i> , 2016, 14, 776-786.	1.5	24
1149	Translating Clinical Evidence-Based Medicine into the Real World: Single-Center Experience with Cabazitaxel in Metastatic Prostate Cancer Patients. <i>Chemotherapy</i> , 2016, 61, 127-133.	0.8	8
1150	Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer. <i>Neoplasia</i> , 2016, 18, 1-9.	2.3	25
1151	Hormonal therapy for cancer. <i>Medicine</i> , 2016, 44, 30-33.	0.2	21
1152	Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. <i>Future Oncology</i> , 2016, 12, 493-502.	1.1	8
1153	Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 2098-2106.	0.8	264
1154	Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. <i>Lancet Oncology</i> , The, 2016, 17, 153-163.	5.1	210
1155	Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both. <i>JAMA Oncology</i> , 2016, 2, 493.	3.4	78
1156	A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer. <i>International Journal of Clinical Oncology</i> , 2016, 21, 773-782.	1.0	10
1158	BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer. <i>Molecular Cancer Research</i> , 2016, 14, 324-331.	1.5	137
1159	Role of corticosteroids in prostate cancer progression: implications for treatment strategy in metastatic castration-resistant patients. <i>Journal of Endocrinological Investigation</i> , 2016, 39, 729-738.	1.8	7
1160	Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells. <i>Onc Immunology</i> , 2016, 5, e1105431.	2.1	11
1161	Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 1-12.	1.6	5
1162	Immunotherapy in prostate cancer: challenges and opportunities. <i>Immunotherapy</i> , 2016, 8, 69-77.	1.0	14
1163	Association of <i>SLCO2B1</i> Genotypes With Time to Progression and Overall Survival in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 352-359.	0.8	35
1164	Multinucleation and Mesenchymal-to-Epithelial Transition Alleviate Resistance to Combined Cabazitaxel and Antiandrogen Therapy in Advanced Prostate Cancer. <i>Cancer Research</i> , 2016, 76, 912-926.	0.4	71

#	ARTICLE	IF	CITATIONS
1165	Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy. <i>Nature Reviews Urology</i> , 2016, 13, 47-60.	1.9	65
1166	HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer. <i>Oncogene</i> , 2016, 35, 3781-3795.	2.6	128
1167	Chemotherapy for metastatic castrate-sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2016, 19, 139-144.	2.0	16
1168	The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2016, 70, 675-683.	0.9	70
1169	Targeting metastasis. <i>Nature Reviews Cancer</i> , 2016, 16, 201-218.	12.8	1,111
1170	Multifaceted and personalized therapy of advanced prostate cancer. <i>Current Opinion in Oncology</i> , 2016, 28, 222-231.	1.1	5
1171	Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data. <i>Cancer Medicine</i> , 2016, 5, 182-191.	1.3	55
1172	Metastatic phenotype in CWR22 prostate cancer xenograft following castration. <i>Prostate</i> , 2016, 76, 359-368.	1.2	8
1173	Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer. <i>Cancer Treatment Reviews</i> , 2016, 44, 61-73.	3.4	56
1174	Radioimmunotherapy for Prostate Cancer—Current Status and Future Possibilities. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 165-179.	2.5	23
1175	Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer. <i>Oncogene</i> , 2016, 35, 4807-4815.	2.6	32
1176	The evolving role of enzalutamide on the treatment of prostate cancer. <i>Future Oncology</i> , 2016, 12, 607-616.	1.1	7
1177	Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide Through the Androgen Receptor V7. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw005.	3.0	56
1178	Managing Metastatic Castration-Resistant Prostate Cancer in the Pre-chemotherapy Setting: A Changing Approach in the Era of New Targeted Agents. <i>Drugs</i> , 2016, 76, 421-430.	4.9	4
1180	Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. <i>Nature Medicine</i> , 2016, 22, 298-305.	15.2	1,193
1181	Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Current Oncology Reports</i> , 2016, 18, 14.	1.8	39
1182	Isolation and analysis of discreet human prostate cellular populations. <i>Differentiation</i> , 2016, 91, 139-151.	1.0	16
1183	Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 254.e7-254.e13.	0.8	12

#	ARTICLE	IF	CITATIONS
1184	Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science. <i>Prostate Cancer and Prostatic Diseases</i> , 2016, 19, 111-121.	2.0	58
1185	Austrian recommendations on Targeted Hormone Therapy for metastatic, castration-resistant prostate cancer. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 156-163.	1.0	3
1186	Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties. <i>Oncogene</i> , 2016, 35, 5963-5976.	2.6	78
1187	Serial <sup>18</sup> F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers. <i>Future Oncology</i> , 2016, 12, 333-342.	1.1	31
1188	Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial. <i>European Journal of Cancer</i> , 2016, 56, 93-100.	1.3	62
1189	Diving Into Cabazitaxel's Mode of Action: More Than a Taxane for the Treatment of Castration-Resistant Prostate Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 265-270.	0.9	18
1190	The Metabolism, Analysis, and Targeting of Steroid Hormones in Breast and Prostate Cancer. <i>Hormones and Cancer</i> , 2016, 7, 149-164.	4.9	62
1191	Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 696-702.	0.4	87
1192	Imaging yield from 133 consecutive patients with prostate cancer and low trigger PSA from a single institution. <i>Clinical Radiology</i> , 2016, 71, e143-e149.	0.5	1
1193	Management of castrate-resistant prostate cancer in older men. <i>Journal of Geriatric Oncology</i> , 2016, 7, 57-63.	0.5	6
1194	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. <i>Journal of Clinical Oncology</i> , 2016, 34, 1402-1418.	0.8	1,089
1195	Practical Guidance on the Role of Corticosteroids in the Treatment of Metastatic Castration-resistant Prostate Cancer. <i>Urology</i> , 2016, 96, 156-164.	0.5	25
1196	Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Prostate Cancer. <i>Medicine (United States)</i> , 2016, 95, e2544.	0.4	63
1197	Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer. <i>Current Urology Reports</i> , 2016, 17, 29.	1.0	22
1198	Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. <i>Nature Medicine</i> , 2016, 22, 369-378.	15.2	572
1199	Using CTCs for pharmacogenomic analysis. <i>Pharmacological Research</i> , 2016, 106, 92-100.	3.1	4
1200	A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer. <i>European Urology</i> , 2016, 70, 35-41.	0.9	63
1201	Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3774-3781.	3.2	21

#	ARTICLE	IF	CITATIONS
1202	Meta-analysis of regression of advanced solid tumors in patients receiving placebo or no anti-cancer therapy in prospective trials. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 122-136.	2.0	24
1203	CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (fAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy. <i>Hormones and Cancer</i> , 2016, 7, 196-210.	4.9	20
1204	Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: A review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 356-367.	0.8	19
1205	Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. <i>Lancet, The</i> , 2016, 387, 1163-1177.	6.3	1,570
1206	Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1356-1363.	3.2	71
1207	Docetaxel plus androgen deprivation withdrawal may restore sensitivity to luteinizing hormone-releasing hormone analog therapy in castration-resistant prostate cancer patients. <i>Endocrine</i> , 2016, 54, 830-833.	1.1	3
1208	A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. <i>Annals of Oncology</i> , 2016, 27, 454-460.	0.6	142
1209	Opportunities and challenges in combination gene cancer therapy. <i>Advanced Drug Delivery Reviews</i> , 2016, 98, 35-40.	6.6	64
1210	Moving Beyond the Androgen Receptor in Advanced Prostate Cancer Commentary on: DNA-repair Defects and Olaparib in Metastatic Prostate Cancer. <i>Urology</i> , 2016, 89, 10-11.	0.5	2
1211	The new and the old that is new again. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 73-74.	12.5	4
1212	Repeatability of Quantitative <sup>18</sup> F-Fluoromethylcholine PET/CT Studies in Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 721-727.	2.8	22
1213	Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials.. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 254-263.	2.0	2
1214	AR-V7 and prostate cancer: The watershed for treatment selection?. <i>Cancer Treatment Reviews</i> , 2016, 43, 27-35.	3.4	49
1215	Spontaneous Regression of Epstein-Barr Virus-Positive Primary Diffuse Large Cell B-Cell Lymphoma of the Urinary Bladder After the Cessation of Enzalutamide. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e215-e218.	0.9	3
1216	Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details. <i>Journal of Clinical Oncology</i> , 2016, 34, 280-285.	0.8	42
1217	Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis. <i>Targeted Oncology</i> , 2016, 11, 345-351.	1.7	56
1218	Management of Prostate Cancer in the Elderly. <i>Clinics in Geriatric Medicine</i> , 2016, 32, 113-132.	1.0	12
1219	Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial. <i>European Urology</i> , 2016, 70, 256-262.	0.9	355

#	ARTICLE	IF	CITATIONS
1220	Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from PREVAIL. <i>Annals of Oncology</i> , 2016, 27, 286-294.	0.6	93
1221	Exercise for Men with Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2016, 69, 693-703.	0.9	207
1222	Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2015. <i>Journal of Urology</i> , 2016, 195, 1444-1452.	0.2	56
1223	The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1969-1977.	3.2	170
1224	Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. <i>European Urology</i> , 2016, 69, 924-932.	0.9	22
1225	What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?. <i>World Journal of Urology</i> , 2016, 34, 617-624.	1.2	15
1226	Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 48-55.	0.9	14
1227	Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2016, 69, 563-573.	0.9	101
1229	Syndrome of inappropriate antidiuretic hormone secretion in a patient with castration-resistant prostate cancer treated with enzalutamide. <i>Acta Oncologica</i> , 2016, 55, 399-400.	0.8	2
1230	Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities. <i>Clinical Cancer Research</i> , 2016, 22, 553-559.	3.2	16
1231	Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer. <i>Endocrine-Related Cancer</i> , 2016, 23, 35-45.	1.6	49
1232	Raloxifene nanomicelles reduce the growth of castrate-resistant prostate cancer. <i>Journal of Drug Targeting</i> , 2016, 24, 441-449.	2.1	15
1233	Epigenetic regulation of steroid inactivating UDP-glucuronosyltransferases by microRNAs in prostate cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2016, 155, 85-93.	1.2	32
1234	Incidence and Correlates of Fatigue in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 5-11.	0.9	12
1235	The UGT2B28 Sex-steroid Inactivation Pathway Is a Regulator of Steroidogenesis and Modifies the Risk of Prostate Cancer Progression. <i>European Urology</i> , 2016, 69, 601-609.	0.9	36
1236	PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer. <i>Oncogene</i> , 2016, 35, 2322-2332.	2.6	38
1237	Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 348-355.	0.8	30
1238	Validation of TNM classification for metastatic prostatic cancer treated using primary androgen deprivation therapy. <i>World Journal of Urology</i> , 2016, 34, 261-267.	1.2	18

#	ARTICLE	IF	CITATIONS
1239	Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 127-136.	2.0	17
1240	Individualization of Adjuvant Therapy After Radical Prostatectomy for Clinically Localized Prostate Cancer: Current Status and Future Directions. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 12-21.	0.9	7
1241	Prostate cancer. <i>Lancet, The</i> , 2016, 387, 70-82.	6.3	801
1242	Endocrinology of Benign Prostatic Hyperplasia and Prostate Cancer. , 2016, , 2467-2484.e5.		0
1243	Androgen Physiology, Pharmacology, and Abuse. , 2016, , 2368-2393.e16.		11
1244	Lack of interaction between enzalutamide and warfarin in a metastatic castration-resistant prostate cancer patient. <i>Journal of Oncology Pharmacy Practice</i> , 2017, 23, 68-70.	0.5	1
1245	Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer. <i>European Urology</i> , 2017, 71, 319-327.	0.9	74
1246	Stem cells and the role of ETS transcription factors in the differentiation hierarchy of normal and malignant prostate epithelium. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 166, 68-83.	1.2	13
1247	Lessons from tissue compartment-specific analysis of androgen receptor alterations in prostate cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 166, 28-37.	1.2	12
1248	A simple method for deriving the confidence regions for the penalized Cox's model via the minimand perturbation. <i>Communications in Statistics - Theory and Methods</i> , 2017, 46, 4791-4808.	0.6	7
1249	SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition. <i>European Urology</i> , 2017, 71, 68-78.	0.9	136
1250	Epithelial-mesenchymal-transition regulators in prostate cancer: Androgens and beyond. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 166, 84-90.	1.2	49
1251	Treatment landscape of metastatic prostate cancer: the role of radium-223. <i>Acta Clinica Belgica</i> , 2017, 72, 19-23.	0.5	1
1252	Chromogranin A and neuron-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy. <i>BJU International</i> , 2017, 119, 30-37.	1.3	42
1253	Toxicity and efficacy of salvage carbon 11-choline positron emission tomography/computed tomography-guided radiation therapy in patients with lymph node recurrence of prostate cancer. <i>BJU International</i> , 2017, 119, 406-413.	1.3	43
1254	Hematologic Toxicity of Concurrent Administration of Radium-223 and Next-generation Antiandrogen Therapies. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 342-347.	0.6	25
1255	Surrogate End Points for All-Cause Mortality in Men With Localized Unfavorable-Risk Prostate Cancer Treated With Radiation Therapy vs Radiation Therapy Plus Androgen Deprivation Therapy. <i>JAMA Oncology</i> , 2017, 3, 652.	3.4	41
1256	Abiraterone or Enzalutamide in Advanced Castration-Resistant Prostate Cancer: An Indirect Comparison. <i>Prostate</i> , 2017, 77, 639-646.	1.2	23



#	ARTICLE	IF	CITATIONS
1257	Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns. <i>European Urology</i> , 2017, 72, 192-200.	0.9	106
1258	The evolving role of chemotherapy in prostate cancer. <i>Future Oncology</i> , 2017, 13, 1091-1095.	1.1	14
1259	Cardiovascular toxicities of systemic treatments of prostate cancer. <i>Nature Reviews Urology</i> , 2017, 14, 230-243.	1.9	15
1260	Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 110-116.	2.0	43
1261	Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer. <i>Asian Journal of Urology</i> , 2017, 4, 37-43.	0.5	39
1262	Comparative Assessment of Efficacies Between 2 Alternative Therapeutic Sequences With Novel Androgen Receptor-Axis-Targeted Agents in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e591-e597.	0.9	39
1263	Prognostic Value of Automated Bone Scan Index in Men With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide or Abiraterone Acetate. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 472-478.	0.9	13
1264	Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel. <i>Acta Oncologica</i> , 2017, 56, 555-562.	0.8	24
1265	Management of Prostate Cancer. , 2017, , .		5
1266	Minnelide Inhibits Androgen Dependent, Castration Resistant Prostate Cancer Growth by Decreasing Expression of Androgen Receptor Full Length and Splice Variants. <i>Prostate</i> , 2017, 77, 584-596.	1.2	30
1267	ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer. <i>Investigational New Drugs</i> , 2017, 35, 599-607.	1.2	41
1270	Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology. <i>European Urology</i> , 2017, 72, 521-531.	0.9	174
1271	Prostate Cancer Metastasis. , 2017, , 33-59.		2
1272	Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155. <i>Molecular Cancer Research</i> , 2017, 15, 521-531.	1.5	17
1273	TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 172-178.	2.0	23
1274	Protein kinase C regulates Twist1 expression via NF- $\kappa$ B in prostate cancer. <i>Endocrine-Related Cancer</i> , 2017, 24, 171-180.	1.6	10
1275	Mechanisms of Therapeutic Resistance in Prostate Cancer. <i>Current Oncology Reports</i> , 2017, 19, 13.	1.8	103
1276	Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling. <i>Cell Reports</i> , 2017, 18, 1970-1981.	2.9	83



#	ARTICLE	IF	CITATIONS
1277	Simultaneous quantitation of abiraterone, enzalutamide, N -desmethyl enzalutamide, and bicalutamide in human plasma by LC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 138, 197-205.	1.4	29
1278	Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone. <i>Clinical Cancer Research</i> , 2017, 23, 3544-3551.	3.2	72
1279	La quimioterapia no debería todavía ser considerada en los pacientes con cáncer de próstata metastásico hormonosensible. <i>Actas Urológicas Españolas</i> , 2017, 41, 347-351.	0.3	0
1280	Falls and Frailty in Prostate Cancer Survivors: Current, Past, and Never Users of Androgen Deprivation Therapy. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 1414-1419.	1.3	66
1281	Custirsén in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial. <i>Lancet Oncology</i> , The, 2017, 18, 473-485.	5.1	67
1282	Fluorocholine PET/CT predicts skeletal progression, skeletal event and cancer specific survival in patients with biochemical relapse for prostate cancer. <i>Clinical Imaging</i> , 2017, 43, 110-116.	0.8	3
1283	Piecing the puzzle together: Docetaxel cycles and current considerations in the treatment of metastatic castration-resistant prostate cancer. <i>Cancer Biology and Therapy</i> , 2017, 18, 203-204.	1.5	1
1284	CCN3-EZH2-AR feedback loop: new targets for enzalutamide and castration resistant prostate cancer. <i>Journal of Cell Communication and Signaling</i> , 2017, 11, 89-91.	1.8	9
1285	Navigating the evolving therapeutic landscape in advanced prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, S1-S13.	0.8	53
1286	LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics. <i>Prostate</i> , 2017, 77, 654-671.	1.2	219
1287	DNA vaccines for prostate cancer. , 2017, 174, 27-42.		36
1288	Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel. <i>Cancer</i> , 2017, 123, 2303-2311.	2.0	32
1289	Molecular Dynamics Studies on the Enzalutamide Resistance Mechanisms Induced by Androgen Receptor Mutations. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 2792-2801.	1.2	37
1290	Implementing Genome-Driven Oncology. <i>Cell</i> , 2017, 168, 584-599.	13.5	405
1291	Which Factors Predict Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel?. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 502-508.	0.9	8
1292	A potential panel of four-long noncoding RNA signature in prostate cancer predicts biochemical recurrence-free survival and disease-free survival. <i>International Urology and Nephrology</i> , 2017, 49, 825-835.	0.6	20
1293	Role of radical prostatectomy in metastatic prostate cancer: A review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 125-134.	0.8	26
1294	Independent association between time to prostate-specific antigen (PSA) nadir and PSA progression-free survival in patients with docetaxel-naïve, metastatic castration-resistant prostate cancer receiving abiraterone acetate, but not enzalutamide. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 432-437.	0.8	8

#	ARTICLE	IF	CITATIONS
1295	C-Met/miR-130b axis as novel mechanism and biomarker for castration resistance state acquisition. <i>Oncogene</i> , 2017, 36, 3718-3728.	2.6	35
1296	Aged patients with metastatic castration resistant prostate cancer: Should we treat with chemotherapy?. <i>Cancer Treatment Reviews</i> , 2017, 55, 173-180.	3.4	3
1297	Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1680-1692.	1.9	44
1298	Effect of <i>N</i> -methyl deuteration on pharmacokinetics and pharmacodynamics of enzalutamide. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2017, 60, 401-409.	0.5	23
1299	A simple HPLC-UV method for quantification of enzalutamide and its active metabolite N-desmethyl enzalutamide in patients with metastatic castration-resistant prostate cancer. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1058, 102-107.	1.2	12
1300	Amino-terminal enhancer of split gene <i>AES</i> encodes a tumor and metastasis suppressor of prostate cancer. <i>Cancer Science</i> , 2017, 108, 744-752.	1.7	15
1301	Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer. <i>Cancer Treatment Reviews</i> , 2017, 57, 16-27.	3.4	156
1302	Darolutamide (ODM-201) for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 945-952.	0.9	52
1303	The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation. <i>BMC Cancer</i> , 2017, 17, 163.	1.1	14
1304	Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1448-1454.	3.3	138
1305	Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naïve castration-resistant prostate cancer: The Kyoto-Baltimore collaboration. <i>International Journal of Urology</i> , 2017, 24, 441-448.	0.5	49
1306	Combination of Carmustine and Selenite Inhibits EGFR Mediated Growth Signaling in Androgen-Independent Prostate Cancer Cells. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 4331-4340.	1.2	11
1307	Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 352-360.	2.0	69
1308	Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 899-908.	0.9	5
1309	Neoadjuvant Enzalutamide Prior to Prostatectomy. <i>Clinical Cancer Research</i> , 2017, 23, 2169-2176.	3.2	80
1310	Efficacy of Therapies After Galeterone in Patients With Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 463-471.	0.9	12
1311	Agonist-specific Protein Interactomes of Glucocorticoid and Androgen Receptor as Revealed by Proximity Mapping. <i>Molecular and Cellular Proteomics</i> , 2017, 16, 1462-1474.	2.5	55
1312	Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet. <i>Targeted Oncology</i> , 2017, 12, 401-412.	1.7	6

#	ARTICLE	IF	CITATIONS
1314	PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. <i>Medicine (United States)</i> , 2017, 96, e6817.	0.4	4
1315	Characterization of a novel p110 <sup>β</sup> -specific inhibitor BL140 that overcomes MDV3100-resistance in castration-resistant prostate cancer cells. <i>Prostate</i> , 2017, 77, 1187-1198.	1.2	17
1316	Steroidogenic Metabolism of Galeterone Reveals a Diversity of Biochemical Activities. <i>Cell Chemical Biology</i> , 2017, 24, 825-832.e6.	2.5	41
1317	Clinical development of immunotherapy for prostate cancer. <i>International Journal of Urology</i> , 2017, 24, 675-680.	0.5	6
1318	Novel thiohydantoin analogues bearing the 1-hydroxyl-2,2,2-trifluoro-1-ethyl moiety as androgen receptor inhibitors for the potential treatment of castration resistant prostate cancer. <i>RSC Advances</i> , 2017, 7, 31866-31874.	1.7	3
1319	Detection of Gene Rearrangements in Circulating Tumor Cells: Examples of ALK-, ROS1-, RET-Rearrangements in Non-Small-Cell Lung Cancer and ERG-Rearrangements in Prostate Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2017, 994, 169-179.	0.8	13
1320	Radiotherapy for cranial and brain metastases from prostate cancer: a systematic review. <i>Journal of Neuro-Oncology</i> , 2017, 133, 531-538.	1.4	16
1321	Treatment strategies for DNA repair-deficient prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 889-898.	1.3	26
1322	Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate Cancer. <i>Endocrinology</i> , 2017, 158, 1533-1542.	1.4	58
1323	Prevalence of Measurable Disease in Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 534-539.	0.9	3
1324	Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 625-633.	1.1	24
1325	Lactate dehydrogenase predicts combined progression-free survival after sequential therapy with abiraterone and enzalutamide for patients with castration-resistant prostate cancer. <i>Prostate</i> , 2017, 77, 1144-1150.	1.2	29
1327	Therapy assessment in prostate cancer using choline and PSMA PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 78-83.	3.3	31
1328	Adjusting Overall Survival Estimates after Treatment Switching: a Case Study in Metastatic Castration-Resistant Prostate Cancer. <i>Targeted Oncology</i> , 2017, 12, 111-121.	1.7	6
1329	Connecting androgen receptor signaling and the DNA damage response: Development of new therapies for advanced prostate cancer. <i>Molecular and Cellular Oncology</i> , 2017, 4, e1321167.	0.3	7
1330	Exercise medicine for advanced prostate cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2017, 11, 247-257.	0.5	52
1331	Circulating Tumor Cells as Cancer Biomarkers in the Clinic. <i>Advances in Experimental Medicine and Biology</i> , 2017, 994, 1-41.	0.8	20
1332	Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1345-1357.	2.0	22

#	ARTICLE	IF	CITATIONS
1333	Efficacy and safety of post-docetaxel therapies in metastatic castration-resistant prostate cancer: a systematic review of the literature. <i>Current Medical Research and Opinion</i> , 2017, 33, 1995-2008.	0.9	20
1334	Controversies and consensus in the innovation access for cancer therapy in the European countries: on the subject of metastatic prostate cancer. <i>Annals of Oncology</i> , 2017, 28, 421-426.	0.6	4
1336	Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models. <i>Clinical Cancer Research</i> , 2017, 23, 4335-4346.	3.2	138
1337	Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial. <i>European Urology Focus</i> , 2017, 3, 606-614.	1.6	18
1338	Androgen Receptor in Health and Disease. , 2017, , 21-73.		2
1339	A comparison of the pharmacokinetics and safety of enzalutamide in subjects with hepatic impairment and matched healthy subjects. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017, 42, 268-275.	0.7	7
1340	Androgen Signaling in Prostate Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a030452.	2.9	278
1341	Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications. <i>Translational Oncology</i> , 2017, 10, 357-366.	1.7	31
1342	Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7). <i>Cancer Letters</i> , 2017, 398, 62-69.	3.2	34
1343	ELF5-Mediated AR Activation Regulates Prostate Cancer Progression. <i>Scientific Reports</i> , 2017, 7, 42759.	1.6	11
1344	Management of metastatic castration-resistant prostate cancer: A focus on radium-223. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 43-51.	2.0	28
1345	Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 610-617.e3.	0.9	25
1346	Novel small molecule guanidine Sigma1 inhibitors for advanced prostate cancer. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 2216-2220.	1.0	4
1347	Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer. <i>Cancer Letters</i> , 2017, 397, 133-143.	3.2	33
1348	Targeting NF-kappa B Signaling by Artesunate Restores Sensitivity of Castrate-Resistant Prostate Cancer Cells to Antiandrogens. <i>Neoplasia</i> , 2017, 19, 333-345.	2.3	62
1349	Analytical Validation of Androgen Receptor Splice Variant 7 Detection in a Clinical Laboratory Improvement Amendments (CLIA) Laboratory Setting. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 115-125.	1.2	41
1350	Improved survival for patients with de novo metastatic prostate cancer in the last 20 years. <i>European Journal of Cancer</i> , 2017, 72, 20-27.	1.3	34
1351	Schiff base-Poloxamer P85 combination demonstrates chemotherapeutic effect on prostate cancer cells in vitro. <i>Biomedicine and Pharmacotherapy</i> , 2017, 86, 492-501.	2.5	15

#	ARTICLE	IF	CITATIONS
1352	Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer. <i>Prostate</i> , 2017, 77, 479-488.	1.2	39
1353	Clusterin as a therapeutic target. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 201-213.	1.5	102
1354	From NETTER to PETTER: PSMA-Targeted Radioligand Therapy. <i>Journal of Nuclear Medicine</i> , 2017, 58, 9-10.	2.8	14
1355	Improving quality of life in patients with advanced cancer: Targeting metastatic bone pain. <i>European Journal of Cancer</i> , 2017, 71, 80-94.	1.3	74
1356	Predictive value of epithelial-mesenchymal transition (EMT) signature and PARP-1 in prostate cancer radioresistance. <i>Prostate</i> , 2017, 77, 1583-1591.	1.2	36
1357	Newly Diagnosed Metastatic Prostate Cancer: Has the Paradigm Changed?. <i>Urologic Clinics of North America</i> , 2017, 44, 611-621.	0.8	46
1358	Cabazitaxel-conjugated nanoparticles for docetaxel-resistant and bone metastatic prostate cancer. <i>Cancer Letters</i> , 2017, 410, 169-179.	3.2	38
1359	Prostate Cancer: An Update on Molecular Pathology with Clinical Implications. <i>European Urology Supplements</i> , 2017, 16, 253-271.	0.1	2
1360	The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: Exploratory analyses of AFFIRM and PREVAIL studies. <i>European Journal of Cancer</i> , 2017, 87, 21-29.	1.3	26
1362	Plumbagin improves the efficacy of androgen deprivation therapy in prostate cancer: A preclinical study. <i>Prostate</i> , 2017, 77, 1550-1562.	1.2	25
1363	Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. <i>Cancer Cell</i> , 2017, 32, 474-489.e6.	7.7	483
1364	Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1532-1542.	5.1	65
1365	Risk Factors for and Incidence of Seizures in Metastatic Castration-Resistant Prostate Cancer: A Real-World Retrospective Cohort Study. <i>Clinical Drug Investigation</i> , 2017, 37, 1183-1190.	1.1	10
1366	BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1391-1397.	1.9	26
1367	Clinical relevance of androgen receptor alterations in prostate cancer. <i>Endocrine Connections</i> , 2017, 6, R146-R161.	0.8	87
1368	Optimal usage of radium-223 in metastatic castration-resistant prostate cancer. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 825-836.	0.8	16
1369	Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer. <i>Oncology Reports</i> , 2017, 38, 2774-2786.	1.2	30
1370	AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide. <i>European Urology</i> , 2017, 72, 828-834.	0.9	86

#	ARTICLE	IF	CITATIONS
1371	Androgen-deprivation therapy with enzalutamide enhances prostate cancer metastasis via decreasing the EPHB6 suppressor expression. <i>Cancer Letters</i> , 2017, 408, 155-163.	3.2	26
1372	Targeted Therapies and Immunotherapy in Prostate Cancer. , 2017, , 367-374.		0
1373	LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression. <i>Cancer Research</i> , 2017, 77, 5479-5490.	0.4	71
1374	The Role of Hormonal Treatment in Prostate Cancer. , 2017, , 333-349.		0
1375	A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer. <i>Pharmacotherapy</i> , 2017, 37, 1406-1414.	1.2	21
1376	Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review. <i>Expert Opinion on Therapeutic Patents</i> , 2017, 27, 1329-1340.	2.4	70
1377	Targeting Prostate Cancer Subtype 1 by Forkhead Box M1 Pathway Inhibition. <i>Clinical Cancer Research</i> , 2017, 23, 6923-6933.	3.2	30
1378	Circulating steroid hormone variations throughout different stages of prostate cancer. <i>Endocrine-Related Cancer</i> , 2017, 24, R403-R420.	1.6	34
1379	Impact of enzalutamide and its main metabolite <i>N</i> -desmethyl enzalutamide on pharmacokinetically important drug metabolizing enzymes and drug transporters. <i>Biopharmaceutics and Drug Disposition</i> , 2017, 38, 517-525.	1.1	18
1380	Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. <i>Journal of Nuclear Medicine</i> , 2017, 58, 67S-76S.	2.8	163
1381	Treatment sequence in castration-resistant prostate cancer: A retrospective study in the new anti-androgen era. <i>Molecular and Clinical Oncology</i> , 2017, 7, 601-603.	0.4	3
1383	Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases. <i>Annals of Oncology</i> , 2017, 28, 2464-2471.	0.6	28
1384	Role of collaboration between urologists and medical oncologists in the advanced prostate cancer space. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 665-669.	0.8	0
1386	Cáncer de próstata y cáncer de testículo. <i>Medicine</i> , 2017, 12, 1966-1979.	0.0	0
1387	A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 742-749.	0.9	21
1388	Inhibition of Androgen Receptor Function and Level in Castration-Resistant Prostate Cancer Cells by 2-[[isoxazol-4-ylmethyl]thio]-1-(4-phenylpiperazin-1-yl)ethanone. <i>Endocrinology</i> , 2017, 158, 3152-3161.	1.4	15
1389	The role of bone-targeted therapies for prostate cancer in 2017. <i>Current Opinion in Supportive and Palliative Care</i> , 2017, 11, 216-224.	0.5	4
1390	The evolution of chemotherapy for the treatment of prostate cancer. <i>Annals of Oncology</i> , 2017, 28, 2658-2669.	0.6	57



#	ARTICLE	IF	CITATIONS
1391	Phase I clinical trial of cell division associated 1 (<scp>CDCA</scp>1) peptide vaccination for castration resistant prostate cancer. <i>Cancer Science</i> , 2017, 108, 1452-1457.	1.7	37
1394	Evidencedâ€based clinical practice guideline for prostate cancer (summary: Japanese Urological) Tj ETQq1 1 0.784314 rgBT /Overlock 111	0.5	111
1395	The Androgen Receptor Supports Tumor Progression After the Loss of Ovarian Function in a Preclinical Model of Obesity and Breast Cancer. <i>Hormones and Cancer</i> , 2017, 8, 269-285.	4.9	14
1396	Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies. <i>Cancer Treatment Reviews</i> , 2017, 59, 123-131.	3.4	49
1397	No significant impact of prior treatment profile with docetaxel on the efficacy of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer. <i>Medical Oncology</i> , 2017, 34, 141.	1.2	9
1398	Prognostic nutritional index predicts initial response to treatment and prognosis in metastatic castrationâ€resistant prostate cancer patients treated with abiraterone. <i>Prostate</i> , 2017, 77, 1233-1241.	1.2	33
1399	The biology of prostate cancer metastases. <i>Current Opinion in Urology</i> , 2017, 27, 542-546.	0.9	8
1400	Targeting AR Variantâ€™Coactivator Interactions to Exploit Prostate Cancer Vulnerabilities. <i>Molecular Cancer Research</i> , 2017, 15, 1469-1480.	1.5	21
1401	Novel androgen axis systemic therapies for metastatic hormone-sensitive prostate cancer. <i>Current Opinion in Urology</i> , 2017, 27, 559-565.	0.9	10
1402	Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2017, 77, 5564-5575.	0.4	105
1403	Predicting Response and Recognizing Resistance: Improving Outcomes in Patients With Castration-resistant Prostate Cancer. <i>Urology</i> , 2017, 109, 6-18.	0.5	15
1404	Predictive Comprehensive Geriatric Assessment in elderly prostate cancer patients. <i>Anti-Cancer Drugs</i> , 2017, 28, 104-109.	0.7	24
1406	Toxicity, Adverse Events, and Quality of Life Associated with the Treatment of Metastatic Castration-Resistant Prostate Cancer. <i>Current Urology</i> , 2017, 10, 169-173.	0.4	12
1407	Impact of prior androgen receptor-axis-targeted agents on the clinical activity of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer: comparative assessment between abiraterone acetate and enzalutamide. <i>Medical Oncology</i> , 2017, 34, 200.	1.2	7
1408	Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer. <i>Scientific Reports</i> , 2017, 7, 15541.	1.6	11
1409	Extracellular Vesicles in the Adaptive Process of Prostate Cancer during Inhibition of Androgen Receptor Signaling by Enzalutamide. <i>Proteomics</i> , 2017, 17, 1600427.	1.3	12
1410	Androgen Receptor-Targeted Therapy for Breast Cancer. <i>Current Breast Cancer Reports</i> , 2017, 9, 242-250.	0.5	1
1411	The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 120, 227-233.	2.0	15



#	ARTICLE	IF	CITATIONS
1412	Castration-Resistant Prostate Cancer. <i>Urologic Clinics of North America</i> , 2017, 44, 647-655.	0.8	2
1413	Second-line therapy in patients with metastatic castration-resistant prostate cancer with progression after or under docetaxel: A systematic review of nine randomized controlled trials. <i>Seminars in Oncology</i> , 2017, 44, 358-371.	0.8	13
1414	Early identification and intervention matters: A comprehensive review of current evidence and recommendations for the monitoring of bone health in patients with cancer. <i>Cancer Treatment Reviews</i> , 2017, 61, 23-34.	3.4	28
1416	Systematic Review of Immune Checkpoint Inhibition in Urological Cancers. <i>European Urology</i> , 2017, 72, 411-423.	0.9	89
1417	The Diagnosis and Treatment of Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2532.	3.8	959
1418	Dose considerations for anti-cancer drugs in metastatic prostate cancer. <i>Prostate</i> , 2017, 77, 1199-1204.	1.2	5
1419	Macrocyclic peptides decrease c-Myc protein levels and reduce prostate cancer cell growth. <i>Cancer Biology and Therapy</i> , 2017, 18, 571-583.	1.5	8
1420	ABCB1 Mediates Cabazitaxel's Docetaxel Cross-Resistance in Advanced Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2257-2266.	1.9	49
1422	Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 809-819.	1.3	3
1423	Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate. <i>Anti-Cancer Drugs</i> , 2017, 28, 110-115.	0.7	6
1424	Prostate cancer immunotherapy: the path forward. <i>Current Opinion in Supportive and Palliative Care</i> , 2017, 11, 225-230.	0.5	8
1425	Inhibition of Androgen Receptor Nuclear Localization and Castration-Resistant Prostate Tumor Growth by Pyrroloimidazole-based Small Molecules. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2120-2129.	1.9	19
1426	Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 130.	1.0	27
1427	Estradiol for the mitigation of adverse effects of androgen deprivation therapy. <i>Endocrine-Related Cancer</i> , 2017, 24, R297-R313.	1.6	13
1428	New Biomarkers for Selecting the Best Therapy Regimens in Metastatic Castration-Resistant Prostate Cancer. <i>Targeted Oncology</i> , 2017, 12, 37-45.	1.7	10
1429	Prostate cancer: Developing novel approaches to castration-sensitive disease. <i>Cancer</i> , 2017, 123, 29-42.	2.0	8
1430	Meeting Report From the Prostate Cancer Foundation Scientific Working Group on Radium-223. <i>Prostate</i> , 2017, 77, 245-254.	1.2	6
1431	Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 35-44.	1.9	100

#	ARTICLE	IF	CITATIONS
1432	Assessment of quality of life in advanced, metastatic prostate cancer: an overview of randomized phase III trials. <i>Quality of Life Research</i> , 2017, 26, 813-822.	1.5	14
1433	Systematic and functional characterization of novel androgen receptor variants arising from alternative splicing in the ligand-binding domain. <i>Oncogene</i> , 2017, 36, 1440-1450.	2.6	6
1434	The molecular underpinnings of prostate cancer: impacts on management and pathology practice. <i>Journal of Pathology</i> , 2017, 241, 173-182.	2.1	36
1435	Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2017, 35, 415-424.	1.7	7
1436	Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1. <i>Cancer Letters</i> , 2017, 385, 150-159.	3.2	70
1437	The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-“Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. <i>Cancer Discovery</i> , 2017, 7, 54-71.	7.7	285
1439	Bone Metastases from Prostate Cancer: From Symptom Control to Pain Palliation. , 2017, , 251-270.		1
1440	Combination of sorafenib and enzalutamide as a potential new approach for the treatment of castration-resistant prostate cancer. <i>Cancer Letters</i> , 2017, 385, 108-116.	3.2	15
1441	Androgen synthesis in prostate cancer: do all roads lead to Rome?. <i>Nature Reviews Urology</i> , 2017, 14, 49-58.	1.9	34
1442	A new dawn for androgens: Novel lessons from 11-oxygenated C19 steroids. <i>Molecular and Cellular Endocrinology</i> , 2017, 441, 76-85.	1.6	112
1443	Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study. <i>Prostate</i> , 2017, 77, 33-40.	1.2	60
1444	Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. <i>European Urology</i> , 2017, 71, 151-154.	0.9	306
1445	Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 166, 16-27.	1.2	35
1446	Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 726-734.	3.2	95
1447	Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial. <i>European Urology</i> , 2017, 71, 534-542.	0.9	28
1448	Enzalutamide in Patients With Castration-Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient Program. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e315-e323.	0.9	5
1449	Simultaneous quantitation of nine hydroxy-androgens and their conjugates in human serum by stable isotope dilution liquid chromatography electrospray ionization tandem mass spectrometry. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 165, 342-355.	1.2	22
1450	Impact of Prior Use of an Androgen Receptor-Axis-Targeted (ARAT) Agent With or Without Subsequent Taxane Therapy on the Efficacy of Another ARAT Agent in Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e217-e222.	0.9	14

#	ARTICLE	IF	CITATIONS
1451	Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered. <i>JAMA Oncology</i> , 2017, 3, 68.	3.4	33
1452	Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with <sup>177</sup> Lu-PSMA-617. <i>Journal of Nuclear Medicine</i> , 2017, 58, 312-319.	2.8	103
1453	Absorption, Distribution, Metabolism, and Excretion of the Androgen Receptor Inhibitor Enzalutamide in Rats and Dogs. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017, 42, 611-626.	0.6	8
1454	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2017, 71, 630-642.	0.9	1,215
1455	An improved and practical route for the synthesis of enzalutamide and potential impurities study. <i>Chinese Chemical Letters</i> , 2017, 28, 426-430.	4.8	15
1456	<sup>68</sup> Ga-PSMA-11 PET as a Gatekeeper for the Treatment of Metastatic Prostate Cancer with <sup>223</sup> Ra: Proof of Concept. <i>Journal of Nuclear Medicine</i> , 2017, 58, 438-444.	2.8	54
1457	<i>BIRC6</i> Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 1542-1551.	3.2	28
1458	Impact of single-agent daily prednisone on outcomes in men with metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 67-71.	2.0	8
1459	In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database. <i>European Urology Focus</i> , 2017, 3, 480-486.	1.6	11
1460	Prostate-Specific Antigen Flare Phenomenon Induced by Abiraterone Acetate in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 320-325.	0.9	28
1461	Reply from Authors re: Emmanuel S. Antonarakis, Howard I. Scher. Do Patients With AR-V7 <sup>+</sup> Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on Definitions. <i>Eur Urol</i> 2017;71:4-6. <i>European Urology</i> , 2017, 71, 6-7.	0.9	5
1462	High-Content Screening Identifies Src Family Kinases as Potential Regulators of AR-V7 Expression and Androgen-Independent Cell Growth. <i>Prostate</i> , 2017, 77, 82-93.	1.2	21
1463	Prostatic Tumors. , 2017, , 95-167.		0
1464	Molecular complexity of taxane-induced cytotoxicity in prostate cancer cells. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 32.e9-32.e16.	0.8	9
1465	Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 40-47.	0.8	577
1466	Addressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins. <i>Future Oncology</i> , 2017, 13, 369-379.	1.1	9
1468	Interplay between Cytoplasmic and Nuclear Androgen Receptor Splice Variants Mediates Castration Resistance. <i>Molecular Cancer Research</i> , 2017, 15, 59-68.	1.5	57
1469	Reply to Marcus V. Cronauer, Axel S. Merseburger, and M. Raschid Hoda's Letter to the Editor re: Christof Bernemann, Thomas J. Schnoeller, Manuel Luedeke, et al. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. <i>Eur Urol</i> 2017;71:1-3. <i>European Urology</i> , 2017, 71, e107-e108.	0.9	1

#	ARTICLE	IF	CITATIONS
1470	Early use of chemotherapy in metastatic prostate cancer. <i>Cancer Treatment Reviews</i> , 2017, 55, 218-224.	3.4	19
1471	Do we need new trials for the abiraterone, enzalutamide and cabazitaxel in metastatic castrate-resistant prostate cancer for confirmation of treatment indications?. <i>World Journal of Urology</i> , 2017, 35, 479-480.	1.2	0
1472	Germline genetic variation in <i>JAK2</i> as a prognostic marker in castration-resistant prostate cancer. <i>BJU International</i> , 2017, 119, 489-495.	1.3	8
1473	Comparative Assessment of Clinical Outcomes Between Abiraterone Acetate and Enzalutamide in Patients With Docetaxel-Naive Metastatic Castration-Resistant Prostate Cancer: Experience in Real-World Clinical Practice in Japan. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 313-319.	0.9	33
1474	AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate. <i>Journal of Urology</i> , 2017, 197, 135-142.	0.2	106
1475	Branched Chain RNA <i>In Situ</i> Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 363-369.	3.2	23
1476	Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 269-283.	12.5	36
1477	The role of GATA2 in lethal prostate cancer aggressiveness. <i>Nature Reviews Urology</i> , 2017, 14, 38-48.	1.9	71
1478	Simvastatin Up-Regulates Annexin A10 That Can Inhibit the Proliferation, Migration, and Invasion in Androgen-Independent Human Prostate Cancer Cells. <i>Prostate</i> , 2017, 77, 337-349.	1.2	31
1479	Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. <i>Lancet Oncology</i> , The, 2017, 18, 132-142.	5.1	124
1480	Induced protein degradation: an emerging drug discovery paradigm. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 101-114.	21.5	971
1482	Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial. <i>Cancer</i> , 2017, 123, 253-262.	2.0	42
1484	Androgen receptor targeted therapies in metastatic castration-resistant prostate cancer – The urologists' perspective. <i>Urological Science</i> , 2017, 28, 190-196.	0.2	5
1485	Efficacy of androgen deprivation therapy and the role of oxidative stress. <i>Annals of Oncology</i> , 2017, 28, 451-453.	0.6	4
1486	Addition of Docetaxel and/or Zoledronic Acid to Standard of Care for Hormone-naive Prostate Cancer: A Cost-effectiveness Analysis. <i>Tumori</i> , 2017, 103, 380-386.	0.6	12
1487	Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. <i>BMJ: British Medical Journal</i> , 2017, 359, j4530.	2.4	423
1488	Feasibility of metronomic chemotherapy with tegafur-uracil, cisplatin, and dexamethasone for docetaxel-refractory prostate cancer. <i>Journal of Rural Medicine: JRM</i> , 2017, 12, 112-119.	0.2	6
1489	Oxibendazole inhibits prostate cancer cell growth. <i>Oncology Letters</i> , 2018, 15, 2218-2226.	0.8	9

#	ARTICLE	IF	CITATIONS
1490	Researching the Research in Prostate Cancer: A Comparative Bibliometric Analysis of the Top 100 Cited Articles in the Field of Prostate Cancer. <i>Current Urology</i> , 2017, 11, 26-35.	0.4	8
1492	Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer. <i>The Cochrane Library</i> , 0, , .	1.5	3
1493	Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review. <i>Asian Journal of Andrology</i> , 2017, 19, 196.	0.8	31
1495	Prostate Cancer Stem Cells and Nanotechnology: A Focus on Wnt Signaling. <i>Frontiers in Pharmacology</i> , 2017, 8, 153.	1.6	23
1496	Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel. <i>Frontiers in Pharmacology</i> , 2017, 8, 836.	1.6	6
1497	Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy. <i>Cancers</i> , 2017, 9, 13.	1.7	40
1499	Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study. <i>Cancer Management and Research</i> , 2017, Volume 9, 789-800.	0.9	16
1500	Triptolide Inhibits the AR Signaling Pathway to Suppress the Proliferation of Enzalutamide Resistant Prostate Cancer Cells. <i>Theranostics</i> , 2017, 7, 1914-1927.	4.6	41
1501	Radium 223 dichloride for prostate cancer treatment. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2643-2651.	2.0	65
1502	Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer. <i>ELife</i> , 2017, 6, , .	2.8	83
1503	Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance. <i>Cancers</i> , 2017, 9, 67.	1.7	83
1504	Androgen receptor splice variants and prostate cancer: From bench to bedside. <i>Oncotarget</i> , 2017, 8, 18550-18576.	0.8	100
1505	Melatonin Inhibits Androgen Receptor Splice Variant-7 (AR-V7)-Induced Nuclear Factor-Kappa B (NF- $\kappa$ B) Activation and NF- $\kappa$ B Activator-Induced AR-V7 Expression in Prostate Cancer Cells: Potential Implications for the Use of Melatonin in Castration-Resistant Prostate Cancer (CRPC) Therapy. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1130.	1.8	26
1506	AR-Signaling in Human Malignancies: Prostate Cancer and Beyond. <i>Cancers</i> , 2017, 9, 7.	1.7	49
1507	Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2017, 9, 22.	1.7	36
1508	AR Signaling and the PI3K Pathway in Prostate Cancer. <i>Cancers</i> , 2017, 9, 34.	1.7	118
1509	Significance of microRNAs in Androgen Signaling and Prostate Cancer Progression. <i>Cancers</i> , 2017, 9, 102.	1.7	31
1510	MYC Deregulation in Primary Human Cancers. <i>Genes</i> , 2017, 8, 151.	1.0	281

#	ARTICLE	IF	CITATIONS
1511	The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone. <i>International Journal of Molecular Sciences</i> , 2017, 18, 380.	1.8	29
1512	Targeting Apoptotic Activity Against Prostate Cancer Stem Cells. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1648.	1.8	17
1513	Knockdown of TRIM44 Inhibits the Proliferation and Invasion in Prostate Cancer Cells. <i>Oncology Research</i> , 2017, 25, 1253-1259.	0.6	27
1514	Efficacy of Abiraterone and Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A Trial-Level Meta-Analysis. <i>Prostate Cancer</i> , 2017, 2017, 1-8.	0.4	15
1515	Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer. <i>ELife</i> , 2017, 6, .	2.8	154
1516	Neutrophil-to-Lymphocyte Ratio Predicts Prognosis in Castration-Resistant Prostate Cancer Patients Who Received Cabazitaxel Chemotherapy. <i>BioMed Research International</i> , 2017, 2017, 1-5.	0.9	27
1517	Value Frameworks for the Patient-Provider Interaction: A Comparison of the ASCO Value Framework Versus NCCN Evidence Blocks in Determining Value in Oncology. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2017, 23, S13-S20.	0.5	14
1518	A population-based study of the use of radium 223 in metastatic castration-resistant prostate cancer: Factors associated with treatment completion. <i>Canadian Urological Association Journal</i> , 2017, 11, 350-5.	0.3	16
1519	Serum Pre-Albumin Predicts the Clinical Outcome in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Abiraterone. <i>Journal of Cancer</i> , 2017, 8, 3448-3455.	1.2	17
1520	First brazilian consensus of advanced prostate cancer: recommendations for clinical practice. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2017, 43, 407-415.	0.7	5
1521	Assessing the relationship between toxicity and economic cost of oncological target agents: A systematic review of clinical trials. <i>PLoS ONE</i> , 2017, 12, e0183639.	1.1	2
1522	Mapping the STK4/Hippo signaling network in prostate cancer cell. <i>PLoS ONE</i> , 2017, 12, e0184590.	1.1	22
1523	An androgen response element driven reporter assay for the detection of androgen receptor activity in prostate cells. <i>PLoS ONE</i> , 2017, 12, e0177861.	1.1	12
1524	Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol. <i>BMC Cancer</i> , 2017, 17, 549.	1.1	19
1525	A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients. <i>BMC Urology</i> , 2017, 17, 70.	0.6	9
1526	Usefulness of Radium-223 in Patients with Bone Metastases. <i>Baylor University Medical Center Proceedings</i> , 2017, 30, 424-426.	0.2	11
1527	The biological and clinical advances of androgen receptor function in age-related diseases and cancer [Review]. <i>Endocrine Journal</i> , 2017, 64, 933-946.	0.7	13
1528	Budgetary Impact of Cabazitaxel Use After Docetaxel Treatment for Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2017, 23, 416-426.	0.5	12



#	ARTICLE	IF	CITATIONS
1530	The treatment of metastatic prostate cancer. <i>NursePrescribing</i> , 2017, 15, 182-187.	0.1	0
1532	An exploratory analysis of the association between levels of hormones implied in steroid biosynthesis and activity of abiraterone in patients with metastatic castration-resistant prostate cancer. <i>Minerva Urology and Nephrology</i> , 2017, 69, 349-358.	1.3	3
1533	Duration of Treatment in Prostate Cancer Patients Treated with Abiraterone Acetate or Enzalutamide. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2017, 23, 225-235.	0.5	13
1534	Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology Setting. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2017, 23, S34-S48.	0.5	15
1535	Degarelix treatment is compatible with diabetes and antithrombotic therapy in patients with prostate cancer. <i>Research and Reports in Urology</i> , 2017, Volume 9, 225-232.	0.6	1
1536	Effect of dutasteride on castration-resistant prostate cancer. <i>Molecular and Clinical Oncology</i> , 2017, 8, 133-136.	0.4	3
1537	The Importance of Economic Perspective and Quantitative Approaches in Oncology Value Frameworks of Drug Selection and Shared Decision Making. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2017, 23, S6-S12.	0.5	7
1538	Treatment Patterns and Trends in Patients Dying of Prostate Cancer in Quebec: A Population-Based Study. <i>Current Oncology</i> , 2017, 24, 240-248.	0.9	6
1539	Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers. <i>Journal of Cancer</i> , 2017, 8, 507-512.	1.2	2
1540	Recent advances in the biology and therapy of medullary thyroid carcinoma. <i>F1000Research</i> , 2017, 6, 2184.	0.8	18
1541	Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D. <i>Journal of Oncology Practice</i> , 2017, 13, e694-e702.	2.5	6
1542	Decipher Postprostatectomy: Is It Ready for Clinical Use?. <i>Journal of Clinical Oncology</i> , 2017, 35, 1976-1977.	0.8	5
1543	Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial—FIRSTANA. <i>Journal of Clinical Oncology</i> , 2017, 35, 3189-3197.	0.8	251
1544	Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. <i>Journal of Clinical Oncology</i> , 2017, 35, 2149-2156.	0.8	371
1545	Exploration of the ASCO and ESMO Value Frameworks for Antineoplastic Drugs. <i>Journal of Oncology Practice</i> , 2017, 13, e653-e665.	2.5	31
1546	Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion. <i>Journal of Clinical Oncology</i> , 2017, 35, 1952-1964.	0.8	53
1547	Reversion of epithelial-mesenchymal transition by a novel agent DZ-50 via IGF binding protein-3 in prostate cancer cells. <i>Oncotarget</i> , 2017, 8, 78507-78519.	0.8	21
1548	Comparing the clinical efficacy of abiraterone acetate, enzalutamide, and orteronel in patients with metastatic castration-resistant prostate cancer by performing a network meta-analysis of eight randomized controlled trials. <i>Oncotarget</i> , 2017, 8, 59690-59697.	0.8	20



#	ARTICLE	IF	CITATIONS
1549	Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials. <i>Oncotarget</i> , 2017, 8, 84572-84578.	0.8	66
1550	Letter-Corrected Net Health Benefit Calculations for Enzalutamide Using ASCO Value Framework Guidelines and NCCN Evidence Blocks. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2017, 23, 1202-1202.	0.5	3
1551	Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients. <i>Prostate</i> , 2018, 78, 336-342.	1.2	41
1552	Cellular plasticity and the neuroendocrine phenotype in prostate cancer. <i>Nature Reviews Urology</i> , 2018, 15, 271-286.	1.9	273
1554	Castration-Resistant Prostate Cancer. <i>Molecular Pathology Library</i> , 2018, , 297-322.	0.1	0
1555	Neuroendocrine Prostate Cancer. <i>Molecular Pathology Library</i> , 2018, , 323-341.	0.1	0
1556	Molecular Targeted Therapies of Prostate Cancer. <i>Molecular Pathology Library</i> , 2018, , 523-546.	0.1	1
1557	Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. <i>European Urology</i> , 2018, 73, 847-855.	0.9	174
1558	Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 240.e13-240.e20.	0.8	7
1559	Endocrinology of prostate cancer. <i>Molecular and Cellular Endocrinology</i> , 2018, 462, 1-2.	1.6	1
1560	TRIM36, a novel androgen-responsive gene, enhances anti-androgen efficacy against prostate cancer by inhibiting MAPK/ERK signaling pathways. <i>Cell Death and Disease</i> , 2018, 9, 155.	2.7	41
1561	AR $\psi$ 7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients. <i>Prostate</i> , 2018, 78, 576-582.	1.2	46
1562	Seven-month prostate-specific antigen (PSA) is prognostic in patients with prostate cancer initially diagnosed with distant metastases. <i>Medical Oncology</i> , 2018, 35, 46.	1.2	3
1563	Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2018, 4, 694.	3.4	46
1564	Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. <i>Annals of Oncology</i> , 2018, 29, 1235-1248.	0.6	196
1565	Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion. <i>Clinical Cancer Research</i> , 2018, 24, 4319-4331.	3.2	36
1566	Sequencing treatment for metastatic prostate cancer. <i>Trends in Urology &amp; Men's Health</i> , 2018, 9, 11-15.	0.2	1
1567	Phenylbutyl isoselenocyanate induces reactive oxygen species to inhibit androgen receptor and to initiate p53-mediated apoptosis in LNCaP prostate cancer cells. <i>Molecular Carcinogenesis</i> , 2018, 57, 1055-1066.	1.3	13

#	ARTICLE	IF	CITATIONS
1568	Improvement in Therapeutic Efficacy and Reduction in Cellular Toxicity: Introduction of a Novel Anti-PSMA-Conjugated Hybrid Antiandrogen Nanoparticle. <i>Molecular Pharmaceutics</i> , 2018, 15, 1778-1790.	2.3	3
1569	Current and potential targets for drug design in the androgen receptor pathway for prostate cancer. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 489-496.	2.5	5
1570	Molecular and cellular mechanisms of castration resistant prostate cancer (Review). <i>Oncology Letters</i> , 2018, 15, 6063-6076.	0.8	116
1571	Cost considerations for systemic therapy for patients with advanced genitourinary malignancies. <i>Cancer</i> , 2018, 124, 2897-2905.	2.0	6
1572	Earlier use of androgen receptor- $\alpha$ -axis-targeted drugs may improve overall survival in patients with non-metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2018, 78, 766-772.	1.2	9
1573	Practice-changing developments in early use of chemohormonal therapy in metastatic prostate cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 33-37.	0.3	0
1574	PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 475-486.	1.3	83
1576	High expression of NPRL2 is linked to poor prognosis in patients with prostate cancer. <i>Human Pathology</i> , 2018, 76, 141-148.	1.1	9
1577	Clinical and molecular features of treatment-related neuroendocrine prostate cancer. <i>International Journal of Urology</i> , 2018, 25, 345-351.	0.5	110
1578	Pharmacokinetic/pharmacodynamic drug evaluation of enzalutamide for treating prostate cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 361-369.	1.5	5
1579	Development and Validation of a Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite N-Desmethylenzalutamide in Human Plasma: Application to Clinical Management of Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 222-229.	1.0	11
1580	Y08060: A Selective BET Inhibitor for Treatment of Prostate Cancer. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 262-267.	1.3	14
1581	Performance comparison of two androgen receptor splice variant 7 (AR $\psi$ 7) detection methods. <i>BJU International</i> , 2018, 122, 219-226.	1.3	11
1582	Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401774581.	1.4	16
1583	Targeting of Steroid Hormone Receptor Function in Breast and Prostate Cancer. <i>Endocrinology</i> , 2018, , 765-785.	0.1	0
1584	Is the fatigue an adverse event of the second generation of hormonal therapy? Data from a literature-based meta-analysis. <i>Medical Oncology</i> , 2018, 35, 29.	1.2	7
1585	Nationwide population-based study on the use of novel antiandrogens in men with prostate cancer in Sweden. <i>Scandinavian Journal of Urology</i> , 2018, 52, 143-150.	0.6	11
1586	Targeted $\beta$ -Therapy of Metastatic Castration-Resistant Prostate Cancer with <sup>225</sup> Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control. <i>Journal of Nuclear Medicine</i> , 2018, 59, 795-802.	2.8	322

#	ARTICLE	IF	CITATIONS
1587	Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast Cancer. <i>Hormones and Cancer</i> , 2018, 9, 82-94.	4.9	21
1588	BMI1 regulates androgen receptor in prostate cancer independently of the polycomb repressive complex 1. <i>Nature Communications</i> , 2018, 9, 500.	5.8	65
1589	Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 645-657.	13.9	386
1590	An Observational Study of Concomitant Use of Emerging Therapies and Denosumab or Zoledronic Acid in Prostate Cancer. <i>Clinical Therapeutics</i> , 2018, 40, 536-549.e3.	1.1	10
1591	When and how to use carboplatin in metastatic castration-resistant prostate cancer?. <i>European Journal of Cancer</i> , 2018, 92, 96-99.	1.3	2
1592	Circulating tumor cells and survival in abiraterone and enzalutamide-treated patients with castration-resistant prostate cancer. <i>Prostate</i> , 2018, 78, 435-445.	1.2	21
1593	Abiraterone acetate and its use in the treatment of metastatic prostate cancer: a review. <i>Future Oncology</i> , 2018, 14, 431-442.	1.1	14
1594	Neoadjuvant and adjuvant treatment in high-risk prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 425-438.	1.3	17
1595	Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2018, 78, 2065-2080.	0.4	60
1596	Molecular Imaging in Cancer Drug Development. <i>Journal of Nuclear Medicine</i> , 2018, 59, 726-732.	2.8	50
1597	Current treatment strategies for advanced prostate cancer. <i>International Journal of Urology</i> , 2018, 25, 220-231.	0.5	164
1598	A randomised phase II trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial. <i>European Journal of Cancer</i> , 2018, 90, 1-9.	1.3	20
1599	The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 306-318.	2.0	21
1600	No significant impact of response to prior androgen receptor-axis-targeted agents on the efficacy of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer. <i>International Journal of Clinical Oncology</i> , 2018, 23, 576-583.	1.0	4
1601	Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration-resistant prostate cancer models. <i>International Journal of Cancer</i> , 2018, 142, 2163-2174.	2.3	39
1602	Comparison of Alternative Androgen Receptor-axis-targeted Agent (ARATA) and Docetaxel as Second-line Therapy for Patients With Metastatic Castration-resistant Prostate Cancer With Progression After Initial ARATA in Real-world Clinical Practice in Japan. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 219-225.	0.9	17
1603	Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 184-190.e2.	0.9	13
1604	Effect of Single-agent Daily Prednisone on Outcomes and Toxicities in Metastatic Castration-resistant Prostate Cancer: Pooled Analysis of Prospective Studies. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e277-e287.	0.9	4

#	ARTICLE	IF	CITATIONS
1605	The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e645-e653.	0.9	115
1606	Systemic immune inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients. <i>Prostate</i> , 2018, 78, 250-256.	1.2	43
1607	Prognostic and Therapeutic Implications of Circulating Androgen Receptor Gene Copy Number in Prostate Cancer Patients Using Droplet Digital Polymerase Chain Reaction. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 197-205.e5.	0.9	7
1608	Radium-223 international early access program: results from the Spanish subset. <i>Future Oncology</i> , 2018, 14, 41-50.	1.1	3
1609	Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 496-508.	3.3	152
1610	Toxicity profile characteristics of novel androgen-deprivation therapy agents in patients with prostate cancer: a meta-analysis. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 193-198.	1.1	24
1611	Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. <i>European Urology</i> , 2018, 73, 715-723.	0.9	105
1612	Integrative transcriptome analysis identifies genes and pathways associated with enzalutamide resistance of prostate cancer. <i>Aging Male</i> , 2018, 21, 231-237.	0.9	8
1613	CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 155-163.	1.5	51
1614	Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer. <i>Nucleic Acids Research</i> , 2018, 46, 1895-1911.	6.5	79
1615	Neuroendocrine tumors of the prostate. <i>Modern Pathology</i> , 2018, 31, 122-132.	2.9	78
1616	Current approaches to incorporation of radium-223 in clinical practice. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 37-47.	2.0	55
1617	Impact of clinical trial participation on survival in patients with castration-resistant prostate cancer: a multi-center analysis. <i>BMC Cancer</i> , 2018, 18, 468.	1.1	12
1618	The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer. <i>Cancer Treatment Reviews</i> , 2018, 68, 25-37.	3.4	37
1619	Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine. , 2018, 6, 21.		33
1620	Validation of an LC-MS/MS method for simultaneous quantitation of enzalutamide, N-desmethylenzalutamide, apalutamide, darolutamide and ORM-15341 in mice plasma and its application to a mice pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 156, 170-180.	1.4	14
1621	The importance of greater speed in drug development for advanced malignancies. <i>Cancer Medicine</i> , 2018, 7, 1824-1836.	1.3	23
1622	Bone Metastases in Prostate Cancer. , 2018, , 323-343.		0

#	ARTICLE	IF	CITATIONS
1623	Inhibition of the Wnt/ $\beta$ 2-Catenin Pathway Overcomes Resistance to Enzalutamide in Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2018, 78, 3147-3162.	0.4	116
1624	PARP inhibitors for homologous recombination-deficient prostate cancer. <i>Expert Opinion on Emerging Drugs</i> , 2018, 23, 123-133.	1.0	24
1625	A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone-and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer. <i>Oncologist</i> , 2018, 23, 656-e64.	1.9	25
1626	LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E4179-E4188.	3.3	160
1627	A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	6
1628	Osimertinib in EGFR Mutation-Positive Advanced NSCLC. <i>New England Journal of Medicine</i> , 2018, 378, 1261-1263.	13.9	20
1629	Long-term outcomes of definitive external-beam radiotherapy for non-metastatic castration-resistant prostate cancer. <i>International Journal of Clinical Oncology</i> , 2018, 23, 749-756.	1.0	5
1630	Optimizing the treatment of metastatic castration-resistant prostate cancer: a Latin America perspective. <i>Medical Oncology</i> , 2018, 35, 56.	1.2	4
1631	Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC). <i>Clinical Cancer Research</i> , 2018, 24, 3149-3162.	3.2	111
1633	Therapeutic Targeting of Sunitinib-Induced AR Phosphorylation in Renal Cell Carcinoma. <i>Cancer Research</i> , 2018, 78, 2886-2896.	0.4	27
1634	New horizons in the management of castrate-resistant prostate cancer. <i>Journal of Clinical Urology</i> , 2018, 11, 258-265.	0.1	2
1635	Transcriptional Regulation in Prostate Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a030437.	2.9	57
1636	Influence of prior oral ethinylestradiol use on the efficacy of enzalutamide for the treatment of castration-resistant prostate cancer in men. <i>International Journal of Urology</i> , 2018, 25, 464-470.	0.5	3
1637	Tumor Growth Kinetics Before and After First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 316-320.	0.6	0
1638	Therapeutic Patterns and Barriers to the Treatment of Advanced Prostate Cancer: A Survey of Academic and Community Urologists in the United States. <i>Urology Practice</i> , 2018, 5, 15-23.	0.2	0
1639	Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey. <i>European Urology Focus</i> , 2018, 4, 235-244.	1.6	14
1640	A case report of enzalutamide administration in a dialysis-dependent patient with castration-resistant prostate cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 143-145.	0.5	6
1641	Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2018, 121, 203-208.	1.3	11

#	ARTICLE	IF	CITATIONS
1642	Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2018, 4, 529-539.	1.6	30
1643	Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-naïve and CYP17 Inhibitor-naïve Patients: Follow-up from the ARADES and ARAFOR Trials. <i>European Urology Focus</i> , 2018, 4, 547-553.	1.6	30
1644	Peri-prostatic Fat Volume Measurement as a Predictive Tool for Castration Resistance in Advanced Prostate Cancer. <i>European Urology Focus</i> , 2018, 4, 858-866.	1.6	22
1645	Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. <i>European Urology Focus</i> , 2018, 4, 874-879.	1.6	30
1646	Neurological complications of new chemotherapy agents. <i>Neuro-Oncology</i> , 2018, 20, 24-36.	0.6	28
1647	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , 2018, 73, 178-211.	0.9	488
1648	Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. <i>European Urology</i> , 2018, 73, 427-435.	0.9	84
1649	Antitumor Activity and Safety of Enzalutamide After Abiraterone Acetate: Seeking the Optimal Treatment Sequence for Castration-resistant Prostate Cancer Patients. <i>European Urology</i> , 2018, 74, 46-47.	0.9	6
1650	Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial. <i>European Urology</i> , 2018, 73, 696-703.	0.9	45
1651	Quality of Life in Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer Using Cabazitaxel or Other Therapies After Previous Docetaxel Chemotherapy: Swiss Observational Treatment Registry. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e151-e159.	0.9	4
1652	Incidence and Characterization of Antiandrogen Withdrawal Syndrome After Discontinuation of Treatment With Enzalutamide in Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e169-e172.	0.9	7
1653	Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naïve Patients With Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 142-148.	0.9	29
1654	Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e233-e242.	0.9	8
1655	Preclinical and Coclinical Studies in Prostate Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a030544.	2.9	3
1656	Drug development for noncastrate prostate cancer in a changed therapeutic landscape. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 168-182.	12.5	7
1657	The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e223-e231.	0.9	27
1658	Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer. <i>Endocrine-Related Cancer</i> , 2018, 25, R1-R9.	1.6	13
1659	Drug-drug interaction potential in men treated with enzalutamide: Mind the gap. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 122-129.	1.1	41



#	ARTICLE	IF	CITATIONS
1660	Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for 24 weeks in Europe. <i>European Urology</i> , 2018, 74, 37-45.	0.9	86
1661	Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial. <i>Journal of Urology</i> , 2018, 199, 147-154.	0.2	33
1662	Multiparametric Magnetic Resonance Imaging of Prostate Cancer Bone Disease. <i>Investigative Radiology</i> , 2018, 53, 96-102.	3.5	36
1663	Treatment-induced changes in the androgen receptor axis: Liquid biopsies as diagnostic/prognostic tools for prostate cancer. <i>Molecular and Cellular Endocrinology</i> , 2018, 462, 56-63.	1.6	12
1664	Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup Results. <i>Journal of Urology</i> , 2018, 199, 459-464.	0.2	24
1665	Treatment of Advanced Prostate Cancer—A Review of Current Therapies and Future Promise. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a030635.	2.9	128
1666	Transition from androgenic to neurosteroidal action of 5 $\alpha$ -androstane-3 $\beta$ , 17 $\beta$ -diol through the type A $\beta$ -aminobutyric acid receptor in prostate cancer progression. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2018, 178, 89-98.	1.2	12
1667	Modeling Clinical Outcomes in Prostate Cancer: Application and Validation of the Discrete Event Simulation Approach. <i>Value in Health</i> , 2018, 21, 416-422.	0.1	12
1668	Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure. <i>JAMA Oncology</i> , 2018, 4, 702.	3.4	35
1669	Expanding the use of abiraterone in prostate cancer: Is earlier always better?. <i>Cancer Biology and Therapy</i> , 2018, 19, 97-100.	1.5	1
1670	HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer. <i>Nature Reviews Urology</i> , 2018, 15, 191-196.	1.9	34
1671	Promising immunotherapy for prostate cancer. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 109-120.	1.4	5
1672	Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. <i>Lancet Oncology</i> , The, 2018, 19, 76-86.	5.1	149
1673	Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program. <i>Oncologist</i> , 2018, 23, 193-202.	1.9	60
1674	Population-based Analysis of Treatment Toxicity Among Men With Castration-resistant Prostate Cancer: A Phase IV Study. <i>Urology</i> , 2018, 113, 138-145.	0.5	6
1675	Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 161.e19-161.e30.	0.8	26
1676	Consensus statements on the management of metastatic prostate cancer from the Hong Kong Urological Association and Hong Kong Society of Urology. <i>BJU International</i> , 2018, 121, 703-715.	1.3	8
1677	Significance and mechanism of androgen receptor overexpression and androgen receptor/mechanistic target of rapamycin cross-talk in hepatocellular carcinoma. <i>Hepatology</i> , 2018, 67, 2271-2286.	3.6	78



#	ARTICLE	IF	CITATIONS
1679	Prognostic value of 18Fâ€“choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 348-354.	3.3	22
1680	Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 81.e9-81.e16.	0.8	15
1681	The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy. <i>Clinical Cancer Research</i> , 2018, 24, 927-938.	3.2	128
1682	SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017). <i>Clinical and Translational Oncology</i> , 2018, 20, 57-68.	1.2	17
1683	Abiraterone acetate + prednisolone treatment beyond prostate specific antigen and radiographic progression in metastatic castration-resistant prostate cancer patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 81.e1-81.e7.	0.8	2
1684	Positron Emission Tomography/Computed Tomographyâ€“Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2018, 4, 217.	3.4	93
1685	Customizing Daily Management of Castrate-resistant Prostate Cancer: Waiting for the Next Step. <i>European Urology</i> , 2018, 74, 24-25.	0.9	0
1686	Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223. <i>Clinical and Translational Oncology</i> , 2018, 20, 679-686.	1.2	5
1687	Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study. <i>International Urology and Nephrology</i> , 2018, 50, 71-78.	0.6	37
1688	Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. <i>Journal of Clinical Oncology</i> , 2018, 36, 376-382.	0.8	75
1689	Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry. <i>Journal of Global Oncology</i> , 2018, 4, 1-12.	0.5	11
1690	Recent trends in the management of advanced prostate cancer. <i>F1000Research</i> , 2018, 7, 1513.	0.8	69
1691	Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. <i>Journal of Clinical Investigation</i> , 2018, 129, 192-208.	3.9	266
1692	Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 363-371.	1.8	27
1693	Circulating Tumor Cell Eradication as an Intermediate Efficacy End Point for Metastatic Castration-Resistant Prostate Cancer: Is There Enough Evidence?. <i>Journal of Clinical Oncology</i> , 2018, 36, 525-527.	0.8	1
1694	Targeting DNA Repair in Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1017-1019.	0.8	4
1695	Balancing Outcomes: Focusing on Value in Treatment of Prostate Cancer. <i>Journal of Oncology Practice</i> , 2018, 14, 588-590.	2.5	0
1696	Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. <i>Journal of Clinical Oncology</i> , 2018, 36, 991-999.	0.8	169

#	ARTICLE	IF	CITATIONS
1697	The Winds of Change: Emerging Therapeutics in Prostate Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 382-390.	1.8	2
1698	Surrogate endpoints in early prostate cancer research. Translational Andrology and Urology, 2018, 7, 472-482.	0.6	14
1699	Efficacy of tasquinimod in men with metastatic castration-resistant prostate cancer. Medicine (United States), 2018, 97, e13145.	0.4	6
1700	Effect of adjuvant hormone therapy in patients with prostate cancer. Medicine (United States), 2018, 97, e13145.	0.4	6
1701	Circulating cell-free DNA is a potential prognostic biomarker of metastatic castration-resistant prostate cancer for taxane therapy. AME Medical Journal, 2018, 3, 68-68.	0.4	5
1702	Expression of Androgen Receptor Variant 7 (AR-V7) in Circulated Tumor Cells and Correlation with Drug Resistance of Prostate Cancer Cells. Medical Science Monitor, 2018, 24, 7051-7056.	0.5	8
1703	The Biological Role of Androgen Receptor in Prostate Cancer Progression. , 2018, , .		1
1704	Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. EJNMMI Research, 2018, 8, 96.	1.1	58
1706	Association between CYP17A1 polymorphisms and response to abiraterone in patients with metastatic castration-resistant prostate cancer: a systematic review. AME Medical Journal, 2018, 3, 50-50.	0.4	2
1708	Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis. Genome Medicine, 2018, 10, 85.	3.6	94
1709	Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer. Scientific Reports, 2018, 8, 17307.	1.6	23
1710	Lutetium-PSMA therapyâ€”a new therapeutic option in metastatic castration-resistant prostate cancer?. Memo - Magazine of European Medical Oncology, 2018, 11, 301-304.	0.3	2
1711	Emerging cell cycle inhibitors for treating metastatic castration-resistant prostate cancer. Expert Opinion on Emerging Drugs, 2018, 23, 271-282.	1.0	15
1712	Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions. OncoTargets and Therapy, 2018, Volume 11, 7353-7368.	1.0	58
1713	Getting to know each other: Integrating radiation and medical oncology training in urology (and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 1	0.3	3
1715	Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials. Therapeutic Advances in Urology, 2018, 10, 445-454.	0.9	10
1716	Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provinces. Canadian Urological Association Journal, 2018, 12, 328-336.	0.3	6
1717	Retrospective Analysis of Patients With Prostate Cancer Initiating GnRH Agonists/Antagonists Therapy Using a German Claims Database: Epidemiological and Patient Outcomes. Frontiers in Oncology, 2018, 8, 543.	1.3	23

#	ARTICLE	IF	CITATIONS
1718	Single-Cell Analysis Identifies LY6D as a Marker Linking Castration-Resistant Prostate Luminal Cells to Prostate Progenitors and Cancer. <i>Cell Reports</i> , 2018, 25, 3504-3518.e6.	2.9	70
1719	scdNet: a computational tool for single-cell differential network analysis. <i>BMC Systems Biology</i> , 2018, 12, 124.	3.0	13
1720	Radium-223 for the treatment of metastatic castration-resistant prostate cancer: A window of opportunity. <i>Actas Urológicas Españolas (English Edition)</i> , 2018, 42, 616-624.	0.2	0
1721	Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review. <i>PLoS ONE</i> , 2018, 13, e0208063.	1.1	24
1722	Targeting Semaphorin 3C in Prostate Cancer With Small Molecules. <i>Journal of the Endocrine Society</i> , 2018, 2, 1381-1394.	0.1	10
1723	Role of the Unconventional Prefoldin Proteins URI and UXT in Transcription Regulation. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1106, 85-94.	0.8	5
1724	Therapy of Advanced Prostate Cancer: Targeting the Androgen Receptor Axis in Earlier Lines of Treatment. <i>Targeted Oncology</i> , 2018, 13, 679-689.	1.7	15
1725	Enzalutamide: A Review in Castration-Resistant Prostate Cancer. <i>Drugs</i> , 2018, 78, 1913-1924.	4.9	60
1726	Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 397.	1.3	20
1727	Castration-Resistant Prostate Cancer Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents: Opportunities and Challenges. <i>Cancers</i> , 2018, 10, 345.	1.7	24
1728	ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. <i>Molecular Cell</i> , 2018, 72, 341-354.e6.	4.5	64
1729	The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2722-2731.	1.9	32
1730	Patient Preferences and Urologist Judgments on Prostate Cancer Therapy in Japan. <i>American Journal of Men's Health</i> , 2018, 12, 1094-1101.	0.7	12
1731	Targeting Crosstalk between Nrf-2, NF- $\kappa$ B and Androgen Receptor Signaling in Prostate Cancer. <i>Cancers</i> , 2018, 10, 352.	1.7	64
1732	Combining anticancer drugs with osteoprotective agents in prostate cancer—A contemporary update. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 488-497.	0.8	0
1733	Management of non-metastatic castrate-resistant prostate cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2018, 70, 223-231.	3.4	17
1734	Aberrations of DNA Repair Pathways in Prostate Cancer: Future Implications for Clinical Practice?. <i>Frontiers in Cell and Developmental Biology</i> , 2018, 6, 71.	1.8	9
1735	Enzalutamide treatment for the whole spectrum of CRPC. <i>Nature Reviews Urology</i> , 2018, 15, 663-665.	1.9	5

#	ARTICLE	IF	CITATIONS
1736	Affinity-Driven Covalent Modulator of the Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) Cascade. <i>Angewandte Chemie</i> , 2018, 130, 7158-7163.	1.6	1
1737	Adrenals Contribute to Growth of Castration-Resistant VCaP Prostate Cancer Xenografts. <i>American Journal of Pathology</i> , 2018, 188, 2890-2901.	1.9	17
1739	Evaluating the Benefits of New Drugs in Health Technology Assessment Using Multiple Criteria Decision Analysis: A Case Study on Metastatic Prostate Cancer With the Dental and Pharmaceuticals Benefits Agency (TLV) in Sweden. <i>MDM Policy and Practice</i> , 2018, 3, 238146831879621.	0.5	5
1740	Neutrophil&ndash;lymphocyte ratio is a predictor of prognosis in patients with castration-resistant prostate cancer: a meta-analysis. <i>Cancer Management and Research</i> , 2018, Volume 10, 3599-3610.	0.9	11
1741	Serum DHEA-S Is a Predictive Parameter of Abiraterone Acetate in Patients with Castration-resistant Prostate Cancer. <i>Anticancer Research</i> , 2018, 38, 5929-5935.	0.5	4
1742	Hormonal treatment and quality of life of prostate cancer patients: new evidence. <i>Minerva Urology and Nephrology</i> , 2018, 70, 144-151.	1.3	25
1743	Utilizing Twitter data for analysis of chemotherapy. <i>International Journal of Medical Informatics</i> , 2018, 120, 92-100.	1.6	50
1745	Design of Peptoid-peptide Macrocycles to Inhibit the $\beta$ -catenin TCF Interaction in Prostate Cancer. <i>Nature Communications</i> , 2018, 9, 4396.	5.8	66
1746	Dormant tumour cells, their niches and the influence of immunity. <i>Nature Cell Biology</i> , 2018, 20, 1240-1249.	4.6	134
1747	Advancing therapies in metastatic castration-resistant prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1797-1804.	0.9	23
1748	Abiraterone acetate, enzalutamide and their sequence for castration-resistant prostate cancer. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 659-664.	1.0	7
1749	Molecular & Diagnostic Imaging in Prostate Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2018, , .	0.8	2
1750	Androgen Deprivation Therapy for Prostate Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1096, 1-30.	0.8	13
1751	Castration-Resistant Prostate Cancer: Mechanisms, Targets and Treatment. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1096, 117-133.	0.8	58
1752	Current therapeutic options in metastatic castration-resistant prostate cancer. <i>Seminars in Oncology</i> , 2018, 45, 303-315.	0.8	63
1753	Plasma androgen receptor and serum chromogranin A in advanced prostate cancer. <i>Scientific Reports</i> , 2018, 8, 15442.	1.6	21
1754	Natural history of castration-resistant prostate cancer in sub-Saharan African black men: a single-centre study of Nigerian men. <i>Ecancermedicalsecience</i> , 2018, 12, 797.	0.6	3
1755	Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program. <i>Future Oncology</i> , 2018, 14, 2691-2699.	1.1	3

#	ARTICLE	IF	CITATIONS
1756	Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 884-890.	0.8	365
1757	Inhibiting Multiple Deubiquitinases to Reduce Androgen Receptor Expression in Prostate Cancer Cells. <i>Scientific Reports</i> , 2018, 8, 13146.	1.6	14
1758	Re: Enzalutamide in Men with Nonmetastatic, Castration-resistant Prostate Cancer. <i>European Urology</i> , 2018, 74, 845.	0.9	0
1759	ERG alterations and mTOR pathway activation in primary prostate carcinomas developing castration-resistance. <i>Pathology Research and Practice</i> , 2018, 214, 1675-1680.	1.0	1
1760	ADT with antiandrogens in prostate cancer induces adverse effect of increasing resistance, neuroendocrine differentiation and tumor metastasis. <i>Cancer Letters</i> , 2018, 439, 47-55.	3.2	35
1761	Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials. <i>BMC Urology</i> , 2018, 18, 77.	0.6	2
1762	RNAs as Candidate Diagnostic and Prognostic Markers of Prostate Cancer—From Cell Line Models to Liquid Biopsies. <i>Diagnostics</i> , 2018, 8, 60.	1.3	15
1763	ASCO 2018: highlights of urothelial cancer and prostate cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 284-290.	0.3	7
1764	Single-centre Experience of Use of Radium 223 with Clinical Outcomes Based on Number of Cycles and Bone Marrow Toxicity. <i>Anticancer Research</i> , 2018, 38, 5423-5427.	0.5	11
1765	Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1404-1416.	5.1	105
1766	Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer. <i>Annals of Oncology</i> , 2018, 29, 2200-2207.	0.6	47
1767	Genome-Based Classification and Therapy of Prostate Cancer. <i>Diagnostics</i> , 2018, 8, 62.	1.3	16
1768	Targeting the turnover of oncoproteins as a new avenue for therapeutics development in castration-resistant prostate cancer. <i>Cancer Letters</i> , 2018, 438, 86-96.	3.2	1
1769	Collateral resistance to taxanes in enzalutamide-resistant prostate cancer through aberrant androgen receptor and its variants. <i>Cancer Science</i> , 2018, 109, 3224-3234.	1.7	21
1770	Evaluation of Response to Enzalutamide Consecutively After Abiraterone Acetate/Prednisone Failure in Patients With Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 429-436.	0.9	8
1771	Genetics and biology of prostate cancer. <i>Genes and Development</i> , 2018, 32, 1105-1140.	2.7	434
1772	Combined androgen blockade achieved better oncological outcome in androgen deprivation therapy for prostate cancer: Analysis of community-based multi-institutional database across Japan using propensity score matching. <i>Cancer Medicine</i> , 2018, 7, 4893-4902.	1.3	18
1773	Role of P53-Senescence Induction in Suppression of LNCaP Prostate Cancer Growth by Cardiotonic Compound Bufalin. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2341-2352.	1.9	32

#	ARTICLE	IF	CITATIONS
1774	Attempt to predict early recurrence of prostate cancer following prostatectomy through machine learning. <i>AME Medical Journal</i> , 2018, 3, 96-96.	0.4	3
1775	Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression. <i>Nature Genetics</i> , 2018, 50, 814-824.	9.4	196
1777	Effectiveness and tolerability of targeted drugs for the treatment of metastatic castration-resistant prostate cancer: a network meta-analysis of randomized controlled trials. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1751-1768.	1.2	11
1778	Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen. <i>British Journal of Radiology</i> , 2018, 91, 20180308.	1.0	50
1779	Impact of GnRH Antagonist and LHRH Agonist on the Gonadal Axis. , 2018, , 31-40.		0
1781	Generation of Prostate Cancer Patient-Derived Xenografts to Investigate Mechanisms of Novel Treatments and Treatment Resistance. <i>Methods in Molecular Biology</i> , 2018, 1786, 1-27.	0.4	7
1782	Amorphous Enzalutamide - Non-isothermal recrystallization kinetics and thermal stability. <i>Thermochimica Acta</i> , 2018, 665, 134-141.	1.2	9
1784	Systemic treatments for high-risk localized prostate cancer. <i>Nature Reviews Urology</i> , 2018, 15, 498-510.	1.9	36
1785	Lu-177-PSMA treatment for metastatic prostate cancer: case examples of major responses. <i>Clinical and Translational Imaging</i> , 2018, 6, 223-237.	1.1	5
1786	Indirect treatment comparison of cabazitaxel for patients with metastatic castrate-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen. <i>PLoS ONE</i> , 2018, 13, e0195790.	1.1	4
1787	Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies. <i>Acta Pharmaceutica Sinica B</i> , 2018, 8, 518-529.	5.7	53
1788	Early Versus Delayed Initiation of Salvage Androgen Deprivation Therapy and Risk of Prostate Cancer-Specific Mortality. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 727-734.	2.3	2
1789	Prognostic and predictive clinical factors in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel. <i>Canadian Urological Association Journal</i> , 2018, 12, E365-E372.	0.3	7
1790	Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 2465-2474.	13.9	782
1791	Local Therapy in Combination with Androgen Deprivation Therapy for Metastatic Prostate Cancer. , 2018, , 189-199.		0
1793	Patterns of Bicalutamide Use in Prostate Cancer Treatment: A U.S. Real-World Analysis Using the SEER-Medicare Database. <i>Advances in Therapy</i> , 2018, 35, 1438-1451.	1.3	9
1794	Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker. <i>Future Oncology</i> , 2018, 14, 2543-2556.	1.1	48
1795	11-Oxygenated androgen precursors are the preferred substrates for aldo-keto reductase 1C3 (AKR1C3): Implications for castration resistant prostate cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2018, 183, 192-201.	1.2	51



#	ARTICLE	IF	CITATIONS
1796	Landmarks in prostate cancer. <i>Nature Reviews Urology</i> , 2018, 15, 627-642.	1.9	78
1797	Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance. <i>Communications Biology</i> , 2018, 1, 100.	2.0	249
1798	Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 572-580.	0.8	187
1799	Survival Outcomes, Prostate-specific Antigen Response, and Tolerance in First and Later Lines of Enzalutamide Treatment for Metastatic Castration-resistant Prostate Cancer: A Real-World Experience in Hong Kong. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 402-412.e1.	0.9	17
1800	The efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer. <i>Cancer Medicine</i> , 2018, 7, 4379-4386.	1.3	29
1801	Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018. <i>Journal of Urology</i> , 2018, 200, 1264-1272.	0.2	91
1802	Baseline prostate-specific antigen levels following treatment with abiraterone acetate as a prognostic factor in castration-resistant prostate cancer. <i>Oncology Letters</i> , 2018, 15, 6806-6814.	0.8	1
1803	Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches. <i>Radiation Oncology</i> , 2018, 13, 98.	1.2	19
1804	Efficacy and safety of different interventions in castration resistant prostate cancer progressing after docetaxel-based chemotherapy: Bayesian network analysis of randomized controlled trials. <i>Journal of Cancer</i> , 2018, 9, 690-701.	1.2	5
1805	Androgen Receptor-CaMKK2 Axis in Prostate Cancer and Bone Microenvironment. <i>Frontiers in Endocrinology</i> , 2018, 9, 335.	1.5	27
1806	Impact of Phosphoproteomics in the Era of Precision Medicine for Prostate Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 28.	1.3	18
1807	Development of Neuroendocrine Prostate Cancers by the Ser/Arg Repetitive Matrix 4-Mediated RNA Splicing Network. <i>Frontiers in Oncology</i> , 2018, 8, 93.	1.3	16
1808	Supraphysiological Testosterone Therapy as Treatment for Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 167.	1.3	11
1809	Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 180.	1.3	33
1810	A novel dried blood spot LC-MS/MS method for the quantification of apalutamide in mouse whole blood: Application to pharmacokinetic study in mice. <i>Biomedical Chromatography</i> , 2018, 32, e4344.	0.8	6
1811	A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. <i>PLoS ONE</i> , 2018, 13, e0198389.	1.1	86
1812	Significance of De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Significant Prognostic But Not Predictive Biomarker in Japanese Patients with Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel. <i>Anticancer Research</i> , 2018, 38, 4179-4185.	0.5	19
1814	An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 457-468.	1.1	18



#	ARTICLE	IF	CITATIONS
1815	Systems pharmacology using mass spectrometry identifies critical response nodes in prostate cancer. <i>Npj Systems Biology and Applications</i> , 2018, 4, 26.	1.4	13
1816	Radio-223 en el tratamiento del c�ncer de pr�stata resistente a la castraci�n metast�sico: una ventana de oportunidad. <i>Actas Urol�gicas Espa�olas</i> , 2018, 42, 616-624.	0.3	0
1817	PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials. <i>Current Drug Targets</i> , 2018, 19, 21-37.	1.0	100
1818	Profiling Prostate Cancer Therapeutic Resistance. <i>International Journal of Molecular Sciences</i> , 2018, 19, 904.	1.8	96
1819	LINE-1 as a therapeutic target for castration-resistant prostate cancer. <i>Frontiers in Bioscience - Landmark</i> , 2018, 23, 1292-1309.	3.0	11
1820	Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5225-5232.	3.2	16
1821	Abiraterone or Enzalutamide in CRPC After Chemotherapy. , 2018, , 139-143.		0
1822	Side Effects and Management of ADT for Prostate Cancer. , 2018, , 149-156.		1
1823	Radiopharmaceutical Therapy in Metastatic CRPC. , 2018, , 175-179.		0
1824	Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2141-2147.	1.0	33
1825	Castration-Resistant Prostate Cancer: Sequencing Oral and Infusion Agents. <i>Current Urology Reports</i> , 2018, 19, 73.	1.0	3
1826	Treatment in the STAMPEDE era for castrate resistant prostate cancer in the UK: ongoing challenges and underappreciated clinical problems. <i>BMC Cancer</i> , 2018, 18, 667.	1.1	4
1827	Novel Approaches of Treatment with Radium-223 Targeted Therapy. , 2018, , 379-391.		0
1828	[ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 825-833.	5.1	823
1829	Palliative Radical Prostatectomy in Men with Metastatic Castration-resistant Prostate Cancer: Only When Your Back Is Against the Wall!. <i>European Urology</i> , 2018, 74, 144-145.	0.9	1
1830	Systematic Review and Network Meta-Analysis of Treatments for Chemotherapy-Naive Patients with Asymptomatic/Mildly Symptomatic Metastatic Castration-Resistant Prostate Cancer. <i>Value in Health</i> , 2018, 21, 1259-1268.	0.1	19
1831	Affinity�Driven Covalent Modulator of the Glyceraldehyde�Phosphate Dehydrogenase (GAPDH) Cascade. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 7040-7045.	7.2	6
1832	Immune Therapy for Castration-Resistant Prostate Cancer. , 2018, , 407-418.		0

#	ARTICLE	IF	CITATIONS
1833	HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumors. <i>Breast Cancer Research</i> , 2018, 20, 8.	2.2	44
1834	Temporal and geographic variation in the systemic treatment of advanced prostate cancer. <i>BMC Cancer</i> , 2018, 18, 258.	1.1	22
1836	Eukaryotic Translation Initiation Factor 4 Gamma 1 (eIF4G1) is upregulated during Prostate cancer progression and modulates cell growth and metastasis. <i>Scientific Reports</i> , 2018, 8, 7459.	1.6	31
1837	Personalization of prostate cancer therapy through phosphoproteomics. <i>Nature Reviews Urology</i> , 2018, 15, 483-497.	1.9	25
1838	Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer. <i>Applied Health Economics and Health Policy</i> , 2018, 16, 133-143.	1.0	9
1839	LSD1 inhibition attenuates androgen receptor V7 splice variant activation in castration resistant prostate cancer models. <i>Cancer Cell International</i> , 2018, 18, 71.	1.8	19
1840	Therapeutic Vaccines for Genitourinary Malignancies. <i>Vaccines</i> , 2018, 6, 55.	2.1	9
1841	Investigational therapies targeting the androgen signaling axis and the androgen receptor and in prostate cancer – recent developments and future directions. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 811-822.	1.9	5
1842	Tumor Cell Autonomous RON Receptor Expression Promotes Prostate Cancer Growth Under Conditions of Androgen Deprivation. <i>Neoplasia</i> , 2018, 20, 917-929.	2.3	12
1843	Mechanistic insights into the differential effects of thalidomide and lenalidomide in metastatic prostate cancer. <i>Future Oncology</i> , 2018, 14, 2383-2401.	1.1	6
1844	Leinal polypeptide promotes NK cells to suppress PCa survival <i>in vitro</i> . <i>Oncology Letters</i> , 2018, 16, 425-430.	0.8	1
1845	The role of ketoconazole in current prostate cancer care. <i>Nature Reviews Urology</i> , 2018, 15, 643-651.	1.9	48
1846	Apalutamide for the treatment of prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 823-836.	1.1	29
1847	Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). <i>Investigational New Drugs</i> , 2018, 36, 919-926.	1.2	7
1848	Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import. <i>Cell</i> , 2018, 174, 1200-1215.e20.	13.5	96
1849	Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 332-340.	0.9	64
1850	PKM2 under hypoxic environment causes resistance to mTOR inhibitor in human castration resistant prostate cancer. <i>Oncotarget</i> , 2018, 9, 27698-27707.	0.8	12
1851	Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens. <i>Journal of Urology</i> , 2018, 200, 956-966.	0.2	105

#	ARTICLE	IF	CITATIONS
1852	Alternative splicing in prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 663-675.	12.5	142
1853	High-Content Screening Campaign to Identify Compounds That Inhibit or Disrupt Androgen Receptor-Transcriptional Intermediary Factor 2 Protein-Protein Interactions for the Treatment of Prostate Cancer. <i>Assay and Drug Development Technologies</i> , 2018, 16, 297-319.	0.6	7
1854	Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2018, 78, 5731-5740.	0.4	40
1855	Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer?. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 419-430.	2.0	3
1856	Options After Chemotherapy for Patients with Metastatic, Castration-Resistant Prostate Cancer. , 2018, , 121-134.		0
1857	Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2197-2205.	1.9	30
1858	Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database. <i>European Urology Oncology</i> , 2018, 1, 467-475.	2.6	25
1859	The efficacy and safety comparison of docetaxel, cabazitaxel, estramustine, and mitoxantrone for castration-resistant prostate cancer: A network meta-analysis. <i>International Journal of Surgery</i> , 2018, 56, 133-140.	1.1	9
1860	Overview of Genetically Engineered Mouse Models of Prostate Cancer and Their Applications in Drug Discovery. <i>Current Protocols in Pharmacology</i> , 2018, 81, e39.	4.0	6
1861	Changes in the Epigenetic Landscape of Prostate Cancer. , 2018, , 59-85.		0
1862	Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy. <i>Prostate</i> , 2018, 78, 1035-1041.	1.2	11
1863	Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 318-324.	0.9	4
1864	Cancer symptom response as an oncology clinical trial end point. <i>Expert Review of Quality of Life in Cancer Care</i> , 2018, 3, 35-46.	0.6	10
1865	Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer. <i>European Urology</i> , 2018, 74, 376-386.	0.9	58
1866	Regulation of prostate cancer by hormone-responsive G protein-coupled receptors. , 2018, 191, 135-147.		22
1867	Bone-Modifying Agents and Anticancer Agents with Bone Effects. , 2019, , 13-25.		1
1868	Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer. <i>Clinical and Translational Oncology</i> , 2019, 21, 249-258.	1.2	4
1869	Hormone-Responsive Cancers. , 2019, , 717-741.e8.		2

#	ARTICLE	IF	CITATIONS
1870	Real world evidence: Abiraterone use post-docetaxel in metastatic castrate-resistant prostate cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1293-1300.	0.5	3
1871	Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 24-38.	2.0	215
1872	Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression. <i>Prostate</i> , 2019, 79, 54-61.	1.2	20
1873	Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer. <i>Targeted Oncology</i> , 2019, 14, 1-12.	1.7	12
1874	An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (<sc>CAPRISTANA</sc>). <i>BJU International</i> , 2019, 123, 456-464.	1.3	15
1875	Potential role of rituximab in metastatic castrate-resistant prostate cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1509-1511.	0.5	8
1876	Inhibiting geranylgeranyl diphosphate synthesis reduces nuclear androgen receptor signaling and neuroendocrine differentiation in prostate cancer cell models. <i>Prostate</i> , 2019, 79, 21-30.	1.2	12
1877	Non-metastatic castration resistant prostate cancer: a review of current and emerging medical therapies. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 16-23.	2.0	22
1878	Management of patients with advanced prostate cancer in the Asia Pacific region: "real world"™ consideration of results from the Advanced Prostate Cancer Consensus Conference <sc>(APCCC)</sc> 2017. <i>BJU International</i> , 2019, 123, 22-34.	1.3	32
1879	Current and potential future role of PSMA-PET in patients with castration-resistant prostate cancer. <i>World Journal of Urology</i> , 2019, 37, 457-467.	1.2	19
1880	In Silico Identification of Piperazine Linked Thiohydantoin Derivatives as Novel Androgen Antagonist in Prostate Cancer Treatment. <i>International Journal of Peptide Research and Therapeutics</i> , 2019, 25, 845-860.	0.9	15
1881	Sequencing strategies in the new treatment landscape of prostate cancer. <i>Future Oncology</i> , 2019, 15, 2967-2982.	1.1	6
1882	Comparison of Radiographic Progression-Free Survival and PSA Response on Sequential Treatment Using Abiraterone and Enzalutamide for Newly Diagnosed Castration-Resistant Prostate Cancer: A Propensity Score Matched Analysis from Multicenter Cohort. <i>Journal of Clinical Medicine</i> , 2019, 8, 1251.	1.0	12
1883	Insulin Enhances Migration and Invasion in Prostate Cancer Cells by Up-Regulation of FOXC2. <i>Frontiers in Endocrinology</i> , 2019, 10, 481.	1.5	22
1884	Nuclear receptors: recent drug discovery for cancer therapies. <i>Endocrine Reviews</i> , 2019, 40, 1207-1249.	8.9	65
1885	Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. <i>Cancer</i> , 2019, 125, 4003-4010.	2.0	15
1886	Increased infiltration of CCR4-positive regulatory T cells in prostate cancer tissue is associated with a poor prognosis. <i>Prostate</i> , 2019, 79, 1658-1665.	1.2	51
1887	The small molecule WNT/β-catenin inhibitor CWP232291 blocks the growth of castration-resistant prostate cancer by activating the endoplasmic reticulum stress pathway. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 342.	3.5	46

#	ARTICLE	IF	CITATIONS
1888	<p>Relative value assessment: characterizing the benefit of oncology therapies through diverse survival metrics from a US perspective</p>. ClinicoEconomics and Outcomes Research, 2019, Volume 11, 199-219.	0.7	1
1889	Results of a Real-world Study of Enzalutamide and Abiraterone Acetate With Prednisone Tolerability (REAAcT). Clinical Genitourinary Cancer, 2019, 17, 457-463.e6.	0.9	34
1890	Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants. European Journal of Medicinal Chemistry, 2019, 182, 111608.	2.6	16
1891	Defining End Points in Phase II Trials of Metastatic Castration-Resistant Prostate Cancer. Re: Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot Study. Clinical Genitourinary Cancer, 2019, 17, e886-e887.	0.9	1
1892	SF3B2-Mediated RNA Splicing Drives Human Prostate Cancer Progression. Cancer Research, 2019, 79, 5204-5217.	0.4	51
1894	Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications. Medicines (Basel, Switzerland), 2019, 6, 82.	0.7	68
1895	A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer. Cancer Chemotherapy and Pharmacology, 2019, 84, 759-770.	1.1	4
1896	Quality-of-Life Assessment and Reporting in Prostate Cancer: Systematic Review of Phase 3 Trials Testing Anticancer Drugs Published Between 2012 and 2018. Clinical Genitourinary Cancer, 2019, 17, 332-347.e2.	0.9	9
1897	No survival benefit found after extended treatment with docetaxel for patients with castration-resistant prostate cancer. Prostate, 2019, 79, 1604-1610.	1.2	1
1898	Bone Target Therapy in Urologic Malignancies. , 2019, , 77-93.		0
1899	<i>BRN4</i> Is a Novel Driver of Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer and Is Selectively Released in Extracellular Vesicles with <i>BRN2</i>. Clinical Cancer Research, 2019, 25, 6532-6545.	3.2	46
1900	Second brazilian consensus on the treatment of advanced prostate cancer: a SBOC-SBU-SBRT panel review. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2019, 45, 449-458.	0.7	6
1901	Sex Steroids, Cognate Receptors, and Aging. , 2019, , 265-296.		0
1902	The Achievement of Long-Term CRPC Control in a Patient with Enzalutamide-Induced Nausea and Fatigue after Overcoming the Adverse Events with a Temporary Drug Holiday. Case Reports in Oncology, 2019, 12, 568-572.	0.3	4
1903	LSD1 Activates PI3K/AKT Signaling Through Regulating p85 Expression in Prostate Cancer Cells. Frontiers in Oncology, 2019, 9, 721.	1.3	14
1904	AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer. Molecular Cancer Therapeutics, 2019, 18, 1875-1886.	1.9	51
1905	Clinical concepts for cabazitaxel in the management of metastatic castration-resistant prostate cancer. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 288-295.	0.7	7
1906	The androgen receptor antagonist enzalutamide induces apoptosis, dysregulates the heat shock protein system, and diminishes the androgen receptor and estrogen receptor $\beta$ 1 expression in prostate cancer cells. Journal of Cellular Biochemistry, 2019, 120, 16711-16722.	1.2	16

#	ARTICLE	IF	CITATIONS
1907	Synthesis of silver nanoparticles (AgNPs) from leaf extract of <i>Salvia miltiorrhiza</i> and its anticancer potential in human prostate cancer LNCaP cell lines. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2019, 47, 2846-2854.	1.9	42
1908	ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2974-2986.	0.8	643
1909	An exploratory retrospective multicenter study of prognostic factors in mCRPC patients undergoing enzalutamide treatment: Focus on early PSA decline and kinetics at time of progression. <i>Prostate</i> , 2019, 79, 1457-1465.	1.2	21
1910	Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 813.e1-813.e9.	0.8	16
1911	Could Circulating Tumor Cells and ARV7 Detection Improve Clinical Decisions in Metastatic Castration-Resistant Prostate Cancer? The Istituto Nazionale dei Tumori (INT) Experience. <i>Cancers</i> , 2019, 11, 980.	1.7	18
1912	Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. <i>Scientific Reports</i> , 2019, 9, 10739.	1.6	69
1913	Novel treatment options in the management of metastatic castration-naïve prostate cancer; which treatment modality to choose?. <i>Annals of Oncology</i> , 2019, 30, 1591-1600.	0.6	16
1914	Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer. <i>Translational Research</i> , 2019, 212, 89-103.	2.2	47
1915	2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guidelines for the management of castration-resistant prostate cancer (CRPC). <i>Canadian Urological Association Journal</i> , 2019, 13, 307-314.	0.3	21
1916	Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 14573-14582.	3.3	69
1917	Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies. <i>Clinical Cancer Research</i> , 2019, 25, 5623-5637.	3.2	23
1918	DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway. <i>Clinical Cancer Research</i> , 2019, 25, 5608-5622.	3.2	17
1919	Phenotypic Profiling of Circulating Tumor Cells in Metastatic Prostate Cancer Patients Using Nanoparticle-Mediated Ranking. <i>Analytical Chemistry</i> , 2019, 91, 9348-9355.	3.2	29
1920	Flutamide as an Alternative Anti-androgen Agent and Predictor of the Efficacy of Novel Androgen Receptor-targeted Agents. <i>Anticancer Research</i> , 2019, 39, 3879-3885.	0.5	4
1921	Abiraterone Acetate and Enzalutamide: Similar Efficacy in Treating Post Docetaxel Metastatic Castration-resistant Prostate Cancer: Single Center Experience. <i>Anticancer Research</i> , 2019, 39, 3901-3908.	0.5	14
1922	Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer. <i>JAMA Network Open</i> , 2019, 2, e196562.	2.8	75
1923	Clonal Evolution and Epithelial Plasticity in the Emergence of AR-Independent Prostate Carcinoma. <i>Trends in Cancer</i> , 2019, 5, 440-455.	3.8	29
1924	Circulating Tumor Cell-Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer. <i>Neoplasia</i> , 2019, 21, 802-809.	2.3	32



#	ARTICLE	IF	CITATIONS
1925	Serum $\hat{3}$ -Glutamyltransferase as a Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide. <i>Anticancer Research</i> , 2019, 39, 5773-5780.	0.5	8
1926	Risk Factors for Poor Survival in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel in Japan. <i>Anticancer Research</i> , 2019, 39, 5803-5809.	0.5	8
1927	Androgen Receptor Modulation Optimized for Responseâ€”Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7â€“expressing Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 76, 843-851.	0.9	36
1928	Exposureâ€Response Assessment of Enzalutamide and Its Major Metabolites in a Realâ€World Cohort of Patients with Metastatic Castrationâ€Resistant Prostate Cancer. <i>Pharmacotherapy</i> , 2019, 39, 1137-1145.	1.2	9
1929	Plasma Androgen Receptor in Prostate Cancer. <i>Cancers</i> , 2019, 11, 1719.	1.7	13
1930	Design and synthesis of a phenyl C-glycoside derivative of Spliceostatin A and its biological evaluation toward prostate cancer treatment. <i>Tetrahedron Letters</i> , 2019, 60, 151313.	0.7	8
1931	&lt;p&gt;Darolutamide For Castration-Resistant Prostate Cancer&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 8769-8777.	1.0	24
1932	Improved Androgen Receptor Splice Variant 7 Detection Using a Highly Sensitive Assay to Predict Resistance to Abiraterone or Enzalutamide in Metastatic Prostate Cancer Patients. <i>European Urology Oncology</i> , 2021, 4, 609-617.	2.6	16
1933	Revealing Metabolic Liabilities of Ralaniten To Enhance Novel Androgen Receptor Targeted Therapies. <i>ACS Pharmacology and Translational Science</i> , 2019, 2, 453-467.	2.5	20
1934	Radium-223 mechanism of action: implications for use in treatment combinations. <i>Nature Reviews Urology</i> , 2019, 16, 745-756.	1.9	71
1935	Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry. <i>European Urology Oncology</i> , 2021, 4, 618-627.	2.6	6
1936	Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 3518-3527.	0.8	47
1937	Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naïve castration-resistant prostate cancer. , 2019, 7, 302.		72
1939	Realâ€world outcomes of sipuleucelâ€ treatment in PROCEED, a prospective registry of men with metastatic castrationâ€resistant prostate cancer. <i>Cancer</i> , 2019, 125, 4172-4180.	2.0	49
1940	TheraP: a randomized phase 2 trial of <sup>177</sup>Luâ€sc>PSMA</sc>â€617 theranostic treatment vs cabazitaxel in progressive metastatic castrationâ€resistant prostate cancer (Clinical Trial Protocol) Tj ETQq0 0 0 rg 1.1/Overl on 1.0 Tf 50	1.1	10
1941	Previous, Current, and Future Pharmacotherapy and Diagnosis of Prostate Cancerâ€”A Comprehensive Review. <i>Diagnostics</i> , 2019, 9, 161.	1.3	17
1942	Metronomic Oral Cyclophosphamide in 2 Heavilyâ€Pretreated Patients With Metastatic Castration-resistant Prostate Cancer With Homologous Recombination Deficiency (HRD): A Case Report. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 157-160.	0.9	3
1943	Preference for enzalutamide capsules versus tablet pills in patients with prostate cancer. <i>International Journal of Urology</i> , 2019, 26, 1161-1162.	0.5	4



#	ARTICLE	IF	CITATIONS
1944	Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel. <i>Cancers</i> , 2019, 11, 1212.	1.7	21
1945	Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers. <i>Cancers</i> , 2019, 11, 1225.	1.7	15
1946	Metastatic Latency, a Veiled Threat. <i>Frontiers in Immunology</i> , 2019, 10, 1836.	2.2	19
1947	CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation. <i>Cancer Discovery</i> , 2019, 9, 1538-1555.	7.7	88
1948	PARP Inhibition Suppresses GR $\alpha$ -MYCN $\alpha$ -CDK5 $\alpha$ -RB1 $\alpha$ -E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6839-6851.	3.2	50
1949	Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer. <i>Current Oncology Reports</i> , 2019, 21, 91.	1.8	14
1950	Sensitivity of 18F-fluorodihydrotestosterone PET-CT to count statistics and reconstruction protocol in metastatic castration-resistant prostate cancer. <i>EJNMMI Research</i> , 2019, 9, 70.	1.1	10
1952	<p></p>Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 7253-7262.	0.9	8
1953	Quality of Life $\alpha$ -Focused Decision-Making for Prostate Cancer. <i>Current Urology Reports</i> , 2019, 20, 57.	1.0	15
1954	The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. <i>Future Oncology</i> , 2019, 15, 1469-1479.	1.1	8
1955	Emerging therapeutic agents for genitourinary cancers. <i>Journal of Hematology and Oncology</i> , 2019, 12, 89.	6.9	33
1956	Role of Androgen Receptor in Prostate Cancer: A Review. <i>World Journal of Men's Health</i> , 2019, 37, 288.	1.7	270
1957	Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance. <i>Journal of Medical Economics</i> , 2019, 22, 1202-1209.	1.0	22
1958	Design, synthesis, and biological evaluation of novel androst-17 $\beta$ -amide structurally related compounds as dual 5 $\alpha$ -reductase inhibitors and androgen receptor antagonists. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2019, 34, 1597-1606.	2.5	4
1959	Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 858.	1.3	125
1960	Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 2961-2967.	0.8	13
1961	TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer. <i>PLoS ONE</i> , 2019, 14, e0213488.	1.1	20
1962	Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy. <i>European Urology Oncology</i> , 2019, 2, 670-676.	2.6	134

#	ARTICLE	IF	CITATIONS
1963	Role of GDF15 in methylseleninic acid-mediated inhibition of cell proliferation and induction of apoptosis in prostate cancer cells. <i>PLoS ONE</i> , 2019, 14, e0222812.	1.1	5
1964	HSD3B1 Genotypes Conferring Adrenal-Restrictive and Adrenal-Permissive Phenotypes in Prostate Cancer and Beyond. <i>Endocrinology</i> , 2019, 160, 2180-2188.	1.4	33
1965	A registry-based study evaluating overall survival and treatment duration in Swedish patients with metastatic castration-resistant prostate cancer treated with enzalutamide. <i>Scandinavian Journal of Urology</i> , 2019, 53, 312-318.	0.6	5
1966	Pursuing Global Equity in Access to Cancer Drugs. <i>JAMA Oncology</i> , 2019, 5, 1535.	3.4	1
1967	Assays to Interrogate the Ability of Compounds to Inhibit the AF-2 or AF-1 Transactivation Domains of the Androgen Receptor. <i>Assay and Drug Development Technologies</i> , 2019, 17, 364-386.	0.6	4
1969	Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer.. <i>Cancers</i> , 2019, 11, 1355.	1.7	54
1970	Increased Risk of Hypertension with Enzalutamide in Prostate Cancer: A Meta-Analysis. <i>Cancer Investigation</i> , 2019, 37, 478-488.	0.6	14
1971	Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2506-2518.	13.9	403
1972	CPT1A Supports Castration-Resistant Prostate Cancer in Androgen-Deprived Conditions. <i>Cells</i> , 2019, 8, 1115.	1.8	23
1973	Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 801.	1.3	205
1974	Chemoprevention of Prostate Cancer by Natural Agents: Evidence from Molecular and Epidemiological Studies. <i>Anticancer Research</i> , 2019, 39, 5231-5259.	0.5	52
1975	Past, Current, and Future of Immunotherapies for Prostate Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 884.	1.3	89
1976	Orally Bioavailable Androgen Receptor Degradar, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6764-6780.	3.2	46
1977	The Potential for Chemotherapy-Free Strategies in Advanced Prostate Cancer. <i>Current Urology</i> , 2019, 13, 57-63.	0.4	4
1978	Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients. <i>Annals of Nuclear Medicine</i> , 2019, 33, 945-954.	1.2	32
1979	Towards precision oncology in advanced prostate cancer. <i>Nature Reviews Urology</i> , 2019, 16, 645-654.	1.9	156
1980	A primer of deuterium in drug design. <i>Future Medicinal Chemistry</i> , 2019, 11, 2039-2042.	1.1	63
1981	Changing the Timing of Enzalutamide Intake from Morning to before Sleep at Night Overcame Enzalutamide-Induced Dysgeusia. <i>Case Reports in Oncology</i> , 2019, 12, 589-594.	0.3	3

#	ARTICLE	IF	CITATIONS
1982	Pharmacokinetics and Safety of Enzalutamide in Healthy Chinese Male Volunteers. <i>Clinical Therapeutics</i> , 2019, 41, 261-268.	1.1	1
1983	Treatment of Advanced Prostate Cancer. <i>Annual Review of Medicine</i> , 2019, 70, 479-499.	5.0	417
1984	Cardiac arrhythmia considerations of hormone cancer therapies. <i>Cardiovascular Research</i> , 2019, 115, 878-894.	1.8	42
1985	Outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 872-881.	1.0	9
1986	Abiraterone acetate in combination with prednisone in the treatment of metastatic hormone-sensitive prostate cancer: clinical evidence and experience. <i>Therapeutic Advances in Urology</i> , 2019, 11, 175628721882080.	0.9	2
1987	Application of Prostate Cancer Models for Preclinical Study: Advantages and Limitations of Cell Lines, Patient-Derived Xenografts, and Three-Dimensional Culture of Patient-Derived Cells. <i>Cells</i> , 2019, 8, 74.	1.8	113
1988	Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program. <i>BMC Cancer</i> , 2019, 19, 12.	1.1	36
1989	Clinical Outcomes of <sup>177</sup> Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy. <i>Journal of Nuclear Medicine</i> , 2019, 60, 955-962.	2.8	93
1990	PLC $\beta$ knockdown overcomes drug resistance to androgen receptor antagonist in castration-resistant prostate cancer by suppressing the wnt3a/ $\beta$ -catenin pathway. <i>Journal of Cellular Physiology</i> , 2019, 234, 15472-15486.	2.0	6
1991	Rational drug design for androgen receptor and glucocorticoids receptor dual antagonist. <i>European Journal of Medicinal Chemistry</i> , 2019, 166, 232-242.	2.6	8
1992	Mechanistic Investigation of the Androgen Receptor DNA-Binding Domain Inhibitor Pyrvinium. <i>ACS Omega</i> , 2019, 4, 2472-2481.	1.6	16
1993	Communication between the Ligand-Binding Pocket and the Activation Function-2 Domain of Androgen Receptor Revealed by Molecular Dynamics Simulations. <i>Journal of Chemical Information and Modeling</i> , 2019, 59, 842-857.	2.5	30
1994	Urine-based liquid biopsy: non-invasive and sensitive AR-V7 detection in urinary EVs from patients with prostate cancer. <i>Lab on A Chip</i> , 2019, 19, 87-97.	3.1	56
1995	Changing the enzalutamide form from a capsule to a tablet improves the adherence of medicine intake: A case of a significant decrease in the prostate-specific antigen level and improvement in radiographic findings. <i>IJU Case Reports</i> , 2019, 2, 143-145.	0.1	3
1996	Adoption of Abiraterone and Enzalutamide by Urologists. <i>Urology</i> , 2019, 131, 176-183.	0.5	18
1997	Androgen receptor modulators: a review of recent patents and reports (2012-2018). <i>Expert Opinion on Therapeutic Patents</i> , 2019, 29, 439-453.	2.4	26
1998	Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 4624-4633.	3.2	21
1999	Prognostic significance of antihypertensive agents in men with castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 813.e21-813.e26.	0.8	0

#	ARTICLE	IF	CITATIONS
2000	FAM84B promotes prostate tumorigenesis through a network alteration. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591984637.	1.4	17
2001	A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA). <i>BMC Cancer</i> , 2019, 19, 572.	1.1	3
2002	Prognostic implication of gait function following treatment for spinal cord compression in men diagnosed with prostate cancer. <i>Scandinavian Journal of Urology</i> , 2019, 53, 222-228.	0.6	1
2003	Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e946-e956.	0.9	5
2004	Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase. <i>British Journal of Cancer</i> , 2019, 121, 237-248.	2.9	15
2005	Biomarkers of Prostate Cancer. , 2019, , 125-132.		0
2006	Systemic Treatment of Prostate Cancer in Elderly Patients: Current Role and Safety Considerations of Androgen-Targeting Strategies. <i>Drugs and Aging</i> , 2019, 36, 701-717.	1.3	14
2007	Who Dies From Prostate Cancer? An Analysis of the Surveillance, Epidemiology and End Results Database. <i>Clinical Oncology</i> , 2019, 31, 630-636.	0.6	19
2008	Inhibition of USP14 enhances the sensitivity of breast cancer to enzalutamide. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 220.	3.5	58
2010	Novel Thienopyrimidine Derivative, RP-010, Induces $\beta$ -Catenin Fragmentation and Is Efficacious against Prostate Cancer Cells. <i>Cancers</i> , 2019, 11, 711.	1.7	13
2011	Lipid Metabolism and Endocrine Resistance in Prostate Cancer, and New Opportunities for Therapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2626.	1.8	80
2012	Abiraterone plus prednisone or enzalutamide in patients with metastatic castration-resistant prostate cancer: is a question of quality?. <i>AME Medical Journal</i> , 2019, 4, 24-24.	0.4	0
2013	Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 121-131.	13.9	982
2014	Radiometabolic Therapy of Bone Metastases. , 2019, , 85-99.		0
2015	Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer. <i>BMC Cancer</i> , 2019, 19, 524.	1.1	12
2016	Targeting Angiogenesis in Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2676.	1.8	94
2017	Blocking the PD-1/PD-L1 axis in advanced prostate cancer: are we moving in the right direction?. <i>Annals of Translational Medicine</i> , 2019, 7, S7-S7.	0.7	20
2018	Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients. <i>European Journal of Cancer</i> , 2019, 116, 116-136.	1.3	134

#	ARTICLE	IF	CITATIONS
2019	Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2019, 116, 158-168.	1.3	29
2020	<i>Nuclear Medicine Therapy.</i> , 2019, , .		5
2021	Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression. <i>Anticancer Research</i> , 2019, 39, 2467-2473.	0.5	10
2022	The Patient Journey in Prostate Cancer: Key Points for Nurses. <i>Principles of Specialty Nursing</i> , 2019, , 195-213.	0.2	0
2023	Upregulation of Scavenger Receptor B1 Is Required for Steroidogenic and Nonsteroidogenic Cholesterol Metabolism in Prostate Cancer. <i>Cancer Research</i> , 2019, 79, 3320-3331.	0.4	33
2024	Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why. <i>Tumori</i> , 2019, 105, 367-377.	0.6	17
2025	Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer. <i>Translational Oncology</i> , 2019, 12, 871-878.	1.7	22
2026	Serum testosterone level is a useful biomarker for determining the optimal treatment for castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 485-491.	0.8	18
2027	Docetaxel-based chemotherapy combined with dexamethasone 1Âmg daily oral administration for castration-resistant prostate cancer: Long-term outcomes. <i>International Journal of Urology</i> , 2019, 26, 797-803.	0.5	8
2028	Castration-resistant prostate cancer: Androgen receptor inactivation induces telomere DNA damage, and damage response inhibition leads to cell death. <i>PLoS ONE</i> , 2019, 14, e0211090.	1.1	10
2029	Cigarette smoking augments androgen receptor activity and promotes resistance to antiandrogen therapy. <i>Prostate</i> , 2019, 79, 1147-1155.	1.2	8
2030	Consideration of breast cancer subtype in targeting the androgen receptor. , 2019, 200, 135-147.		65
2031	Bispecific radioligands targeting prostate-specific membrane antigen and gastrin-releasing peptide receptors on the surface of prostate cancer cells. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2019, 62, 510-522.	0.5	7
2032	Management of advanced prostate cancer in a middle-income country: real-world consideration of the Advanced Prostate Cancer Consensus Conference 2017. <i>BJU International</i> , 2019, 124, 373-382.	1.3	11
2033	Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer. <i>Acta Pharmacologica Sinica</i> , 2019, 40, 1436-1447.	2.8	30
2034	Quantification of Bone Metastasis of Castration-resistant Prostate Cancer After Enzalutamide and Abiraterone Acetate Using Bone Scan Index on Bone Scintigraphy. <i>Anticancer Research</i> , 2019, 39, 2553-2559.	0.5	11
2036	A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities. <i>Nucleic Acids Research</i> , 2019, 47, 5634-5647.	6.5	41
2037	Red Cell Distribution Width Predicts Prostate-Specific Antigen Response and Survival of Patients With Castration-Resistant Prostate Cancer Treated With Androgen Receptor Axis-Targeted Agents. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 223-230.	0.9	13

#	ARTICLE	IF	CITATIONS
2038	Factors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer. JAMA Network Open, 2019, 2, e192589.	2.8	44
2039	Enzalutamide-induced severe thrombocytopenia complicated by a seizure in a 76-year-old man with castration-resistant prostate cancer. IJU Case Reports, 2019, 2, 9-11.	0.1	3
2040	Neoadjuvant chemotherapy for high-risk prostatic adenocarcinoma. IJU Case Reports, 2019, 2, 61-64.	0.1	1
2041	Interplay Between SOX9, Wnt/ $\beta$ 2-Catenin and Androgen Receptor Signaling in Castration-Resistant Prostate Cancer. International Journal of Molecular Sciences, 2019, 20, 2066.	1.8	43
2042	Multimodal Approach to Outcome Prediction in Metastatic Castration-Resistant Prostate Cancer by Integrating Functional Imaging and Plasma DNA Analysis. JCO Precision Oncology, 2019, 3, 1-13.	1.5	8
2043	Management algorithms for metastatic prostate cancer. Canadian Urological Association Journal, 2019, 13, 50-60.	0.3	6
2045	Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer. European Urology, 2019, 76, 676-685.	0.9	62
2046	A bypass mechanism of abiraterone-resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling. Prostate, 2019, 79, 937-948.	1.2	14
2047	Loss of Notch1 Activity Inhibits Prostate Cancer Growth and Metastasis and Sensitizes Prostate Cancer Cells to Antiandrogen Therapies. Molecular Cancer Therapeutics, 2019, 18, 1230-1242.	1.9	36
2049	Targeting hormone refractory prostate cancer by in vivo selected DNA libraries in an orthotopic xenograft mouse model. Scientific Reports, 2019, 9, 4976.	1.6	14
2050	Meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer. Medicine (United States), 2019, 98, e14254.	0.4	1
2051	The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer. Clinical Medicine Insights: Oncology, 2019, 13, 117955491983392.	0.6	30
2052	Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer. Future Oncology, 2019, 15, 1115-1123.	1.1	9
2053	Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs. Journal of Market Access & Health Policy, 2019, 7, 1562861.	0.8	11
2054	The Pioneering Role of GATA2 in Androgen Receptor Variant Regulation Is Controlled by Bromodomain and Extraterminal Proteins in Castrate-Resistant Prostate Cancer. Molecular Cancer Research, 2019, 17, 1264-1278.	1.5	16
2055	<i>In situ</i> hydrogelation of bicalutamide-peptide conjugates at prostate tissue for smart drug release based on pH and enzymatic activity. Nanoscale, 2019, 11, 5030-5037.	2.8	22
2056	Organoids Increase the Predictive Value of in vitro Cancer Chemoprevention Studies for in vivo Outcome. Frontiers in Oncology, 2019, 9, 77.	1.3	4
2058	Emerging therapeutic targets for patients with advanced prostate cancer. Cancer Treatment Reviews, 2019, 76, 1-9.	3.4	26



#	ARTICLE	IF	CITATIONS
2059	Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer. <i>European Journal of Medicinal Chemistry</i> , 2019, 171, 265-281.	2.6	12
2060	Combination of phospholipase C $\mu$ knockdown with GANT61 sensitizes castration-resistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway. <i>Oncology Reports</i> , 2019, 41, 2689-2702.	1.2	10
2061	Enzalutamide, an oral androgen receptor inhibitor for treatment of castration-resistant prostate cancer. <i>Future Oncology</i> , 2019, 15, 1437-1457.	1.1	16
2062	Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study. <i>World Journal of Urology</i> , 2019, 37, 2631-2637.	1.2	69
2063	Systemic treatment for metastatic prostate cancer. <i>Asian Journal of Urology</i> , 2019, 6, 162-168.	0.5	31
2064	Assessment of Simplified Methods for Quantification of 18F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1221-1227.	2.8	10
2065	Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-14.	1.5	23
2066	Effect of bisphosphonates on overall survival in subgroups of patients with prostate cancer. <i>Clinical and Experimental Metastasis</i> , 2019, 36, 199-209.	1.7	8
2067	Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable ROR $\gamma$ 3 Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 4716-4730.	2.9	34
2068	Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the Tj ETQq1 1 0.7&4314 rgBT/Overlo		
2069	Synergistic effects of hormone therapy drugs and usnic acid on hormone receptor-positive breast and prostate cancer cells. <i>Journal of Biochemical and Molecular Toxicology</i> , 2019, 33, e22338.	1.4	5
2070	Functional and Mechanistic Interrogation of BET Bromodomain Degradors for the Treatment of Metastatic Castration-resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 4038-4048.	3.2	26
2071	Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond. <i>Endocrine-Related Cancer</i> , 2019, 26, R31-R52.	1.6	49
2072	Effectiveness of Platinum-Based Chemotherapy in Patients With Metastatic Prostate Cancer: Systematic Review and Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e627-e644.	0.9	17
2073	Metastatic castration-sensitive prostate cancer: Abiraterone, docetaxel, or enzalutamide. <i>Cancer</i> , 2019, 125, 1777-1788.	2.0	50
2074	Hematologic toxicity of radium-223 in elderly patients with metastatic Castration Resistant Prostate Cancer: a Real-life experience. <i>Prostate International</i> , 2019, 7, 25-29.	1.2	10
2075	The Contributions of Prostate Cancer Stem Cells in Prostate Cancer Initiation and Metastasis. <i>Cancers</i> , 2019, 11, 434.	1.7	74
2076	NCL1, A Highly Selective Lysine-Specific Demethylase 1 Inhibitor, Suppresses Castration-Resistant Prostate Cancer Growth via Regulation of Apoptosis and Autophagy. <i>Journal of Clinical Medicine</i> , 2019, 8, 442.	1.0	19



#	ARTICLE	IF	CITATIONS
2077	Synthesis of gold nanoparticles from leaf <i>Panax notoginseng</i> and its anticancer activity in pancreatic cancer PANC-1 cell lines. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2019, 47, 1216-1223.	1.9	35
2078	Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers. <i>Endocrine Connections</i> , 2019, 8, R10-R26.	0.8	33
2079	Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer. <i>Cancer Research</i> , 2019, 79, 2580-2592.	0.4	85
2080	Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 1051-1061.	0.8	174
2081	Clinical Trial Outcomes. <i>JACC: Heart Failure</i> , 2019, 7, 272-273.	1.9	6
2082	DHX15 is upregulated in castration-resistant prostate cancer and required for androgen receptor sensitivity to low DHT concentrations. <i>Prostate</i> , 2019, 79, 657-666.	1.2	10
2083	Prostate Cancer Disparity, Chemoprevention, and Treatment by Specific Medicinal Plants. <i>Nutrients</i> , 2019, 11, 336.	1.7	16
2084	Current Status and Growth of Nuclear Theranostics in Singapore. <i>Nuclear Medicine and Molecular Imaging</i> , 2019, 53, 96-101.	0.6	1
2085	Management algorithms for prostate-specific antigen progression in prostate cancer: Biochemical recurrence after definitive therapy and progression to non-metastatic castrate-resistant prostate cancer. <i>Canadian Urological Association Journal</i> , 2019, 13, 420-426.	0.3	9
2086	Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer. <i>Oncogene</i> , 2019, 38, 4875-4884.	2.6	27
2087	Effective and well tolerated: where do these drugs fit now?. <i>Lancet Oncology, The</i> , 2019, 20, 469-470.	5.1	0
2088	Optimal sequencing strategy using docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant prostate cancer: utilization of neutrophil-to-lymphocyte ratio. <i>World Journal of Urology</i> , 2019, 37, 2375-2384.	1.2	10
2089	Zoledronic acid for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 657-666.	0.9	23
2090	Age Adjusted Charlson Comorbidity Index Strongly Influences Survival, Irrespective of Performance Status and Age, in Patients With Advanced Prostatic Cancer Treated With Enzalutamide. <i>Anticancer Research</i> , 2019, 39, 863-866.	0.5	4
2091	Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: a retrospective study. <i>International Journal of Clinical Oncology</i> , 2019, 24, 848-856.	1.0	14
2092	Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction. <i>Current Treatment Options in Oncology</i> , 2019, 20, 14.	1.3	16
2093	The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer. <i>Drugs</i> , 2019, 79, 381-400.	4.9	23
2095	TGF $\beta$ 2 receptor I inhibitor enhances response to enzalutamide in a preclinical model of advanced prostate cancer. <i>Prostate</i> , 2019, 79, 31-43.	1.2	46

#	ARTICLE	IF	CITATIONS
2096	Safety and outcomes of new generation hormone-therapy in elderly chemotherapy-naive metastatic castration-resistant prostate cancer patients in the real world. <i>Archives of Gerontology and Geriatrics</i> , 2019, 82, 179-185.	1.4	15
2097	Increased Serine and One-Carbon Pathway Metabolism by PKC $\delta$ / $\beta$ 1 Deficiency Promotes Neuroendocrine Prostate Cancer. <i>Cancer Cell</i> , 2019, 35, 385-400.e9.	7.7	128
2098	A Population-Based Study of Palliative Radiation Therapy for Bone Metastases in Patients Dying of Prostate Cancer. <i>Practical Radiation Oncology</i> , 2019, 9, e274-e282.	1.1	7
2099	A positive role of c-Myc in regulating androgen receptor and its splice variants in prostate cancer. <i>Oncogene</i> , 2019, 38, 4977-4989.	2.6	80
2100	Combined Androgen receptor blockade overcomes the resistance of breast cancer cells to palbociclib. <i>International Journal of Biological Sciences</i> , 2019, 15, 522-532.	2.6	18
2102	Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer. <i>Canadian Urological Association Journal</i> , 2019, 14, 17-23.	0.3	17
2103	The importance of antiandrogen in prostate cancer treatment. <i>Annals of Translational Medicine</i> , 2019, 7, S362-S362.	0.7	6
2104	A Novel Small Molecule Inhibits Tumor Growth and Synergizes Effects of Enzalutamide on Prostate Cancer. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 371, 703-712.	1.3	13
2105	A rare case of idiopathic cholestasis: Clinical conundrums complicating enzalutamide therapy in metastatic prostate cancer. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 2068-2073.	0.2	3
2106	Safety Profile and Therapeutic Efficacy of One Cycle of Lu177-PSMA in End-Stage Metastatic Castration-Resistant Prostate Cancer Patients with Low Performance Status. <i>Nuclear Medicine and Molecular Imaging</i> , 2019, 53, 423-431.	0.6	10
2108	Radium-223 in Metastatic Castration-Resistant Prostate Cancer: Clinical Development and Use in Contemporary Practice. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2019, 50, S26-S30.	0.2	2
2109	Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer. <i>The Cochrane Library</i> , 2019, . .	1.5	1
2111	A novel approach to assess real-world efficacy of cancer therapy in metastatic prostate cancer. Analysis of national data on Veterans treated with abiraterone and enzalutamide. <i>Seminars in Oncology</i> , 2019, 46, 351-361.	0.8	15
2113	ABT-737 and erufosine combination against castration-resistant prostate cancer. <i>Anti-Cancer Drugs</i> , 2019, 30, 383-393.	0.7	9
2114	GV1001 inhibits cell viability and induces apoptosis in castration-resistant prostate cancer cells through the AKT/NF- $\kappa$ B/VEGF pathway. <i>Journal of Cancer</i> , 2019, 10, 6269-6277.	1.2	10
2115	CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer. <i>Cell Reports</i> , 2019, 29, 2355-2370.e6.	2.9	45
2116	Characterization of a Prostate- and Prostate Cancer-Specific Circular RNA Encoded by the Androgen Receptor Gene. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 18, 916-926.	2.3	30
2117	Reduced dose of cabazitaxel in metastatic castration-resistant prostate cancer. <i>Anti-Cancer Drugs</i> , 2019, 30, 854-858.	0.7	2

#	ARTICLE	IF	CITATIONS
2119	Patient and Provider Variables Associated with Systemic Treatment of Advanced Prostate Cancer. <i>Urology Practice</i> , 2019, 6, 234-242.	0.2	12
2120	Efficacy and safety of abiraterone and enzalutamide for castration-resistant prostate cancer. <i>Medicine (United States)</i> , 2019, 98, e17748.	0.4	11
2121	GABARAPL1 Promotes AR+ Prostate Cancer Growth by Increasing FL-AR/AR-V Transcription Activity and Nuclear Translocation. <i>Frontiers in Oncology</i> , 2019, 9, 1254.	1.3	10
2122	Monitoring Patients with Metastatic Hormone-Sensitive and Metastatic Castration-Resistant Prostate Cancer: A Multidisciplinary Consensus Document. <i>Cancers</i> , 2019, 11, 1908.	1.7	1
2123	Circular RNA ITCH suppressed prostate cancer progression by increasing HOXB13 expression via spongy miR-17-5p. <i>Cancer Cell International</i> , 2019, 19, 328.	1.8	52
2124	Cancer Drug Use in the Last Month of Life in Men With Castration-Resistant Prostate Cancer. <i>Journal of Oncology Practice</i> , 2019, 15, e510-e519.	2.5	1
2125	SRRM4 gene expression correlates with neuroendocrine prostate cancer. <i>Prostate</i> , 2019, 79, 96-104.	1.2	25
2126	Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 52-63.	3.2	44
2127	Importance of androgen-deprivation therapy during enzalutamide treatment in men with metastatic castration-resistant prostate cancer following chemotherapy: results from retrospective, multicenter data. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 150-158.	2.0	6
2128	Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers. <i>Molecular Cancer Research</i> , 2019, 17, 97-108.	1.5	17
2129	Urologic Malignancies. , 2019, , 115-133.		0
2130	Combination of novel systemic agents and radiotherapy for solid tumors – Part II: An AIRO (Italian) Tj ETQq1 1 0.784314 rgBT /Over Reviews in Oncology/Hematology, 2019, 134, 104-119.	2.0	10
2131	Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 631-640.	3.3	198
2132	Long-term outcomes of combining prostate brachytherapy and metastasis-directed radiotherapy in newly diagnosed oligometastatic prostate cancer: A retrospective cohort study. <i>Prostate</i> , 2019, 79, 506-514.	1.2	25
2133	Reversibility of castration resistance status after Radium-223 dichloride treatment: clinical evidence and review of the literature. <i>International Journal of Radiation Biology</i> , 2019, 95, 554-561.	1.0	20
2134	Initiation of Systemic Therapy During the Last 30 Days of Life in Patients With Metastatic Castration-resistant Prostate Cancer. <i>Anticancer Research</i> , 2019, 39, 335-340.	0.5	3
2135	Impact of timing of administration of bone supportive therapy on pain palliation from radium-223. <i>Cancer Treatment and Research Communications</i> , 2019, 18, 100114.	0.7	9
2136	MicroRNA-150 suppresses epithelial-mesenchymal transition, invasion, and metastasis in prostate cancer through the TRPM4-mediated $\beta$ -catenin signaling pathway. <i>American Journal of Physiology - Cell Physiology</i> , 2019, 316, C463-C480.	2.1	49

#	ARTICLE	IF	CITATIONS
2137	Dietary interventions for cancer survivors. <i>Proceedings of the Nutrition Society</i> , 2019, 78, 135-145.	0.4	6
2138	Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer. <i>Investigational New Drugs</i> , 2019, 37, 331-337.	1.2	18
2139	Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies. <i>Nature Reviews Urology</i> , 2019, 16, 7-22.	1.9	39
2140	Treatment Experiences, Information Needs, Pain and Quality of Life in Men with Metastatic Castrate-resistant Prostate Cancer: Results from the EXTREQOL Study. <i>Clinical Oncology</i> , 2019, 31, 99-107.	0.6	12
2141	Qualitative study of patients with metastatic prostate cancer to adherence of hormone therapy. <i>European Journal of Oncology Nursing</i> , 2019, 38, 8-12.	0.9	12
2142	Fatigue, treatment satisfaction and health-related quality of life among patients receiving novel drugs suppressing androgen signalling for the treatment of metastatic castrate-resistant prostate cancer. <i>European Journal of Cancer Care</i> , 2019, 28, e12949.	0.7	11
2143	Detection of CTC Clusters and a Dedifferentiated RNA $\epsilon$ Expression Survival Signature in Prostate Cancer. <i>Advanced Science</i> , 2019, 6, 1801254.	5.6	30
2144	Results From a Large, Multicenter, Retrospective Analysis On Radium223 Use in Metastatic Castration-resistant Prostate Cancer (mCRPC) in the Triveneto Italian Region. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e187-e194.	0.9	14
2145	Quantification of 2-aminoisobutyric acid impurity in enzalutamide bulk drug substance using hydrophilic interaction chromatography with fluorescence detection. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 164, 296-301.	1.4	3
2146	Metastatic bone disease: Pathogenesis and therapeutic options. <i>Journal of Bone Oncology</i> , 2019, 15, 100205.	1.0	153
2147	A Territory-wide, Multicenter, Age- and Prostate-specific Antigen-matched Study Comparing Chemohormonal Therapy and Hormonal Therapy Alone in Chinese Men With Metastatic Hormone-sensitive Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e203-e208.	0.9	6
2148	Selective Castration-resistant Prostate Cancer Photothermal Ablation With Copper Sulfide Nanoplates. <i>Urology</i> , 2019, 125, 248-255.	0.5	4
2149	Perspectives on the current and emerging chemical androgen receptor antagonists for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 163-172.	0.9	24
2150	Apalutamide and its use in the treatment of prostate cancer. <i>Future Oncology</i> , 2019, 15, 591-599.	1.1	5
2151	Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 420-427.	2.0	49
2152	Circulating tumor DNA alterations in patients with metastatic castration $\epsilon$ resistant prostate cancer. <i>Cancer</i> , 2019, 125, 1459-1469.	2.0	38
2153	Neuroendocrine differentiation markers guide treatment sequence selection in metastatic castration $\epsilon$ resistant prostate cancer. <i>Prostate</i> , 2019, 79, 567-573.	1.2	11
2154	Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer. <i>Cells</i> , 2019, 8, 43.	1.8	38

#	ARTICLE	IF	CITATIONS
2155	Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHARTED and LATITUDE era. <i>Cancer Treatment Reviews</i> , 2019, 74, 35-42. Reply to Fabiana Gregucci and Alba Fiorentino's Letter to the Editor re: Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomized Clinical Trial: Data from the HORRAD Trial. <i>Eur Urol</i> 2019;75:410-8. <i>European Urology</i> , 2019, 75, e131-e132.	3.4	30
2156	C.C.M. Hulshof, André N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomized Clinical Trial: Data from the HORRAD Trial. <i>Eur Urol</i> 2019;75:410-8. <i>European Urology</i> , 2019, 75, e131-e132.	0.9	1
2157	Cell-based evidence regarding the role of FSH in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 290.e1-290.e8.	0.8	8
2158	Influence of Age and the Gleason Score in the Choice of Novel Hormonal Therapies Before and After Chemotherapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2019, 34, 141-146.	0.7	2
2159	The importance of targeting intracrinology in prostate cancer management. <i>World Journal of Urology</i> , 2019, 37, 751-757.	1.2	2
2160	Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer. <i>European Urology</i> , 2019, 75, 35-41.	0.9	18
2161	Structural and Functional Biology of Aldo-Keto Reductase Steroid-Transforming Enzymes. <i>Endocrine Reviews</i> , 2019, 40, 447-475.	8.9	73
2162	Clinical effectiveness of docetaxel for castration-sensitive prostate cancer in a real-world population-based analysis. <i>Prostate</i> , 2019, 79, 281-287.	1.2	15
2163	Pharmacokinetics and bioequivalence of generic and branded abiraterone acetate tablet: a single-dose, open-label, and replicate designed study in healthy Chinese male volunteers. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 509-517.	1.1	9
2164	New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 491-511.	2.9	49
2165	Permanent 125 I prostate brachytherapy for castration-resistant prostate cancer. <i>International Journal of Urology</i> , 2019, 26, 278-283.	0.5	4
2166	Utilizing precision medicine to modulate the prostate tumor microenvironment and enhance immunotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 535-542.	0.8	2
2167	Academic Discovery of Anticancer Drugs: Historic and Future Perspectives. <i>Annual Review of Cancer Biology</i> , 2019, 3, 385-408.	2.3	17
2168	Serum Neuroendocrine Markers Predict Therapy Outcome of Patients with Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis. <i>Urologia Internationalis</i> , 2019, 102, 373-384.	0.6	11
2169	Abiraterone and spironolactone in prostate cancer: a combination to avoid. <i>Acta Clinica Belgica</i> , 2019, 74, 439-444.	0.5	14
2170	Management of advanced prostate cancer: A systematic review of existing guidelines and recommendations. <i>Cancer Treatment Reviews</i> , 2019, 73, 54-61.	3.4	28
2171	Metastatic prostate cancer remains incurable, why?. <i>Asian Journal of Urology</i> , 2019, 6, 26-41.	0.5	103
2172	Combination of novel systemic agents and radiotherapy for solid tumors - part I: An AIRO (Italian) Tj ETQq1 1 0.784314 rgBT /Over Reviews in Oncology/Hematology, 2019, 134, 87-103.	2.0	7

#	ARTICLE	IF	CITATIONS
2173	Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 39-50.	1.9	25
2174	Consensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncology. <i>Clinical and Translational Oncology</i> , 2019, 21, 420-432.	1.2	6
2175	Impact of age on exposure to oral antiandrogen therapies in clinical practice. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 168-175.	2.0	4
2176	Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. <i>European Urology</i> , 2019, 75, 88-99.	0.9	333
2177	Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts. <i>European Urology</i> , 2020, 77, 144-155.	0.9	46
2178	Pharmacokinetic/Pharmacodynamic Relationship of Enzalutamide and Its Active Metabolite N-Desmethyl Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 155-160.	0.9	13
2179	Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer. <i>European Urology</i> , 2020, 77, 14-21.	0.9	51
2180	Drug-Drug Interactions in Prostate Cancer Treatment. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e71-e82.	0.9	13
2181	Impact of the introduction of novel hormonal agents on metastatic castration-resistant prostate cancer treatment choice. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 293-305.	0.5	3
2182	Intracellular Signaling. , 2020, , 24-46.e12.		0
2183	Androgen receptor in breast cancer: A wolf in sheep's clothing? A lesson from prostate cancer.. <i>Seminars in Cancer Biology</i> , 2020, 60, 132-137.	4.3	38
2184	Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review. <i>World Journal of Urology</i> , 2020, 38, 601-611.	1.2	6
2185	Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients. <i>European Urology Oncology</i> , 2020, 3, 119-127.	2.6	20
2186	Enzalutamide and Apalutamide: In Vitro Chemical Reactivity Studies and Activity in a Mouse Drug Allergy Model. <i>Chemical Research in Toxicology</i> , 2020, 33, 211-222.	1.7	31
2187	Combination treatment in metastatic castration-resistant prostate cancer: can we safely boost efficacy by adding radium-223?. <i>Cancer Biology and Therapy</i> , 2020, 21, 1-3.	1.5	8
2188	Clinical utility of emerging biomarkers in prostate cancer liquid biopsies. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 219-230.	1.5	36
2189	Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: the OCUU-CRPC study. <i>International Journal of Clinical Oncology</i> , 2020, 25, 486-494.	1.0	10
2190	A Case of Switching from GnRH Agonist to Antagonist for Castration Resistant Prostate Cancer Control. <i>Case Reports in Oncology</i> , 2020, 12, 688-692.	0.3	2



#	ARTICLE	IF	CITATIONS
2191	Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework. <i>Social Science and Medicine</i> , 2020, 246, 112595.	1.8	23
2192	Sex Hormones and Prostate Cancer. <i>Annual Review of Medicine</i> , 2020, 71, 33-45.	5.0	58
2193	Sequential Use of Androgen Receptor Axis-targeted Agents in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Retrospective Analysis With 3-Year Follow-up. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e46-e54.	0.9	9
2194	Treatment Facility Volume and Survival in Patients with Advanced Prostate Cancer. <i>European Urology Oncology</i> , 2020, 3, 104-111.	2.6	11
2195	Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities. <i>European Urology</i> , 2020, 77, 158-166.	0.9	36
2197	Clinicopathologic Diagnostic Approach to Aggressive Variant Prostate Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 18-23.	1.2	13
2198	Values of alkaline phosphatase at the diagnosis of castration resistance and response to primary androgen deprivation therapy as predictors of subsequent metastasis in non-metastatic castration-resistant prostate cancer. <i>International Journal of Clinical Oncology</i> , 2020, 25, 479-485.	1.0	1
2199	PSMA-Based Theranostics: A Step-by-Step Practical Approach to Diagnosis and Therapy for mCRPC Patients. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 98-109.	2.5	37
2200	Syntaxin 6-mediated exosome secretion regulates enzalutamide resistance in prostate cancer. <i>Molecular Carcinogenesis</i> , 2020, 59, 62-72.	1.3	41
2201	Disparities in prostate cancer incidence and mortality rates: Solvable or not?. <i>Prostate</i> , 2020, 80, 3-16.	1.2	30
2202	Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 225-239.	1.5	18
2203	Anti-androgen hormonal therapy for cancer and other diseases. <i>European Journal of Pharmacology</i> , 2020, 866, 172783.	1.7	38
2204	Hormone Effects on Tumors. , 2020, , 667-693.		2
2205	Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 9-21.	0.7	27
2206	Adverse events related to abiraterone and enzalutamide treatment: analysis of the EudraVigilance database and meta-analysis of registrational phase III studies. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 199-206.	2.0	20
2207	The role of adrenal derived androgens in castration resistant prostate cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2020, 197, 105506.	1.2	37
2208	The Use of Transdermal Estrogen in Castrate-resistant, Steroid-refractory Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e217-e223.	0.9	3
2209	Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 69-76.e4.	0.9	11



#	ARTICLE	IF	CITATIONS
2210	Response Prediction of <sup>177</sup> Lu-PSMA-617 Radioligand Therapy Using Prostate-Specific Antigen, Chromogranin A, and Lactate Dehydrogenase. <i>Journal of Nuclear Medicine</i> , 2020, 61, 689-695.	2.8	39
2211	Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 284-294.	0.9	91
2212	Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment. <i>Neoplasia</i> , 2020, 22, 111-119.	2.3	101
2213	Health-related Quality of Life and Pain in a Real-world Castration-resistant Prostate Cancer Population: Results From the PRO-CAPRI Study in the Netherlands. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e233-e253.	0.9	4
2214	METastasis Reporting and Data System for Prostate Cancer as a Prognostic Imaging Marker in Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e391-e396.	0.9	12
2215	Novel immunotherapy combinations for genitourinary cancers. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 253-262.	1.4	11
2216	A castrate-resistant metastatic prostate cancer patient with severe pancytopenia, successfully treated with docetaxel chemotherapy. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1254-1258.	0.5	4
2217	A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population. <i>International Journal of Cancer</i> , 2020, 147, 1143-1151.	2.3	16
2218	A novel androgen receptor antagonist JI-450 inhibits enzalutamide-resistant mutant AR F876L nuclear import and function. <i>Prostate</i> , 2020, 80, 319-328.	1.2	10
2219	Multiparametric MRI as a Biomarker of Response to Neoadjuvant Therapy for Localized Prostate Cancer—A Pilot Study. <i>Academic Radiology</i> , 2020, 27, 1432-1439.	1.3	9
2220	Bone Metastasis: Current State of Play. <i>Translational Oncology</i> , 2020, 13, 308-320.	1.7	30
2221	PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study. <i>Prostate</i> , 2020, 80, 99-108.	1.2	45
2222	Discovery and optimization of novel N-benzyl-3,6-dimethylbenzo[d]isoxazol-5-amine derivatives as potent and selective TRIM24 bromodomain inhibitors with potential anti-cancer activities. <i>Bioorganic Chemistry</i> , 2020, 94, 103424.	2.0	10
2224	Is androgen deprivation therapy for prostate cancer associated with cardiovascular disease? A meta-analysis and systematic review. <i>Andrology</i> , 2020, 8, 559-574.	1.9	14
2225	Noncanonical Wnt as a prognostic marker in prostate cancer: "you can't always get what you Wnt." <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 245-254.	1.5	4
2226	Economic burden of illness associated with localized prostate cancer in the United States. <i>Future Oncology</i> , 2020, 16, 4265-4277.	1.1	14
2227	Impact of progression at baseline and on-treatment progression events in three large prostate cancer trials. <i>European Journal of Cancer</i> , 2020, 125, 142-152.	1.3	7
2228	A review of prostate cancer treatment impact on the CNS and cognitive function. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 207-219.	2.0	59

#	ARTICLE	IF	CITATIONS
2229	Propensity score-matched comparison of docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant intraductal carcinoma of the prostate. <i>BJU International</i> , 2020, 125, 702-708.	1.3	16
2230	Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen deprivation therapy. <i>Journal of Medical Economics</i> , 2020, 23, 330-346.	1.0	21
2231	Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes. <i>JAMA Oncology</i> , 2020, 6, 206.	3.4	22
2232	Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide. <i>JAMA Oncology</i> , 2020, 6, 217.	3.4	18
2233	Prostate cancer research: The next generation; report from the 2019 Coffey-Holden Prostate Cancer Academy Meeting. <i>Prostate</i> , 2020, 80, 113-132.	1.2	25
2234	Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer. <i>Carcinogenesis</i> , 2020, 41, 1145-1157.	1.3	37
2235	Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by antiandrogens. <i>Prostate</i> , 2020, 80, 214-224.	1.2	10
2236	Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 395-405.	0.8	450
2238	Towards personalizing treatment strategies in mCRPC: can dual-tracer PET-CT provide insights into tumor biology, guide the optimal treatment sequence, and individualize decision-making (between) disease course?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1793-1797.	8.3	5
2239	Comparison of Oncologic Outcomes between Two Alternative Sequences with Abiraterone Acetate and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2020, 12, 8.	1.7	18
2240	Therapies Targeted to Androgen Receptor Signaling Axis in Prostate Cancer: Progress, Challenges, and Hope. <i>Cancers</i> , 2020, 12, 51.	1.7	37
2241	Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide. <i>Frontiers in Oncology</i> , 2020, 10, 567809.	1.3	5
2242	Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer. <i>Cancers</i> , 2020, 12, 2855.	1.7	16
2244	Efficacy, Prognostic Factors, and Safety Profile of Enzalutamide for Non-metastatic and Metastatic Castration-Resistant Prostate Cancer: A Retrospective Single-Center Analysis in Japan. <i>Targeted Oncology</i> , 2020, 15, 635-643.	1.7	7
2245	A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer. <i>Advances in Therapy</i> , 2020, 37, 4910-4929.	1.3	9
2246	Autocatalytic polymerization of selenium/polypyrrole nanocomposites as functional theranostic agents for multi-spectral photoacoustic imaging and photothermal therapy of tumor. <i>Materials Today Chemistry</i> , 2020, 17, 100344.	1.7	8
2247	MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer. <i>Oncogene</i> , 2020, 39, 7209-7223.	2.6	28
2248	Impact of antiandrogen withdrawal syndrome in castration-resistant prostate cancer patients treated with abiraterone or enzalutamide. <i>International Journal of Urology</i> , 2020, 27, 1109-1115.	0.5	3

#	ARTICLE	IF	CITATIONS
2249	A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6149-6157.	3.2	29
2250	A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment. <i>BMC Cancer</i> , 2020, 20, 919.	1.1	12
2251	Development and prevalence of castration-resistant prostate cancer subtypes. <i>Neoplasia</i> , 2020, 22, 566-575.	2.3	65
2252	Are we there yet? Understanding androgen receptor signaling in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 47.	2.3	57
2253	Computational methods-guided design of modulators targeting protein-protein interactions (PPIs). <i>European Journal of Medicinal Chemistry</i> , 2020, 207, 112764.	2.6	26
2254	Emerging role of tumor cell plasticity in modifying therapeutic response. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 228.	7.1	120
2255	Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer. <i>Cancer Treatment and Research Communications</i> , 2020, 24, 100193.	0.7	2
2256	Treatment of Metastasized Prostate Cancer Beyond Progression After Upfront Docetaxel: A Real-world Data Assessment. <i>European Urology Focus</i> , 2021, 7, 1308-1315.	1.6	3
2257	Considerations for the use of gonadotropin-releasing hormone agonists and antagonists in patients with prostate cancer. <i>International Journal of Urology</i> , 2020, 27, 830-837.	0.5	19
2259	Predictors of resistance to abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer in post-docetaxel setting: a single-center cohort study. <i>Anti-Cancer Drugs</i> , 2020, 31, 742-746.	0.7	0
2260	Phenotypic plasticity and lineage switching in prostate cancer. , 2020, , 591-615.		3
2261	High Health-Related Quality of Life During Dendritic Cell Vaccination Therapy in Patients With Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 536700.	1.3	4
2262	Cardiovascular Complications of Prostate Cancer Therapy. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2020, 22, 1.	0.4	6
2263	Accelerating precision medicine in metastatic prostate cancer. <i>Nature Cancer</i> , 2020, 1, 1041-1053.	5.7	45
2264	Comparison of effectiveness and safety outcomes of abiraterone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2020, 23, 451-461.	0.9	4
2265	Evaluation of Fall and Fracture Risk Among Men With Prostate Cancer Treated With Androgen Receptor Inhibitors. <i>JAMA Network Open</i> , 2020, 3, e2025826.	2.8	24
2266	Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 594023.	1.3	7
2267	The Genetic Complexity of Prostate Cancer. <i>Genes</i> , 2020, 11, 1396.	1.0	9

#	ARTICLE	IF	CITATIONS
2268	Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9054.	1.8	32
2269	Metabolic Reprogramming and Predominance of Solute Carrier Genes during Acquired Enzalutamide Resistance in Prostate Cancer. <i>Cells</i> , 2020, 9, 2535.	1.8	22
2270	Long Non-Coding RNA SNHG1 Regulates the Wnt/ $\beta$ -Catenin and PI3K/AKT/mTOR Signaling Pathways via EZH2 to Affect the Proliferation, Apoptosis, and Autophagy of Prostate Cancer Cell. <i>Frontiers in Oncology</i> , 2020, 10, 552907.	1.3	33
2271	Molecular mechanisms and clinical management of cancer bone metastasis. <i>Bone Research</i> , 2020, 8, 30.	5.4	78
2272	Epidemiology, Staging and Management of Prostate Cancer. <i>Medical Sciences (Basel, Switzerland)</i> , 2020, 8, 28.	1.3	55
2273	Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092006.	1.4	1
2274	The Movember Prostate Cancer Landscape Analysis: an assessment of unmet research needs. <i>Nature Reviews Urology</i> , 2020, 17, 499-512.	1.9	15
2275	Identification of Potential Key Genes and Pathways in Enzalutamide-Resistant Prostate Cancer Cell Lines: A Bioinformatics Analysis with Data from the Gene Expression Omnibus (GEO) Database. <i>BioMed Research International</i> , 2020, 2020, 1-12.	0.9	4
2276	Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4616-4624.	3.2	10
2277	Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer. <i>Molecular Oncology</i> , 2020, 14, 2455-2470.	2.1	31
2278	Adding carboplatin to chemotherapy regimens for metastatic castration-resistant prostate cancer in postsecond generation hormone therapy setting: Impact on treatment response and survival outcomes. <i>Prostate</i> , 2020, 80, 1216-1222.	1.2	2
2279	Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer. <i>Cancers</i> , 2020, 12, 2092.	1.7	14
2280	Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5484.	1.8	36
2281	Nursing Implications of Recent Changes in Management Practices for Metastatic Prostate Cancer. <i>Seminars in Oncology Nursing</i> , 2020, 36, 151047.	0.7	3
2282	Development of Androgen-Antagonistic Coumarinamides with a Unique Aromatic Folded Pharmacophore. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5584.	1.8	4
2283	Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2091-2099.	0.9	8
2284	The evolving options in metastatic castration-sensitive prostate cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2020, 14, 270-275.	0.5	0
2285	Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 581515.	1.3	27

#	ARTICLE	IF	CITATIONS
2286	Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer. <i>Cell Death and Disease</i> , 2020, 11, 942.	2.7	10
2287	Inhibition of microRNA-300 inhibits cell adhesion, migration, and invasion of prostate cancer cells by promoting the expression of <i>DAB1</i> . <i>Cell Cycle</i> , 2020, 19, 2793-2810.	1.3	7
2288	Neuronal/astrocytic expression of chemokine (C-C motif) ligand 2 is associated with monocyte/macrophage recruitment in male chronic pelvic pain. <i>Pain</i> , 2020, 161, 2581-2591.	2.0	7
2289	Novel therapies are changing treatment paradigms in metastatic prostate cancer. <i>Journal of Hematology and Oncology</i> , 2020, 13, 144.	6.9	80
2290	Assessing consistency in clinical trials with two subgroups and binary endpoints: A new test within the logistic regression model. <i>Statistics in Medicine</i> , 2020, 39, 4551-4573.	0.8	1
2291	Prostate Cancer Central Nervous System Metastasis in a Contemporary Cohort. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 217-222.e1.	0.9	7
2292	Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma. <i>BMJ Open</i> , 2020, 10, e039639.	0.8	13
2293	Efficacy of cabazitaxel and the influence of clinical factors on the overall survival of patients with castration-resistant prostate cancer: A local experience of a multicenter retrospective study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 238-244.	0.7	5
2294	Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. <i>Clinical Cancer Research</i> , 2020, 26, 6122-6131.	3.2	9
2295	The clinical benefit of sequential therapy with androgen receptor axis-targeted agents alone in patients with castration-resistant prostate cancer: A propensity score-matched comparison study. <i>Prostate</i> , 2020, 80, 1373-1380.	1.2	0
2296	Boosting Chemodynamic Therapy by the Synergistic Effect of Co-Catalyze and Photothermal Effect Triggered by the Second Near-Infrared Light. <i>Nano-Micro Letters</i> , 2020, 12, 180.	14.4	49
2297	Prescribing practices for tumour aggressiveness and castration resistance in risk-stratified prostate cancer patients. <i>Journal of Prescribing Practice</i> , 2020, 2, 392-397.	0.1	0
2298	Androgen Receptor in Breast Cancer: From Bench to Bedside. <i>Frontiers in Endocrinology</i> , 2020, 11, 573.	1.5	31
2299	The potential of PSMA-targeted alpha therapy in the management of prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 823-829.	1.1	30
2300	p62 promotes proliferation, apoptosis-resistance and invasion of prostate cancer cells through the Keap1/Nrf2/ARE axis. <i>Oncology Reports</i> , 2020, 43, 1547-1557.	1.2	18
2301	Optimizing skeletal-related events prevention in patients with advanced prostate cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 4-6.	0.7	1
2302	Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. <i>Prostate</i> , 2020, 80, 1273-1296.	1.2	16
2303	Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer. <i>Nature Genetics</i> , 2020, 52, 1011-1017.	9.4	78

#	ARTICLE	IF	CITATIONS
2304	Is There a Role for Immunotherapy in Prostate Cancer?. <i>Cells</i> , 2020, 9, 2051.	1.8	65
2305	Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1892-1900.	1.0	45
2306	Evaluation of Cognitive Function in Trials Testing New-Generation Hormonal Therapy in Patients with Prostate Cancer: A Systematic Review. <i>Cancers</i> , 2020, 12, 2568.	1.7	8
2307	Health economic impact of a biopsy-based cell cycle gene expression assay in localized prostate cancer. <i>Future Oncology</i> , 2020, 16, 3061-3074.	1.1	3
2308	Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6064-6074.	3.2	16
2309	Dynamics of the cell-free DNA methylome of metastatic prostate cancer during androgen-targeting treatment. <i>Epigenomics</i> , 2020, 12, 1317-1332.	1.0	15
2310	Exploring Spatial-Temporal Changes in <sup>18</sup> F-Sodium Fluoride PET/CT and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide. <i>Journal of Clinical Oncology</i> , 2020, 38, 3662-3671.	0.8	16
2311	Influence of Intratumor Microbiome on Clinical Outcome and Immune Processes in Prostate Cancer. <i>Cancers</i> , 2020, 12, 2524.	1.7	40
2312	Aberrant activation of super enhancer and choline metabolism drive antiandrogen therapy resistance in prostate cancer. <i>Oncogene</i> , 2020, 39, 6556-6571.	2.6	29
2313	YB-1 variant and androgen receptor axis-targeted agents in metastatic castration-resistant prostate cancer patients. <i>Pharmacogenomics</i> , 2020, 21, 919-928.	0.6	3
2314	Interleukin-10 Induces Expression of Neuroendocrine Markers and PDL1 in Prostate Cancer Cells. <i>Prostate Cancer</i> , 2020, 2020, 1-12.	0.4	10
2315	A Walk with Lu-177 PSMA: How Close we Have Reached from Bench to Bedside?. <i>Cancer Investigation</i> , 2020, 38, 486-492.	0.6	5
2316	Neuroendocrine and Aggressive-Variant Prostate Cancer. <i>Cancers</i> , 2020, 12, 3792.	1.7	42
2317	Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 606133.	1.3	1
2318	Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer. <i>The Cochrane Library</i> , 2020, 12, CD013245.	1.5	3
2319	Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes. <i>European Urology Open Science</i> , 2020, 22, 34-44.	0.2	7
2322	Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel â€” A Final Analysis of the Prosty II Trial. <i>Anticancer Research</i> , 2020, 40, 6915-6921.	0.5	2
2323	Clinical implications of genomic evaluations for prostate cancer risk stratification, screening, and treatment: a narrative review. <i>Prostate International</i> , 2020, 8, 99-106.	1.2	16



#	ARTICLE	IF	CITATIONS
2324	Pharmacokinetic drug-drug interactions: an insight into recent US FDA-approved drugs for prostate cancer. <i>Bioanalysis</i> , 2020, 12, 1647-1664.	0.6	7
2325	Drug Repurposing for Triple-Negative Breast Cancer. <i>Journal of Personalized Medicine</i> , 2020, 10, 200.	1.1	29
2326	The Role of Crosstalk between AR3 and E2F1 in Drug Resistance in Prostate Cancer Cells. <i>Cells</i> , 2020, 9, 1094.	1.8	9
2327	Systemic Management for Nonmetastatic Castration-resistant Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 288-297.	0.6	15
2328	Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer. <i>Asian Journal of Urology</i> , 2020, 7, 271-283.	0.5	17
2329	Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry. <i>European Urology Focus</i> , 2021, 7, 788-796.	1.6	1
2330	Design and Synthesis of 1,2-Deoxy-pyranose Derivatives of Spliceostatin A toward Prostate Cancer Treatment. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 1310-1315.	1.3	14
2331	Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation. <i>Case Reports in Oncology</i> , 2020, 13, 456-461.	0.3	2
2332	Treatment in hormone-sensitive metastatic prostate cancer: factors to consider when personalizing therapy. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 483-490.	1.1	3
2333	A Novel Small Molecule Targets Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 75-88.	1.9	14
2334	The management of patients with metastatic prostate cancer during the COVID-19 pandemic. <i>Future Oncology</i> , 2020, 16, 1455-1461.	1.1	6
2335	Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 12315-12323.	3.3	87
2336	2,4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer. <i>Nature Communications</i> , 2020, 11, 2508.	5.8	108
2337	Docetaxel Rechallenge in Patients with Metastatic Prostate Cancer: A Comprehensive Review. <i>Oncology Research and Treatment</i> , 2020, 43, 299-306.	0.8	17
2338	Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion. <i>ESMO Open</i> , 2020, 5, e000652.	2.0	23
2339	Mithramycin suppresses DNA damage repair via targeting androgen receptor in prostate cancer. <i>Cancer Letters</i> , 2020, 488, 40-49.	3.2	11
2340	Clinical Theragnostic Potential of Diverse miRNA Expressions in Prostate Cancer: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2020, 12, 1199.	1.7	20
2341	Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 680-688.	2.0	20



#	ARTICLE	IF	CITATIONS
2342	Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype. <i>Annals of Oncology</i> , 2020, 31, 1178-1185.	0.6	27
2343	Effects of estrogen receptor signaling on prostate cancer carcinogenesis. <i>Translational Research</i> , 2020, 222, 56-66.	2.2	7
2344	Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study. <i>Clinical Chemistry</i> , 2020, 66, 842-851.	1.5	25
2345	Recent Advances in the Management of High-Risk Localized Prostate Cancer: Local Therapy, Systemic Therapy, and Biomarkers to Guide Treatment Decisions. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e241-e252.	1.8	16
2346	Pharmacotherapeutic strategies for castrate-resistant prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1431-1448.	0.9	23
2347	Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer. <i>Molecules</i> , 2020, 25, 2448.	1.7	33
2348	Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 258-267.e1.	0.9	11
2349	Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 2197-2206.	13.9	253
2350	Advanced Prostate Cancer: Treatment Advances and Future Directions. <i>Trends in Cancer</i> , 2020, 6, 702-715.	3.8	122
2351	p300-Mediated Acetylation of Histone Demethylase JMJD1A Prevents Its Degradation by Ubiquitin Ligase STUB1 and Enhances Its Activity in Prostate Cancer. <i>Cancer Research</i> , 2020, 80, 3074-3087.	0.4	36
2352	Abiraterone acetate plus Prednisone/Prednisolone compared with Enzalutamide in metastatic castration resistant prostate cancer before or after chemotherapy: A retrospective study of real-world data (ACES). <i>BJU International</i> , 2020, 1, 21-31.	0.7	1
2353	Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted $\alpha$ -particle therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 15172-15181.	3.3	16
2354	Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer. <i>Prostate</i> , 2020, 80, 926-937.	1.2	3
2355	Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes. <i>Cancer Treatment Reviews</i> , 2020, 88, 102057.	3.4	28
2356	Clinical outcomes of $^{177}\text{Lu}$ -prostate-specific membrane antigen therapy in advanced prostate cancer—a prospective pilot study in an Asian population. <i>Nuclear Medicine Communications</i> , 2020, Publish Ahead of Print, 618-628.	0.5	8
2357	Cell-Free DNA Alterations in the <i>AR</i> Enhancer and Locus Predict Resistance to AR-Directed Therapy in Patients With Metastatic Prostate Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 680-713.	1.5	20
2358	A Systematic Review and Meta-Analysis on the Predictive Value of Cell-Free DNA-Based Androgen Receptor Copy Number Gain in Patients With Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 714-729.	1.5	18
2359	Emerging promising biomarkers for treatment decision in metastatic castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 801-815.	0.8	7

#	ARTICLE	IF	CITATIONS
2360	Hormonal prostate cancer therapies and cardiovascular disease: a systematic review. <i>Heart Failure Reviews</i> , 2022, 27, 119-134.	1.7	13
2361	PAWI-2: A novel inhibitor for eradication of cancer. <i>Medicinal Chemistry Research</i> , 2020, 29, 1147-1159.	1.1	1
2362	Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma. <i>Oncologist</i> , 2020, 25, e1825-e1836.	1.9	13
2363	An evaluation of apalutamide for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1537-1546.	0.9	8
2364	Recent developments in the treatment of non-metastatic castration resistant prostate cancer. <i>Cancer Treatment and Research Communications</i> , 2020, 24, 100181.	0.7	2
2365	Non-metastatic castration-resistant prostate cancer: current status and future directions. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 513-522.	1.1	4
2366	Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5162-5171.	3.2	29
2367	Early Chemotherapy in Metastatic Prostate Cancer Improves Survival: a Quick Note to Surgical Colleagues. <i>Indian Journal of Surgery</i> , 2020, 82, 1206-1211.	0.2	1
2368	Cellular rewiring in lethal prostate cancer: the architect of drug resistance. <i>Nature Reviews Urology</i> , 2020, 17, 292-307.	1.9	59
2369	Influence of short-term dexamethasone on the efficacy of <sup>177</sup> Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2020, 80, 619-631.	1.2	20
2370	Prostate Cancer Brain Metastases: A Single-Institution Experience. <i>World Neurosurgery</i> , 2020, 138, e445-e449.	0.7	26
2371	Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 381-397.	2.0	34
2372	Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 539-548.	2.0	27
2373	Molecular principles of metastasis: a hallmark of cancer revisited. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 28.	7.1	1,075
2374	Olaparib and enzalutamide synergistically suppress HCC progression via the AR-mediated miR-146a/pBRCA1 signaling. <i>FASEB Journal</i> , 2020, 34, 5877-5891.	0.2	9
2375	Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy. <i>PLoS ONE</i> , 2020, 15, e0229754.	1.1	6
2377	Second-line Hormonal Therapy for the Management of Metastatic Castration-resistant Prostate Cancer: a Real-World Data Study Using a Claims Database. <i>Scientific Reports</i> , 2020, 10, 4240.	1.6	9
2378	KLF5 Is Crucial for Androgen-AR Signaling to Transactivate Genes and Promote Cell Proliferation in Prostate Cancer Cells. <i>Cancers</i> , 2020, 12, 748.	1.7	14

#	ARTICLE	IF	CITATIONS
2379	Inhibitor 9 Combined With Androgen Deprivation Therapy or Chemotherapy Delays the Malignant Behavior of Castration-Resistant Prostate Cancer Through K-Ras/PLC $\beta$ /PKC $\beta$ Signaling Pathway. <i>Frontiers in Oncology</i> , 2020, 10, 75.	1.3	1
2380	11-Oxygenated androgens in health and disease. <i>Nature Reviews Endocrinology</i> , 2020, 16, 284-296.	4.3	99
2381	Personalized Treatment Approach to Metastatic Castration-Resistant Prostate Cancer with BRCA2 and PTEN Mutations: A Case Report. <i>Case Reports in Oncology</i> , 2020, 13, 55-61.	0.3	3
2382	Incidence of second primary malignancies in metastatic castration-resistant prostate cancer: results from observational studies in three countries. <i>Future Oncology</i> , 2020, 16, 1889-1901.	1.1	3
2383	Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 826-834.	0.8	26
2384	A novel gene signature to predict immune infiltration and outcome in patients with prostate cancer. <i>Oncoimmunology</i> , 2020, 9, 1762473.	2.1	33
2385	Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 1950.	1.0	3
2386	Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2020, 31, 1119-1134.	0.6	485
2387	LncRNA <i>HORAS5</i> promotes taxane resistance in castration-resistant prostate cancer via a BCL2A1-dependent mechanism. <i>Epigenomics</i> , 2020, 12, 1123-1138.	1.0	17
2388	Androgen receptor variants: RNA-based mechanisms and therapeutic targets. <i>Human Molecular Genetics</i> , 2020, 29, R19-R26.	1.4	14
2389	Renal and Cardiovascular Toxicities by New Systemic Treatments for Prostate Cancer. <i>Cancers</i> , 2020, 12, 1750.	1.7	10
2390	DNA Damage- But Not Enzalutamide-Induced Senescence in Prostate Cancer Promotes Senolytic Bcl-xL Inhibitor Sensitivity. <i>Cells</i> , 2020, 9, 1593.	1.8	31
2391	Acute Promyelocytic Leukemia After Radium-223 Exposure for Prostate Cancer in a Chemotherapy-Naïve Patient. <i>Nuclear Medicine and Molecular Imaging</i> , 2020, 54, 256-260.	0.6	1
2392	Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer. <i>Cells</i> , 2020, 9, 1495.	1.8	8
2393	New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?. <i>Cells</i> , 2020, 9, 1522.	1.8	6
2394	Role of the neutrophil/lymphocyte ratio in patients with metastatic castration-resistant prostate cancer treated first-line with abiraterone. <i>Actas Urológicas Españolas (English Edition)</i> , 2020, 44, 164-171.	0.2	0
2395	A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone. , 2020, 8, e000642.		77
2396	Enzalutamide plus androgen-deprivation therapy in hormone-sensitive prostate cancer: new perspectives from a current Phase III clinical trial. <i>Future Oncology</i> , 2020, 16, 1511-1523.	1.1	1

#	ARTICLE	IF	CITATIONS
2397	Cancer-driven IgG promotes the development of prostate cancer through the SOX2-IgG pathway. <i>Prostate</i> , 2020, 80, 1134-1144.	1.2	15
2398	Glucuronidation of Abiraterone and Its Pharmacologically Active Metabolites by UGT1A4, Influence of Polymorphic Variants and Their Potential as Inhibitors of Steroid Glucuronidation. <i>Drug Metabolism and Disposition</i> , 2020, 48, 75-84.	1.7	10
2399	Engineering Prostate Cancer from Induced Pluripotent Stem Cells—New Opportunities to Develop Preclinical Tools in Prostate and Prostate Cancer Studies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 905.	1.8	15
2400	Expression of Kisspeptin (KISS1) and its Receptor GPR54 (KISS1R) in Prostate Cancer. <i>Anticancer Research</i> , 2020, 40, 709-718.	0.5	2
2401	Survival estimation through the cumulative hazard with monotone natural cubic splines using convex optimization—the HCNS approach. <i>Computer Methods and Programs in Biomedicine</i> , 2020, 190, 105357.	2.6	4
2402	The Impact of Cand1 in Prostate Cancer. <i>Cancers</i> , 2020, 12, 428.	1.7	13
2403	The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 753-760.	1.1	5
2404	Regulation of androgen receptor variants in prostate cancer. <i>Asian Journal of Urology</i> , 2020, 7, 251-257.	0.5	19
2405	The addition of apalutamide to ADT in the treatment of metastatic castration-sensitive prostate cancer: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 147-150.	1.1	3
2406	Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure. <i>Annals of Oncology</i> , 2020, 31, 369-376.	0.6	17
2407	Glucocorticoids mediate adverse events of deep androgen receptor axis inhibition in prostate cancer patients. <i>Annals of Oncology</i> , 2020, 31, 323-325.	0.6	5
2408	A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer. <i>Annals of Oncology</i> , 2020, 31, 619-625.	0.6	54
2409	Health-related Quality of Life in Patients with Advanced Prostate Cancer: A Systematic Review. <i>European Urology Focus</i> , 2021, 7, 742-751.	1.6	19
2410	Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial. <i>European Urology Oncology</i> , 2021, 4, 948-954.	2.6	18
2411	Long non-coding RNA <i>PRRT3-AS1</i> silencing inhibits prostate cancer cell proliferation and promotes apoptosis and autophagy. <i>Experimental Physiology</i> , 2020, 105, 793-808.	0.9	40
2412	Metastatic Hormone-Sensitive Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 64-75.	1.0	26
2413	Next Generation of Androgen Deprivation Therapy Combined With Radiotherapy for N0 M0 Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 21-28.	1.0	1
2414	Treatment of Primary in Metastatic Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 83-86.	1.0	1

#	ARTICLE	IF	CITATIONS
2415	Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 847-857.	2.0	15
2416	Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone. <i>Advances in Therapy</i> , 2020, 37, 2083-2097.	1.3	12
2417	Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression. <i>British Journal of Cancer</i> , 2020, 122, 1068-1076.	2.9	13
2418	Molecular Links Between Angiogenesis and Neuroendocrine Phenotypes in Prostate Cancer Progression. <i>Frontiers in Oncology</i> , 2019, 9, 1491.	1.3	10
2419	<i>HSD3B1</i> Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer. <i>JAMA Oncology</i> , 2020, 6, e196496.	3.4	50
2420	A Phase I Trial of IGF-1R Inhibitor Cixutumumab and mTOR Inhibitor Temsirolimus in Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 171-178.e2.	0.9	25
2421	Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer. <i>Cells</i> , 2020, 9, 203.	1.8	15
2422	Exendin-4 enhances the sensitivity of prostate cancer to enzalutamide by targeting Akt activation. <i>Prostate</i> , 2020, 80, 367-375.	1.2	7
2423	Circulating cell-free DNA: Translating prostate cancer genomics into clinical care. <i>Molecular Aspects of Medicine</i> , 2020, 72, 100837.	2.7	6
2424	Alleviation of Multidrug Resistance by Flavonoid and Non-Flavonoid Compounds in Breast, Lung, Colorectal and Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 401.	1.8	48
2425	Systemic treatment for metastatic castrate resistant prostate cancer: Does sequence matter?. <i>Prostate</i> , 2020, 80, 399-406.	1.2	12
2426	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020, 77, 508-547.	0.9	278
2427	Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis. <i>Cell Communication and Signaling</i> , 2020, 18, 11.	2.7	54
2428	A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2020, 127, 67-75.	1.3	6
2429	Biomarkers of response to advanced prostate cancer therapy. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 195-205.	1.5	12
2430	Treatment of non-metastatic castration resistant prostate cancer in 2020: What is the best?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 129-136.	0.8	24
2431	Amrubicin for Patients With Platinum-refractory Small-cell Prostate Cancer: Two Case Reports. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e324-e329.	0.9	4
2432	Pharmacological cancer treatment and venous thromboembolism risk. <i>European Heart Journal Supplements</i> , 2020, 22, C2-C14.	0.0	11

#	ARTICLE	IF	CITATIONS
2433	Loss of a Negative Feedback Loop between IRF8 and AR Promotes Prostate Cancer Growth and Enzalutamide Resistance. <i>Cancer Research</i> , 2020, 80, 2927-2939.	0.4	13
2434	Targeting USP1â€dependent KDM4A protein stability as a potential prostate cancer therapy. <i>Cancer Science</i> , 2020, 111, 1567-1581.	1.7	34
2435	&lt;p&gt;Chinese Expert Consensus on the Diagnosis and Treatment of Castration-Resistant Prostate Cancer (2019 Update)&lt;/p&gt;. <i>Cancer Management and Research</i> , 2020, Volume 12, 2127-2140.	0.9	12
2437	Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2633-2638.	3.3	7
2438	Metabolically stable diphenylamine derivatives suppress androgen receptor and BET protein in prostate cancer. <i>Biochemical Pharmacology</i> , 2020, 177, 113946.	2.0	5
2439	Dithiocarbamate prodrugs activated by prostate specific antigen to target prostate cancer. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127148.	1.0	12
2440	A Systematic Review and Network Meta-analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 343-350.	0.9	33
2441	Low-Dose Enzalutamide in Late-Elderly Patients (â‰¥ 75 Years Old) Presenting With Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e660-e668.	0.9	14
2442	Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 2032-2042.	3.3	85
2443	Survival in patients diagnosed with castration-resistant prostate cancer: a population-based observational study in Sweden. <i>Scandinavian Journal of Urology</i> , 2020, 54, 115-121.	0.6	36
2444	Harnessing the patient voice in prostate cancer research: Systematic review on the use of patientâ€reported outcomes in randomized controlled trials to support clinical decisionâ€making. <i>Cancer Medicine</i> , 2020, 9, 4039-4058.	1.3	11
2446	Phase 2 Trial of GTx-758, an Estrogen Receptor Alpha Agonist, in Men With Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 436-443.	0.9	1
2447	Drug Selection for Formulary Inclusion: An Exploratory Case Study of Oncology Medicines in Jordan. <i>Value in Health Regional Issues</i> , 2020, 21, 211-221.	0.5	2
2448	Pharmacological and genetic targeting of 5-lipoxygenase interrupts c-Myc oncogenic signaling and kills enzalutamide-resistant prostate cancer cells via apoptosis. <i>Scientific Reports</i> , 2020, 10, 6649.	1.6	18
2449	Sorting Through the Maze of Treatment Options for Metastatic Castration-Sensitive Prostate Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 198-207.	1.8	5
2450	Therapeutic Effect of Ethinylestradiol in Castration-resistant Prostate Cancer. <i>Anticancer Research</i> , 2020, 40, 2291-2296.	0.5	8
2451	Effect of Baseline Characteristics on Cabazitaxel Treatment Duration in Patients with Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the Compassionate Use/Expanded Access Programs and CAPRISTANA Registry. <i>Cancers</i> , 2020, 12, 995.	1.7	2
2452	Use of record linkage to evaluate treatment outcomes and trial eligibility in a realâ€world metastatic prostate cancer population in Scotland. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 653-663.	0.9	9



#	ARTICLE	IF	CITATIONS
2454	Metastatic castration-resistant prostate cancer: Academic insights and perspectives through bibliometric analysis. <i>Medicine (United States)</i> , 2020, 99, e19760.	0.4	34
2455	Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk,). <i>Tj ETQq1 1 0.784814 rgBT2/Overlo</i>	3.2	55
2456	The Prospect of Identifying Resistance Mechanisms for Castrate-Resistant Prostate Cancer Using Circulating Tumor Cells: Is Epithelial-to-Mesenchymal Transition a Key Player?. <i>Prostate Cancer</i> , 2020, 2020, 1-16.	0.4	10
2457	Diverse <i>AR</i> Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1965-1976.	3.2	55
2458	Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation. <i>Cancers</i> , 2020, 12, 831.	1.7	11
2459	Abiraterone vs. docetaxel for metastatic hormone-sensitive prostate cancer: A microsimulation model. <i>Canadian Urological Association Journal</i> , 2020, 14, E418-E427.	0.3	4
2460	Comparing the clinical efficacy and safety of abiraterone and enzalutamide in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 614-622.	0.5	11
2461	Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer. <i>European Urology Oncology</i> , 2021, 4, 447-455.	2.6	52
2462	Endocrine consequences of treatment with the new androgen receptor axis-targeted agents for advanced prostate cancer. <i>Hormones</i> , 2021, 20, 73-84.	0.9	4
2463	FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious <i>BRCA</i> -Mutated Metastatic Castrate-Resistant Prostate Cancer. <i>Oncologist</i> , 2021, 26, 139-146.	1.9	42
2464	Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive disease. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 36-42.	0.7	6
2465	Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it. <i>British Journal of Pharmacology</i> , 2021, 178, 239-261.	2.7	53
2466	An up-to-date evaluation of darolutamide for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 397-402.	0.9	2
2467	The FGF/FGFR system in the physiopathology of the prostate gland. <i>Physiological Reviews</i> , 2021, 101, 569-610.	13.1	37
2468	Risk stratification for the prediction of overall survival could assist treatment decision-making at diagnosis of castration-resistant prostate cancer: a multicentre collaborative study in Japan. <i>BJU International</i> , 2021, 127, 212-221.	1.3	2
2469	Expanding armamentarium in advanced prostate cancer management: are all novel antiandrogens the same?. <i>Prostate International</i> , 2021, 9, 1-5.	1.2	3
2470	The development of apalutamide for the treatment of prostate cancer. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 217-226.	2.5	5
2471	Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response. <i>Clinical Cancer Research</i> , 2021, 27, 429-437.	3.2	22



#	ARTICLE	IF	CITATIONS
2472	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part IIâ€”2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. <i>European Urology</i> , 2021, 79, 263-282.	0.9	633
2473	Cabozantinib plus docetaxel and prednisone in metastatic castrationâ€”resistant prostate cancer. <i>BJU International</i> , 2021, 127, 435-444.	1.3	7
2474	Promotional Payments Made to Urologists by the Pharmaceutical Industry and Prescribing Patterns for Targeted Therapies. <i>Urology</i> , 2021, 148, 134-140.	0.5	1
2475	Use of Chemotherapy and Androgen Signalingâ€”targeted Inhibitors in Patients with Metastatic Prostate Cancer. <i>European Urology</i> , 2021, 79, 170-172.	0.9	3
2476	To treat or not to treat: is it acceptable to avoid active therapies in advanced prostate cancer today?. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 389-400.	1.1	2
2477	Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103185.	2.0	41
2478	KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer. <i>Cancer Research</i> , 2021, 81, 1026-1039.	0.4	35
2479	Effects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC Resistant to Second-Line Antiandrogen Therapy. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 490-499.	1.9	55
2480	Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 301-309.	2.0	19
2481	SLX4IP Promotes Telomere Maintenance in Androgen Receptorâ€”Independent Castration-Resistant Prostate Cancer through ALT-like Telomeric PML Localization. <i>Molecular Cancer Research</i> , 2021, 19, 301-316.	1.5	4
2482	The Role of Theranostics in Prostate Cancer. <i>Seminars in Radiation Oncology</i> , 2021, 31, 71-82.	1.0	20
2483	Impact of prostate cancer stem cell niches on prostate cancer tumorigenesis and progression. <i>Advances in Stem Cells and Their Niches</i> , 2021, 5, 177-204.	0.1	0
2484	The long nonâ€”coding RNA PCAL7 promotes prostate cancer by strengthening androgen receptor signaling. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e23645.	0.9	5
2485	Mechanisms of docetaxel resistance in prostate cancer: The key role played by miRNAs. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188481.	3.3	24
2486	The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103199.	2.0	16
2487	Identification of Genes Required for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells <i>in Vitro</i> . <i>Molecular Cancer Therapeutics</i> , 2021, 20, 398-409.	1.9	17
2488	Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 31, 115953.	1.4	10
2489	BRD9 Is a Critical Regulator of Androgen Receptor Signaling and Prostate Cancer Progression. <i>Cancer Research</i> , 2021, 81, 820-833.	0.4	43

#	ARTICLE	IF	CITATIONS
2490	Novel case of androgen receptor $\alpha$ -positive cancer of unknown primary without serum prostate $\alpha$ -specific antigen elevation that became progression free in the long term after primary combined androgen blockade. <i>IJU Case Reports</i> , 2021, 4, 59-63.	0.1	0
2491	Treatment and resistance mechanisms in castration-resistant prostate cancer: new implications for clinical decision making?. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 149-163.	1.1	4
2492	Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer. <i>British Journal of Cancer</i> , 2021, 124, 552-563.	2.9	63
2493	Safety evaluation of enzalutamide dose-escalation strategy in patients with castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 233.e15-233.e20.	0.8	5
2494	Prognostic significance of complete blood count parameters in castration-resistant prostate cancer patients treated with androgen receptor pathway inhibitors. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 365.e1-365.e7.	0.8	3
2495	Overall Survival Among Chemotherapy-Naive Patients With Castration-Resistant Prostate Cancer Under Abiraterone Versus Enzalutamide: A Direct Comparison Based on a 2014 $\hat{a}$ 2018 French Population Study (the SPEAR Cohort). <i>American Journal of Epidemiology</i> , 2021, 190, 413-422.	1.6	16
2496	Prognosis and safety of radium $\hat{a}$ 223 with concurrent abiraterone acetate or enzalutamide use for metastatic castration $\hat{a}$ resistant prostate cancer: Real $\hat{a}$ world data of Japanese patients. <i>BJUI Compass</i> , 2021, 2, 31-38.	0.7	4
2497	Inferences About Drug Safety in Phase $\hat{A}$ III Trials in Oncology: Examples From Advanced Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 553-561.	3.0	12
2498	Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases. <i>International Journal of Clinical Oncology</i> , 2021, 26, 192-198.	1.0	21
2499	Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 341-348.	2.0	8
2500	Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 244-252.	2.0	22
2501	MOCRPC overview of management options. <i>World Journal of Urology</i> , 2021, 39, 349-356.	1.2	6
2502	ALP bouncing and LDH normalization in bone metastatic castration-resistant prostate cancer patients under therapy with Enzalutamide: an exploratory analysis. <i>Translational Andrology and Urology</i> , 2021, 10, 0-0.	0.6	3
2503	New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer. <i>Cells</i> , 2021, 10, 193.	1.8	26
2504	Ferroptosis Inducers Are a Novel Therapeutic Approach for Advanced Prostate Cancer. <i>Cancer Research</i> , 2021, 81, 1583-1594.	0.4	140
2505	Radium-223 in combination with enzalutamide in metastatic castration-resistant prostate cancer: a multi-centre, phase II open-label study. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110426.	1.4	8
2506	A comparison of parametric propensity $\langle$ score $\hat{a}$ based $\rangle$ methods for causal inference with multiple treatments and $\hat{A}$ binary outcome. <i>Statistics in Medicine</i> , 2021, 40, 1653-1677.	0.8	6
2507	Androgen Receptors in the Pathology of Disease. , 2021, , 411-461.		0

#	ARTICLE	IF	CITATIONS
2508	Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 524-531.	2.0	32
2509	Circulating Tumor Cells in Prostate Cancer. , 2021, , 93-102.		0
2510	Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 526.	1.7	5
2511	Development of novel androgen receptor inhibitors to overcome castrate-resistant prostate cancer. , 2021, , 23-46.		0
2512	Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592098765.	1.4	19
2513	Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 334.	1.7	44
2514	The advance of adjuvant treatment for triple-negative breast cancer. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	1.4	11
2515	CDK13 upregulation-induced formation of the positive feedback loop among circCDK13, miR-212-5p/miR-449a and E2F5 contributes to prostate carcinogenesis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 2.	3.5	28
2516	Resistance to Antiandrogens in Prostate Cancer: Is It Inevitable, Intrinsic or Induced?. <i>Cancers</i> , 2021, 13, 327.	1.7	27
2517	Optimizing outcomes for patients with metastatic prostate cancer: insights from South East Asia Expert Panel. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592098546.	1.4	1
2518	A novel long non-coding RNA PCLN16 facilitates androgen receptor signaling in prostate cancer. <i>Biochemical and Biophysical Research Communications</i> , 2021, 537, 78-84.	1.0	11
2519	Effective Prediction of Prostate Cancer Recurrence through the IQGAP1 Network. <i>Cancers</i> , 2021, 13, 430.	1.7	7
2520	The Role of Androgen Receptor Splicing Variant 7 in Predicting the Prognosis of Metastatic Castration-Resistant Prostate Cancer: Systematic Review and Meta-Analysis. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110352.	0.8	8
2521	Current treatment options for newly diagnosed metastatic hormone-sensitive prostate cancer—a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 3918-3930.	0.6	10
2522	Finding the optimal treatment sequence in metastatic castration-resistant prostate cancer—a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 3931-3945.	0.6	3
2523	Using biochemistry and biophysics to extinguish androgen receptor signaling in prostate cancer. <i>Journal of Biological Chemistry</i> , 2021, 296, 100240.	1.6	17
2524	Malignant Evaluation and Clinical Prognostic Values of M6A RNA Methylation Regulators in Prostate Cancer. <i>Journal of Cancer</i> , 2021, 12, 3575-3586.	1.2	7
2525	Sequential Docetaxel in 7 Cycles Followed by Cabazitaxel Improves Oncological Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Scientific World Journal, The</i> , 2021, 2021, 1-9.	0.8	1

#	ARTICLE	IF	CITATIONS
2526	Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance. <i>BMC Cancer</i> , 2021, 21, 35.	1.1	7
2527	Serum Testosterone Level as Possible Predictive Marker for Prognosis in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Enzalutamide. <i>The Korean Journal of Urological Oncology</i> , 2021, 19, 60-69.	0.1	0
2528	SEOM clinical guidelines for the treatment of advanced prostate cancer (2020). <i>Clinical and Translational Oncology</i> , 2021, 23, 969-979.	1.2	18
2529	JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer. <i>Cancer Research</i> , 2022, 81, 1087-1100.	0.4	23
2530	Androgen Receptor Signaling and the Emergence of Lethal Neuroendocrine Prostate Cancer With the Treatment-Induced Suppression of the Androgen Receptor: A Literature Review. <i>Cureus</i> , 2021, 13, e13402.	0.2	4
2531	Prognostic impact of prior local therapy in castration-resistant prostate cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1142-1148.	0.6	6
2532	Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1032-1040.	2.0	28
2533	Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 812-825.	2.0	5
2534	Non-Coding RNAs Set a New Phenotypic Frontier in Prostate Cancer Metastasis and Resistance. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2100.	1.8	13
2535	Căncer de prăstata. <i>Medicine</i> , 2021, 13, 1454-1466.	0.0	0
2536	Huaier Extract Inhibits Prostate Cancer Growth via Targeting AR/AR-V7 Pathway. <i>Frontiers in Oncology</i> , 2021, 11, 615568.	1.3	9
2537	Nomogram predicting survival to assist decision-making of radical prostatectomy in patients with metastatic prostate cancer. <i>Translational Andrology and Urology</i> , 2021, 10, 879-887.	0.6	3
2538	Response to Concomitant Enzalutamide and 177Lu-PSMA-617 Radioligand Therapy in ATM-Mutated Metastatic Castration Resistant Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2021, Publish Ahead of Print, 582-583.	0.7	10
2539	LSD1 Promotes Prostate Cancer Cell Survival by Destabilizing FBXW7 at Post-Translational Level. <i>Frontiers in Oncology</i> , 2020, 10, 616185.	1.3	13
2540	Optimal treatment sequencing of abiraterone acetate plus prednisone and enzalutamide in patients with castration-resistant metastatic prostate cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 93, 102152.	3.4	10
2541	Diagnostic Strategies for Treatment Selection in Advanced Prostate Cancer. <i>Diagnostics</i> , 2021, 11, 345.	1.3	14
2542	Medication patterns of abiraterone acetate plus prednisone or enzalutamide and PSA progression in veterans with metastatic castration-resistant prostate cancer. <i>Current Medical Research and Opinion</i> , 2021, 37, 635-642.	0.9	5
2543	Treating the patient and not just the cancer: therapeutic burden in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 647-661.	2.0	25

#	ARTICLE	IF	CITATIONS
2544	Treating Prostate Cancer by Antibody-Drug Conjugates. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1551.	1.8	38
2545	Predicting toxicity-related docetaxel discontinuation and overall survival in metastatic castration-resistant prostate cancer: a pooled analysis of open phase 3 clinical trial data. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 743-749.	2.0	4
2546	Differential Expression of a Panel of Ten CNTN1-Associated Genes during Prostate Cancer Progression and the Predictive Properties of the Panel towards Prostate Cancer Relapse. <i>Genes</i> , 2021, 12, 257.	1.0	2
2547	Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness Analysis. <i>Frontiers in Public Health</i> , 2021, 9, 608375.	1.3	5
2548	An analysis of survival in patients with castrate-resistant prostate cancer receiving enzalutamide with treatment breaks. <i>Journal of Clinical Urology</i> , 0, , 205141582199376.	0.1	1
2549	A narrative review of proteolytic targeting chimeras (PROTACs): future perspective for prostate cancer therapy. <i>Translational Andrology and Urology</i> , 2021, 10, 954-962.	0.6	5
2550	EDITORIAL COMMENT. <i>Urology</i> , 2021, 148, 140.	0.5	0
2551	Risk of cardiovascular events in men on abiraterone or enzalutamide combined with GnRH agonists: nation-wide, population-based cohort study in Sweden. <i>Acta Oncologica</i> , 2021, 60, 459-465.	0.8	7
2552	MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	31
2553	[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. <i>Lancet, The</i> , 2021, 397, 797-804.	6.3	552
2554	The Real-World Experience of Single-Center, Retrospective Study of the Prognostic Effect of Secondary Hormone Agent on Survival in Patients With Hormone-Refractory Metastatic Prostate Cancer. <i>The Korean Journal of Urological Oncology</i> , 2021, 19, 48-59.	0.1	0
2555	Prostate Adenocarcinoma with Brain Metastasis: A Surveillance, Epidemiology, and End Results Database Analysis 2010-2015. <i>Medical Science Monitor</i> , 2021, 27, e930064.	0.5	4
2556	Next-Generation Androgen Receptor-Signaling Inhibitors for Prostate Cancer: Considerations for Older Patients. <i>Drugs and Aging</i> , 2021, 38, 111-123.	1.3	8
2557	Regulation and targeting of androgen receptor nuclear localization in castration-resistant prostate cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	30
2558	Racial disparity in prostate cancer in the African American population with actionable ideas and novel immunotherapies. <i>Cancer Reports</i> , 2021, 4, e1340.	0.6	13
2559	Prostate cancer. <i>Nature Reviews Disease Primers</i> , 2021, 7, 9.	18.1	434
2560	2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC) (full-text). <i>Canadian Urological Association Journal</i> , 2020, 15, E81-9.	0.3	10
2561	Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives. <i>Cancers</i> , 2021, 13, 549.	1.7	13

#	ARTICLE	IF	CITATIONS
2562	Cyproterone acetate acts as a disruptor of the aryl hydrocarbon receptor. <i>Scientific Reports</i> , 2021, 11, 5457.	1.6	3
2563	Distinct DNA methylation patterns associated with treatment resistance in metastatic castration resistant prostate cancer. <i>Scientific Reports</i> , 2021, 11, 6630.	1.6	8
2564	Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE). <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 25-37.	1.1	19
2565	Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer. , 2021, 9, e001556.		9
2566	Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation. <i>Cancers</i> , 2021, 13, 1483.	1.7	18
2567	Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients. <i>Future Oncology</i> , 2021, 17, 807-815.	1.1	1
2568	Novel Strategies for Treating Castration-Resistant Prostate Cancer. <i>Biomedicines</i> , 2021, 9, 339.	1.4	14
2569	Current Status and Future Perspectives of Androgen Receptor Inhibition Therapy for Prostate Cancer: A Comprehensive Review. <i>Biomolecules</i> , 2021, 11, 492.	1.8	26
2570	Stereotactic radiotherapy to oligoprogressive lesions detected with 68Ga-PSMA-PET/CT in castration-resistant prostate cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3683-3692.	3.3	21
2571	A noncanonical AR addiction drives enzalutamide resistance in prostate cancer. <i>Nature Communications</i> , 2021, 12, 1521.	5.8	43
2572	Influence of prostate cancer status on the prevalence of medication-related osteonecrosis of the jaw. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2021, 131, 312-318.	0.2	2
2573	Resistance to second-generation androgen receptor antagonists in prostate cancer. <i>Nature Reviews Urology</i> , 2021, 18, 209-226.	1.9	59
2574	Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments. <i>Journal of Clinical Oncology</i> , 2021, 39, 950-955.	0.8	28
2575	Darolutamide in hormone-sensitive and castration-resistant prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 535-544.	1.3	2
2576	The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 871-879.	2.0	8
2577	Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. <i>Nature Communications</i> , 2021, 12, 1979.	5.8	70
2578	Stunning Response with Low-Dose Enzalutamide after Abiraterone Acetate Failure in a Patient Diagnosed with Metastatic Castration-Resistant Prostate Cancer: A Case Report. <i>Case Reports in Oncology</i> , 2021, 14, 634-640.	0.3	3
2579	Management of Prostate Cancer with Systemic Therapy: A Prostate Cancer Unit Perspective. <i>Current Cancer Drug Targets</i> , 2021, 21, 107-116.	0.8	0



#	ARTICLE	IF	CITATIONS
2580	Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments. <i>Cells</i> , 2021, 10, 659.	1.8	77
2581	Effects of Medical Treatment of Prostate Cancer on Bone Health. <i>Trends in Endocrinology and Metabolism</i> , 2021, 32, 135-158.	3.1	21
2582	Y06014 is a selective BET inhibitor for the treatment of prostate cancer. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 2120-2131.	2.8	3
2583	Orphan nuclear receptors as regulators of intratumoral androgen biosynthesis in castration-resistant prostate cancer. <i>Oncogene</i> , 2021, 40, 2625-2634.	2.6	19
2584	Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 763-774.	1.9	2
2585	YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer. <i>Oncogene</i> , 2021, 40, 2407-2421.	2.6	37
2586	Factors influencing treatment of veterans with advanced prostate cancer. <i>Cancer</i> , 2021, 127, 2311-2318.	2.0	6
2587	Comparison of metastatic castration-resistant prostate cancer in bone with other sites: clinical characteristics, molecular features and immune status. <i>PeerJ</i> , 2021, 9, e11133.	0.9	1
2588	Validation of circulating steroid hormone measurements across different matrices by liquid chromatography-tandem mass spectrometry. <i>Steroids</i> , 2021, 167, 108800.	0.8	5
2590	Urinary oestrogen steroidome as an indicator of the risk of localised prostate cancer progression. <i>British Journal of Cancer</i> , 2021, 125, 78-84.	2.9	5
2591	Novel, non-invasive markers for detecting therapy induced neuroendocrine differentiation in castration-resistant prostate cancer patients. <i>Scientific Reports</i> , 2021, 11, 8279.	1.6	28
2592	A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide. <i>ESMO Open</i> , 2021, 6, 100082.	2.0	2
2593	Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4712.	1.8	14
2594	Pembrolizumab with or without enzalutamide in selected populations of men with previously untreated metastatic castration-resistant prostate cancer harbouring programmed cell death ligand-1 staining: a retrospective study. <i>BMC Cancer</i> , 2021, 21, 399.	1.1	17
2595	Pulmonary metastasectomy in germ cell tumors and prostate cancer. <i>Journal of Thoracic Disease</i> , 2021, 13, 2661-2668.	0.6	3
2596	Prostate-specific antigen nadir and testosterone level at prostate-specific antigen failure following radiation and androgen suppression therapy for unfavorable-risk prostate cancer and the risk of all-cause and prostate cancer-specific mortality. <i>Cancer</i> , 2021, 127, 2623-2630.	2.0	2
2597	<i>MAP3K7</i> Loss Drives Enhanced Androgen Signaling and Independently Confers Risk of Recurrence in Prostate Cancer with Joint Loss of <i>CHD1</i> . <i>Molecular Cancer Research</i> , 2021, 19, 1123-1136.	1.5	8
2598	Which Way to Choose for the Treatment of Metastatic Prostate Cancer: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2021, 11, 659442.	1.3	3

#	ARTICLE	IF	CITATIONS
2599	Consensus on the Treatment and Follow-Up for Metastatic Castration-Resistant Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC). <i>JCO Global Oncology</i> , 2021, 7, 559-571.	0.8	10
2600	Targeting ADT-Induced Activation of the E3 Ubiquitin Ligase Siah2 to Delay the Occurrence of Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 637040.	1.3	3
2601	Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment. <i>Prostate</i> , 2021, 81, 543-552.	1.2	20
2602	Concordance between Response Assessment Using Prostate-Specific Membrane Antigen PET and Serum Prostate-Specific Antigen Levels after Systemic Treatment in Patients with Metastatic Castration Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. <i>Diagnostics</i> , 2021, 11, 663.	1.3	16
2603	Deep and ongoing response of castrate-resistant prostate cancer on very low-dose enzalutamide in an elderly chemotherapy-naïve patient: a case report. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 165-168.	1.1	2
2606	An analysis of health-related quality of life in the phase III PROSELICA and FIRSTANA studies assessing cabazitaxel in patients with metastatic castration-resistant prostate cancer. <i>ESMO Open</i> , 2021, 6, 100089.	2.0	4
2607	Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance. <i>Clinical Cancer Research</i> , 2021, 27, 3610-3619.	3.2	17
2608	<sup>225</sup> Ac-PSMA-targeted alpha therapy for the treatment of metastatic castration-resistant prostate cancer: A systematic review and meta-analysis. <i>Prostate</i> , 2021, 81, 580-591.	1.2	18
2609	Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. <i>Clinical Cancer Research</i> , 2021, 27, 4077-4088.	3.2	21
2611	Interim and end-treatment 18F-Fluorocholine PET/CT and bone scan in prostate cancer patients treated with Radium 223 dichloride. <i>Scientific Reports</i> , 2021, 11, 7389.	1.6	7
2612	Healthcare Funding Decisions and Real-World Benefits: Reducing Bias by Matching Untreated Patients. <i>Pharmacoeconomics</i> , 2021, 39, 741-756.	1.7	0
2613	Resistance to the Androgen Receptor Centred Therapies: Biology and Management. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 1593-1609.	0.3	0
2614	Digital Medicine in Men with Advanced Prostate Cancer – A Feasibility Study of Electronic Patient-reported Outcomes in Patients on Systemic Treatment. <i>Clinical Oncology</i> , 2021, 33, 751-760.	0.6	7
2615	Can 68Ga-PSMA PET/CT-derived prostate-specific membrane antigen expression parameters predict prostate-specific antigen response to enzalutamide treatment?. <i>Nuclear Medicine Communications</i> , 2021, 42, 1011-1016.	0.5	4
2616	Novel Target Opportunities in Non-Metastatic Castrate Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 2426.	1.7	2
2617	Efficacy and tolerability of current treatments for hormone-refractory prostate cancer patients with visceral metastases. <i>Future Oncology</i> , 2021, 17, 1611-1624.	1.1	1
2618	Recent Advances in the Treatment of Metastatic Prostate Cancer. <i>Advances in Oncology</i> , 2021, 1, 263-272.	0.1	1
2619	11-Ketotestosterone: the resilience of a potent androgen in prostate cancer patients after castration. <i>JCI Insight</i> , 2021, 6, .	2.3	5

#	ARTICLE	IF	CITATIONS
2621	Transperineal Parallel Biopsy of the Prostate: A New Approach of Tissue Sampling for Precision Medicine. <i>International Journal of General Medicine</i> , 2021, Volume 14, 1631-1640.	0.8	1
2622	Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	23
2623	Triple-arm androgen blockade for advanced prostate cancer: a review. <i>Medical Oncology</i> , 2021, 38, 75.	1.2	4
2624	2020 Korean guidelines for the management of metastatic prostate cancer. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 491-514.	0.7	5
2626	Cross-resistance and drug sequence in prostate cancer. <i>Drug Resistance Updates</i> , 2021, 56, 100761.	6.5	36
2627	Advances in PSMA-targeted therapy for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 11-26.	2.0	48
2628	Heart Failure With Targeted Cancer Therapies. <i>Circulation Research</i> , 2021, 128, 1576-1593.	2.0	33
2629	AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5515.	1.8	20
2630	Large-cell neuroendocrine tumor of the prostate: a case report and review of the literature. <i>Journal of Medical Case Reports</i> , 2021, 15, 254.	0.4	7
2631	Sipuleucelâ€ associated inflammatory cardiomyopathy: a case report and observations from a large pharmacovigilance database. <i>ESC Heart Failure</i> , 2021, 8, 3360-3368.	1.4	3
2632	Combination Treatment Options for Castration-Resistant Prostate Cancer. , 0, , 59-80.		5
2633	Therapeutic efficacy of <sup>225</sup> Ac-PSMA-617 targeted alpha therapy in patients of metastatic castrate resistant prostate cancer after taxane-based chemotherapy. <i>Annals of Nuclear Medicine</i> , 2021, 35, 794-810.	1.2	12
2634	Construction of enzalutamide-resistant cell model of prostate cancer and preliminary screening of potential drug-resistant genes. <i>Experimental Biology and Medicine</i> , 2021, 246, 1776-1787.	1.1	6
2635	Efficacy and Safety of [ <sup>225</sup> Ac]Ac-PSMA-617 Augmented [ <sup>177</sup> Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis. <i>Pharmaceutics</i> , 2021, 13, 722.	2.0	25
2636	Dissecting the Hormonal Signaling Landscape in Castration-Resistant Prostate Cancer. <i>Cells</i> , 2021, 10, 1133.	1.8	13
2637	Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide. <i>Frontiers in Pharmacology</i> , 2021, 12, 669236.	1.6	3
2638	MUCIN 1 in Prostate Cancer. , 0, , 125-138.		1
2639	MicroRNAs as Epigenetic Determinants of Treatment Response and Potential Therapeutic Targets in Prostate Cancer. <i>Cancers</i> , 2021, 13, 2380.	1.7	12

#	ARTICLE	IF	CITATIONS
2640	Recent Development and Future Prospects of Molecular Targeted Therapy in Prostate Cancer. <i>Current Molecular Pharmacology</i> , 2021, 14, .	0.7	3
2641	Cardiovascular toxicities associated with abiraterone compared to enzalutamideâ€“A pharmacovigilance study. <i>EClinicalMedicine</i> , 2021, 36, 100887.	3.2	16
2642	Novel Treatment Strategy Using Second-Generation Androgen Receptor Inhibitors for Non-Metastatic Castration-Resistant Prostate Cancer. <i>Biomedicines</i> , 2021, 9, 661.	1.4	7
2644	Toxicity and Efficacy of Concurrent Androgen Deprivation Therapy, Pelvic Radiotherapy, and Radium-223 in Patients with <i>De Novo</i> Metastatic Hormone-Sensitive Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4549-4556.	3.2	5
2645	Identification of immune cell infiltration pattern and related critical genes in metastatic castration-resistant prostate cancer by bioinformatics analysis. <i>Cancer Biomarkers</i> , 2021, 32, 1-15.	0.8	6
2646	Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e190-e202.	1.8	9
2647	Real-World Data on Outcomes in Metastatic Castrate-Resistant Prostate Cancer Patients Treated With Abiraterone or Enzalutamide: A Regional Experience. <i>Frontiers in Oncology</i> , 2021, 11, 656146.	1.3	7
2648	Serum and hematologic responses after three cycles of cabazitaxel therapy as predictors of survival in castration-resistant prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 525-531.	1.1	3
2649	Zeb1 and SK3 Channel Are Up-Regulated in Castration-Resistant Prostate Cancer and Promote Neuroendocrine Differentiation. <i>Cancers</i> , 2021, 13, 2947.	1.7	9
2650	Tracing steroidogenesis in prostate biopsy samples to unveil prostate tissue androgen metabolism characteristics and potential clinical application. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2021, 210, 105859.	1.2	6
2651	A Review of the Pathophysiological Mechanisms Underlying Castration-resistant Prostate Cancer. <i>Research and Reports in Urology</i> , 2021, Volume 13, 457-472.	0.6	21
2652	Renal Safety of [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function. <i>Cancers</i> , 2021, 13, 3095.	1.7	27
2653	Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 1245-1252.	1.3	3
2654	A pharmacoeconomic evaluation of pharmaceutical treatment options for prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1685-1728.	0.9	4
2655	A drug safety evaluation of enzalutamide to treat advanced prostate cancer. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 741-749.	1.0	3
2656	Androgen Receptor Signaling in Prostate Cancer Genomic Subtypes. <i>Cancers</i> , 2021, 13, 3272.	1.7	14
2657	A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer. <i>PLoS ONE</i> , 2021, 16, e0253021.	1.1	6
2658	Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without 223Ra. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, 36, 391-396.	0.7	2

#	ARTICLE	IF	CITATIONS
2659	Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib?. <i>European Urology</i> , 2021, 79, 710-712.	0.9	9
2660	CBP/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers. <i>Cancers</i> , 2021, 13, 2872.	1.7	45
2661	The heavy chain of 4F2 antigen promote prostate cancer progression via SKP-2. <i>Scientific Reports</i> , 2021, 11, 11478.	1.6	10
2662	Pretreatment neutrophil-to-lymphocyte ratio as a potential prognostic biomarker for newly diagnosed patients with metastatic castration-sensitive prostate cancer. <i>Cancer Reports</i> , 2021, 4, e1392.	0.6	2
2663	The value of new drugs for advanced prostate cancer. <i>Cancer</i> , 2021, 127, 3457-3465.	2.0	6
2664	Olaparib for the treatment of metastatic prostate cancer. <i>Future Oncology</i> , 2021, 17, 2413-2429.	1.1	2
2665	Extracellular Vesicles in Advanced Prostate Cancer: Tools to Predict and Thwart Therapeutic Resistance. <i>Cancers</i> , 2021, 13, 3791.	1.7	5
2666	A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer. <i>Scientific Reports</i> , 2021, 11, 13683.	1.6	8
2667	LOC100996425 acts as a promoter in prostate cancer by mediating hepatocyte nuclear factor 4A and the AMPK/mTOR pathway. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 8174-8186.	1.6	7
2668	ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling. <i>Oncogene</i> , 2021, 40, 5379-5392.	2.6	16
2669	Adverse events related to radium-223 treatment: "real-life" data from the Eudra-Vigilance database. <i>Minerva Urology and Nephrology</i> , 2021, 73, 342-348.	1.3	8
2670	The Prostate Cancer Therapy Enzalutamide Compared with Abiraterone Acetate/Prednisone Impacts Motivation for Exploration, Spatial Learning and Alters Dopaminergic Transmission in Aged Castrated Mice. <i>Cancers</i> , 2021, 13, 3518.	1.7	5
2671	Prostate Cancer Theranostics. <i>PET Clinics</i> , 2021, 16, 391-396.	1.5	11
2672	Cardiovascular Toxicity of Androgen Deprivation Therapy. <i>Current Cardiology Reports</i> , 2021, 23, 109.	1.3	14
2673	Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223. <i>Cancer Medicine</i> , 2021, 10, 5775-5782.	1.3	7
2674	Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors. <i>Advances in Therapy</i> , 2021, 38, 4520-4540.	1.3	32
2675	Clinical outcomes and prognosis of metastatic prostate cancer patients 60-year-old. <i>World Journal of Urology</i> , 2021, 39, 4319-4325.	1.2	3
2676	A Population-based Study Comparing Outcomes for Patients With Metastatic Castrate Resistant Prostate Cancer Treated by Urologists or Medical Oncologists With First Line Abiraterone Acetate or Enzalutamide. <i>Urology</i> , 2021, 153, 147-155.	0.5	5

#	ARTICLE	IF	CITATIONS
2677	Molecular events in neuroendocrine prostate cancer development. <i>Nature Reviews Urology</i> , 2021, 18, 581-596.	1.9	65
2678	Prognostic significance of third-line treatment for patients with metastatic castration-resistant prostate cancer: comparative assessments between cabazitaxel and other agents. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1745-1751.	1.0	6
2679	Phase I clinical trial of $^{11}C$ -119: A deuterated form of enzalutamide. <i>International Journal of Cancer</i> , 2021, 149, 1473-1482.	2.3	9
2680	Hormonal manipulation in androgen signaling: a narrative review on using novel androgen therapy agents to optimize clinical outcomes and minimize side effects for prostate cancer patients. <i>Translational Andrology and Urology</i> , 2021, 10, 3199-3207.	0.6	6
2681	A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177 $\alpha$ -labeled Prostate-specific Membrane Antigen $\alpha$ -targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2021, 80, 82-94.	0.9	53
2682	Overview of Olaparib as a treatment option for metastatic castration-resistant prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1955-1959.	0.9	0
2683	A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging Countries. <i>Oncology and Therapy</i> , 2021, 9, 311-327.	1.0	1
2684	Response Assessment and Prediction of Progression-Free Survival by $^{68}Ga$ -PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing $^{177}Lu$ -PSMA-617 Radioligand Therapy. <i>Biomolecules</i> , 2021, 11, 1099.	1.8	14
2685	rAAV-based and intraprostatically delivered miR-34a therapeutics for efficient inhibition of prostate cancer progression. <i>Gene Therapy</i> , 2022, 29, 418-424.	2.3	2
2686	A Prospective Study of the Relationship Between Clinical Outcomes After Enzalutamide and Serum Androgen Levels Measured via Liquid Chromatography-tandem Mass Spectrometry in Patients with Castration-resistant Prostate Cancer. <i>European Urology Open Science</i> , 2021, 29, 59-67.	0.2	4
2687	Characteristics and progression-free survival of Afro-Caribbean men with metastatic hormone-sensitive prostate cancer at the time of diagnosis. <i>Prostate</i> , 2021, 81, 1091-1096.	1.2	1
2688	Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted <i>Listeria monocytogenes</i> -based immunotherapy, in metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 219-228.	2.0	12
2689	ENZA $\alpha$ trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). <i>BJU International</i> , 2021, 128, 642-651.	1.3	18
2690	Revision of CHARTED and LATITUDE criteria among Japanese de novo metastatic prostate cancer patients. <i>Prostate International</i> , 2021, 9, 208-214.	1.2	5
2691	Hematologic safety of $^{177}Lu$ -PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. <i>EJNMMI Research</i> , 2021, 11, 61.	1.1	16
2692	Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 5223-5237.	0.9	30
2693	Activation of the <i>ABC B1</i> Amplicon in Docetaxel- and Cabazitaxel-Resistant Prostate Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2061-2070.	1.9	10
2694	Value of Combined PET Imaging with $^{18}F$ FDG and $^{68}Ga$ PSMA-11 in mCRPC Patients with Worsening Disease during $^{177}Lu$ PSMA-617 RLT. <i>Cancers</i> , 2021, 13, 4134.	1.7	15



#	ARTICLE	IF	CITATIONS
2695	Prognostic Score and Benefit from Abiraterone in First-line Metastatic, Castration-resistant Prostate Cancer. <i>European Urology</i> , 2021, 80, 641-649.	0.9	4
2696	Genetic Suppressor Element 1 (GSE1) Promotes the Oncogenic and Recurrent Phenotypes of Castration-Resistant Prostate Cancer by Targeting Tumor-Associated Calcium Signal Transducer 2 (TACSTD2). <i>Cancers</i> , 2021, 13, 3959.	1.7	8
2697	Salvage Radioligand Therapy with Repeated Cycles of <sup>177</sup> Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer with Diffuse Bone Marrow Involvement. <i>Cancers</i> , 2021, 13, 4017.	1.7	5
2698	Differential prognostic impact of complete blood count-related parameters by prior use of novel androgen receptor pathway inhibitors in docetaxel-treated castration-resistant prostate cancer patients. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, .	0.7	5
2699	Efficacy of <sup>68</sup> Ga-PSMA PET/CT-derived whole-body volumetric parameters in predicting response to second-generation androgen receptor axis-targeted therapy, and the prognosis in metastatic hormone-refractory prostate cancer patients. <i>Nuclear Medicine Communications</i> , 2021, 42, 1336-1346.	0.5	6
2700	Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation. <i>Cancers</i> , 2021, 13, 4346.	1.7	15
2701	Titration of Androgen Signaling: How Basic Studies Have Informed Clinical Trials Using High-Dose Testosterone Therapy in Castrate-Resistant Prostate Cancer. <i>Life</i> , 2021, 11, 884.	1.1	5
2703	Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma. <i>Clinical Drug Investigation</i> , 2021, 41, 795-808.	1.1	4
2704	Enzalutamide+androgen deprivation therapy (ADT) versus flutamide+ADT in Japanese men with castration-resistant prostate cancer: AFTERCAB study. <i>BJUI Compass</i> , 2022, 3, 26-36.	0.7	9
2705	Breaking androgen receptor addiction of prostate cancer by targeting different functional domains in the treatment of advanced disease. <i>Translational Oncology</i> , 2021, 14, 101115.	1.7	7
2706	Manejo actual de las metástasis vertebrales: un trabajo en equipo. <i>Revista Chilena De Ortopedia Y Traumatología</i> , 2021, 62, e136-e142.	0.0	0
2707	Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503). <i>European Urology Oncology</i> , 2021, 4, 543-552.	2.6	11
2708	Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 274-282.	2.0	11
2709	Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3679-3692.	2.0	15
2710	High Tumor Burden Predicts Poor Response to Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients. <i>Cancers</i> , 2021, 13, 3966.	1.7	4
2711	A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer. <i>Annual Review of Pharmacology and Toxicology</i> , 2022, 62, 131-153.	4.2	55
2712	Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer. <i>Nature Cancer</i> , 2021, 2, 978-993.	5.7	52
2713	Study to Compare Capsule and Liquid Formulations of Enzalutamide After <sc>Single-Dose</sc> Administration Under Fasting Conditions in Prostate Cancer. <i>Oncologist</i> , 2021, 26, 729-e1493.	1.9	2

#	ARTICLE	IF	CITATIONS
2714	Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition. <i>Cancer Research</i> , 2021, 81, 4981-4993.	0.4	43
2715	KEYNOTE-641: a Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2021, 17, 3017-3026.	1.1	19
2716	Outcome of 177Lu-PSMA-617 Radioligand Therapy in Chemo-Refractory Patients with Metastatic Castration-Resistant Early-Onset Prostate Cancer. <i>Cancers</i> , 2021, 13, 4193.	1.7	5
2717	A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design. <i>BMJ Open</i> , 2021, 11, e046588.	0.8	14
2718	The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches. <i>Endocrine-Related Cancer</i> , 2021, 28, T51-T66.	1.6	28
2719	MiR-205-driven downregulation of cholesterol biosynthesis through SQLE-inhibition identifies therapeutic vulnerability in aggressive prostate cancer. <i>Nature Communications</i> , 2021, 12, 5066.	5.8	34
2720	Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 905-914.	2.3	21
2722	Increasing prevalence of metastatic castration-resistant prostate cancer in a managed care population in the United States. <i>Cancer Causes and Control</i> , 2021, 32, 1365-1374.	0.8	10
2723	Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T. , 2021, 9, e002931.		18
2724	SLX4IP N-terminus dictates telomeric localization in ALT-like castration-resistant prostate cancer cell lines. <i>Prostate</i> , 2021, 81, 1235-1251.	1.2	1
2725	Comparative Cardiovascular Safety of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 17-24.	0.9	15
2726	Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC). <i>Biomedicines</i> , 2021, 9, 1247.	1.4	22
2727	Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States. <i>Cancers</i> , 2021, 13, 4951.	1.7	19
2728	Survival trends for patients with primary metastatic prostate cancer before and after the introduction of new antitumor drugs. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 53-58.	2.0	7
2729	Chemotherapy in metastatic castration-resistant prostate cancer: Current scenario and future perspectives. <i>Cancer Letters</i> , 2021, 523, 162-169.	3.2	24
2730	Time on treatment with abiraterone and enzalutamide in the Patient-overview Prostate Cancer in The National Prostate Cancer Register of Sweden. <i>Acta Oncologica</i> , 2021, 60, 1589-1596.	0.8	3
2731	Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer. <i>Nature Reviews Urology</i> , 2021, 18, 739-762.	1.9	38
2732	Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer. <i>International Journal of Urology</i> , 2022, 29, 26-32.	0.5	5

#	ARTICLE	IF	CITATIONS
2733	Efficacy and safety of bipolar androgen therapy in mCRPC after progression on abiraterone or enzalutamide: A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 4.e19-4.e28.	0.8	7
2734	Targeting steroid hormone receptors for anti-cancer therapy: A review on small molecules and nanotherapeutic approaches. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2022, 14, e1755.	3.3	9
2735	TAXOMET: A French Prospective Multicentric Randomized Phase II Study of Docetaxel Plus Metformin Versus Docetaxel Plus Placebo in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 501-509.	0.9	18
2736	Enzalutamide in patients with castration-resistant prostate cancer: retrospective, multicenter, real life study. <i>Minerva Urology and Nephrology</i> , 2021, 73, 489-497.	1.3	7
2737	Clinical Relevance of Circulating Tumor Cells in Prostate Cancer Management. <i>Biomedicines</i> , 2021, 9, 1179.	1.4	17
2738	Androgens in prostate cancer: A tale that never ends. <i>Cancer Letters</i> , 2021, 516, 1-12.	3.2	23
2739	Predicting cancer drug TARGETS - Treatment Response Generalized Elastic-net Signatures. <i>Npj Genomic Medicine</i> , 2021, 6, 76.	1.7	10
2740	Designed, synthesized and biological evaluation of proteolysis targeting chimeras (PROTACs) as AR degraders for prostate cancer treatment. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 45, 116331.	1.4	10
2741	Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial. <i>European Journal of Cancer</i> , 2021, 155, 56-63.	1.3	8
2742	Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients. <i>Prostate</i> , 2021, 81, 1374-1381.	1.2	8
2743	AR-negative prostate cancer is vulnerable to loss of JMJD1C demethylase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	6
2744	Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer. <i>Cancers</i> , 2021, 13, 4522.	1.7	22
2745	Evaluating the Role of Stereotactic Body Radiation Therapy With Respect to Androgen Receptor Signaling Inhibitors for Oligometastatic Prostate Cancer. <i>Advances in Radiation Oncology</i> , 2022, 7, 100808.	0.6	4
2746	A Case Report of Metastatic Castration-Resistant Prostate Cancer Harboring a PTEN Loss. <i>Frontiers in Oncology</i> , 2021, 11, 731002.	1.3	3
2747	The tumor suppressor miR-642a-5p targets Wilms Tumor 1 gene and cell-cycle progression in prostate cancer. <i>Scientific Reports</i> , 2021, 11, 18003.	1.6	10
2748	25-year perspective on prostate cancer: Conquering frontiers and understanding tumor biology. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 521-527.	0.8	3
2749	Profiling of Androgen-Dependent Enhancer RNAs Expression in Human Prostate Tumors: Search for Malignancy Transition Markers. <i>Research and Reports in Urology</i> , 2021, Volume 13, 705-713.	0.6	5
2750	PD05-06: PROMOTIONAL PAYMENTS TO MEDICAL ONCOLOGISTS AND UROLOGISTS AND PRESCRIPTIONS FOR ABIRATERONE AND ENZALUTAMIDE. <i>Journal of Urology</i> , 2021, 206, .	0.2	1

#	ARTICLE	IF	CITATIONS
2751	Clinicopathological characteristics of androgen receptor splicing variant 7 (AR-V7) expression in patients with castration resistant prostate cancer: A systematic review and meta-analysis. <i>Translational Oncology</i> , 2021, 14, 101145.	1.7	8
2752	Recent Advances in the Management of Metastatic Prostate Cancer. <i>JCO Oncology Practice</i> , 2022, 18, 45-55.	1.4	75
2753	Prostate cancer. <i>Lancet, The</i> , 2021, 398, 1075-1090.	6.3	240
2754	Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, , .	2.0	2
2755	Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer. <i>Cell Reports</i> , 2021, 36, 109665.	2.9	24
2756	Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 695136.	1.3	6
2757	Retrospective analysis of serum testosterone levels by LC-MS/MS in chemically castrated prostate cancer patients: Biological variation and analytical performance specifications. <i>Clinica Chimica Acta</i> , 2021, 521, 70-75.	0.5	8
2758	Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients. <i>ESMO Open</i> , 2021, 6, 100261.	2.0	14
2759	Assessment of Total, PTEN <sup>+</sup> , and AR-V7+ Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e286-e298.	0.9	18
2760	Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer. <i>PLoS ONE</i> , 2021, 16, e0258160.	1.1	7
2761	Neurotoxicities of novel non-steroidal anti-androgens for prostate cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 166, 103463.	2.0	3
2762	Stereotactic radiosurgery for prostate cancer cerebral metastases: an international multicenter study. <i>Journal of Neurosurgery</i> , 2022, 136, 1307-1313.	0.9	3
2763	Mechanisms and markers of resistance to androgen signaling inhibitors in patients with metastatic castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 728.e13-728.e24.	0.8	8
2764	Risk of Cognitive Effects in Comorbid Patients With Prostate Cancer Treated With Androgen Receptor Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 467.e1-467.e11.	0.9	6
2765	The treatment landscape of metastatic prostate cancer. <i>Cancer Letters</i> , 2021, 519, 20-29.	3.2	50
2766	miRNAs and androgen deprivation therapy for prostate cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188625.	3.3	19
2767	Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics. , 2021, 228, 107932.		44
2768	Therapies of bone metastases in castration-resistant prostate cancer. , 2022, , 967-975.		0

#	ARTICLE	IF	CITATIONS
2769	An Invisible Oncologist: Health Implications of Financing Frictions. SSRN Electronic Journal, 0, , .	0.4	0
2770	The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer. Clinical Cancer Research, 2021, 27, 2928-2937.	3.2	42
2771	Geriatric Nutritional Risk Index as a Prognostic Marker for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel. Frontiers in Pharmacology, 2020, 11, 601513.	1.6	12
2772	Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC). Journal of Medicinal Chemistry, 2021, 64, 909-924.	2.9	16
2773	Risk of major adverse cardiovascular events among secondâ€line hormonal therapy for metastatic castrationâ€resistant prostate cancer: A realâ€world evidence study. Prostate, 2021, 81, 194-201.	1.2	6
2774	Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer. Cancers, 2021, 13, 173.	1.7	14
2775	Hormonal Therapy for Prostate Cancer. Endocrine Reviews, 2021, 42, 354-373.	8.9	136
2777	Methods for Evaluation of a Snake Venom-Derived Disintegrin in Animal Models of Human Cancer. Methods in Molecular Biology, 2020, 2068, 185-204.	0.4	5
2778	Canonical and Noncanonical Androgen Metabolism and Activity. Advances in Experimental Medicine and Biology, 2019, 1210, 239-277.	0.8	8
2779	Androgen Receptor Dependence. Advances in Experimental Medicine and Biology, 2019, 1210, 333-350.	0.8	19
2780	The Tumor Microenvironments of Lethal Prostate Cancer. Advances in Experimental Medicine and Biology, 2019, 1210, 149-170.	0.8	7
2781	Current Landscape of Immunotherapy in Genitourinary Malignancies. Advances in Experimental Medicine and Biology, 2020, 1244, 107-147.	0.8	3
2782	Neue Arzneimittel 2013. , 2014, , 47-145.		2
2783	Onkologika. , 2016, , 583-619.		1
2784	Onkologika. , 2017, , 597-639.		1
2785	Age, Gleason Score, and PSA are important prognostic factors for survival in metastatic castration-resistant prostate cancer. Results of The Uroncor Group (Uro-Oncological Tumors) of the Spanish Society of Radiation Oncology (SEOR). Clinical and Translational Oncology, 2020, 22, 1378-1389.	1.2	11
2786	Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer. Drugs, 2021, 81, 191-206.	4.9	11
2787	GLUT1 is an AR target contributing to tumor growth and glycolysis in castration-resistant and enzalutamide-resistant prostate cancers. Cancer Letters, 2020, 485, 45-55.	3.2	42

#	ARTICLE	IF	CITATIONS
2788	Bipolar androgen therapy in prostate cancer: Current evidences and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 152, 102994.	2.0	13
2789	Influence of abiraterone and enzalutamide on body composition in patients with metastatic castration resistant prostate cancer. <i>Cancer Treatment and Research Communications</i> , 2020, 25, 100256.	0.7	10
2790	Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group. <i>Journal of Bone Oncology</i> , 2020, 25, 100311.	1.0	27
2791	The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer. <i>Urologic Clinics of North America</i> , 2020, 47, e17-e54.	0.8	39
2793	Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer. <i>Oncogene</i> , 2018, 37, 710-721.	2.6	69
2799	Theranostics in Nuclear Medicine: Emerging and Re-emerging Integrated Imaging and Therapies in the Era of Precision Oncology. <i>Radiographics</i> , 2020, 40, 1715-1740.	1.4	65
2800	Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1708-1718.	1.9	42
2801	Tumor fraction in cell-free DNA as a biomarker in prostate cancer. <i>JCI Insight</i> , 2018, 3, .	2.3	94
2802	Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy. <i>JCI Insight</i> , 2019, 4, .	2.3	26
2803	Molecular determinants of response to high-dose androgen therapy in prostate cancer. <i>JCI Insight</i> , 2019, 4, .	2.3	17
2804	An imaging agent to detect androgen receptor and its active splice variants in prostate cancer. <i>JCI Insight</i> , 2016, 1, .	2.3	16
2805	Targeting FOXA1-mediated repression of TGF- $\beta$ 2 signaling suppresses castration-resistant prostate cancer progression. <i>Journal of Clinical Investigation</i> , 2018, 129, 569-582.	3.9	116
2806	Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. <i>Journal of Clinical Investigation</i> , 2019, 129, 4492-4505.	3.9	250
2807	Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer. <i>Journal of Clinical Investigation</i> , 2017, 127, 2326-2338.	3.9	40
2808	Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097813.	1.4	11
2809	Nonhormone Therapy for Metastatic Castration-Resistant Prostate Cancer: Chemotherapy, Bone-Targeted Treatments, and Others. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, e161-e165.	1.8	2
2810	Application of the ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale to Assess the Value of Abiraterone and Enzalutamide in Advanced Prostate Cancer. <i>JCO Oncology Practice</i> , 2020, 16, e201-e210.	1.4	13
2811	Performance status of real-world oncology patients before and after first course of chemotherapy. <i>Journal of Community and Supportive Oncology</i> , 2014, 12, 163-170.	0.1	3



#	ARTICLE	IF	CITATIONS
2812	20(S)-Protopanaxadiol Inhibition of Progression and Growth of Castration-Resistant Prostate Cancer. PLoS ONE, 2014, 9, e111201.	1.1	31
2813	Prostate Cancer Characteristics Associated with Response to Pre-Receptor Targeting of the Androgen Axis. PLoS ONE, 2014, 9, e111545.	1.1	6
2814	Mutation of Androgen Receptor N-Terminal Phosphorylation Site Tyr-267 Leads to Inhibition of Nuclear Translocation and DNA Binding. PLoS ONE, 2015, 10, e0126270.	1.1	12
2815	Divergent Androgen Receptor and Beta-Catenin Signaling in Prostate Cancer Cells. PLoS ONE, 2015, 10, e0141589.	1.1	38
2816	Arg-Gly-Asp (RGD)-Modified E1A/E1B Double Mutant Adenovirus Enhances Antitumor Activity in Prostate Cancer Cells In Vitro and in Mice. PLoS ONE, 2016, 11, e0147173.	1.1	15
2817	Inhibition of androgen receptor by decoy molecules delays progression to castration-recurrent prostate cancer. PLoS ONE, 2017, 12, e0174134.	1.1	10
2818	Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells. PLoS ONE, 2017, 12, e0189007.	1.1	45
2819	Observational study on time on treatment with abiraterone and enzalutamide. PLoS ONE, 2020, 15, e0244462.	1.1	8
2820	Mechanism and Function of Angiogenin in Prostate Cancer. Zhongguo Sheng Wu Hua Xue Yu Fen Zi Sheng Wu Xue Bao = Chinese Journal of Biochemistry and Molecular Biology, 2015, 31, 1261-1266.	0.0	12
2821	Progress in the Treatment of Advanced Prostate Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , 117-131.	1.8	31
2822	Inhibition of TAMs improves the response to docetaxel in castration-resistant prostate cancer. Endocrine-Related Cancer, 2019, 26, 131-140.	1.6	28
2823	Roles of the HOXA10 gene during castrate-resistant prostate cancer progression. Endocrine-Related Cancer, 2019, 26, 279-292.	1.6	8
2824	PEG10 is associated with treatment-induced neuroendocrine prostate cancer. Journal of Molecular Endocrinology, 2019, 63, 39-49.	1.1	25
2825	Impact of the COVID-19 Pandemic on the Urologist's clinical practice in Brazil: a management guideline proposal for low- and middle-income countries during the crisis period. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2020, 46, 501-510.	0.7	59
2826	Clinical and surgical assistance in prostate cancer during the COVID-19 Pandemic: implementation of assistance protocols. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2020, 46, 50-61.	0.7	10
2827	NEW TREATMENT STANDARD FOR PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER. Onkourologiya, 2018, 14, 68-77.	0.1	1
2828	The National Registry of treatment regimens in patients with metastatic castration-resistant prostate cancer in the Russian Federation. Onkourologiya, 2019, 15, 78-88.	0.1	2
2829	Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 538-549.	0.5	7

#	ARTICLE	IF	CITATIONS
2830	Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma. <i>Aging</i> , 2020, 12, 11466-11484.	1.4	27
2831	miR-5089-5p suppresses castration-resistant prostate cancer resistance to enzalutamide and metastasis via miR-5089-5p/SPINK1/ MAPK/MMP9 signaling. <i>Aging</i> , 2020, 12, 14418-14433.	1.4	3
2832	Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration-resistant prostate cancer: a report from the PETRUS prospective study. <i>Oncotarget</i> , 2016, 7, 55069-55082.	0.8	33
2833	Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. <i>Oncotarget</i> , 2016, 7, 64447-64470.	0.8	130
2834	Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide. <i>Oncotarget</i> , 2016, 7, 59781-59794.	0.8	52
2835	Dual targeting of androgen receptor and mTORC1 by salinomycin in prostate cancer. <i>Oncotarget</i> , 2016, 7, 62240-62254.	0.8	23
2836	Targeted suppression of AR-V7 using PIP5K1 $\beta$ inhibitor overcomes enzalutamide resistance in prostate cancer cells. <i>Oncotarget</i> , 2016, 7, 63065-63081.	0.8	38
2837	Nutlin-3 inhibits androgen receptor-driven c-FLIP expression, resulting in apoptosis of prostate cancer cells. <i>Oncotarget</i> , 2016, 7, 74724-74733.	0.8	4
2838	Combination effect of therapies targeting the PI3K- and AR-signaling pathways in prostate cancer. <i>Oncotarget</i> , 2016, 7, 76181-76196.	0.8	18
2839	Amplification of MUC1 in prostate cancer metastasis and CRPC development. <i>Oncotarget</i> , 2016, 7, 83115-83133.	0.8	27
2840	Combinatorial antitumor effect of HDACs and the PI3K-Akt-mTOR pathway inhibition in a Pten deficient model of prostate cancer. <i>Oncotarget</i> , 2013, 4, 2225-2236.	0.8	64
2841	Epigenetic therapy in urologic cancers: an update on clinical trials. <i>Oncotarget</i> , 2017, 8, 12484-12500.	0.8	35
2842	A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer. <i>Oncotarget</i> , 2017, 8, 6796-6808.	0.8	8
2843	Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures. <i>Oncotarget</i> , 2017, 8, 10324-10347.	0.8	34
2844	Radioligand therapy of metastatic prostate cancer using <sup>177</sup> Lu-PSMA-617 after radiation exposure to <sup>223</sup> Ra-dichloride. <i>Oncotarget</i> , 2017, 8, 55567-55574.	0.8	59
2845	Alternative RNA splicing of the MEAF6 gene facilitates neuroendocrine prostate cancer progression. <i>Oncotarget</i> , 2017, 8, 27966-27975.	0.8	27
2846	Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade. <i>Oncotarget</i> , 2017, 8, 56051-56065.	0.8	70
2847	Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy. <i>Oncotarget</i> , 2014, 5, 1646-1656.	0.8	166

#	ARTICLE	IF	CITATIONS
2848	Vinculin and filamin-C are two potential prognostic biomarkers and therapeutic targets for prostate cancer cell migration. <i>Oncotarget</i> , 2017, 8, 82430-82436.	0.8	31
2849	Nuclear Eg5 (kinesin spindle protein) expression predicts docetaxel response and prostate cancer aggressiveness. <i>Oncotarget</i> , 2014, 5, 7357-7367.	0.8	24
2850	Establishment of a neuroendocrine prostate cancer model driven by the RNA splicing factor SRRM4. <i>Oncotarget</i> , 2017, 8, 66878-66888.	0.8	21
2851	Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy. <i>Oncotarget</i> , 2017, 8, 103108-103116.	0.8	67
2852	Integrative molecular network analysis identifies emergent enzalutamide resistance mechanisms in prostate cancer. <i>Oncotarget</i> , 2017, 8, 111084-111095.	0.8	11
2853	Apatinib alone or combined with radiotherapy in metastatic prostate cancer: Results from a pilot, multicenter study. <i>Oncotarget</i> , 2017, 8, 110774-110784.	0.8	8
2854	Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. <i>Oncotarget</i> , 2018, 9, 10284-10293.	0.8	44
2855	Molecular pathways and targets in prostate cancer. <i>Oncotarget</i> , 2014, 5, 7217-7259.	0.8	84
2856	Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway. <i>Oncotarget</i> , 2014, 5, 9335-9348.	0.8	64
2857	Testosterone metabolites inhibit proliferation of castration- and therapy-resistant prostate cancer. <i>Oncotarget</i> , 2018, 9, 16951-16961.	0.8	10
2858	Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer. <i>Oncotarget</i> , 2018, 9, 25586-25596.	0.8	66
2859	Prostate cancer susceptibility gene <i>HIST1H1A</i> is a modulator of androgen receptor signaling and epithelial to mesenchymal transition. <i>Oncotarget</i> , 2018, 9, 28532-28546.	0.8	7
2860	A prognostic score for overall survival in patients treated with abiraterone in the pre- and post-chemotherapy setting. <i>Oncotarget</i> , 2019, 10, 5082-5091.	0.8	4
2861	Evaluation of the genomic alterations in the androgen receptor gene during treatment with high-dose testosterone for metastatic castrate-resistant prostate cancer. <i>Oncotarget</i> , 2020, 11, 15-21.	0.8	9
2862	Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer. <i>Oncotarget</i> , 2015, 6, 1806-1820.	0.8	40
2863	Androgen receptors beyond prostate cancer: an old marker as a new target. <i>Oncotarget</i> , 2015, 6, 592-603.	0.8	31
2864	Manipulation of prostate cancer metastasis by locus-specific modification of the CRMP4 promoter region using chimeric TALE DNA methyltransferase and demethylase. <i>Oncotarget</i> , 2015, 6, 10030-10044.	0.8	35
2865	Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression. <i>Oncotarget</i> , 2015, 6, 20474-20484.	0.8	20

#	ARTICLE	IF	CITATIONS
2866	Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. <i>Oncotarget</i> , 2015, 6, 18192-18205.	0.8	111
2867	Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy. <i>Oncotarget</i> , 2015, 6, 26029-26040.	0.8	27
2868	Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents. <i>Oncotarget</i> , 2015, 6, 23358-23371.	0.8	79
2869	FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer. <i>Oncotarget</i> , 2015, 6, 29782-29794.	0.8	35
2870	AR-v7 protein expression is regulated by protein kinase and phosphatase. <i>Oncotarget</i> , 2015, 6, 33743-33754.	0.8	43
2871	The promise of dual targeting Akt/mTOR signaling in lethal prostate cancer. <i>Oncotarget</i> , 2012, 3, 1483-1484.	0.8	11
2872	Implication of NPM1 phosphorylation and preclinical evaluation of the nucleoprotein antagonist N6L in prostate cancer. <i>Oncotarget</i> , 2016, 7, 69397-69411.	0.8	17
2873	Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer. <i>Oncotarget</i> , 2016, 7, 26259-26274.	0.8	83
2874	Brachyury as a potential modulator of androgen receptor activity and a key player in therapy resistance in prostate cancer. <i>Oncotarget</i> , 2016, 7, 28891-28902.	0.8	19
2875	Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer. <i>Oncotarget</i> , 2016, 7, 35818-35831.	0.8	55
2876	Circulating <i>AR</i> copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer. <i>Oncotarget</i> , 2016, 7, 37839-37845.	0.8	69
2877	GRK3 is a direct target of CREB activation and regulates neuroendocrine differentiation of prostate cancer cells. <i>Oncotarget</i> , 2016, 7, 45171-45185.	0.8	40
2878	Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer. <i>Oncotarget</i> , 2016, 7, 38551-38565.	0.8	36
2879	Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors. <i>Oncotarget</i> , 2013, 4, 691-704.	0.8	57
2880	SSX2 regulates focal adhesion but does not drive the epithelial to mesenchymal transition in prostate cancer. <i>Oncotarget</i> , 2016, 7, 50997-51011.	0.8	9
2881	Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor. <i>Oncotarget</i> , 2016, 7, 40690-40703.	0.8	12
2882	Medical management of metastatic prostate cancer. <i>Australian Prescriber</i> , 2018, 41, 154-159.	0.5	11
2883	Overcoming the mechanisms of primary and acquired resistance to new generation hormonal therapies in advanced prostate cancer: focus on androgen receptor independent pathways. , 2020, 3, 726-741.		6

#	ARTICLE	IF	CITATIONS
2884	Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms. , 2020, 3, 742-761.		13
2885	Immunobiology and immunotherapy in genitourinary malignancies. <i>Annals of Translational Medicine</i> , 2016, 4, 270-270.	0.7	14
2886	Application of liquid biopsies to identify genomic factors associated with therapy resistance in castration resistant prostate cancer. <i>Annals of Translational Medicine</i> , 2016, 4, S64-S64.	0.7	1
2887	Restoration of FKBP51 protein promotes the progression of castration resistant prostate cancer. <i>Annals of Translational Medicine</i> , 2019, 7, 729-729.	0.7	13
2888	Analysis of novel enzalutamide-resistant cells: upregulation of testis-specific Y-encoded protein gene promotes the expression of androgen receptor splicing variant 7. <i>Translational Cancer Research</i> , 2020, 9, 6232-6245.	0.4	2
2889	A Clinical Evaluation of Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer: Guiding Principles for Treatment Selection and Perspectives on Research. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 13247-13263.	1.0	8
2890	Non-Steroidal Androgen Receptor Antagonists and Prostate Cancer: A Survey on Chemical Structures Binding this Fast-Mutating Target. <i>Current Medicinal Chemistry</i> , 2019, 26, 6053-6073.	1.2	7
2891	Androgen Receptor Gene Rearrangements: New Perspectives on Prostate Cancer Progression. <i>Current Drug Targets</i> , 2013, 14, 441-449.	1.0	31
2892	Efficacy and Safety of Non-Steroidal Anti-Androgens in Patients with Metastatic Prostate Cancer: Meta-Analysis of Randomized Controlled Trials. <i>Reviews on Recent Clinical Trials</i> , 2020, 15, 34-47.	0.4	2
2893	A Systematic Review and Meta-Analysis about the Effect of Bisphosphonates on the Risk of Skeletal-Related Event in Men with Prostate Cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020, 20, 1604-1612.	0.9	2
2894	Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer. <i>Anticancer Research</i> , 2016, 36, 5719-5730.	0.5	10
2895	Consequences of an Early PSA Response to Enzalutamide Treatment for Japanese Patients with Metastatic Castration-resistant Prostate Cancer. <i>Anticancer Research</i> , 2016, 36, 6141-6150.	0.5	21
2896	Bone-targeted Novel Cytotoxic Polybisphosphonate Conjugate in Castration-resistant Prostate Cancer: A Multicenter Phase 1 Study. <i>Anticancer Research</i> , 2016, 36, 6499-6504.	0.5	12
2897	The Clinical Efficacy of Enzalutamide in Metastatic Prostate Cancer: Prospective Single-center Study. <i>Anticancer Research</i> , 2017, 37, 1475-1480.	0.5	9
2898	Enzalutamide Versus Abiraterone as a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer: Protocol for a Multicenter Randomized Phase 3 Trial. <i>JMIR Research Protocols</i> , 2018, 7, e11191.	0.5	8
2899	Prognostic role of early PSA drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamide. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 737-745.	3.9	6
2900	Enzalutamide Treatment in Metastatic Castration-resistant Prostate Cancer: Before and after Docetaxel. <i>Journal of the College of Physicians and Surgeons--Pakistan: JCPSP</i> , 2020, 30, 815-821.	0.2	2
2901	TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer. <i>Health Technology Assessment</i> , 2016, 20, 1-288.	1.3	29

#	ARTICLE	IF	CITATIONS
2902	Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news. <i>Ecanermedalscience</i> , 2020, 14, 1036.	0.6	5
2903	Development of an immunofluorescent AR-V7 circulating tumor cell assay – A blood-based test for men with metastatic prostate cancer. <i>Journal of Circulating Biomarkers</i> , 2020, 9, 13-19.	0.8	7
2904	Cardiovascular Complications of Prostate Cancer Treatment. <i>Frontiers in Pharmacology</i> , 2020, 11, 555475.	1.6	14
2905	Prostate Cancer Stem-like Cells Contribute to the Development of Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2015, 7, 2290-2308.	1.7	51
2906	Advanced metastatic castration-resistant prostate cancer (mCRPC) treated with ARTA (androgen) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.6	2
2907	Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain. <i>Journal of Health Economics and Outcomes Research</i> , 2018, 6, 1-14.	0.6	2
2908	Assessment of biochemical recurrence of prostate cancer (Review). <i>International Journal of Oncology</i> , 2019, 55, 1194-1212.	1.4	14
2909	Ailanthone: A novel potential drug for treating human cancer (Review). <i>Oncology Letters</i> , 2020, 20, 1489-1503.	0.8	15
2910	A randomized phase III trial of personalized peptide vaccination for castration-resistant prostate cancer progressing after docetaxel. <i>Oncology Reports</i> , 2020, 45, 159-168.	1.2	17
2911	Enzalutamide: The emperor of all anti-androgens. <i>Translational Andrology and Urology</i> , 2013, 2, 119-120.	0.6	8
2912	Current clinical challenges in prostate cancer. <i>Translational Andrology and Urology</i> , 2013, 2, 122-36.	0.6	34
2913	Decoding the androgen receptor splice variants. <i>Translational Andrology and Urology</i> , 2013, 2, 178-186.	0.6	115
2914	Novel non-AR therapeutic targets in castrate resistant prostate cancer. <i>Translational Andrology and Urology</i> , 2013, 2, 265-77.	0.6	4
2915	Sequence of treatment in locally advanced and metastatic renal cell carcinoma. <i>Translational Andrology and Urology</i> , 2015, 4, 310-25.	0.6	16
2916	Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer. <i>Translational Andrology and Urology</i> , 2015, 4, 355-64.	0.6	19
2917	Chemotherapy for advanced cancers. <i>Annals of Palliative Medicine</i> , 2014, 3, 203-28.	0.5	11
2918	Radioisotopes in management of metastatic prostate cancer. <i>Indian Journal of Urology</i> , 2016, 32, 277.	0.2	4
2919	Immunotherapy in metastatic prostate cancer. <i>Indian Journal of Urology</i> , 2016, 32, 271.	0.2	6



#	ARTICLE	IF	CITATIONS
2920	Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer. <i>Asian Journal of Andrology</i> , 2014, 16, 341.	0.8	9
2921	Chemotherapy and its evolving role in the management of advanced prostate cancer. <i>Asian Journal of Andrology</i> , 2014, 16, 334.	0.8	19
2922	Improving intermittent androgen deprivation therapy: lessons learned from basic and translational research. <i>Asian Journal of Andrology</i> , 2014, 16, 505.	0.8	4
2923	Treatment sequencing in metastatic castrate-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2014, 16, 426.	0.8	41
2924	New developments in the treatment of castration resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2014, 16, 555.	0.8	6
2925	Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2014, 16, 387.	0.8	43
2926	Enzalutamide in chemo-naïve castration-resistant prostate cancer: effective for most but not for all. <i>Asian Journal of Andrology</i> , 2014, 16, 807.	0.8	5
2927	DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer. <i>Asian Journal of Andrology</i> , 2016, 18, 533.	0.8	18
2928	Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2016, 18, 580.	0.8	38
2929	Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice. <i>Asian Journal of Andrology</i> , 2017, 19, 143.	0.8	23
2930	Personalized prostate cancer care: from screening to treatment. <i>Asian Journal of Andrology</i> , 2016, 18, 505.	0.8	8
2931	Transcriptional repression by androgen receptor: roles in castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2019, 21, 215.	0.8	26
2932	PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China. <i>Asian Journal of Andrology</i> , 2018, 20, 173.	0.8	5
2933	External validation and newly development of a nomogram to predict overall survival of abiraterone-treated, castration-resistant patients with metastatic prostate cancer. <i>Asian Journal of Andrology</i> , 2018, 20, 184.	0.8	9
2934	The path forward in prostate cancer therapeutics. <i>Asian Journal of Andrology</i> , 2018, 20, 213.	0.8	3
2935	Current concepts and trends in the treatment of bone metastases in patients with advanced prostate cancer. <i>Asian Journal of Andrology</i> , 2019, 21, 12.	0.8	5
2936	Clinical activity of abiraterone plus prednisone in docetaxel-naïve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2019, 21, 131.	0.8	6
2937	Enzalutamide: a new indication for nonmetastatic castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2019, 21, 107.	0.8	1

#	ARTICLE	IF	CITATIONS
2938	Perspectives on the clinical development of immunotherapy in prostate cancer. <i>Asian Journal of Andrology</i> , 2018, 20, 253.	0.8	13
2939	Experience with using fosfestrol for treating metastatic castrate-resistant prostate cancer in resource-limited setting. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2019, 40, 79-84.	0.1	1
2940	Health-related quality-of-life outcomes with actinium-225-prostate-specific membrane antigen-617 therapy in patients with heavily pretreated metastatic castration-resistant prostate cancer. <i>Indian Journal of Nuclear Medicine</i> , 2020, 35, 299.	0.1	16
2941	Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for prostate cancer 2017. <i>Urology Annals</i> , 2018, 10, 138.	0.3	12
2942	Efficacy and safety of <sup>177</sup> Lutetium-prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer patients: First experience in West Asia – A prospective study. <i>World Journal of Nuclear Medicine</i> , 2019, 18, 258.	0.3	21
2943	Enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A retrospective Korean multicenter study in a real-world setting. <i>Investigative and Clinical Urology</i> , 2020, 61, 19.	1.0	6
2944	Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2016, 10, 1.	0.6	68
2945	Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05). <i>Cancer Research and Treatment</i> , 2018, 50, 1252-1259.	1.3	27
2946	New Molecular Targets in Metastatic Prostate Cancer. <i>Journal of Cancer Therapy</i> , 2016, 07, 388-401.	0.1	2
2947	Hormonal therapy and chemotherapy for advanced prostate cancer. <i>Journal of the Korean Medical Association</i> , 2015, 58, 30.	0.1	3
2948	How Precisely Can Prostate Cancer Be Managed?. <i>International Neurourology Journal</i> , 2016, 20, S120-130.	0.5	10
2949	Is there still a place for docetaxel rechallenge in prostate cancer?. <i>World Journal of Clinical Oncology</i> , 2015, 6, 99.	0.9	17
2950	Optimising TNM Staging of Patients with Prostate Cancer Using WB-MRI. <i>Journal of the Belgian Society of Radiology</i> , 2016, 100, 101.	0.2	7
2951	Efficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abiraterone. <i>Canadian Urological Association Journal</i> , 2016, 10, 102.	0.3	12
2952	Bone Health Issues in Patients with Prostate Cancer: An Evidence-Based Review. <i>World Journal of Men's Health</i> , 2020, 38, 151.	1.7	7
2953	End points of clinical trials in metastatic castration-resistant prostate cancer: A systematic review. <i>World Journal of Methodology</i> , 2014, 4, 123.	1.1	1
2954	Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 479-505.	2.3	943
2955	Conditional PTEN-deficient Mice as a Prostate Cancer Chemoprevention Model. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 1827-1831.	0.5	7

#	ARTICLE	IF	CITATIONS
2956	Lenalidomide in Treating Patients with Castration-Resistant Prostate Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 3969-3972.	0.5	2
2957	Designer antiandrogens join the race against drug resistance. <i>ELife</i> , 2013, 2, e00692.	2.8	6
2958	Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer. <i>ELife</i> , 2017, 6, .	2.8	32
2959	Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis. <i>ELife</i> , 2020, 9, .	2.8	104
2960	Bone Health in Cancer Patients. <i>UNIPA Springer Series</i> , 2021, , 365-380.	0.1	0
2961	Docetaxel Rechallenge Improves Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study. <i>In Vivo</i> , 2021, 35, 3509-3519.	0.6	5
2962	Prostate Cancer: Advanced and Metastatic Disease. <i>UNIPA Springer Series</i> , 2021, , 805-821.	0.1	0
2963	Loss of NEIL3 activates radiotherapy resistance in the progression of prostate cancer. <i>Cancer Biology and Medicine</i> , 2022, 19, 1193-1210.	1.4	12
2965	Comparative pathology of dog and human prostate cancer. <i>Veterinary Medicine and Science</i> , 2022, 8, 110-120.	0.6	11
2966	A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE. <i>International Journal of Cancer</i> , 2022, 150, 837-846.	2.3	14
2967	Mortality in men with castration-resistant prostate cancer: A long-term follow-up of a population-based real-world cohort. <i>BJUI Compass</i> , 2022, 3, 173-183.	0.7	12
2968	Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase. <i>EBioMedicine</i> , 2021, 72, 103625.	2.7	23
2969	Ratio of the expression levels of androgen receptor splice variant 7 to androgen receptor in castration refractory prostate cancer. <i>Oncology Letters</i> , 2021, 22, 831.	0.8	3
2970	Extracellular Matrix in Synthetic Hydrogel-Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors. <i>Advanced Materials</i> , 2022, 34, e2100096.	11.1	24
2971	Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC. <i>Future Oncology</i> , 2022, 18, 35-45.	1.1	4
2972	Whole-body MRI: detecting bone metastases from prostate cancer. <i>Japanese Journal of Radiology</i> , 2022, 40, 229-244.	1.0	18
2973	Treatment of Advanced Prostate Cancer. , 2005, , 18-25.		5
2975	Malignome des Urogenitaltrakts. , 2012, , 667-722.		0

#	ARTICLE	IF	CITATIONS
2976	Prostate Cancer-The More We Know, the More We Get Confused?. , 2012, 01, .		0
2977	Castrate Resistant Metastatic Prostate Cancer: Options for a Patient in 2012. Open Journal of Urology, 2012, 02, 210-215.	0.0	0
2978	The changing landscape of hormonal therapy in castration-resistant prostate cancer. South Asian Journal of Cancer, 2012, 01, 53-55.	0.2	0
2979	Future Directions in Metastatic Castration Resistant Prostate Cancer (mCRPC): Clinical Rationale and Use of New-Generation Hormonal Therapies. Journal of Cancer Therapy, 2013, 04, 698-703.	0.1	0
2980	The Effect of AR Overexpression on Androgen Signaling in Prostate Cancer. , 2013, , 187-200.		1
2982	Castration-resistant Prostate Cancer – Chemotherapies and Molecular Targets. European Oncology and Haematology, 2013, 09, 27.	0.0	0
2983	Enzalutamide and Ruxolitinib. Hospital Pharmacy, 2013, 48, 104-107.	0.4	0
2984	Nonhormone Therapy for Metastatic Castration-Resistant Prostate Cancer: Chemotherapy, Bone-Targeted Treatments, and Others. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e161-e165.	1.8	0
2985	Enzalutamide: A New Agent for the Prostate Cancer Treatment Armamentarium. Journal of the Advanced Practitioner in Oncology, 2013, 4, 182-5.	0.2	1
2986	Scaffold attachment factor B1: an intrinsic inhibitor of androgen receptor downregulated in prostate cancer. Asian Journal of Andrology, 2013, 15, 703-704.	0.8	1
2989	Impact of initial time to prostate-specific antigen nadir on survival in prostate cancer with bone metastasis initially treated with maximum androgen blockade therapy. Journal of Cancer Research & Therapy, 2013, 1, 201-207.	0.1	1
2990	Defining Clinical Endpoints in Castration-Resistant Prostate Cancer. Current Clinical Urology, 2014, , 187-199.	0.0	0
2991	Bone-Targeted Therapy: Rationale and Current Status. Current Clinical Urology, 2014, , 139-153.	0.0	0
2992	Knochenmetastasen bei urologischen Malignomen. , 2014, , 177-192.		0
2993	Prostate Cancer in Older Adults. , 2014, , 273-288.		0
2996	Evidence-Based Therapeutic Approaches for mCRPC Patients: Rational Sequence of Standard Treatment Options and Design for Future Drug Development. Current Clinical Urology, 2014, , 321-327.	0.0	0
2997	Prostate Cancer Vaccines Generated with the Disruptive RNActive® Technology Follow the Path Paved by Sipuleucel-T and Prostavac-VF. , 2014, , 155-169.		0
2998	Management of Patients with Prostate Cancer. , 2014, , 17-47.		0

#	ARTICLE	IF	CITATIONS
2999	Tratamiento sist�mico. , 2014, , 61-67.		0
3000	Intracellular Signaling. , 2014, , 22-39.e8.		1
3002	Clinical Trials of Low-Dose Metronomic Chemotherapy in Castration-Resistant Prostate Cancer. , 2014, , 119-134.		1
3003	Phase II Targeted Treatments. Current Clinical Urology, 2014, , 177-186.	0.0	0
3005	New Medical Strategies: The Role of Oncologist in an MDT. , 2014, , 119-142.		1
3006	Evolution of Clinical States and the Castration Resistant Clinical Paradigm. Current Clinical Urology, 2014, , 9-29.	0.0	0
3007	Androgen Receptor Biology in Castration Resistant Prostate Cancer. Current Clinical Urology, 2014, , 67-75.	0.0	0
3008	The Androgen Receptor as a Therapeutic Target for Castration-Resistant Prostate Cancer. Current Clinical Urology, 2014, , 77-94.	0.0	0
3009	Geriatric considerations in the treatment of advanced prostate cancer. F1000prime Reports, 2014, 6, 33.	5.9	4
3010	Neuroendocrine differentiation in carcinoma of the prostate: An institutional review.. Journal of Clinical Oncology, 2014, 32, e16109-e16109.	0.8	0
3012	Metastatic Castrate-resistant Prostate Cancer: When and How to Treat?. The Journal of Oncopathology, 2014, 1, 33-43.	0.1	0
3013	Macroscopic Extramedullary Hematopoiesis Resembling Hepatic Metastases in Prostate Cancer. Journal of Cytology & Histology, 2015, 06, .	0.1	0
3014	Targeted Therapies for Prostate Cancer. Current Clinical Pathology, 2015, , 229-248.	0.0	0
3016	A Case of Ischemic Heart Disease in Hormone Treatment with Castration Resistant Prostate Cancer. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2015, 41, 695-700.	0.0	0
3017	Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer. Asian Journal of Andrology, 2015, 17, 936.	0.8	1
3018	Prostatakarzinom: palliative Therapie. , 2015, , 1-29.		1
3019	Comparative Effectiveness Research in Urologic Cancers. Cancer Treatment and Research, 2015, 164, 221-235.	0.2	0
3020	Onkologika. , 2015, , 833-876.		0

#	ARTICLE	IF	CITATIONS
3021	E28 Literaturhinweise und Internetadressen. , 2015, , e1-e79.		0
3022	Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: Long term outcome of the Temporary Authorization for Use program in France.. Journal of Clinical Oncology, 2015, 33, 264-264.	0.8	0
3023	How to approach castration-resistant prostate cancer?. Marmara Medical Journal, 2015, 28, 24.	0.2	1
3024	Metastatic prostate cancer and spinal cord compression. , 2015, , 155-164.		0
3026	Is it Time to Change the Control Placebo Arms in Phase III Trials of Metastatic Castration Resistant Prostate Cancer?. Asian Pacific Journal of Cancer Prevention, 2015, 16, 6167-6169.	0.5	0
3027	Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer. Urology Annals, 2016, 8, 123.	0.3	3
3028	Hormonal Anticancer Drugs. , 2016, , 155-174.		0
3029	Prostate Cancer in the Elderly. , 2016, , 63-72.		0
3030	Targeting of Steroid Hormone Receptor Function in Breast and Prostate Cancer. Endocrinology, 2016, , 1-21.	0.1	0
3031	Rapid bench to bed in management of metastatic prostate cancer. Indian Journal of Urology, 2016, 32, 255.	0.2	0
3032	Prostatakarzinom: Palliative Therapie. , 2016, , 1363-1383.		0
3033	Switching of GnRH Agent from Agonist to Antagonist in Patients with Castration-Resistant Prostate Cancer. Open Journal of Urology, 2016, 06, 190-198.	0.0	0
3034	Cancer Vaccines in Castration Resistant Prostate Cancer – An Evolution in Design. , 2016, , 107-124.		0
3035	Gleason score and the risk of cause-specific and overall mortality following radiation with or without 6 months of androgen deprivation therapy for men with unfavorable-risk prostate cancer.. Journal of Clinical Oncology, 2016, 34, 171-171.	0.8	0
3036	Effect of Hyperthermia in Combination with Chemotherapy and Radiation Therapy for Treatment of Urological Cancer: Prostate Cancer and Urothelial Cancer. , 2016, , 287-294.		0
3037	Outcome of Combination Chemotherapy with Docetaxel, Estramustine Phosphate, and Carboplatin after Docetaxel and Prednisolone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer. Journal of Cancer Therapy, 2016, 07, 471-479.	0.1	0
3038	Enzalutamide in Metastatic Castration Resistant Prostate Cancer. , 2016, , 157-169.		0
3039	Sequencing Therapies in Metastatic Castration – Resistant Prostate Cancer. , 2016, , 215-230.		0



#	ARTICLE	IF	CITATIONS
3040	Radium-223 in Metastatic Castrate Resistant Prostate Cancer. , 2016, , 171-185.		0
3041	Abiraterone Acetate in Patients with Advanced Castrate Resistant Prostate Cancer: Initial Real Life Experience in 2 Cancer Units. Journal of Analytical Oncology, 2016, 5, 42-46.	0.1	1
3042	Assessing the utility of cabazitaxel in mCRPC. Canadian Urological Association Journal, 2016, 10, 111.	0.3	0
3043	Abiraterone: A Review of its Pharmacokinetic, Pharmacodynamic Profile and Clinical Efficacy. Urology & Nephrology Open Access Journal, 2016, 3, .	0.1	0
3046	Approaches for Assessment of Response of Bone Metastases to Therapies. , 2017, , 223-249.		0
3048	Bone Metastases from Prostate Cancer: Hormonal Therapy. , 2017, , 105-120.		0
3049	Bone-Seeking Radionuclide for Therapy. , 2017, , 193-207.		0
3050	Chapter 1 Prostate Cancer: An Introduction. Traditional Herbal Medicines for Modern Times, 2016, , 1-16.	0.1	0
3051	New Neurological Disorders in a New Patient. Long Term VEGFR Inhibitors Effects. , 2016, 2, .		0
3052	Chemotherapy and Androgen Receptor-Directed Treatment of Castration Resistant Metastatic Prostate Cancer. , 2017, , 327-342.		0
3053	Role of Chemohormonal Therapy in Management of Patients with Metastatic Hormone Sensitive Prostate Cancer. Journal of Cancer Therapy, 2017, 08, 1149-1159.	0.1	0
3054	Molecules, Drugs, and First-Line Therapies: A Guide for the Cardiologist. , 2017, , 91-106.		0
3055	Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients. Farmakoekonomika, 2017, 10, 12-21.	0.4	3
3056	Combination of Androgen Deprivation Therapy and Radiation Therapy for Locally Advanced and Localized Prostate Cancer. , 2017, , 217-230.		0
3057	Targeting the Androgen Receptor Signaling Axis. , 2017, , 134-153.		0
3058	Bone Target Therapy in Urologic Malignancies. , 2017, , 1-16.		0
3059	Management of Prostate Cancer. , 2017, , 19-26.		0
3060	Drug interaction (39. Drug interaction in prostate cancer therapy). Okayama Igakkai Zasshi, 2017, 129, 131-136.	0.0	0

#	ARTICLE	IF	CITATIONS
3061	Malignome des Urogenitaltrakts. , 2017, , 725-785.		0
3062	$^{223}\text{Ra}$ -Dichloride for Bone Metastasis of Castration Resistant Prostate Cancer. Radioisotopes, 2017, 66, 695-700.	0.1	0
3063	Drug therapy methods in patients with metastatic castration-resistant prostate cancer: Role of somatostatin analogues. Onkologiya Zhurnal Imeni P A Gertsena, 2017, 6, 76.	0.0	0
3065	Korean Treatment Guidelines for Metastatic Prostate Cancer Developed by the Korean Association for Clinical Oncology. Korean Journal of Medicine, 2017, 92, 124-141.	0.1	2
3066	Chemotherapy With Androgen Deprivation for Hormone-Naïve Prostate Cancer. The Korean Journal of Urological Oncology, 2017, 15, 11-15.	0.1	0
3068	Epidemiology and Etiology. Molecular Pathology Library, 2018, , 13-26.	0.1	0
3069	Mifepristone Has Limited Activity to Enhance the In Vivo Efficacy of Docetaxel and Enzalutamide Against Bone Metastatic and Castration-Resistant Prostate Cancer. Anticancer Research, 2017, 37, 6235-6243.	0.5	4
3070	Current treatment management of metastatic castration-resistant prostate cancer. Onkologie (Czech Republic), 2017, 11, 200-204.	0.0	1
3071	The Cell Cycle and Androgen Signaling Interactions in Prostate Cancer. Molecular Pathology Library, 2018, , 381-404.	0.1	1
3072	Enzalutamide Therapy for mCRPC in Japanese Men. , 2018, , 231-239.		0
3073	Alternative Antiandrogen Therapy for CRPC. , 2018, , 215-223.		0
3074	Side Effects of Medical Cancer Therapy in Genitourinary Malignancies. , 2018, , 179-212.		0
3075	Optimization of Sequential AR Targeted Therapy for CRPC. , 2018, , 225-229.		0
3076	New Targeted Approach to CRPC. , 2018, , 375-385.		0
3077	Onkologika. , 2018, , 645-691.		1
3078	Efficacy and safety of enzalutamide, abiraterone and cabazitaxel in post-docetaxel treatment of castration-resistant prostate cancer: meta-analysis data. Onkourologiya, 2018, 13, 91-100.	0.1	0
3079	Detection of Circulating Tumor Cells in Castration-Resistant Prostate Cancer. , 2018, , 299-305.		0
3080	Prostate Cancer: Management in Elderly Men Population in 2017. , 2018, , 1-16.		0

#	ARTICLE	IF	CITATIONS
3081	Synthesis and Binding of a Novel PSMA-specific Conjugate. <i>Anticancer Research</i> , 2018, 38, 1531-1537.	0.5	2
3084	The role of taxanes in prostate cancer: literature review. <i>Onkourologiya</i> , 2018, 14, 130-141.	0.1	0
3085	Role of the androgen signaling axis in genitourinary malignancies. <i>Translational Cancer Research</i> , 2018, 7, 1135-1142.	0.4	2
3087	Is age the limitation of metastatic treatment prostate cancer?. <i>Onkologie (Czech Republic)</i> , 2018, 12, 224-230.	0.0	0
3088	Androgen Deprivation Therapy for Advanced Prostate Cancer. , 2019, , 1-22.		0
3089	Literatur zu Giordano/Wenz: Strahlentherapie kompakt, 3. Auflage. , 2019, , e.1-e.39.		0
3091	Onkologika. , 2019, , 817-875.		0
3092	Metastatic hormone-sensitive prostate cancer: Practical guidelines and optimization of therapy selection. <i>Onkourologiya</i> , 2019, 14, 139-149.	0.1	2
3093	Radionuclide therapy with radium-223 chloride. A few strokes to the patient's portrait. <i>Onkourologiya</i> , 2019, 14, 87-94.	0.1	0
3094	Androgen Deprivation Therapy for Advanced Prostate Cancer. , 2019, , 255-276.		0
3096	Nanoparticles as theranostic vehicles in prostate cancer. <i>Annals of Translational Medicine</i> , 2019, 7, S29-S29.	0.7	1
3098	The Treatment of Metastatic and Castration-Resistant Prostate Cancer Patients in Korea. <i>The Korean Journal of Urological Oncology</i> , 2019, 17, 48-59.	0.1	0
3099	Survival in men diagnosed with castration resistant prostate cancer: A population-based observational study in Sweden.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16555-e16555.	0.8	1
3100	The role of ARTAs in treating metastatic castration-resistant prostate cancer. <i>Urologie Pro Praxi</i> , 2019, 20, 62-65.	0.0	0
3101	Modern drug therapy of prostate cancer through the example of Moscow. <i>Onkourologiya</i> , 2019, 15, 77-85.	0.1	1
3102	Radium-223 systemic alpha-radiotherapy: targeted treatment of castration-resistant prostate cancer with bone metastases. <i>Onkourologiya</i> , 2019, 15, 134-142.	0.1	0
3106	The Systematic Review of the Efficacy and Safety of Immune Checkpoint Inhibitor in Urological Cancers. <i>The Korean Journal of Urological Oncology</i> , 2019, 17, 75-80.	0.1	0
3107	Identification of favorable subgroups for alternative anti-androgen therapy in castration-resistant prostate cancer. <i>Molecular and Clinical Oncology</i> , 2019, 11, 523-530.	0.4	3

#	ARTICLE	IF	CITATIONS
3110	New treatment options in hormone-sensitive prostate cancer. <i>Onkologie (Czech Republic)</i> , 2019, 13, 150-156.	0.0	0
3111	Therapy Management of Metastatic Prostate Carcinoma in General Practice. <i>Healthbook TIMES Oncology Hematology</i> , 2019, , 12-15.	0.1	2
3112	Immunotherapy Landscape in Prostate Cancer: Successes, Failures and Promises. <i>Annals of Urologic Oncology</i> , 2019, , 1-18.	0.0	0
3113	Enzalutamide in treatment of the metastatic castrate resistant prostate cancer. <i>Onkologie (Czech)</i> Tj ETQq1 1 0.784314 rgBJ /Overlo	0.0	0
3115	New possibilities of combined antiandrogen therapy in patients with metastatic hormone-sensitive prostate cancer. <i>Onkourologiya</i> , 2019, 15, 89-101.	0.1	0
3116	Behandlungspläne medikamentöser Therapie des Prostatakarzinoms. <i>Springer Reference Medizin</i> , 2020, , 1-11.	0.0	0
3117	Possibilities of treatment of patients with castrationrefractory prostate cancer using enzalutamide. <i>Meditinskiy Sovet</i> , 2019, , 176-180.	0.1	0
3118	Combined Androgen Blockade in Localized Prostate Cancer Treated With Definitive Radiation Therapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1497-1504.	2.3	1
3119	Prostate Cancer: Management in Elderly Men Population in 2017. , 2020, , 655-670.		0
3120	A Single-center Retrospective Analysis of the Effect of Radium-223 (Xofigo) on Pancytopenia in Patients with Metastatic Castration-resistant Prostate Cancer. <i>Cureus</i> , 2020, 12, e6806.	0.2	3
3121	<i>Onkologika.</i> , 2020, , 671-732.		2
3122	Corticosteroids alleviate adverse events associated with enzalutamide in patients with metastatic castration-resistant prostate cancer. <i>Molecular and Clinical Oncology</i> , 2020, 12, 495-500.	0.4	1
3124	The Current Status of Metastatic Castration-Resistant Prostate Cancer Management. <i>The Korean Journal of Urological Oncology</i> , 2020, 18, 11-17.	0.1	0
3125	Actualización del protocolo de manejo del cáncer de próstata resistente a la castración metastásico de la Asociación Andaluza de Urología. <i>Actas Urológicas Españolas</i> , 2020, 44, 125-130.	0.3	0
3128	Deubiquitination in prostate cancer progression: role of USP22. <i>Journal of Cancer Metastasis and Treatment</i> , 2020, 2020, .	0.5	3
3129	New Androgen Receptor Axis-Targeted Agents in the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer: From Bench to Clinical Trials. <i>The Korean Journal of Urological Oncology</i> , 2020, 18, 99-108.	0.1	0
3130	Management of Patients With Advanced Prostate Cancer: Establishment of Treatment Guidelines Through Prostate Cancer Summit (PCAS) 2016 Composed of Korean Prostate Cancer Experts. <i>The Korean Journal of Urological Oncology</i> , 2020, 18, 124-139.	0.1	0
3131	Is the duration of castration resistance predictive for sequential treatment responses in the metastatic castration-resistant prostate cancer setting?. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 1388-1394.	0.5	0

#	ARTICLE	IF	CITATIONS
3133	Androgen Receptor Signaling in Prostate Cancer and Therapeutic Strategies. <i>Cancers</i> , 2021, 13, 5417.	1.7	34
3134	Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer. <i>Prostate International</i> , 2021, 10, 50-55.	1.2	3
3135	Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second-line antiandrogen therapy era. <i>Cancer Medicine</i> , 2021, 10, 7909-7920.	1.3	2
3136	Identification of DNA Damage Repair-Associated Prognostic Biomarkers for Prostate Cancer Using Transcriptomic Data Analysis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11771.	1.8	6
3137	Deciphering Evolutionary Dynamics and Lineage Plasticity in Aggressive Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11645.	1.8	0
3138	Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1584-1594.	3.3	24
3139	Choice of treatment options for metastatic hormone-sensitive prostate cancer. <i>Meditsinskiy Sovet</i> , 2020, , 90-99.	0.1	0
3140	Efficacy and safety of radium-223 in the treatment of metastatic castration-resistant prostate cancer. <i>Meditsinskiy Sovet</i> , 2020, , 70-82.	0.1	0
3141	Development of an Albumin-Based PSMA Probe With Prolonged Half-Life. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 585024.	1.6	6
3142	Efficacy and Safety of Enzalutamide in a Real-World Cohort of Japanese Patients With Castration-resistant Prostate Cancer. <i>Anticancer Research</i> , 2020, 40, 7101-7108.	0.5	2
3143	The evolving role of immune cells in prostate cancer. <i>Cancer Letters</i> , 2022, 525, 9-21.	3.2	34
3144	Prostatakarzinom beim geriatrischen Patienten. , 2020, , 141-172.		0
3146	Metastatic and Secondary Orbital Tumors. , 2020, , 1-15.		0
3147	More Than Androgens: Hormonal and Paracrine Signaling in Prostate Development and Homeostasis. , 2020, , 195-223.		0
3148	Malignome des Urogenitaltrakts. , 2020, , 759-822.		0
3149	Alpha-therapy using radium-223 chloride in patients with castration-resistant prostate cancer. From clinical researches to routine practice. <i>Onkourologiya</i> , 2020, 15, 84-92.	0.1	0
3150	Docetaxel rechallenge in metastatic castration-resistant prostate cancer: A retrospective, single-center study. <i>Investigative and Clinical Urology</i> , 2020, 61, 588.	1.0	4
3151	Sequential Treatment with Abiraterone and Enzalutamide in Swedish Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Universal Journal of Oncology</i> , 2020, 02, ,	0.0	0

#	ARTICLE	IF	CITATIONS
3152	ERKRANKUNGEN DES BLUTES UND DES GERINNINGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE. , 2020, , B-1-B30-3.		0
3153	Defining Value in Metastatic Prostate Cancer: What Is the Cost of Living Longer and Better?. JCO Oncology Practice, 2020, 16, 53-54.	1.4	1
3154	O cenário mundial de radiofármacos emissores de positrões para diagnóstico e estadiamento de câncer de próstata em medicina nuclear. Brazilian Journal of Radiation Sciences, 2020, 8, .	0.0	0
3155	Radium chloride [ <sup>223</sup> Ra] for patients with prostate cancer and skeletal metastases. Clinical recommendations. Onkourologiya, 2020, 16, 114-123.	0.1	0
3157	Papel del Índice neutrófilo/linfocito en pacientes con cáncer de próstata resistente a castración metastásicos tratados en primera línea con abiraterona. Actas Urológicas Españolas, 2020, 44, 164-171.	0.3	1
3158	Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer. Gynecologic Oncology, 2022, 164, 12-17.	0.6	6
3159	Prostate cancer research in the 21st century; report from the 2021 Coffey-Holden prostate cancer academy meeting. Prostate, 2021, , .	1.2	2
3160	Efficacy of Combination Chemotherapy With Docetaxel, Estramustine and Carboplatin in Men With Castration-resistant Prostate Cancer. Cancer Diagnosis & Prognosis, 2021, 1, 451-457.	0.3	3
3161	Protocol for GET FIT Prostate: a randomized, controlled trial of group exercise training for fall prevention and functional improvements during and after treatment for prostate cancer. Trials, 2021, 22, 775.	0.7	7
3162	Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer. Molecular Cancer Therapeutics, 2022, 21, 193-205.	1.9	10
3163	Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology. Pharmacogenomics, 2021, 22, 1237-1250.	0.6	1
3166	Enzalutamide-induced and PTH1R-mediated TGFBR2 degradation in osteoblasts confers resistance in prostate cancer bone metastases. Cancer Letters, 2022, 525, 170-178.	3.2	6
3168	Screening to Identify an Immune Landscape-Based Prognostic Predictor and Therapeutic Target for Prostate Cancer. Frontiers in Oncology, 2021, 11, 761643.	1.3	1
3169	KIF15 Promotes Progression of Castration Resistant Prostate Cancer by Activating EGFR Signaling Pathway. Frontiers in Oncology, 2021, 11, 679173.	1.3	2
3170	Clinical outcome of Lu-177 PSMA in metastatic castration-resistant prostate cancer: An initial experience from a tertiary care cancer hospital. Annals of Cancer Research and Therapy, 2020, 28, 156-163.	0.1	0
3171	Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naïve prostate cancer cells. Aging, 2020, 12, 17694-17712.	1.4	2
3173	Abiraterone acetate and acute leukemia: a casual association?. Anti-Cancer Drugs, 2021, 32, 102-104.	0.7	2
3174	Evolving Natural History of Metastatic Prostate Cancer. Cureus, 2020, 12, e11484.	0.2	4



#	ARTICLE	IF	CITATIONS
3176	Abiraterone for the Treatment of Advanced Prostate Cancer. <i>The International Journal of Targeted Therapies in Cancer</i> , 2012, 1, 40-42.	0.0	1
3177	Drugs that offer a survival advantage for men with bone metastases resulting from castration-resistant prostate cancer: new and emerging treatment options. <i>P and T</i> , 2014, 39, 130-43.	1.0	9
3179	Current treatments and novel therapeutic targets for castration resistant prostate cancer with bone metastasis. <i>American Journal of Clinical and Experimental Urology</i> , 2013, 1, 30-8.	0.4	3
3180	Splicing variants of androgen receptor in prostate cancer. <i>American Journal of Clinical and Experimental Urology</i> , 2013, 1, 18-24.	0.4	8
3181	Wnt signaling in castration-resistant prostate cancer: implications for therapy. <i>American Journal of Clinical and Experimental Urology</i> , 2014, 2, 27-44.	0.4	46
3182	Revisiting nomenclature for the description of prostate cancer androgen-responsiveness. <i>American Journal of Clinical and Experimental Urology</i> , 2014, 2, 121-6.	0.4	1
3183	Potent increased risk of the initiation of DNA replication in human prostate cancer with the use of 5 $\alpha$ -reductase inhibitors. <i>American Journal of Clinical and Experimental Urology</i> , 2014, 2, 136-44.	0.4	4
3184	PI-3 kinase p110 $\beta$ : a therapeutic target in advanced prostate cancers. <i>American Journal of Clinical and Experimental Urology</i> , 2014, 2, 188-98.	0.4	16
3185	Treatment Sequences and Pharmacy Costs of 2 New Therapies for Metastatic Castration-Resistant Prostate Cancer. <i>American Health and Drug Benefits</i> , 2015, 8, 185-95.	0.5	15
3186	Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies. <i>American Journal of Clinical and Experimental Urology</i> , 2015, 3, 64-76.	0.4	49
3187	The HSP90 inhibitor 17-PAG effectively inhibits the proliferation and migration of androgen-independent prostate cancer cells. <i>American Journal of Cancer Research</i> , 2015, 5, 3198-209.	1.4	4
3188	Translating insights of AR signaling from mouse models. <i>Translational Andrology and Urology</i> , 2013, 2, 197-201.	0.6	0
3189	Enzalutamide (formerly MDV3100) prolongs survival in docetaxel-pretreated castration-resistant prostate cancer patients. <i>Translational Andrology and Urology</i> , 2013, 2, 92-3.	0.6	1
3190	Androgen Receptor Structure, Function and Biology: From Bench to Bedside. <i>Clinical Biochemist Reviews</i> , 2016, 37, 3-15.	3.3	265
3191	Role of the androgen receptor in triple-negative breast cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2016, 14, 186-93.	0.3	68
3192	Assessment of Real-World Central Nervous System Events in Patients with Advanced Prostate Cancer Using Abiraterone Acetate, Bicalutamide, Enzalutamide, or Chemotherapy. <i>American Health and Drug Benefits</i> , 2017, 10, 143-153.	0.5	20
3194	Medication Adherence, Treatment Patterns, and Dose Reduction in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone Acetate or Enzalutamide. <i>American Health and Drug Benefits</i> , 2017, 10, 296-303.	0.5	20
3195	Prostate Cancer Academy 2017 Summaries. <i>Reviews in Urology</i> , 2017, 19, 252-260.	0.9	2

#	ARTICLE	IF	CITATIONS
3196	A Systematic Review of Clinical Practice Guidelines for Castration-Resistant Prostate Cancer. Iranian Journal of Pharmaceutical Research, 2018, 17, 17-37.	0.3	2
3197	Treatment of Advanced Prostate Cancer. Missouri Medicine, 2018, 115, 156-161.	0.3	8
3198	Wntless promotes cellular viability and resistance to enzalutamide in castration-resistant prostate cancer cells. American Journal of Clinical and Experimental Urology, 2019, 7, 203-214.	0.4	6
3199	Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol. BMJ Open, 2019, 9, e034708.	0.8	2
3200	Differential expression profiles of circRNAs in human prostate cancer based on chip and bioinformatic analysis. International Journal of Clinical and Experimental Pathology, 2020, 13, 1045-1052.	0.5	5
3201	Targeting treatment options for castration-resistant prostate cancer. American Journal of Clinical and Experimental Urology, 2021, 9, 101-120.	0.4	4
3202	Rapidly evolving treatment paradigm and considerations for sequencing therapies in metastatic prostate cancer-a narrative review. Translational Andrology and Urology, 2021, 10, 3188-3198.	0.6	1
3203	Dysregulated androgen synthesis and anti-androgen resistance in advanced prostate cancer. American Journal of Clinical and Experimental Urology, 2021, 9, 292-300.	0.4	0
3204	Epigenetics and precision medicine in prostate cancer. , 2022, , 69-108.		0
3205	Cardiovascular complications during the treatment of castration-resistant prostate cancer with the use of modern antiandrogens: abiraterone acetate and enzalutamide. OnCORReview, 2021, 11, 61-67.	0.1	0
3206	Overall and progression-free survival of Afro-Caribbean men with metastatic castration-resistant prostate cancer (mCRPC). Prostate, 2022, 82, 269-275.	1.2	3
3207	The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical Trials. Cancers, 2021, 13, 5872.	1.7	3
3208	rAAV-delivered PTEN therapeutics for prostate cancer. Molecular Therapy - Nucleic Acids, 2022, 27, 122-132.	2.3	8
3209	Biomarkers for Treatment Response in Advanced Prostate Cancer. Cancers, 2021, 13, 5723.	1.7	14
3210	Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients. Frontiers in Oncology, 2021, 11, 778858.	1.3	7
3211	Disparities in germline testing among racial minorities with prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 403-410.	2.0	22
3212	Inferring Differential Networks by Integrating Gene Expression Data With Additional Knowledge. Frontiers in Genetics, 2021, 12, 760155.	1.1	0
3213	Correlation Between Imaging-Based Intermediate Endpoints and Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: Analysis of 28 Randomized Trials Using the Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria in 16,511 Patients. Clinical Genitourinary Cancer, 2022, 20, 69-79.	0.9	2

#	ARTICLE	IF	CITATIONS
3214	Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian context. Canadian Urological Association Journal, 2021, 16, .	0.3	2
3215	Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan. International Journal of Clinical Oncology, 2021, , 1.	1.0	2
3216	Highlighting the Place of Metastasis-Directed Therapy in Isolated Liver Metastases in Prostate Cancer: A Case Report. Frontiers in Oncology, 2021, 11, 764758.	1.3	3
3217	The modern therapeutic & imaging landscape of metastatic prostate cancer: a primer for radiologists. Abdominal Radiology, 2021, 47, 781.	1.0	0
3219	Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region. European Journal of Cancer, 2021, 159, 237-246.	1.3	6
3220	Promotional Payments to Medical Oncologists and Urologists and Prescriptions for Abiraterone and Enzalutamide. Urology, 2022, 161, 50-58.	0.5	2
3221	Landscape of Immunotherapy in Genitourinary Malignancies. Advances in Experimental Medicine and Biology, 2021, 1342, 143-192.	0.8	2
3222	Onkologika. , 2021, , 579-638.		0
3223	Progress in Clinical Application of Abiraterone in the Treatment of mCRPC. Advances in Clinical Medicine, 2021, 11, 5507-5513.	0.0	0
3224	Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nature Medicine, 2022, 28, 144-153.	15.2	102
3226	Estimation of Overall Survival with Subsequent Treatment Effect by Applying Inverse Probability of Censoring Weighting in the LATITUDE Study. European Urology Open Science, 2022, 36, 51-58.	0.2	2
3227	Design, synthesis, and evaluation of novel pyridone derivatives as potent BRD4 inhibitors for the potential treatment of prostate cancer. Bioorganic Chemistry, 2022, 119, 105575.	2.0	6
3228	Systemtherapie des mCRPC. , 2021, , 339-360.		0
3229	Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide. Minerva Urology and Nephrology, 2022, 73, .	1.3	4
3230	Rapidly evolving treatment paradigm and considerations for sequencing therapies in metastatic prostate cancer—a narrative review. Translational Andrology and Urology, 2021, 10, 3188-3198.	0.6	3
3231	Metastatic Prostate Cancer: Treatment Options. Oncology, 2022, 100, 48-59.	0.9	47
3232	An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT. International Journal of Molecular Sciences, 2021, 22, 13519.	1.8	13
3233	Androgen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids. Prostate Cancer and Prostatic Diseases, 2023, 26, 293-301.	2.0	12

#	ARTICLE	IF	CITATIONS
3235	A single-center, multidisciplinary experience with radium-223 dichloride in men with metastatic castrate-resistant prostate cancer. <i>Canadian Urological Association Journal</i> , 2022, 16, .	0.3	3
3236	Prostate cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 577-590.	1.4	17
3237	Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling. <i>Prostate</i> , 2022, 82, 505-516.	1.2	9
3238	Prostate luminal progenitor cells: from mouse to human, from health to disease. <i>Nature Reviews Urology</i> , 2022, 19, 201-218.	1.9	12
3239	Risk of Fatigue and Anemia in Patients With Prostate Cancer Treated With Novel Oral Anti-androgens: A Meta-Analysis of Randomized Controlled Trials. <i>Cureus</i> , 2022, 14, e21560.	0.2	0
3240	RB1 loss in castration-resistant prostate cancer confers vulnerability to LSD1 inhibition. <i>Oncogene</i> , 2022, 41, 852-864.	2.6	18
3242	RB1, Cancer Lineage Plasticity, and Therapeutic Resistance. <i>Annual Review of Cancer Biology</i> , 2022, 6, 201-221.	2.3	5
3243	Insights into the therapeutic potential of histone deacetylase inhibitor/immunotherapy combination regimens in solid tumors. <i>Clinical and Translational Oncology</i> , 2022, 24, 1262-1273.	1.2	12
3245	Rational Second-Generation Antiandrogen Use in Prostate Cancer. <i>Oncologist</i> , 0, , .	1.9	10
3246	Macrophages as a Therapeutic Target in Metastatic Prostate Cancer: A Way to Overcome Immunotherapy Resistance?. <i>Cancers</i> , 2022, 14, 440.	1.7	20
3247	Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer. <i>Cancers</i> , 2022, 14, 503.	1.7	21
3248	HER2 Mediates PSMA/mGluR1-Driven Resistance to the DS-7423 Dual PI3K/mTOR Inhibitor in PTEN Wild-type Prostate Cancer Models. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 667-676.	1.9	5
3249	Differential Gene Expression Profiles between N-Terminal Domain and Ligand-Binding Domain Inhibitors of Androgen Receptor Reveal Ralaniten Induction of Metallothionein by a Mechanism Dependent on MTF1. <i>Cancers</i> , 2022, 14, 386.	1.7	4
3250	Ethnic Pharmacogenomic Differences in the Management of Asian Patients with Metastatic Prostate Cancer. <i>Cancers</i> , 2022, 14, 407.	1.7	5
3251	Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus. <i>Oncology and Therapy</i> , 2022, 10, 143-165.	1.0	1
3252	Enzalutamide in metastatic castration-resistant prostate cancer, real-world data. <i>Medical Science and Discovery</i> , 2022, 9, 738-743.	0.1	0
3253	Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer. <i>Prostate International</i> , 2022, 10, 7-13.	1.2	4
3254	Comparison of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer After Docetaxel Failure: A Systematic Review and Network Meta-analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 789319.	1.6	9

#	ARTICLE	IF	CITATIONS
3256	Ra-223 and Ethinylestradiol Combination Therapy in Castration-resistant Prostate Cancer. <i>Anticancer Research</i> , 2022, 42, 1065-1071.	0.5	4
3257	A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2022, 18, 1185-1198.	1.1	10
3258	Association of Novel Androgen Receptor Axis-Targeted Therapies With Diarrhea in Patients With Prostate Cancer: A Bayesian Network Analysis. <i>Frontiers in Medicine</i> , 2021, 8, 800823.	1.2	2
3259	SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer. <i>Cell Reports Medicine</i> , 2022, 3, 100502.	3.3	18
3260	Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1549-1559.	3.2	24
3261	Evaluation of JQ1 Combined With Docetaxel for the Treatment of Prostate Cancer Cells in 2D- and 3D-Culture Systems. <i>Frontiers in Pharmacology</i> , 2022, 13, 839620.	1.6	4
3262	Advances with androgen deprivation therapy for prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1015-1033.	0.9	10
3263	PP2A promotes apoptosis and facilitates docetaxel sensitivity via the PP2A/p53/FOXO signaling pathway in prostate cancer. <i>Oncology Letters</i> , 2022, 23, 101.	0.8	5
3264	Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: experience at Dana Farber and in the PROCEED Registry. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 314-319.	2.0	6
3265	Angiogenesis as Therapeutic Target in Metastatic Prostate Cancer – Narrowing the Gap Between Bench and Bedside. <i>Frontiers in Immunology</i> , 2022, 13, 842038.	2.2	7
3266	Modeled Early Longitudinal PSA Kinetics Prognostic Value in Rising PSA Prostate Cancer Patients after Local Therapy Treated with ADT + Docetaxel. <i>Cancers</i> , 2022, 14, 815.	1.7	3
3267	P2Y1 agonist HIC in combination with androgen receptor inhibitor abiraterone acetate impairs cell growth of prostate cancer. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2022, 27, 283-295.	2.2	3
3268	Effect of enzalutamide on PK of CYP and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters. <i>Clinical and Translational Science</i> , 2022, , .	1.5	4
3269	Therapeutic potential of p53 reactivation in prostate cancer: Strategies and opportunities. <i>European Journal of Pharmacology</i> , 2022, 919, 174807.	1.7	17
3270	Neighborhood and Individual Socioeconomic Disadvantage and Survival Among Patients With Nonmetastatic Common Cancers. <i>JAMA Network Open</i> , 2021, 4, e2139593.	2.8	55
3271	Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP) Trial. <i>Over</i> 837-846.	0.8	29
3272	Identification and Characterization of Key Differentially Expressed Genes Associated With Metronomic Dosing of Topotecan in Human Prostate Cancer. <i>Frontiers in Pharmacology</i> , 2021, 12, 736951.	1.6	8
3273	New and Emerging Therapeutics for Non-metastatic Castrate-resistant Prostate Cancer. <i>Touch Reviews in Oncology &amp; Haematology</i> , 2021, 17, 107.	0.1	0

#	ARTICLE	IF	CITATIONS
3274	Combination therapy in metastatic hormone-sensitive prostate cancer: is three a crowd?. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210868.	1.4	7
3275	Current and Emerging Therapies for Neuroendocrine Prostate Cancer. SSRN Electronic Journal, 0, , .	0.4	0
3276	Neurological complications of systemic cancer and antineoplastic therapy. , 2022, , 479-500.		0
3277	Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer. Cancers, 2022, 14, 1169.	1.7	15
3278	Arrestin1 regulates glucocorticoid receptor mitogenic signaling in castration-resistant prostate cancer. Prostate, 2022, 82, 816-825.	1.2	4
3279	Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021. Cancers, 2022, 14, 1253.	1.7	69
3280	PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What's Now, What's New, and What's Coming?. Cancers, 2022, 14, 907.	1.7	8
3281	Establishment and Validation of Coagulation Factor-Based Nomogram for Predicting the Recurrence-Free Survival of Prostate Cancer. Urologia Internationalis, 2022, , 1-9.	0.6	0
3282	Antiandrogen enzalutamide induced genetic, cellular, and hepatic damages: amelioration by triterpene Lupeol. Drug and Chemical Toxicology, 2023, 46, 380-391.	1.2	11
3283	Lipid Metabolism and Epigenetics Crosstalk in Prostate Cancer. Nutrients, 2022, 14, 851.	1.7	17
3284	Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. Cancer Management and Research, 2022, Volume 14, 673-686.	0.9	4
3285	Dendritic cell-based vaccine prolongs survival and time to next therapy independently of the vaccine cell number. Biology Direct, 2022, 17, 5.	1.9	1
3286	Non-Invasive Profiling of Advanced Prostate Cancer via Multi-Parametric Liquid Biopsy and Radiomic Analysis. International Journal of Molecular Sciences, 2022, 23, 2571.	1.8	8
3287	Efficacy of New Therapies for Relapse After Docetaxel Treatment of Bone Metastatic Castration-resistant Prostate Cancer in Clinical Practice. Anticancer Research, 2022, 42, 1465-1475.	0.5	5
3288	Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?. Frontiers in Pharmacology, 2022, 13, 843110.	1.6	3
3289	Application of Surface-Enhanced Raman Spectroscopy to Guide Therapy for Advanced Prostate Cancer Patients. ACS Sensors, 2022, 7, 827-838.	4.0	7
3291	A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sensitive prostate cancer (EXTEND). Prostate Cancer and Prostatic Diseases, 2022, 25, 58-64.	2.0	4
3292	miR-145-5p Inhibits Neuroendocrine Differentiation and Tumor Growth by Regulating the SOX11/MYCN Axis in Prostate cancer. Frontiers in Genetics, 2022, 13, 790621.	1.1	5



#	ARTICLE	IF	CITATIONS
3293	Clinical Applications of Liquid Biopsy in Prostate Cancer: From Screening to Predictive Biomarker. <i>Cancers</i> , 2022, 14, 1728.	1.7	9
3294	Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review. <i>Cancers</i> , 2022, 14, 1792.	1.7	15
3295	Upregulation of PSMA Expression by Enzalutamide in Patients with Advanced mCRPC. <i>Cancers</i> , 2022, 14, 1696.	1.7	10
3296	Prostate Cancer and Sleep Disorders: A Systematic Review. <i>Cancers</i> , 2022, 14, 1784.	1.7	5
3297	Prognostic nutritional index is an independent prognostic factor for treatment response, survival and drug choice in metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide. <i>Actas Urológicas Españolas (English Edition)</i> , 2022, 46, 301-309.	0.2	4
3298	Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw. <i>Current Oncology</i> , 2022, 29, 1709-1722.	0.9	7
3299	Clinical Outcome and Prognostic Variables of Second-line Therapy for Patients With Castration-resistant Prostate Cancer After Failure of First-line Androgen Receptor Axis-targeted Therapy. <i>Anticancer Research</i> , 2022, 42, 2123-2130.	0.5	3
3300	Treatment Outcomes in Neuroendocrine Prostate Cancer. <i>Anticancer Research</i> , 2022, 42, 2167-2176.	0.5	7
3301	Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer. <i>Drugs - Real World Outcomes</i> , 2022, , 1.	0.7	0
3302	Diagnostic and prognostic significance of extracellular vesicles in prostate cancer drug resistance: A systematic review of the literature. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 228-239.	2.0	3
3303	Addition of Enzalutamide to Leuprolide and Definitive Radiotherapy is Tolerable and Effective in High-Risk Localized or Regional Non-Metastatic Prostate Cancer: Results from a Phase II Trial. <i>Advances in Radiation Oncology</i> , 2022, , 100941.	0.6	2
3304	Physician Dispensing Among Urology Practices and the Use of Abiraterone or Enzalutamide for Men With Advanced Prostate Cancer. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	1.4	3
3305	Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC). , 2022, 10, e004198.		19
3306	Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan. <i>Frontiers in Oncology</i> , 2022, 12, 822375.	1.3	2
3307	Patterns of indolence in prostate cancer (Review). <i>Experimental and Therapeutic Medicine</i> , 2022, 23, 351.	0.8	5
3308	High-dose-androgen-induced autophagic cell death to suppress the Enzalutamide-resistant prostate cancer growth via altering the circRNA-BCL2/miRNA-198/AMBRA1 signaling. <i>Cell Death Discovery</i> , 2022, 8, 128.	2.0	9
3309	Androgen-targeting therapeutics mitigate the adverse effect of <sc>GnRH</sc> agonist on the risk of neurodegenerative disease in men treated for prostate cancer. <i>Cancer Medicine</i> , 2022, , .	1.3	4
3310	Inhibiting 3 $\beta$ HSD1 to eliminate the oncogenic effects of progesterone in prostate cancer. <i>Cell Reports Medicine</i> , 2022, 3, 100561.	3.3	12



#	ARTICLE	IF	CITATIONS
3311	Identification of a Steroid Hormone-Associated Gene Signature Predicting the Prognosis of Prostate Cancer through an Integrative Bioinformatics Analysis. <i>Cancers</i> , 2022, 14, 1565.	1.7	4
3312	Characterization of long-term survivors of primary metastatic prostate cancer patients in Norway. <i>Acta Oncol</i> , 2022, 61, 615-618.	0.8	0
3313	Evolution of Androgen Deprivation Therapy (ADT) and Its New Emerging Modalities in Prostate Cancer: An Update for Practicing Urologists, Clinicians and Medical Providers. <i>Research and Reports in Urology</i> , 2022, Volume 14, 87-108.	0.6	13
3314	Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial. <i>BMC Medicine</i> , 2022, 20, 84.	2.3	11
3315	The prognostic potential of alkaline phosphatase and lactic acid dehydrogenase in bmCRPC patients without significant PSA response under enzalutamide. <i>BMC Cancer</i> , 2022, 22, 375.	1.1	0
3316	Targeting the androgen receptor signaling pathway in advanced prostate cancer. <i>American Journal of Health-System Pharmacy</i> , 2022, 79, 1224-1235.	0.5	5
3317	Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study. <i>European Urology</i> , 2022, 82, 22-30.	0.9	34
3318	Androgen Deprivation Therapy in High-Risk Localized and Locally Advanced Prostate Cancer. <i>Cancers</i> , 2022, 14, 1803.	1.7	5
3319	Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis. <i>Cell Reports</i> , 2022, 39, 110595.	2.9	25
3320	Key Notes on Pembrolizumab and Docetaxel Combination Therapy for Metastatic Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2022, 82, 31-33.	0.9	2
3321	Molecular landscape of c-Myc signaling in prostate cancer: A roadmap to clinical translation. <i>Pathology Research and Practice</i> , 2022, 233, 153851.	1.0	15
3322	m6A-induced repression of SIAH1 facilitates alternative splicing of androgen receptor variant 7 by regulating CPSF1. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 28, 219-230.	2.3	7
3323	A repositioning screen using an FGFR2 splicing reporter reveals compounds that regulate epithelial-mesenchymal transitions and inhibit growth of prostate cancer xenografts. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 25, 147-157.	1.8	3
3324	Novel hormonal agents for metastatic Castration-Resistant Prostate Cancer: comparing outcomes. A single-center retrospective study. <i>Archivio Italiano Di Urologia Andrologia</i> , 2021, 93, 393-398.	0.4	4
3325	Role of solute carrier transporters SLC25A17 and SLC27A6 in acquired resistance to enzalutamide in castration-resistant prostate cancer. <i>Molecular Carcinogenesis</i> , 2022, 61, 397-407.	1.3	8
3326	Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 785-810.	2.9	23
3327	AR imposes different effects on <i>ZFH3</i> transcription depending on androgen status in prostate cancer cells. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 800-812.	1.6	3
3328	Efficacy of enzalutamide in patients with metastatic hormone-sensitive and castration-refractory prostate cancer: authors' experience. <i>Meditinskiy Sovet</i> , 2021, , 130-136.	0.1	0

#	ARTICLE	IF	CITATIONS
3329	Targeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer. <i>Cancers</i> , 2022, 14, 51.	1.7	12
3330	Current androgen receptor antagonists under investigation for resistant prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 191-202.	1.1	5
3331	The Andrographolide Analogue 3A.1 Synergizes with Taxane Derivatives in Aggressive Metastatic Prostate Cancers by Upregulation of Heat Shock Proteins and Downregulation of MAT2A-Mediated Cell Migration and Invasion. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2022, 380, 180-201.	1.3	4
3332	hsa_circ_0001275 Is One of a Number of circRNAs Dysregulated in Enzalutamide Resistant Prostate Cancer and Confers Enzalutamide Resistance In Vitro. <i>Cancers</i> , 2021, 13, 6383.	1.7	3
3333	The value of anticancer drugs â€” a regulatory view. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 207-215.	12.5	14
3334	The Crosstalk of Long Non-Coding RNA and MicroRNA in Castration-Resistant and Neuroendocrine Prostate Cancer: Their Interaction and Clinical Importance. <i>International Journal of Molecular Sciences</i> , 2022, 23, 392.	1.8	15
3335	Treatment outcome and identification of factors influencing overall survival after Lu-177-PSMA-617 radioligand therapy in metastatic prostate cancer. <i>Nuklearmedizin - NuclearMedicine</i> , 2022, 61, 25-32.	0.3	6
3336	The Anti-Proliferative Activity of Secondary Metabolite from the Marine <i>Streptomyces</i> sp. against Prostate Cancer Cells. <i>Life</i> , 2021, 11, 1414.	1.1	9
3337	The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial. <i>Clinical Cancer Research</i> , 2022, 28, 860-869.	3.2	4
3338	Neuroendocrine Carcinoma as an Independent Prognostic Factor for Patients With Prostate Cancer: A Population-Based Study. <i>Frontiers in Endocrinology</i> , 2021, 12, 778758.	1.5	7
3339	Insights of RKIP-Derived Suppression of Prostate Cancer. <i>Cancers</i> , 2021, 13, 6388.	1.7	6
3340	Management of prostate cancer by targeting 3Î²HSD1 after enzalutamide and abiraterone treatment. <i>Cell Reports Medicine</i> , 2022, 3, 100608.	3.3	11
3341	Risk of Metabolic and Cardiovascular Adverse Events With Abiraterone or Enzalutamide Among Men With Advanced Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1127-1134.	3.0	11
3342	Overexpression of Nucleolin and Associated Genes in Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4491.	1.8	7
3343	OCT1-target neural gene PFN2 promotes tumor growth in androgen receptor-negative prostate cancer. <i>Scientific Reports</i> , 2022, 12, 6094.	1.6	6
3344	A Genome-Wide CRISPR Activation Screen Identifies PRRX2 as a Regulator of Enzalutamide Resistance in Prostate Cancer. <i>Cancer Research</i> , 2022, 82, 2110-2123.	0.4	11
3345	RNF8 up-regulates AR/ARV7 action to contribute to advanced prostate cancer progression. <i>Cell Death and Disease</i> , 2022, 13, 352.	2.7	5
3346	Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study. <i>Advances in Therapy</i> , 2022, 39, 2641-2656.	1.3	7

#	ARTICLE	IF	CITATIONS
3347	The emerging role of cross-resistance between taxanes and AR-targeting therapy in metastatic prostate cancer. <i>Journal of Clinical Urology</i> , 2024, 17, 182-189.	0.1	0
3348	Hormone Treatment of Prostate Cancer. <i>Urologic Clinics of North America</i> , 2022, 49, 309-321.	0.8	1
3365	Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada. <i>Journal of Medical Economics</i> , 2022, 25, 583-590.	1.0	2
3366	Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol. <i>BMJ Open</i> , 2019, 9, e034708.	0.8	6
3367	Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216). <i>Journal of Clinical Oncology</i> , 2022, 40, 3301-3309.	0.8	14
3369	WHO SHOULD RECEIVE RADIOTHERAPY IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER?. <i>Acta Clinica Croatica</i> , 2019, 58, 36-41.	0.1	0
3373	Prostate-specific membrane antigen-targeted theranostics: past, present, and future approaches. <i>Clinical Advances in Hematology and Oncology</i> , 2022, 20, 227-238.	0.3	0
3374	Metastatic and Secondary Orbital Tumors. , 2022, , 5403-5417.		0
3376	A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide. <i>Oncologist</i> , 2022, 27, 718-e694.	1.9	3
3377	Androgen Receptor Gene Pathway Upregulation and Radiation Resistance in Oligometastatic Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4786.	1.8	4
3378	Mechanisms of Resistance to Second-Generation Antiandrogen Therapy for Prostate Cancer: Actual Knowledge and Perspectives. <i>Medical Sciences (Basel, Switzerland)</i> , 2022, 10, 25.	1.3	10
3379	Impact of Novel Hormonal Agents (Abiraterone, Enzalutamide) on the Development of Visceral and/or Brain Metastases in Patients With Bone-metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2022, , .	0.9	0
3380	Comprehensive analysis of the associations between clinical factors and outcomes by machine learning, using post marketing surveillance data of cabazitaxel in patients with castration-resistant prostate cancer. <i>BMC Cancer</i> , 2022, 22, 470.	1.1	1
3381	Protein kinase C $\delta$ 1 in cancer: a contextual balance of time and signals. <i>Trends in Cell Biology</i> , 2022, 32, 1023-1034.	3.6	5
3382	Lower Fracture Rates in Patients Treated with Radium-223, Abiraterone or Enzalutamide, When Given Concurrently with Bone Health Agents: A Real-World Analysis. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 399-403.	0.9	4
3383	Real-world cabazitaxel use and outcomes in metastatic castrate-resistant prostate cancer: the impact of response to first ARPI. <i>Clinical Genitourinary Cancer</i> , 2022, , .	0.9	0
3384	Abiraterone acetate in combination with apigenin attenuates survival of human castration-sensitive prostate cancer cells. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, .	0.9	2
3385	ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer. <i>Nature Communications</i> , 2022, 13, 2282.	5.8	34

#	ARTICLE	IF	CITATIONS
3386	High intratumoral dihydrotestosterone is associated with antiandrogen resistance in VCaP prostate cancer xenografts in castrated mice. <i>IScience</i> , 2022, 25, 104287.	1.9	4
3387	A novel inhibitor of AR $\alpha$ and AR $\gamma$ induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer. <i>Acta Pharmaceutica Sinica B</i> , 2022, , .	5.7	1
3388	The Novel Function of Unsymmetrical Chiral CCN Pincer Nickel Complexes as Chemotherapeutic Agents Targeting Prostate Cancer Cells. <i>Molecules</i> , 2022, 27, 3106.	1.7	2
3389	Assessment and Management of Cognitive Function in Patients with Prostate Cancer Treated with Second-Generation Androgen Receptor Pathway Inhibitors. <i>CNS Drugs</i> , 2022, 36, 419-449.	2.7	6
3390	Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer. <i>Scientific Reports</i> , 2022, 12, 7319.	1.6	1
3391	Pharmacoeconomic evaluation of using enzalutamide for treatment of patients with metastatic hormone-sensitive prostate cancer. <i>Onkourologiya</i> , 2022, 18, 90-105.	0.1	0
3392	Antagonistic action of a synthetic androgen ligand mediated by chromatin remodeling in a human prostate cancer cell line. <i>Biochemical and Biophysical Research Communications</i> , 2022, 612, 110-118.	1.0	4
3394	Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer—Prevalence and Current Clinical Practice. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	3
3395	Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review. <i>Cancers</i> , 2022, 14, 2470.	1.7	4
3396	H3K9 methylation drives resistance to androgen receptor antagonist therapy in prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2114324119.	3.3	21
3397	Diagnosis and treatment of metastatic prostate cancer. , 2022, , 23-47.		0
3398	Pharmacist-Urologist Collaborative Management Improves Clinical Outcomes in Patients With Castration-Resistant Prostate Cancer Receiving Enzalutamide. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	2
3399	Metronomic Chemotherapy in Prostate Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 2853.	1.0	6
3400	Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER. <i>European Journal of Cancer</i> , 2022, 170, 285-295.	1.3	9
3401	Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial. <i>European Urology Open Science</i> , 2022, 41, 16-23.	0.2	3
3402	Testosterone analysis in prostate cancer patients. <i>Advances in Clinical Chemistry</i> , 2022, , 73-104.	1.8	5
3403	Neutropenia, neutrophilia, and neutrophil-lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211000.	1.4	4
3404	Current Trends in Advanced Prostate Cancer Medical Setting. <i>Proceedings of the Latvian Academy of Sciences</i> , 2022, 76, 168-180.	0.0	0

#	ARTICLE	IF	CITATIONS
3405	Addition of Standard Enzalutamide Medication Shows Synergistic Effects on Response to [177Lu]Lu-PSMA-617 Radioligand Therapy in mCRPC Patients with Imminent Treatment Failure—Preliminary Evidence of Pilot Experience. <i>Cancers</i> , 2022, 14, 2691.	1.7	5
3406	Gremlin1 is a therapeutically targetable FGFR1 ligand that regulates lineage plasticity and castration resistance in prostate cancer. <i>Nature Cancer</i> , 2022, 3, 565-580.	5.7	18
3407	Enzalutamide-resistant related lncRNA NONHSAT210528 promotes the proliferation and invasion of prostate cancer. <i>Translational Andrology and Urology</i> , 2022, 11, 643-658.	0.6	1
3408	Use of Glycoproteins—Prostate-Specific Membrane Antigen and Galectin-3 as Primary Tumor Markers and Therapeutic Targets in the Management of Metastatic Prostate Cancer. <i>Cancers</i> , 2022, 14, 2704.	1.7	7
3409	Efficacy of Androgen Receptor-targeted Drugs After Prostate Cancer Recurrence With Bone Metastases: PROSTAT-BSI Sub-analysis. <i>Anticancer Research</i> , 2022, 42, 3099-3108.	0.5	0
3411	PTEN—PI3K pathway alterations in advanced prostate cancer and clinical implications. <i>Prostate</i> , 2022, 82, .	1.2	20
3412	Prostate Cancer Treatment: <sup>177</sup> Lu-PSMA-617 Considerations, Concepts, and Limitations. <i>Journal of Nuclear Medicine</i> , 2022, 63, 823-829.	2.8	6
3413	Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo. <i>Cancer Drug Resistance (Alhambra, Calif )</i> , 2022, 5, 667-90.	0.9	8
3414	Metastasis Model to Test the Role of Notch Signaling in Prostate Cancer. <i>Methods in Molecular Biology</i> , 2022, , 221-233.	0.4	1
3416	Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified <i>ALCAM</i> as marker of resistance in castration-resistant prostate cancer. <i>International Journal of Cancer</i> , 0, , .	2.3	3
3417	Low-Dose Enzalutamide in Metastatic Prostate Cancer—Longevity Over Conventional Survival Analysis. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e473-e484.	0.9	4
3419	Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	40
3420	Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer. <i>BJUI Compass</i> , 0, , .	0.7	1
3421	Skeletal-related events after abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer: A population-based study using the SEER-Medicare linked dataset. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, , .	0.8	1
3422	Tumour invasion and dissemination. <i>Biochemical Society Transactions</i> , 2022, 50, 1245-1257.	1.6	8
3423	Usefulness of serum CCL2 as prognostic biomarker in prostate cancer: a long-term follow-up study. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	0.6	3
3424	US Population Reference Values for Health-Related Quality of Life Questionnaires Based on Demographics of Patients with Prostate Cancer. <i>Advances in Therapy</i> , 2022, 39, 3696-3710.	1.3	1
3425	Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer. <i>JAMA Oncology</i> , 2022, 8, 1128.	3.4	26

#	ARTICLE	IF	CITATIONS
3426	Cell Line Characteristics Predict Subsequent Resistance to Androgen Receptor-Targeted Agents (ARTA) in Preclinical Models of Prostate Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
3427	The Androgen Receptor and Its Crosstalk With the Src Kinase During Castrate-Resistant Prostate Cancer Progression. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
3428	Is docetaxel-free interval a predictive factor for castration-resistant prostate cancer?. <i>Actas Urológicas Españolas (English Edition)</i> , 2022, , .	0.2	0
3429	Concurrent Androgen Deprivation Therapy for Prostate Cancer Improves Survival for Synchronous or Metachronous Non-Small Cell Lung Cancer: A SEER Medicare Database Analysis. <i>Cancers</i> , 2022, 14, 3206.	1.7	4
3430	Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence. <i>Cancer Discovery</i> , 2022, 12, 2074-2097.	7.7	22
3432	A Novel Angiogenesis-Related Gene Signature to Predict Biochemical Recurrence of Patients with Prostate Cancer following Radical Therapy. <i>Journal of Oncology</i> , 2022, 2022, 1-13.	0.6	0
3433	An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective. <i>BMC Health Services Research</i> , 2022, 22, .	0.9	0
3434	Castration-resistant prostate cancer with bone metastases: toward the best therapeutic choice. , 2022, 39, .		5
3435	A case of castration-resistant metastatic prostate cancer who continued treatment with enzalutamide after epileptic seizure. <i>Journal of Oncology Pharmacy Practice</i> , 0, , 107815522211120.	0.5	1
3436	Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis. <i>European Urology Oncology</i> , 2022, 5, 494-502.	2.6	21
3437	Synergistic Benefit of Adoptive T Cells in Combination With Chemoradiotherapy Against Metastatic Prostate Cancer Cells. <i>Anticancer Research</i> , 2022, 42, 3427-3434.	0.5	0
3438	Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends. <i>Clinical Drug Investigation</i> , 2022, 42, 631-642.	1.1	9
3439	Understanding the Current Therapeutic Landscape for Advanced Prostate Cancer (CME article). <i>International Journal of Cancer Care and Delivery</i> , 2022, 2, .	0.0	0
3440	Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3979-3989.	3.2	8
3441	The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	9
3442	<i>Aspalathus linearis</i> suppresses cell survival and proliferation of enzalutamide-resistant prostate cancer cells via inhibition of c-Myc and stability of androgen receptor. <i>PLoS ONE</i> , 2022, 17, e0270803.	1.1	2
3443	2-weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trial. <i>Acta Oncológica</i> , 2022, 61, 963-971.	0.8	1
3444	Neuroendocrine differentiation in the setting of prostatic carcinoma: contemporary assessment of a consecutive series. <i>Histopathology</i> , 2022, 81, 246-254.	1.6	6



#	ARTICLE	IF	CITATIONS
3445	Emerging Biomarker-Guided Therapies in Prostate Cancer. <i>Current Oncology</i> , 2022, 29, 5054-5076.	0.9	10
3446	Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer. <i>ESMO Open</i> , 2022, 7, 100518.	2.0	10
3447	Singapore Cancer Network (SCAN) Guidelines for the Management of Advanced Castrate-Resistant Prostate Cancer. <i>Annals of the Academy of Medicine, Singapore</i> , 2015, 44, 397-405.	0.2	7
3448	Current and emerging therapies for neuroendocrine prostate cancer. , 2022, 238, 108255.		13
3449	A Drug Repurposing Screen Identifies Fludarabine Phosphate as a Potential Therapeutic Agent for N-MYC Overexpressing Neuroendocrine Prostate Cancers. <i>Cells</i> , 2022, 11, 2246.	1.8	7
3450	Diffuse Synaptophysin Expression in Aggressive Recurrent Castration-Resistant Acinar (Usual) Prostate Cancer: Case Report and Review of Prostatic Neuroendocrine Tumors. <i>AJSP Review and Reports</i> , 2020, 25, 114-122.	0.0	0
3452	A Novel Enolase-1 Antibody Targets Multiple Interacting Players in the Tumor Microenvironment of Advanced Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1337-1347.	1.9	7
3453	Androgen receptor signaling and spatial chromatin organization in castration-resistant prostate cancer. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
3455	Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404). <i>Journal of Clinical Oncology</i> , 2022, 40, 4240-4249.	0.8	20
3456	Second generation androgen receptor antagonists and challenges in prostate cancer treatment. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	32
3457	The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8535.	1.8	9
3458	Adaptation to Hypoxia May Promote Therapeutic Resistance to Androgen Receptor Inhibition in Triple-Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8844.	1.8	4
3459	Health-related quality of life with enzalutamide versus flutamide in castration-resistant prostate cancer from the AFTERCAB study. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1632-1643.	1.0	1
3460	Developing New Treatment Options for Castration-Resistant Prostate Cancer and Recurrent Disease. <i>Biomedicines</i> , 2022, 10, 1872.	1.4	6
3461	Patterns of structural variation define prostate cancer across disease states. <i>JCI Insight</i> , 2022, 7, .	2.3	3
3462	Prostate-specific membrane antigen targeted, glutathione-sensitive nanoparticles loaded with docetaxel and enzalutamide for the delivery to prostate cancer. <i>Drug Delivery</i> , 2022, 29, 2705-2712.	2.5	4
3463	Cancer vaccines: the next immunotherapy frontier. <i>Nature Cancer</i> , 2022, 3, 911-926.	5.7	207
3464	Comprehensive analysis of androgen receptor status in prostate cancer with neuroendocrine differentiation. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5



#	ARTICLE	IF	CITATIONS
3465	Transcriptomic Signature and Growth Factor Regulation of Castration-Tolerant Prostate Luminal Progenitor Cells. <i>Cancers</i> , 2022, 14, 3775.	1.7	7
3466	Androgen receptor axis-targeted agents are not superior to conventional hormonal therapy for treatment of metastatic prostate cancer. <i>Oncology Letters</i> , 2022, 24, .	0.8	0
3467	Resistance to prostate cancer treatments. <i>IUBMB Life</i> , 2023, 75, 390-410.	1.5	4
3468	The STAT3 inhibitor GPB730 enhances the sensitivity to enzalutamide in prostate cancer cells. <i>Translational Oncology</i> , 2022, 24, 101495.	1.7	3
3469	Simulating androgen receptor selection in designer yeast. <i>Synthetic and Systems Biotechnology</i> , 2022, 7, 1108-1116.	1.8	2
3470	Bone-only oligometastatic prostate cancer: can SABR improve outcomes? A single-center experience. <i>Radiation Oncology Journal</i> , 2022, 40, 192-199.	0.7	1
3471	Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 1297-1307.	5.1	12
3472	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. , 2022, , 1-55.		0
3473	AR Structural Variants and Prostate Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 195-211.	0.8	2
3474	Prostate Cancer Epigenetic Plasticity and Enhancer Heterogeneity: Molecular Causes, Consequences and Clinical Implications. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 255-275.	0.8	1
3475	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. , 2022, , 1023-1075.		0
3477	The androgen receptor couples promoter recruitment of RNA processing factors to regulation of alternative polyadenylation at the 3' end of transcripts. <i>Nucleic Acids Research</i> , 2022, 50, 9780-9796.	6.5	2
3478	Androgen receptor in breast cancer: The "5W" questions. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	10
3479	Novel AR/AR-V7 and Mnk1/2 Degradar, VNPP433-3 <sup>rd</sup> : Molecular Mechanisms of Action and Efficacy in AR-Overexpressing Castration Resistant Prostate Cancer In Vitro and In Vivo Models. <i>Cells</i> , 2022, 11, 2699.	1.8	8
3480	GSTM2 is a key molecular determinant of resistance to SG-ARIs. <i>Oncogene</i> , 2022, 41, 4498-4511.	2.6	1
3481	Antagonizing CD105 and androgen receptor to target stromal-epithelial interactions for clinical benefit. <i>Molecular Therapy</i> , 2023, 31, 78-89.	3.7	2
3482	Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study. <i>European Urology</i> , 2023, 83, 15-26.	0.9	22
3483	Predictive factors for the effectiveness of novel androgen receptor axis-targeted agents in patients with metastatic prostate cancer. <i>International Journal of Urology</i> , 0, , .	0.5	1

#	ARTICLE	IF	CITATIONS
3484	Radiographic paradoxical response in metastatic castrate-resistant prostate cancer (mCRPC) managed with new generation anti-androgens: a retrospective analysis. <i>Prostate</i> , 2022, 82, 1483-1490.	1.2	4
3485	Investigation into the Optimal Strategy of Radium-223 Therapy for Metastatic Castration-Resistant Prostate Cancer. <i>Radiation</i> , 2022, 2, 273-284.	0.6	3
3487	PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures. <i>Cancers</i> , 2022, 14, 4751.	1.7	4
3488	Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for) TJ ETQq1 1 0.784314 r/BT /Overlock 10 T prospective single-arm interventional study. <i>BMC Urology</i> , 2022, 22, .	0.6	0
3489	Bibliometric analysis of the global research development of bone metastases in prostate cancer: A 22-year study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
3490	Treatment Landscape for Patients with Castration-Resistant Prostate Cancer: Patient Selection and Unmet Clinical Needs. <i>Research and Reports in Urology</i> , 0, Volume 14, 339-350.	0.6	8
3491	Celastrol recruits UBE3A to recognize and degrade the DNA binding domain of steroid receptors. <i>Oncogene</i> , 2022, 41, 4754-4767.	2.6	3
3492	Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 743-750.	2.0	7
3493	Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1 <i>H</i> -pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 13074-13093.	2.9	2
3494	A single-center, open-label, single-arm, fixed-sequence pharmacokinetic study of SHR3680 on repaglinide and bupropion in prostate cancer patients. <i>British Journal of Clinical Pharmacology</i> , 0, , .	1.1	2
3495	Metastatic prostate cancer gets into the biomarker era. <i>Canadian Urological Association Journal</i> , 2022, 16, 333.	0.3	0
3496	HMGBl promotes the development of castration-resistant prostate cancer by regulating androgen receptor activation. <i>Oncology Reports</i> , 2022, 48, .	1.2	11
3497	Applications for open access normalized synthesis in metastatic prostate cancer trials. <i>Frontiers in Artificial Intelligence</i> , 0, 5, .	2.0	0
3498	Emerging hormonal agents for the treatment of prostate cancer. <i>Expert Opinion on Emerging Drugs</i> , 2022, 27, 301-309.	1.0	2
3499	UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naïve and castration-sensitive prostate cancer. <i>Canadian Urological Association Journal</i> , 2022, 16, .	0.3	0
3500	Establishment of a five-enzalutamide-resistance-related gene-based classifier for recurrence-free survival predicting of prostate cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 5379-5390.	1.6	1
3501	Systematic review of antitumour efficacy and mechanism of metformin activity in prostate cancer models. <i>BJUI Compass</i> , 2023, 4, 44-58.	0.7	6
3502	Efficacy of Novel Hormone Agents in the Treatment of Metastatic Castration-resistant Prostate Cancer: A Real-world Retrospective Study. <i>Anticancer Research</i> , 2022, 42, 4857-4866.	0.5	0

#	ARTICLE	IF	CITATIONS
3504	Modern paradigms for prostate cancer detection and management. Medical Journal of Australia, 2022, 217, 424-433.	0.8	13
3505	A convenient total synthesis of PSMA-617: A prostate specific membrane antigen (PSMA) ligand for prostate cancer endotherapeutic applications. European Journal of Medicinal Chemistry Reports, 2022, 6, 100084.	0.6	2
3506	EFFECT OF NEW ANDROGEN RECEPTOR AXIS-TARGETED AGENTS ON SURVIVAL OF CASTRATION-RESISTANT PROSTATE CANCER. Japanese Journal of Urology, 2021, 112, 207-214.	0.0	0
3508	Druggable Metabolic Vulnerabilities Are Exposed and Masked during Progression to Castration Resistant Prostate Cancer. Biomolecules, 2022, 12, 1590.	1.8	6
3509	A Phase 1b Adaptive Androgen Deprivation Therapy Trial in Metastatic Castration Sensitive Prostate Cancer. Cancers, 2022, 14, 5225.	1.7	7
3511	Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study. British Journal of Cancer, 0, , .	2.9	1
3512	The Crucial Role of AR-V7 in Enzalutamide-Resistance of Castration-Resistant Prostate Cancer. Cancers, 2022, 14, 4877.	1.7	12
3513	Targeting aldehyde dehydrogenase for prostate cancer therapies. Frontiers in Oncology, 0, 12, .	1.3	0
3514	Impact of treatment on elder-relevant physical function and quality of life outcomes in older adults with metastatic castration-resistant prostate cancer. Journal of Geriatric Oncology, 2023, 14, 101395.	0.5	2
3515	2022 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). Canadian Urological Association Journal, 2022, 16, E506-15.	0.3	4
3517	A COPI1-GATA2 axis suppresses AR signaling and prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	5
3518	Repression of <i>SLC22A3</i> by the AR-YAP1-TAZ axis in enzalutamide-resistant castration-resistant prostate cancer. FEBS Journal, 2023, 290, 1645-1662.	2.2	2
3519	Juglone promotes antitumor activity against prostate cancer via suppressing glycolysis and oxidative phosphorylation. Phytotherapy Research, 2023, 37, 515-526.	2.8	3
3520	The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors. Nature Communications, 2022, 13, .	5.8	25
3522	Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer. Expert Review of Anticancer Therapy, 2022, 22, 1163-1175.	1.1	6
3523	Increased AR expression in castration-resistant prostate cancer rapidly induces AR signaling reprogramming with the collaboration of EZH2. Frontiers in Oncology, 0, 12, .	1.3	5
3524	Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study. Lancet Oncology, The, 2022, 23, 1398-1408.	5.1	12
3525	The evolving landscape of PARP inhibitors in castration-resistant prostate cancer: a spotlight on treatment combinations. Expert Review of Clinical Pharmacology, 2022, 15, 1293-1304.	1.3	0

#	ARTICLE	IF	CITATIONS
3526	Efficacy and safety of therapies for advanced prostate cancer in Asia: Evidence from a systematic literature review. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211315.	1.4	1
3527	Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial. <i>Journal of Clinical Oncology</i> , 2023, 41, 1307-1317.	0.8	6
3528	Predictive value of low testosterone concentrations during and prior to enzalutamide treatment in metastatic castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, , .	0.8	0
3529	Constitutively Active Androgen Receptor in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13768.	1.8	8
3530	French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Management of metastatic disease and castration resistance. <i>Progres En Urologie</i> , 2022, 32, 1373-1419.	0.3	5
3531	Stereotactic body radiotherapy in oligoprogressive metastatic castration-resistant prostate cancer during abiraterone or enzalutamide. <i>Tumori</i> , 0, , 030089162211325.	0.6	0
3532	Risk of cognitive impairment in men with advanced prostate cancer treated with NHAs: A systematic review and network meta-analysis. <i>Clinical and Translational Science</i> , 2023, 16, 313-325.	1.5	3
3533	Long Term Use and Risk of Major Adverse Cardiac Events: Comparing Enzalutamide and Abiraterone in Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer. <i>International Journal of Cancer</i> , 0, , .	2.3	1
3534	Cardiovascular complications of treatment for prostate cancer. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2022, 83, 1-12.	0.2	3
3535	SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXR±/FOXO1 pathway independently of REV-ERBs. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	7
3536	Utilization Trends of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer in Quebec. <i>Current Oncology</i> , 2022, 29, 8626-8637.	0.9	2
3537	Metastatic castrate-resistant prostate cancer: a new horizon beyond the androgen receptors. <i>Current Opinion in Supportive and Palliative Care</i> , 2022, 16, 223-229.	0.5	2
3539	A Novel Biguanide Derivative, IM176, Induces Prostate Cancer Cell Death via AMPK-mTOR Pathway and Androgen Receptor Signalling Pathway. <i>Prostate International</i> , 2022, , .	1.2	3
3540	Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes. <i>Cancer Discovery</i> , 2023, 13, 632-653.	7.7	13
3541	A population-based study of factors associated with systemic treatment in advanced prostate cancer decedents. <i>Cancer Medicine</i> , 0, , .	1.3	3
3542	Design and synthesis of ether derivatives of spliceostatin A and their biological evaluation towards prostate cancer treatment. <i>Tetrahedron Letters</i> , 2023, 114, 154288.	0.7	2
3543	Prostatakarzinom: palliative Therapie. <i>Springer Reference Medizin</i> , 2022, , 1-24.	0.0	0
3544	Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer. <i>Cell Death Discovery</i> , 2022, 8, .	2.0	1

#	ARTICLE	IF	CITATIONS
3545	Current Developments in Cellular Therapy for Castration Resistant Prostate Cancer: A Systematic Review of Clinical Studies. <i>Cancers</i> , 2022, 14, 5719.	1.7	2
3546	Clinical Application and Synthesis Methods of Deuterated Drugs. <i>Current Medicinal Chemistry</i> , 2023, 30, 4096-4129.	1.2	1
3547	Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit. <i>Annals of Oncology</i> , 2023, 34, 431-439.	0.6	7
3548	Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis. <i>Current Oncology</i> , 2022, 29, 9511-9524.	0.9	3
3549	The Neuropilin-1/PKC axis promotes neuroendocrine differentiation and drug resistance of prostate cancer. <i>British Journal of Cancer</i> , 2023, 128, 918-927.	2.9	4
3550	Quality of life for men with metastatic castrate-resistant prostate cancer participating in an aerobic and resistance exercise pilot intervention. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2023, 41, 146.e1-146.e11.	0.8	2
3551	Integrating Pharmacogenomics Data-Driven Computational Drug Prediction with Single-Cell RNAseq to Demonstrate the Efficacy of a NAMPT Inhibitor against Aggressive, Taxane-Resistant, and Stem-like Cells in Lethal Prostate Cancer. <i>Cancers</i> , 2022, 14, 6009.	1.7	2
3552	Liver Microenvironment Response to Prostate Cancer Metastasis and Hormonal Therapy. <i>Cancers</i> , 2022, 14, 6189.	1.7	4
3553	Androgen Receptor Signaling Inhibition in Advanced Castration Resistance Prostate Cancer: What Is Expected for the Near Future?. <i>Cancers</i> , 2022, 14, 6071.	1.7	7
3554	The role of carboplatin in combination with paclitaxel in patients with castration-resistant prostate cancer. <i>Future Oncology</i> , 2022, 18, 4183-4192.	1.1	1
3555	Treatment Patterns Among Patients With Advanced Prostate Cancer in Brazil: An Analysis of a Private Healthcare System Database. <i>World Journal of Oncology</i> , 2022, 13, 350-358.	0.6	0
3556	The testosterone paradox of advanced prostate cancer: mechanistic insights and clinical implications. <i>Nature Reviews Urology</i> , 2023, 20, 265-278.	1.9	10
3557	TRIM59 is suppressed by androgen receptor and acts to promote lineage plasticity and treatment-induced neuroendocrine differentiation in prostate cancer. <i>Oncogene</i> , 2023, 42, 559-571.	2.6	4
3559	Prostate-specific antigen response and clinical progression-free survival in Black and White men with chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide in a real-world setting. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 523-530.	2.0	3
3560	Idarubicin combats abiraterone and enzalutamide resistance in prostate cells via targeting XPA protein. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	0
3561	Examining the Effect of PARP-1 Inhibitors on Transcriptional Activity of Androgen Receptor in Prostate Cancer Cells. <i>Methods in Molecular Biology</i> , 2023, , 329-335.	0.4	2
3562	Prevalence of mutations in DNA repair genes in Russian patients with metastatic castration-resistant prostate cancer. <i>Onkourologiya</i> , 2022, 18, 60-66.	0.1	1
3563	Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4

#	ARTICLE	IF	CITATIONS
3564	Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2023, 23, 231-239.	0.7	1
3565	Oncolytic Adenovirus, a New Treatment Strategy for Prostate Cancer. <i>Biomedicines</i> , 2022, 10, 3262.	1.4	2
3566	AKT1 regulates UHRF1 protein stability and promotes the resistance to abiraterone in prostate cancer. <i>Oncogenesis</i> , 2023, 12, .	2.1	4
3567	Epigenetic and post-translational modifications in autophagy: biological functions and therapeutic targets. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	25
3568	Chaperone-mediated autophagy promotes PCa survival during ARPI through selective proteome remodeling. <i>Oncogene</i> , 0, , .	2.6	1
3569	Molecular Mechanisms of Noncoding RNA in the Occurrence of Castration-Resistant Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1305.	1.8	2
3570	Metastatic Prostate Cancer—A Review of Current Treatment Options and Promising New Approaches. <i>Cancers</i> , 2023, 15, 461.	1.7	22
3571	How to Improve the Quality of Life of Patients with Prostate Cancer Treated with Hormone Therapy?. <i>Research and Reports in Urology</i> , 0, Volume 15, 9-26.	0.6	1
3572	Should one use the combination of abiraterone and poly(ADP-ribose) polymerase inhibitors as first-line therapy for all patients with metastatic castration-resistant prostate cancer?. <i>Future Oncology</i> , 0, , .	1.1	0
3573	Role of transcription factors and chromatin modifiers in driving lineage reprogramming in treatment-induced neuroendocrine prostate cancer. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	1.8	4
3574	STAT3 signaling in prostate cancer progression and therapy resistance: An oncogenic pathway with diverse functions. <i>Biomedicine and Pharmacotherapy</i> , 2023, 158, 114168.	2.5	3
3575	Targeting the N-terminal domain of the androgen receptor: The effective approach in therapy of CRPC. <i>European Journal of Medicinal Chemistry</i> , 2023, 247, 115077.	2.6	8
3576	The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer. <i>International Journal of Clinical Oncology</i> , 0, , .	1.0	0
3577	Adrenal Steroids and Resistance to Hormonal Blockade of Prostate and Breast Cancer. <i>Endocrinology</i> , 2023, 164, .	1.4	4
3578	Enzalutamide or Abiraterone Acetate With Prednisone in the Treatment of Metastatic Castration-resistant Prostate Cancer in Real-life Clinical Practice: A Long-term Single Institution Experience. <i>Anticancer Research</i> , 2023, 43, 463-471.	0.5	1
3579	Recent Advances in Advance Prostate Cancer. <i>Annals of Urologic Oncology</i> , 2022, , 81-88.	0.0	0
3581	Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2189.	1.8	1
3582	Emerging systemic treatment for metastatic castration-resistant prostate cancer: a review of recent randomized controlled trials. <i>Current Opinion in Urology</i> , 2023, 33, 219-229.	0.9	3



#	ARTICLE	IF	CITATIONS
3584	AR and PI3K/AKT in Prostate Cancer: A Tale of Two Interconnected Pathways. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2046.	1.8	12
3585	Adverse Events and Androgen Receptor Signaling Inhibitors in the Treatment of Prostate Cancer: A Systematic Review and Multivariate Network Meta-analysis. <i>European Urology Oncology</i> , 2023, 6, 237-250.	2.6	4
3586	Effects of In-office Dispensing by Single-specialty Urology Practices on Management of Advanced Prostate Cancer. <i>Urology Practice</i> , 2023, 10, 230-235.	0.2	1
3587	Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review. <i>World Journal of Men's Health</i> , 2023, 41, 769.	1.7	10
3588	IQGAP3 is relevant to prostate cancer: A detailed presentation of potential pathomechanisms. <i>Journal of Advanced Research</i> , 2023, 54, 195-210.	4.4	2
3589	Computational strategies for PROTAC drug discovery. , 2023, 2, .		1
3590	State-Of-The-Art Treatment in Castration-Resistant Prostate Cancer. <i>European Medical Journal Oncology</i> , 0, , 10-105.	0.0	0
3591	Analysis of Risk Factors for Early Progression of Prostate Cancer After Initial Endocrine Therapy. <i>Journal of Cancer</i> , 2023, 14, 519-531.	1.2	0
3592	Epigenetic mechanism of therapeutic resistance and potential of epigenetic therapeutics in chemorefractory prostate cancer. <i>International Review of Cell and Molecular Biology</i> , 2023, , 173-210.	1.6	0
3593	Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16). <i>Journal of Clinical Oncology</i> , 2023, 41, 3608-3615.	0.8	2
3594	Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents. <i>Annals of Oncology</i> , 2023, 34, 557-563.	0.6	10
3595	Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer. <i>Biomarker Research</i> , 2023, 11, .	2.8	0
3596	Proxalutamide in metastatic castration-resistant prostate cancer: Primary analysis of a multicenter, randomized, open-label, phase 2 trial. <i>International Journal of Cancer</i> , 0, , .	2.3	0
3597	Prostate cancer metastasis and health disparities: a systematic review. <i>Prostate Cancer and Prostatic Diseases</i> , 0, , .	2.0	0
3598	Activity and safety of KEES - an oral multi-drug chemo-hormonal metronomic combination regimen in metastatic castration-resistant prostate cancer. <i>BMC Cancer</i> , 2023, 23, .	1.1	0
3599	Current therapy and drug resistance in metastatic castration-resistant prostate cancer. <i>Drug Resistance Updates</i> , 2023, 68, 100962.	6.5	30
3600	Sequential Androgen Receptor Pathway Inhibitor in Prostate Cancer: Piling-Up The Benefits or a Case for Cross-Resistance?. <i>European Medical Journal Oncology</i> , 0, , 40-47.	0.0	0
3601	Immune Checkpoint Inhibitors in Urological Cancers. , 2023, , 1-25.		0



#	ARTICLE	IF	CITATIONS
3602	Antibody-Drug Conjugates in Prostate Cancer: A Systematic Review. <i>Cureus</i> , 2023, , .	0.2	1
3603	SMAD3 promotes expression and activity of the androgen receptor in prostate cancer. <i>Nucleic Acids Research</i> , 2023, 51, 2655-2670.	6.5	7
3604	HÄmatologische Neoplasien und solide Tumore. , 2022, , 85-151.		0
3605	Mechanisms of Prostate Cancer Cells Survival and Their Therapeutic Targeting. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2939.	1.8	5
3606	Preclinical Efficacy of a PARP-1 Targeted Auger-Emitting Radionuclide in Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3083.	1.8	6
3607	Characteristics, properties, and analytical and bioÄanalytical methods of enzalutamide: A review. <i>Separation Science Plus</i> , 2023, 6, .	0.3	0
3608	Circular RNAs in Prostate Cancer: Is it Time to Further Explore Liquid Biopsies?. <i>Mini-Reviews in Medicinal Chemistry</i> , 2023, 23, .	1.1	0
3609	Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer. <i>Cancer Treatment Reviews</i> , 2023, 115, 102524.	3.4	4
3610	Bayesian Machine Learning Enables Identification of Transcriptional Network Disruptions Associated with Drug-Resistant Prostate Cancer. <i>Cancer Research</i> , 2023, 83, 1361-1380.	0.4	3
3611	Differential adoption of castrationÄresistant prostate cancer treatment across facilities in a national healthcare system. <i>Cancer Medicine</i> , 2023, 12, 6945-6955.	1.3	0
3612	Prostate cancer and novel pharmacological treatment optionsÄ“whatÄ™s new for 2022?. <i>Expert Review of Clinical Pharmacology</i> , 2023, 16, 231-244.	1.3	1
3613	miR-29a-5p modulates ferroptosis by targeting ferritin heavy chain FTH1 in prostate cancer. <i>Biochemical and Biophysical Research Communications</i> , 2023, 652, 6-13.	1.0	4
3614	Taxanes Versus Androgen Receptor Therapy as Second-Line Treatment for Castrate-Resistant Metastatic Prostate Cancer After First-Line Androgen Receptor Therapy. <i>Clinical Genitourinary Cancer</i> , 2023, 21, 349-356.e2.	0.9	1
3615	Daclatasvir, an Antiviral Drug, Downregulates Tribbles 2 Pseudokinase and Resensitizes Enzalutamide-Resistant Prostate Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2023, 22, 381-392.	1.9	0
3616	Radioligand Therapy of Patients with Metastatic Castrate-Resistant Prostate Cancer. <i>Biology Bulletin</i> , 2022, 49, 2285-2297.	0.1	0
3617	Emerging RNA-Based Therapeutic and Diagnostic Options: Recent Advances and Future Challenges in Genitourinary Cancers. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4601.	1.8	2
3619	Bone Metastases and Health in Prostate Cancer: From Pathophysiology to Clinical Implications. <i>Cancers</i> , 2023, 15, 1518.	1.7	7
3620	A compendium of Androgen Receptor Variant 7 target genes and their role in Castration Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3

#	ARTICLE	IF	CITATIONS
3622	Imaging Recommendations for Theranostic PET-CT in Oncology. Indian Journal of Medical and Paediatric Oncology, 0, , .	0.1	0
3623	Vaccines as treatments for prostate cancer. Nature Reviews Urology, 2023, 20, 544-559.	1.9	8
3624	Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain. Journal of Health Economics and Outcomes Research, 0, , 1-14.	0.6	0
3625	Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide. BMC Cancer, 2023, 23, .	1.1	0
3626	Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial. European Urology, 2023, 83, 571-579.	0.9	3
3627	A prospective study of the relationship between CRPC patient's quality of life after enzalutamide and serum testosterone levels measured via LC-MS/MS. Prostate, 2023, 83, 759-764.	1.2	0
3628	Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis. Frontiers in Endocrinology, 0, 14, .	1.5	0
3629	Prognostic factors of overall and prostate-specific antigen-free survival in metastatic castration-resistant prostate cancer patients treated with <sup>177</sup> Lu-PSMA-617. A single-center prospective observational study. Prostate, 2023, 83, 792-800.	1.2	3
3630	Antiandrogen-Equipped Histone Deacetylase Inhibitors Selectively Inhibit Androgen Receptor (AR) and AR-Splice Variant (AR-SV) in Castration-Resistant Prostate Cancer (CRPC). Cancers, 2023, 15, 1769.	1.7	3
3631	Hormones and antihormones in cancer chemotherapy. , 2023, , 589-613.		0
3632	Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer. Clinical Cancer Research, 2023, 29, 2324-2335.	3.2	7
3633	Advances in PARP Inhibitors for Prostate Cancer. Cancers, 2023, 15, 1849.	1.7	10
3634	The epigenetic function of androgen receptor in prostate cancer progression. Frontiers in Cell and Developmental Biology, 0, 11, .	1.8	2
3635	How to Optimally Sequence Available Therapy Lines in Advanced Prostate Cancer. Acta Clinica Croatica, 2022, , .	0.1	0
3636	Molecular testing of DNA damage response pathways in prostate cancer patients. Current Opinion in Oncology, 2023, 35, 224-230.	1.1	0
3637	Adherence to oral hormonal therapy in advanced prostate cancer: a scoping review. Therapeutic Advances in Medical Oncology, 2023, 15, 175883592311528.	1.4	2
3638	Toward Precision Medicine: Development and Validation of A Machine Learning Based Decision Support System for Optimal Sequencing in Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2023, 21, e211-e218.e4.	0.9	0
3639	Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer. Journal of Personalized Medicine, 2023, 13, 608.	1.1	1

#	ARTICLE	IF	CITATIONS
3640	Real-life data of abiraterone acetate and enzalutamide treatment in post-chemotherapy metastatic castration-resistant prostate cancer in Poland. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
3641	Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer. <i>Oncologist</i> , 2023, 28, 465-473.	1.9	3
3642	Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learning. <i>Nature Communications</i> , 2023, 14, .	5.8	4
3643	Cardiovascular Complications in Patients with Prostate Cancer: Potential Molecular Connections. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6984.	1.8	5
3644	External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Na <sup>+</sup> ve Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2023, 41, 2736-2746.	0.8	3
3645	Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy. <i>Nature Communications</i> , 2023, 14, .	5.8	15
3646	Hormonal Therapies for Patients with Advanced Prostate Cancer. <i>European Medical Journal (Chelmsford, England)</i> , 0, , 39-51.	3.0	0
3647	Is The Patient Actually Failing On Enzalutamide? A Case Report And Issues To Consider In Enzalutamide-Resistant Oligo Progressive Metastatic Castrate-Resistant Prostate Cancer. <i>Reviews on Recent Clinical Trials</i> , 2023, 18, .	0.4	0
3648	Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials. <i>Clinical Cancer Research</i> , 2023, 29, 2426-2434.	3.2	2
3649	Implications of metastatic stage at presentation in docetaxel na <sup>+</sup> ve metastatic castrate resistant prostate cancer. <i>Prostate</i> , 0, , .	1.2	1
3650	IMPACT OF GENERAL FATIGUE ON TREATMENT PERIOD AFTER INDUCTION OF ENZALUTAMIDE FOR CASTRATION-RESISTANT PROSTATE CANCER. <i>Japanese Journal of Urology</i> , 2022, 113, 63-67.	0.0	0
3652	Visceral Metastasis Predicts Response to New Hormonal Agents in Metastatic Castration-Sensitive Prostate Cancer. <i>Oncologist</i> , 2023, 28, 596-603.	1.9	1
3661	Therapeutic applications of the prostate cancer epigenome. , 2023, , 301-337.		0
3676	Models of multidisciplinary management. , 2024, , 39-44.		0
3677	Case Report: Long-term complete response to PSMA-targeted radioligand therapy and abiraterone in a metastatic prostate cancer patient. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
3683	Management of bone metastasis in prostate cancer. <i>Journal of Bone and Mineral Metabolism</i> , 2023, 41, 317-326.	1.3	2
3695	Genetic and epigenetic features of neuroendocrine prostate cancer and their emerging applications. <i>International Review of Cell and Molecular Biology</i> , 2024, , 41-66.	1.6	1
3703	Clinical Pharmacokinetics and Pharmacodynamics of the Next Generation Androgen Receptor Inhibitor <sup>®</sup> Darolutamide. <i>Clinical Pharmacokinetics</i> , 0, , .	1.6	1

#	ARTICLE	IF	CITATIONS
3708	Prostatakarzinom: palliative Therapie. Springer Reference Medizin, 2023, , 1593-1616.	0.0	0
3709	Androgen Receptor in Health and Disease. , 2023, , 21-75.		0
3720	Editorial: Hormone resistance in cancer. Frontiers in Endocrinology, 0, 14, .	1.5	0
3735	Current Pathophysiology, Treatment, and Future Perspective for Prostate Cancer. , 2023, , 1-22.		0
3739	Androgen Receptor Signaling: A Central and Evolving Theme in Prostate Cancer Treatment. , 2023, , 1-29.		0
3743	Metastatic Prostate Cancer. , 2023, , 241-255.		0
3747	Metastasiertes kastrationsresistentes Prostatakarzinom mit Therapiesequenz (mCRPC). , 2023, , 77-92.		0
3755	Therapeutic, diagnostic and prognostic values of TRIM proteins in prostate cancer. Pharmacological Reports, 2023, 75, 1445-1453.	1.5	1
3756	Novel treatment strategies to overcome resistance in prostate cancer. , 2024, , 289-308.		0
3757	Overcoming resistance in prostate cancer with targeted and small molecule-based therapies. , 2024, , 255-287.		0
3774	Case Study #8: Alpha-Therapy with Radium-223 Dichloride for Metastatic Castration-Resistant Prostate Cancer. , 2023, , 387-405.		0
3775	Case Study #7: PSMA-617. , 2023, , 369-386.		0
3784	Perspectives in ROS/Redox Regulation Cancer Therapy. , 2023, , 411-431.		0
3803	Therapy of Castration-Resistant Prostate Cancer: Where Is the Place of 225Ac-PSMA?. , 2024, , 255-265.		0
3814	Cardiovascular risks of androgen receptor targeted agents in prostate cancer: a systematic review and meta-analysis. Prostate Cancer and Prostatic Diseases, 0, , .	2.0	0
3828	Malignome des Urogenitaltrakts. , 2024, , 801-864.		0
3834	HÄmatologische Neoplasien und solide Tumore. , 2023, , 99-174.		0
3842	Urologische Tumoren. , 2024, , 239-274.		0

#	ARTICLE	IF	CITATIONS
3847	Diagnostic, Prognostic and Theranostic Potential of miRNAs in Prostate Cancer. , 2024, , 147-168.		0